

Acta Haematologica, Vol 42

Acta Haematologica

International Journal of Haematology – Journal International
d'Hématologie – Internationale Zeitschrift für Hämatologie

Official Organ of the European Division of the International Society
of Haematology

EDITORS

A. ALDER, Aarau	L. GRÖN, Bronx, N.Y.	L.M. MITER, Brooklyn, N.Y.
H. ALEXANDER, Santiago	J. GROSS, Barcelona	W.P. MURPHY, Boston, Mass.
G. BACHLI, Genève	G. HENRIKSEN, Lausanne	N.G. NORDENFLOD, Stockholm
B.M. VON BOWENHOF, Helsinki	A. HITTMANN, Innsbruck	A. PAVLOVSKY, Buenos Aires
W. O. CRUZ, Rio de Janeiro	P. INTERRIEL, Pavia	E. PODDER, Buenos Aires
C.R. DAS GUPTA, Calcutta	P. KOLLER, Basel	F. REIDMAN, Istanbul
C. JENSEN DIAZ, Madrid	J.H. LAWRENCE, Berkeley Calif.	L. SAPPERS, Brooklyn, N.Y.
H. DEMOS-FERRELL, Genève	P. LEVINE, Raritan, N.J.	E. STORRI, Modena
P. FARRERAS, Barcelona	W. LÖFFLER, Zürich	E. UNGER, Basel
A. FISCHER, Genova	J. MALLARD, Paris	M. VARELA, Buenos Aires
		M.C. VERLOOF, Utrecht

CONTRIBUTING EDITORS

L. Hellmeyer † Freiburg im Br.	S. Moeschlin Solothurn	A. Videbaek København
	J. Waldenström Malmö	

EDITORS-IN-CHIEF

H. Löffler Basel	G. Rosenow New York, N.Y.
---------------------	------------------------------



1969

Vol. 42

BASEL (Schweiz) S. KARGER NEW YORK

All rights, including that of translation into other languages, reserved.
Photomechanical reproduction (photocopy, microcopy) of this volume or parts thereof without special permission of the publisher is prohibited.



Copyright 1969 by S. Karger A.G., Basel
Printed in Switzerland by Buchdruckerei National-Zürcher A.G., Basel
Cicchi's Baker & Co. A.G., Basel

Contents — Inhaltsverzeichnis — Sommaire

Vol. 42

AMMER, H. and BRAUNWEINER, H.: Der zytologische Immunoglobulinnachweis in lymphatischen Reizketten	249
AROCCHIARI, O.: vide MALAMOCK, B.	
BABAKOVA, N. F.: vide HAUT, J.	
BALGASZI, G. M.: vide RONDANELLI, E. G.	
BARTHEL, H.: vide HADIM, Y., K.	
BELL, T. K. and LEE, D.: Evaluation of a Dual Radioisotope Urinary Excretion Test in the Diagnosis of Pernicious Anemia	153
BER-EZER, JUDITH: vide SCHENBERG, A.	
BERWITZ, E. F.: vide GARTIN, S. R.	
BLANCO, G.: vide RIZZO, G.	
BOLGER, C. DENISE: vide LEE, MACHLEN B.	
BOROVICHKO, K. G., SCHULTZ WUNDERLICH, H., HILLE, H., JENDERSKY H. J. and GÖPFERT H.: Über die Wirkung des Mähdgryphallamas und des Weizens auf das Elutbild	231
BRAUNWEINER, H.: vide AMMER, H.	
BREIDEN, K.: vide LEIBROCK, K.	
BREIDEN, J. M.: vide LEE, MACHLEN B.	
CHAM, BRADLEY S. T.: Electron Microscopic Study of the Centrioles in Guinea-Pig Bone Marrow Eosinophils	28
CONSTANTOCLAIR, M.: vide MALAMOCK, B.	
DUEL, M.: vide MALKERAND, T.	
D WICK, A. A. and OOSTON, D.: Exercise-Induced Thrombocytosis	11
DEL PUZO, ENLIO: vide LEIBREITER, R. B.	
DES GOUTTES, D. et LEIBER, H.: Etude de la fixation non spécifique des immunoglobulines G sur les érythrocytes. I. Influence de la variation de différents paramètres	154
DES GOUTTES, D. et LEIBER, H.: Etude de la fixation non spécifique des immunoglobulines G sur les érythrocytes. II. Essais d'inhibition par des immunoglobulines G natives ou modifiées et par d'autres protéines	219
ECKELING, E.: vide HINTEN, W.	
FALCHI, F.: vide RONDANELLI, E. G.	
FET F: Studies on the Pathogenesis and Mechanism of Hematologic Differentiation by Re-Isolation of the Myeloid Leukemia Virus (Graft)	63
FISCHER, DORA: vide ROSENSTAJN, L.	
FISHER, E. R.: vide ZAWATSKI, Z. A.	
FREDRICK, A.: vide RACCOLTA, GOTVANDT	
GALLO, E.: vide RIZZO, G.	

GARDIN, S. R.; SHUK, M. A. and BERENSON, E. F.: Effect of Lysolecithin on Bovine Erythrocyte Osmotic Fragility	106
GAVERDO, SLAVA: vide SEIDENBERG, A.	
GÖFFERT H.: vide BOROVICKOV K. G.	
GRAMLICH, F. und KIRCHHOFF F.: Der Einfluss dysproteinaemischer Seren auf die Resistenz normaler Erythrocyten	296
GYPFAK, E. vide MALAMOUR, B.	
HAGT J. and BARAKDA, N. F.: Quantitative Study of the Hemopoietic Recovery after a Sublethal X-Irradiation in the Mouse	347
HAIDMANN K., KÖRZ, R., SONNENBERG, O. W.; BARTHEL, H. and HEDERICH, H. C.: Inter-Relations between Iron Stores, General Factors and Intestinal Iron Absorption	193
HEIDENBERG, R.: vide MARKKANT, T.	
HEDERICH, H. C.: vide HAIDMANN, K.	
HILL, H. vide BOROVICKOV K. G.	
HUDSON, G. vide KAUL, M.	
HUNTER, W.; PERDOW, E., ZOGELDOW, B. und UFF, N.: Panmyelophthie und Virushepatitis. Experimentelle Untersuchungen mit dem Affenhepatitis-Virus MHV	336
ILSENER, H.: vide DES GOUTTES, D.	
JEDROCKY H. J.: vide BOROVICKOV K. G.	
JOHNSON, D. M. vide RABY P. G.	
KAHANA, D.: vide SEIDENBERG, A.	
KALLONCH-MANGAT, ALON: Megakaryocytes and Platelets in Central Venous and Arterial Blood	550
KAUL, M. and HUDSON, G.: Cell-Degeneration Pattern in Bone Marrow and Blood of Guinea Pigs Following Administration of Cyclophosphamide	42
KATNO, D. T.: Periodic Acid-Schiff Reaction in Human Basophilic Leucocytes	269
KEMM-ELLIS, M. vide MALAMOUR, B.	
KHAN, M. H. and MARTIN, H.: Presence of Two Ph1 Chromosomes in Cells with 49 Clone from Patient in Blast Crisis of Granulocytic Leukaemia	357
KINDLERER, JUDITH L. vide RANBAR, S.	
KIRCHHOFF F.: vide GRAMLICH, F.	
KÖRZ, R.: vide HAIDMANN, K.	
LECHNER, K., MOHR, K., STOCKSBERG, L., BRUNCK, K. und WENZEL, E.: May-Hegglin'sche Anomalie. Beschreibung einer neuen Familie und Untersuchungen zur Funktion, Biochemie und Ultrastruktur der Thrombocyten	303
LEIBETTER, R. B. and DEL PURO, EMILIO: Severe Megaloblastic Anemia Due to Nutritional Vitamin B ¹² Deficiency	247
LEIDER, L.-D.: A Case of Acute Leukemia with Pseudo-Pelger Cells Containing Auer Bodies	58
LEE, MAUREEN B., BOLOTO, C., DINGER and BAIDERS, J. M.: Distribution of Amlao	

Contents

Acids in Urine, Plasma, Leucocytes and Erythrocytes of Leukaemic and Normal Subjects	86
LEE, D. vide BELL, T. K.	
LEFOMAN, H.; vide RAHMAN, S.	
MAGRULO, E. vide RONDANELLI, E. G.	
MALAMOS, B. CONSTANTOULAKIS, M.; GYFEAKI, E. KIRK ELIAS, M. and ADDOU-STAKI, O. Urinary and Faecal Iron Excretion in Thalassemia	321
MARKERAKIS, T.; HEDTVERING, R. and DAVIL, M. Transketolase Activity of Red Blood Cells from Infancy to Old Age	148
MARTIN, H. vide KIRK, M. H.	
MATTHEI, K.; vide RUDOL, J. R.	
MAYER, G. NOËL, GENEVIEVE et WATTE, R. Le rôle des inhibiteurs faibles du facteur VIII	27
MAZZA, U. vide RUCCO, G.	
MORSE, K. vide LEBERER, K.	
MÜLLER, D. Zytologische Untersuchungen zur Diagnostik und Ätiologie der Erythroblastikose	208
NAKATANI, T. Ultrastructural Localization of Alkaline Phosphatase in Human Neutrophils	275
NOËL, GENEVIEVE; vide MAYER, G.	
OOSTON, D. vide DAWSON, A. A.	
ÖZSOYLU, S. vide YAMAK, B.	
PERA, C. E. vide ZAWADZKI, Z. A.	
PERROW, E. vide HUNTER, W.	
PILLA, G. vide RONDANELLI, E. G.	
POCKERTON, P. H. vide RA P. K.	
PRATO, V. vide RUCCO, G.	
RACCOLOIA, GUYANON FREDCH, A. and ZARAFONETH, C. J. D. Absorption and Excretion of Cyanocobalamin after Oral Administration of Large Dose in Various Conditions	1
RACHOWLEWITZ, E. A. vide ZLOTNICK, A.	
RAHMAN, S. KINDERLEIKER, JUDITH L. and LEBMAN, H. Haemoglobin L Perden Gln 437 (E6) Glycine → Arginine	169
RAND, L. vide RUDOL, J. R.	
RA P. K. and POCKERTON, P. H. Leucocyte Alkaline Phosphatase. The Effect of Age and Sex	18
RUCCO, G.; GALLO, E.; MAZZA, U.; BRANCO, G. and PRATO, V. The Starch Gel Quantitative Electrophoresis of Haemoglobin as Screening in the Thalassemia Syndromes	99
RUBY, P. G. and JOHNSON, D. M. Suppression by RNA of Human Lymphocyte Transformation	94
RONDANELLI, E. G.; MAGRULO, E.; PILLA, G. FALONI, F. and BAREGGATI, G. M. Chronology of the Mitotic Cycle of Acute Leukemia Cells	76

Contents

ROZENBLAYN, L. and FISHER, DONALD: Enzymatic and Chemical Changes in Human Lymphocyte Cultures	138
RUBIN, J. R., MAYNIE, K. and RAKE, L.: Blood Prothrombocytes in Human and Animal Malaria	129
SCHULTE WEIDEMANN, H. vide BOROVICKÝ, K. G.	
SEARIN, W.: vide ZLOTNICK, A.	
SEIZ, M. A. vide GARFEN, S. R.	
SCHODDERO, O. W. vide HADIMANN, K.	
STOCKINGER, L. vide LECHNER, K.	
SEIDENBERG, A., KAHANA, D., GAVIYEDO, SEAVA ZARIMAN, J. and BEN-ELZER, JUDITH: Hereditary Deficiency of Adenylate Kinase in Red Blood Cells	111
THORP, J.: Lymphopoiesis	23
UHL, N. vide HUGSTEN, W.	
WATZ, R. vide MAYER, G.	
WENZEL, E. vide LECHNER, K.	
YAMAR, B. and ÖZBOYLU S.: Haptoglobins in Thalassemia	176
ZARIMAN, J. vide SEIDENBERG, A.	
ZARAPONETIS, C. J. D. vide RACCOVILLA, GIOVANNI	
ZAWADZKI, Z. A., PEKA, C. E. and FISHER, E. R.: Histiocytic Medullary Reticulosis. Case Report with Electron Microscopic Study	50
ZLOTNICK, A., SEARIN, W. and RACHINSKI, E. A.: Studies in Cryofibrinogenemia	8
LEHRI	127 188 254 361
Necrologium	256, 257
VARIA	64 363
INDEX RECUR AD V OL. 42	368
INDEX ACTURUM AD V OL. 42	373

University of Louisville, School of Medicine, Louisville, Ky. and University of Michigan Medical Center Ann Arbor Mich.

Absorption and Excretion of Cyanocobalamin after Oral Administration of a Large Dose in Various Conditions¹

G. RACCUGLIA, A. FRENCH and C. J. D. ZARAFONETIS

The absorption, retention and excretion of vitamin B₁₂ after oral intake of physiologic amounts have been exhaustively studied. Less well known is the mechanism of absorption after oral intake of large amounts of this substance. The most important difference is that oral intake of large doses results in absorption of the compound even in absence of intrinsic factor. UMOLLY [1] demonstrated that 5,000 µg of crystalline B₁₂ administered orally without intrinsic factor could induce remission of pernicious anemia. Further studies of absorption, excretion and therapeutic response in patients with megaloblastic anemias receiving 1,000 to 5,000 µg of cyanocobalamin *per os* were carried out by CONLEY *et al.* [2], UNGLAUB *et al.* [3] and PITNEY and BEARD [4].

Eliminating the influence of intrinsic factor on vitamin B₁₂ utilization, the changes of serum concentrations of the vitamin immediately following its ingestion reflect the combined abilities of the intestine to absorb the compound and of the liver to retain it. If the renal functions are reasonably preserved, the persistence of the vitamin in circulation after absorption and the magnitude of its urinary excretion are mainly functions related to the serum binding capacity for the compound [5, 6, 7] but its retention is also influenced by the degree of tissue saturation [8].

In view of the above facts it was thought of interest to study the serum levels and urinary excretion of vitamin B₁₂ after the administration of 5,000 µg *per os* to normal individuals and to patients with

gastrointestinal defects, pernicious anemia chronic granulocytic leukemia and chronic lymphocytic leukemia. Abnormalities of tissue saturation and serum binding capacity are known to take place in such conditions [7-9].

Since this simple vitamin B₁₂ tolerance test indicated that agents different from intrinsic factor may be of significance in regulating the uptake of cyanocobalamine, further investigation of the mechanism of intestinal absorption of physiologic quantities of vitamin B₁₂ was carried out in normal individuals and patients suffering from chronic granulocytic leukemia who manifested increased serum avidity for vitamin B₁₂.

Materials and Methods

Vitamin B₁₂ was assayed with the microbiological method of HUTNER *et al.* [10] using the Z strain of *Escherichia gracilis*. Para-aminobenzoic acid was constantly added to the culture medium.

Collection of specimens was carried out in vitamin free, sterile glassware. Urine specimens were collected without addition of preservative, but the single samples were refrigerated immediately after voiding. The urine specimens were pooled in 24 hour batches, the volume excreted in this period was measured and an aliquot stored at -20°C until the time of assay. Venous blood was collected with the same precautions for sterility and contamination of vitamin B₁₂. The patient specimens were allowed to clot at room temperature and the serum separated and stored at -20°C until the time of assay.

The test dose of 3,000 µg of cyanocobalamine was administered to the fasting subject early in the morning, after samples of urine and blood for determination of baseline values had been collected for at least 1 full 24 hour period. Blood samples were subsequently obtained 2, 4, 6, 24 and 48 h after the ingestion of vitamin. Breakfast was allowed 2 1/2 h following ingestion of the test dose and meals were given without restrictions thereafter.

Fecal excretion of vitamin B₁₂ was studied by administering 0.5 µc of ⁵⁷Co cyanocobalamine, using the commercial material (Abbott) given for the performance of the SCHILLING test. Stools were collected for 6 days following the administration of the test dose, diluted, homogenized in a Waring blender and pooled. The radioactivity contained in an aliquot was measured and the excretion of the compound calculated as percentage of the dose administered.

The tolerance test was performed in 14 normal individuals, 3 patients with untreated and 4 with treated pernicious anemia, 6 patients with untreated and 3 with treated chronic granulocytic leukemia, 3 patients with chronic lymphocytic leukemia, 7 patients with non-tropical sprue, 6 patients with postgastrectomy status. Normal volunteers were medical students and hospital personnel. Eleven were white and 3 were Negro. Their ages ranged between 25 and 57 years. Six were females and 8 were males. The patients with untreated pernicious anemia were diagnosed on the basis of the usual clinical, hematologic and therapeutic criteria. SCHILLING tests were performed in all of these patients after completion of the studies to confirm the diagnosis. The patients with pernicious anemia in remission had

SCHILLING test done at least 2 years previous to the study. Their therapy consisted of 50 µg of cyanocobalamine every 15 days and the last dose had been administered 2 weeks before the test. The diagnosis of non-tropical sprue with intestinal malabsorption was made on the

basis of clinical evaluation, small bowel biopsy, glucose tolerance test, stool fat, stool nitrogen and the vitamin A absorption test. These patients were on no therapy and SCHILLING tests were delayed until the completion of the vitamin B₁₂ tolerance test. Gastrectomized patients had either total or sub-total gastrectomy for various primary clinical conditions. The patients were asymptomatic at the time of the test. Patients with active chronic granulocytic leukemia and chronic lymphocytic leukemia had either never been treated or had relapsed after interruption of therapy. Patients with chronic granulocytic leukemia in remission had been treated with busulfan but received no therapy at the time of the test.

Statistical evaluation was carried out by computer center. The significance of differences between normal serum and urinary values and values obtained in patients was calculated by variance analysis⁸

Results

Table I shows the means of the vitamin B₁₂ determinations in the normal and patients serum before administration of vitamin B₁₂ and at 2, 4, 6, 24 and 48 h following the administration of the compound. Total excretion of vitamin B₁₂ in the urine during the 24 h preceding the test and in the following two 24 hour periods is also indicated.

The retention of vitamin B₁₂ when a physiologic quantity was given was estimated in 4 normal individuals and 5 patients with chronic granulocytic leukemia in relapse by calculating the fecal excretion of labelled cyanocobalamine described in 'Materials and Methods'. These subjects had not undergone the tolerance test and received only approximately 0.5-1 µg of the vitamin, the quantity contained in the dose used in the performance of the SCHILLING test. Four normal subjects retained respectively 93, 82, 40 and 71% (mean 71.5%) of the administered radioactive compound. Five patients with chronic granulocytic leukemia retained 26, 0, 14, 16 and 10% (mean 13.2%) of the same dose of ⁵⁷Co cyanocobalamine given. The difference was statistically significant at the 0.01 level.

A balance study was carried out in a healthy individual who received 3 000 µg of cold vitamin B₁₂ by mouth to which 1 µg of labelled ⁵⁷Co cyanocobalamine was added. Stools and urine collection and analysis were then carried out as described for the retention of 'physiologic' quantities. The fecal excretion of vitamin B₁₂ in 6 day pooled collection was 2.64×10^6 ng (88% of the given dose). The urinary excretion was 195 ng (<0.01%). The retention was therefore 12% of which less than 0.1% (1 150 ng) could be accounted for by the plasma level at the highest peak attained.

Dr RONALD KIRBY of Louisville Computer Service kindly performed this analysis.

Discussion

The results of this study suggest that the pattern of absorption and excretion of vitamin B₁₂ following the ingestion of a large dose of the substance in normal subjects, consists in a modest increase of serum levels followed by an increment of urinary concentrations. Within 48 h both serum and urinary concentrations return to pre-test values. The balance study shows that 88 % of the orally administered 3 000 µg of the substance is recovered in the stools. Urinary excretion is only a minimal fraction of the substance unaccounted for by fecal excretion. The retained vitamin is also unaccounted for by plasma content at the highest levels observed. The substance, therefore, must be retained by tissues.

In the case of chronic granulocytic leukemia in relapse however the plasma retention is much greater and longer in duration. Correspondingly the urinary excretion is substantially less than normal. Hematologic improvement consequent to anti-leukemic therapy is associated with a marked decrease of plasma retention of vitamin B₁₂ [6-7]. In view of these facts the B₁₂ metabolic pattern in chronic granulocytic leukemia is one of 'high plasma avidity for that compound'.

In patients with chronic lymphocytic leukemia circulating vitamin B₁₂ reached levels which are lower than normal and urinary excretion was less than in normal subjects. This suggests decreased intestinal absorption of vitamin perhaps related to the lower binding capacity of plasma for vitamin B₁₂ which these patients manifest [7]. The metabolic pattern of these individuals is one of 'low plasma avidity'.

In pernicious anemia in relapse the plasma increment is very substantial, the return of plasma levels to low values is rapid, and the urinary excretion after absorption modest. This suggests rapid retention of the vitamin by tissues. The metabolic pattern of these patients is one of 'high tissue avidity'. Patients with treated pernicious anemia, in contrast, manifest modest plasma increments and urinary excretion twice the normal and three times that of patients in relapse. The metabolic pattern is that which can be expected in case of 'low tissue avidity' in these patients receiving vitamin B₁₂ parenterally in large quantities.

Patients suffering with intestinal malabsorption manifest a pattern similar to that of pernicious anemia in relapse but exaggerated,

Table 1 Mean serum and urinary Haman B₁₂ levels before and after oral dose of 3,000 µg

Type of patients	No. of patients	Serum (ln µg/ml)		Urine (ln mg/24 h)					Significance of difference of curves from normal (ln %)		
		Before	After	2 h	4 h	6 h	24 h	48 h		Before	After
Normal	14	470 (SD 223)	748 (SD 311)	783 (SD 300)	722 (SP 334)	580 (SD 272)	501 (SD 191)	120 (SD 77)	368 (SD 199)	178 (SD 150)	
Peridontal anemia in relapse	3	97	573	500	402	317	178	57	284	50	0.1 N.S.
Peridontal anemia in remission	4	163	540	492	480	380	312	118	177	80	0.1 N.S.
Postgastricomy	6	418	707	527	835	711	722	41	143	85	0.05
Alkaliocytosis, sprue	7	263	1,314	1,180	923	561	449	59	370	74	0.01
Chronic lymphocytic leukemia untreated	3	231	461	552	515	308	302	72	140	76	0.05
Chronic granulocytic leukemia untreated	6	3,180	7,051	7,362	8,001	7,908	7,148	93	132	101	0.1
Chronic granulocytic leukemia treated	3	2,967	5,767	4,147	3,673	3,025	3,678	191	372	329	0.01

References

1. UNOLLY C. C. Absorption of vitamin B₁₂ in pernicious anemia. Oral administration without source of intrinsic factor. *Brit. med. J.* **41**, 905 (1950).
2. COVLEY L. C.; KREYMAN, J. R.; CHOW B. F.; BARROWS, C. and LANG, C.: Observations on the absorption, utilization and excretion of vitamin B₁₂. *J. Lab. clin. Med.* **57**, III (1951).
3. UNGLACH, W. G.; ROSENTHAL, H. L. and GOLDSMITH, G. A. Studies of vitamin B₁₂ in serum and urine following oral and parenteral administration. *J. Lab. clin. Med.* **42**, 143 (1954).
4. FITZKY W. R. and BEARD, M. F.: Serum and urine concentrations of vitamin B₁₂ following oral administration of the vitamin. *J. clin. Nutr.* **2**, 89 (1954).
5. CROWTHER, E. P.; HENDLEY E.; DUNCAN, D. H.; MEYER, L. M.; CURTIS, F. D., Jr.; RICHDS, J. R. and WOLFE, W. Studies on the kinetics of intravenously injected Cobalt 60 labelled vitamin B₁₂ in man. *Haemat. lat.* **2**, 263 (1959).
6. MEYER, L. M. Studies on serum binding of vitamin B₁₂. Mechanism and clinical implications. *Series haemat.* **3**, 91 (1963).
7. RACCOLTA, G. and SACKS, M. S. Vitamin B₁₂ binding capacity of normal and leukemic sera. *J. Lab. clin. Med.* **50**, 69 (1957).
8. ESTRADA, S. C.; LANG, C. A. and CHOW B. C.: The application of vitamin B₁₂ tolerance tests to American and Mexican subjects. *J. Lab. clin. Med.* **42**, 406 (1954).
9. FITZKY W. R.; BEARD, M. F. and VAN LOON, E. J. Observations on the bound form of vitamin B₁₂ in human serum. *J. biol. Chem.* **207**, 143 (1954).
10. HUTNER, S. H.; BACH, M. K. and ROSE, G. I. M. A sugar-containing basal medium for vitamin B₁₂-assay with *Escherichia*. Application to body fluids. *J. Protocool.* **3**, 101 (1956).

Departments of Medicine A and B, Hadassah University Hospital and Medical School,
Jerusalem

Studies in Cryofibrinogenemia¹

A. ZLOTNICK, W. SHAIKH² and E. A. RACHMILEWITZ

A cold-precipitable protein was first described in a case of multiple myeloma by WENTROBE and BUELL in 1933 [1] and named cryoglobulin by LERNER and WATSON in 1947 [2]. The cryoglobulins are mostly γ G (7 S) globulins or γ M (19 S) globulins, which precipitate upon cooling of the serum. In 1956 HORST and KRATOCHVIL [3] observed in a patient with carcinoma of the lung associated with thrombophlebitis migrans, a protein which precipitated on cooling of the plasma but not of the serum. They called this protein cryofibrinogen. Cryofibrinogenemia was found to be associated with acute infections [4], metastatic carcinoma, leukemia [5] and pregnancy [6]. Essential cryofibrinogenemia, in which no underlying disease is present, is apparently rare, as only a few cases have been reported [7, 8, 9].

The purpose of the present study was to determine the incidence of cryofibrinogenemia in patients with a highly increased sedimentation rate, and to compare the composition of the cryoprecipitate of heparinized and oxalated plasmas, using immunochemical methods. This study reports the finding of a cryofibrinogen in 71 patients and of a cryoglobulin in 9 patients out of a total of 89 patients with an increased sedimentation rate examined consecutively. The splitting of the fibrinogen molecule into two fractions having different mobilities, as was observed with the oxalated cryoprecipitate in a previous work [10] did not occur in the cryoprecipitate obtained from heparinized plasma. Evidence is presented that plasmin splits the fibrinogen in the cryoprecipitate obtained from oxalated plasma.

This work has been supported in part by grant from the Israel Cancer Association. Part of this work was submitted as an M.D. thesis.

Material and Methods

Eighty-nine patients with an increased sedimentation rate ranging from 45 to 99 mm in the first hour and 100 to 165 mm in the second hour were the subjects of this study. Twenty-two medical students and interns with a normal sedimentation rate (mean \pm 16 mm) served as controls.

Blood was collected from an antecubital vein, and 10 ml were put into each of 4 test tubes. The first did not contain any anticoagulant, the second contained 1 mg heparin, the third 2 mg heparin and the fourth 70 mg of dry ammonium-potassium oxalate. The serum, heparinized and oxalated plasmas obtained were left for 48 h at 4°C. The cryoprecipitate was separated from the supernatant by centrifugation in refrigerated centrifuge at 4,000 rpm for 20 min and washed twice in cold buffered saline, pH 7.4. It was resuspended in 1.2 ml of saline and dissolved by incubating for 12 h at 37°C.

Total serum protein was determined by WUNDERLICH method [11]. Fibrinogen was determined in the oxalated plasma, in the redissolved cryoprecipitate and in the supernatant plasma according to RATHOFF and MENDEL [12].

Paper electrophoresis of the serum, plasma, and of the cryoprecipitate was performed with Spino model R apparatus using citrate buffer pH 8.6, ionic strength 0.1. The strips were heat fixed and stained by azaleo B, black and were scanned in Spino Analytrol.

Immunoelectrophoresis was performed with the macro-apparatus of SCHWIMMER [13] using 25-75 mm microscope slides. A 2 percent agar solution in sodium barbital buffer pH 8.2, ionic strength 0.04 was used as medium for electrophoretic separation.

Antisera Three different antisera were used: 1. Hyland JEP horse anti-human total antiserum lot No. 3803. This antiserum was found to contain antibodies also to fibrinogen. 2. Rabbit anti-human fibrinogen serum, Hyland RP 4-760. 3. Rabbit anti-cryofibrinogen serum, obtained by immunizing rabbits with the dissolved oxalated cryoprecipitate of patient with cryofibrinogenemia. Four injections of 10 mg each of cryoprecipitate protein, incorporated in complete Freund's adjuvant, were given subcutaneously to 4 rabbits at weekly intervals. Ten days after the last injection, the animals were bled and their serum was absorbed with different amounts of normal human serum, until monovalent anti-cryofibrinogen serum was obtained.

Results

Table I indicates that out of 89 patients with an increased sedimentation rate, 71 had a cryoprecipitate in the plasma only 9 had it both in the serum and the plasma and 9 did not show any cryoprecipitate. The first group was considered to have cryofibrinogenemia and the second, cryoglobulinemia. Eight patients in the first group and 5 in the second showed signs and symptoms which could be attributed to the presence of a cryoprecipitate. These were cutis marmorata, RAYNAUD's phenomena, acrocyanosis, skin hemorrhages or necrosis of the extremities. Table II shows the different diseases in which cryoprecipitates were found in the plasma.

The present study deals with the cases of cryofibrinogenemia only the cases of cryoglobulinemia will be reported subsequently Table III

Table I Incidence of cold-precipitable proteins among patients with raised sedimentation rate

	No. of patients	Asymptomatic	Symptomatic ¹
Cryofibrinogenemia	71	63	8
Cryoglobulinemia	9	5	4
Without cryoprecipitate	9	—	—
Total	89	68	13

¹ Caris marionata, Raynaud phenomena, acrocyanosis, necrosis of extremities, hemorrhages.

Table II Association of cryofibrinogenemia with various disorders

	Total No.	Symptomatic
Essential	3	3
Infection	17	
Metastatic carcinoma	14	1
Macroglobulinemia of WALDENSTROM	2	
Chronic lymphatic leukemia with macroglobulinemia	1	
Hodgkin disease	2	
Myocardial infarction	4	1
Collagen disease	11	3
Miscellaneous ¹	17	
Total	71	8

¹ Familial mediterranean fever, amyloidosis, thyroiditis, bone fracture, diabetes mellitus.

shows the sedimentation rate, the fibrinogen level, the serum globulins and the protein content of the cryoprecipitate of 60 patients with cryofibrinogenemia, and of 22 normal control subjects. In the controls, who had a normal sedimentation rate, no cryoprecipitate was observed in the oxalated plasmas and in the plasmas which contained 2 mg/ml of heparin. Only unmeasurable traces of a cryoprecipitate were seen in the plasmas which contained 1 mg/ml of heparin. The concentrations of serum proteins and of the plasma fibrinogen were within normal limits.

Table III Sedimentation rate (1/2 h) fibrinogen level, serum globulin and protein content of the cryoprecipitate in patients with cryoglobulinemia

Group	No. of cases	Sedimentation rate, mm	Fibrinogen mg%	α_2 -Globulin g% TP	γ -Globulin g% TP	Pp osalate mg%	Pp heparin I mg%	Pp heparin II mg%
A	56	M	680 \pm 207	1.19 \pm 0.23	1.75 \pm 0.35	101 \pm 71	228 \pm 109	172 \pm 93
		R	(429-1100)	(0.76-1.89)	(0.79-2.84)	(18-267)	(42-150)	(31-399)
	8	M	354 \pm 53	1.14 \pm 0.18	1.71 \pm 0.61	70 \pm 27	145 \pm 33	80 \pm 27
		R	(264-396)	(0.81-1.45)	(0.81-2.59)	(36-128)	(100-195)	(50-151)
B	10	M	583 \pm 115	1.11 \pm 0.22	1.85 \pm 0.32	95 \pm 64	182 \pm 46	127 \pm 91
		R	(410-869)	(0.91-1.36)	(1.22-2.47)	(23-213)	(20-392)	(31-290)
	6	M	327 \pm 68	1.20 \pm 0.23	2.41 \pm 0.54	79 \pm 35	144 \pm 40	102 \pm 31
		R	(209-400)	(0.95-1.55)	(1.01-2.51)	(20-124)	(106-238)	(71-153)
Control	3	M	305	0.63	1.54	0	Trace	0
		R	(200-400)	(0.48-0.89)	(1.40-1.75)			

A = Patients with sedimentation rate above 100
 B = Patients with sedimentation rate below 100
 M = Mean and standard deviation
 R = Ranges of experimental values
 TP = Total protein

Pp osalate = Cryoprecipitate of osalated plasma
 Pp heparin I = Cryoprecipitate of blood containing 0.1 mg% of heparin
 Pp heparin II = Cryoprecipitate of blood containing 0.1 mg% of heparin

The patients with cryofibrinogenemia were divided into two main groups—those with a sedimentation rate of above and below 100 mm (groups A and B respectively) in the second hour. In 8 out of 44 patients in group A, the plasma fibrinogen level was within normal limits, in the remaining 36, the plasma fibrinogen was elevated. A cryoprecipitate was found in both of these subgroups. There was no correlation between the fibrinogen level of the plasma or the concentration of the serum proteins and the amount of the protein in the plasma cryoprecipitates. Sometimes patients with a high plasma fibrinogen showed less cryofibrinogen than patients with a normal plasma fibrinogen. In all of the cases, the heparinized plasma cryoprecipitate had a higher protein content than the oxalated plasma cryoprecipitate. However, an increase of the heparin in the plasma from 0.1 to 0.2 mg/ml caused




Fig. 1. Immunoelectrophoretic pattern of the plasma (central well) and the heparinized cryoprecipitate (outer wells) run against a polyvalent antiserum (lower trough) and an antifibrinogen serum (upper trough). Note the normal position of the fibrinogen arc.

Fig. 2. The same patient and the same arrangement as in figure 1 except that the outer wells contain the oxalated cryoprecipitate. Note the double curvature of the fibrinogen arc.



Fig 3. Immunoelectrophoretic pattern of cryoprecipitate obtained from oxalated plasma, run against an antifibrinogen serum (upper trough) and polyvalent antiserum (lower trough). Note the two fibrinogen arcs and the presence of other proteins in the cryoprecipitate.




Fig 4. Immunoelectrophoretic tracing of heparinized cryoprecipitate with epsilon aminocaproic acid (lower well) and without it (upper well) run against an antifibrinogen serum.

Fig 5. The same arrangement as in figure 4, except that the cryoprecipitate was obtained from oxalated plasma. Note the change in mobility of the fibrinogen arc of the cryoprecipitate without epsilon aminocaproic acid.

a diminution of the cryoprecipitate. Similar results were obtained with 16 patients with cryofibrinogenemia whose sedimentation rate was below 100 mm for the second hour (group B)

Immunoelectrophoresis (IEP) was performed on plasma and on redissolved oxalated - and heparinized - plasma cryoprecipitates (fig 1 and 2). In both oxalated and heparinized plasmas the fibrinogen appeared as a single band near the antigen well. However in the cryoprecipitates there was a difference: whereas in heparinized cryoprecipitates the fibrinogen appeared also as a single precipitin band (fig 1) it appeared in oxalated cryoprecipitates either as a double curved band (fig 2) or as two bands of different mobilities (fig 3). In some instances, the fibrinogen appeared as a single band but its mobility differed from that of normal fibrinogen. The dissolved plasma cryoprecipitate run against a polyvalent antiserum showed that besides the cryofibrinogen other proteins were also present in the cryoprecipitates (fig 1, 2, 3). The form or intensity of the fibrinogen band of plasma or of the cryoprecipitates did not differ when the antifibrinogen antiserum was substituted for the commercial antifibrinogen antiserum.

When epsilon aminocaproic acid (EACA) in a concentration of 50 mg was added to heparinized or oxalated plasma the formation of a cryoprecipitate was not inhibited. When these cryoprecipitates were dissolved and examined by immunoelectrophoresis against a monovalent antifibrinogen antiserum, there was no difference in form or mobility of the cryofibrinogens in the cryoprecipitate from heparinized plasma either with or without EACA (fig 4). However IEP of the oxalated plasma cryoprecipitate to which EACA was added did not show the splitting or any change in mobility of the fibrinogen precipitin arc as seen in the oxalated plasma cryoprecipitate which had formed without EACA (fig 5). IEP revealed more precipitation bands in the heparin cryoprecipitate than in the oxalate cryoprecipitate.

Discussion

The present study indicates that cryofibrinogenemia occurs more frequently than cryoglobulinemia. Whereas cryoglobulinemia is mainly associated with lymphoproliferative disorders, cryofibrinogenemia is mostly associated with processes of tissue destruction such as acute infections, metastatic carcinoma, myocardial infarction and pregnancy though it can also be found in macroglobulinemia and collagen disorders reputed for the proliferation of their lympho-plasma cellular series.

It is apparent that there is no correlation between the plasma fibrinogen level and the amount of cryoprecipitate formed for the plasmas of some patients with normal fibrinogen levels showed heavier cryoprecipitates than those of other patients with increased fibrinogen levels. A similar observation was reported by McKEE *et al.* [5] who found cryofibrinogens at all ranges of plasma fibrinogen levels in 22 out of their 665 hospitalized patients. The only possible deduction from our results is that the higher the sedimentation rate the heavier is the plasma cryoprecipitate.

In all our cases the cryoprecipitate of the heparinized plasma was heavier than that of the oxalated plasma. IEP of these cryoprecipitates showed more precipitation bands in the heparin-cryoprecipitate than in the oxalate-cryoprecipitate. SWAN *et al.* [4] showed that cryofibrinogen occurs more frequently and in higher concentrations when heparin is used as an anticoagulant. Their optimal concentration was 0.1 to 0.15 mg/ml of heparin. We confirmed this observation, for when the heparin concentration was increased from 0.1 to 0.2 mg/ml, the amount of cryoprecipitate diminished.

In a previous publication [10] we reported that the fibrinogen precipitation band obtained by immunoelectrophoresis of the dissolved cryoprecipitate formed from oxalated plasma was split into two arcs of different mobilities, whereas the fibrinogen in oxalated plasma incubated at 37°C for an identical period showed a single precipitin arc near the antigen well. In the present work it has been shown that the fibrinogen band of the dissolved cryoprecipitate formed from heparinized plasma did not split and remained at the same place as the plasma fibrinogen. Since heparin is known to inhibit the transformation of plasminogen into plasmin [14] it was assumed that the splitting of the fibrinogen in the oxalate-cryoprecipitate was due to plasmin activity. This hypothesis was tested by adding epsilon aminocaproic acid to oxalated plasma to inhibit plasmin activity. When IEP was performed with the dissolved cryoprecipitate from EACA-treated plasma, the fibrinogen band was not split. This provided evidence suggesting that the splitting was due to plasmin activity in the cryoprecipitate.

The mechanism of the precipitation of the cryofibrinogen was not elucidated in this study. Though the cryoprecipitate was washed thoroughly it still contained other proteins besides the fibrinogen. The role of these proteins in the cryoprecipitation process is not clear. Whether they are an active factor in the process or whether they

coprecipitate passively with the fibrinogen remains to be established. The fact that an identical precipitation reaction was obtained with the asparagofibrinogen serum and with the antinormal fibrinogen acting against the fibrinogen in the cryoprecipitate, indicates that the cryoprecipitation did not change the antigenicity of the fibrinogen. Thus if there is a structural change in the fibrinogen molecule on precipitation in the cold, it cannot be detected by immunochemical methods.

Cryofibrinogenemia is sometimes associated with thrombohemorrhagic and Raynaud-like phenomena. In some cases [15] it was shown that the cryofibrinogen formed complexes with clotting factors, thus explaining the hemorrhagic phenomena. Since cryofibrinogenemia is associated with processes of tissue destruction, we may assume that the blood of these patients contains intracellular enzymes, some of which have a proteolytic activity and produce vasoactive polypeptides, which may cause the Raynaud like phenomena.

Summary

In 8 patients with increased sedimentation rates cryofibrinogen was found in 1 and cryoglobulin in 9. In the derived cryofibrinogen only plasma proteins were also present. Immunoelectrophoresis of the derived cryoprecipitate obtained from heparinized plasma showed a single precipitation band, but two bands were observed when the cryoprecipitate had been obtained from oxalated plasma. The splitting was caused by the action of plasmin on fibrinogen, because it could be prevented by heparin and by epsilon aminocaproic acid. It is suggested that cryofibrinogenemia is associated with processes that liberate intracellular enzymes.

References

- 1 WEISSMAN, M. M. and BRILL, M. I. Hypertension associated with multiple cryoglobulins, with report of a case in which an extraordinary hypertension was associated with peripheral vascular disease and symptoms suggesting Raynaud's disease. *J. Clin. Hosp.* 21: 18, 1963.
- 2 LARSEN, A. B. and WILSON, C. J. Studies of cryoglobulins. I. renal purpura associated with the presence of high concentration of cryoglobulin. *Amst. J. int. Sci.* 21: 410, 1964.
- 3 JARVIS, D. R. and KATZMAN, L. H. Cryofibrinogen in case of late congenital asplenia. *J. cryofibrinogenemia* abstract. *Kend.* 1: 54, 1967.
- 4 SERRA, P. T. and VAN KOTTEN, P. W. I. Heparin-precipitable fraction of human plasma. I. Isolation and characterization of the fraction. *J. Clin. Invest.* 39: 58, 1967.
- 5 MULLER, H. A., FERNANDEZ, J. M. and BASS, P. M. Incidence and significance of cryofibrinogenemia. *J. Lab. Clin. Med.* 61: 693, 1963.

6. GLECK, H. and HARM, V. L. G. Cold precipitable fibrinogen and cryofibrinogen. *Arch. intern. Med.* 113, 748-57 (1964).
7. KESSEL, J. A. Essentielle Kryofibrinogenämie. *Verh. dtsch. Ges. inn. Med.* 66, 732 (1960).
8. RITENOUR, S. E.; LEVIN, W. C.; IVERS, J. B. and KUCH, J. L. I. Cryoproteinemia. 2. Primary cryofibrinogenemia, its association with cryopathy and telangiectasia. *Texas Rep. Biol. Med.* 21, 566 (1963).
9. HAMMACK, W. J., CAMPBELL, M. L. and FROMMETER, J. R.: Idiopathic (essential) cryofibrinogenemia. *Texas Rep. Biol. Med.* 21, 339 (1963).
10. ZLOTNICK, A. and LAXDAU, S.: Immunoelectrophoretic studies in patients with cryofibrinogenemia. *J. Lab. clin. Med.* 68, 70 (1966).
11. WEICHELBAUM, T. E.: An accurate and rapid method for the determination of protein in small amounts of blood serum and plasma. *Amer. J. clin. Path.* 19, 40 (1946).
12. RATHOFF, O. D. and MIEDE, C.: New method for determination of fibrinogen in small samples of plasma. *J. Lab. clin. Med.* 37, 316 (1951).
13. SCHLESINGER, J. J.: Une micro-méthode de Plasmino-electrophorèse. *Int. Arch. Allergy* 7, 103 (1953).
14. NISSEN, I. M., BELAWIEC, M. and BJÖRKMAN, S. E.: The effect of heparin in fibrinolytic activations and plasmin. *Scand. J. Haemat.* 1, 73 (1964).
15. KALAFLEKIS, J. M. and BRAD, R. M.: Cryofibrinogenemia. *New Engl. J. Med.* 273, 881 (1966).

Department of Laboratory Haematology University of Toronto Clinic, Sunnybrook
Hospital, Toronto

Leukocyte Alkaline Phosphatase

The Effect of Age and Sex

P. K. RAY and P. H. PINKERTON

The histochemical assessment of leukocyte (neutrophil) alkaline phosphatase (LAP) activity has been used for some time in the laboratory diagnosis of myeloproliferative disease. Low levels of enzyme activity are characteristically found in chronic myeloid leukaemia and in myeloblastic leukaemia in relapse; normal or elevated levels are generally found in association with other leukaemias, leukaemoid reactions, polycythaemia vera and reactive leukocytosis [1-9].

Fluctuations in LAP activity are seen during the menstrual cycle [10, 11] and both pregnancy and the use of oral contraceptives raise the LAP level [10, 12-16]. Using an enzyme assay method, ROBERTS and LEE [17] demonstrated differences in LAP activity between males and females, and between pre menopausal and post menopausal females. Employing a histochemical assessment of LAP activity we have noted similar differences between males and females and have also observed a significant decrease in LAP activity with ageing in both sexes.

Materials and Methods

59 males and 27 females, aged between 15 and 95 years were studied. The majority were blood donors. The remainder were healthy hospital employees, convalescent patients recovering from fractures and orthopaedic procedures, but otherwise well patients in chronic care wards and attending a geriatric clinic, but believed not to be suffering from neoplastic or inflammatory disorders. All showed morphologically normal blood smears. None of the female subjects admitted to being pregnant at the time of study and it is not known how many were taking oral contraceptives.

The staining technique was modified from that of HAYDON *et al.* [18]; blood films were exposed to substrate at 37°C for 40 min, instead of incubating at room temperature for 8–10 min. The smears were washed, counterstained with 0.5% methyl green, rinsed, mounted and scored according to standard criteria [18]. In most instances 100 cells, and, in the remainder 50 cells were scored, and the results expressed as total LAP score per 100 neutrophils; the LAP score may thus lie between zero and 400.

Results

The results are presented in figure 1. The LAP score is significantly higher in females than in males up to the age of 50 years; thereafter there is no significant difference between the sexes.

Statistical analysis of the age changes in LAP score shows a highly significant decline in enzyme activity after the 7th decade in men ($p < 0.001$) and after the sixth decade in women ($p < 0.001$). The fall in LAP activity after the age of 60 years is somewhat sharper in women than in men. Significantly lower LAP scores are found in youths in the




Fig 1 The changes in the mean leucocyte alkaline phosphatase score (LAP score) with age and sex. Stippled columns represent females and the closed columns, males. All subjects in the second decade (11–20 years) were 15 years of age or over. When the LAP scores for males and females are compared for the second to fifth decades, the differences are significant (second to fourth decades, $p < 0.001$; fifth decade $p < 0.005$). Thereafter, no significant difference is seen between the sexes ($p > 0.5$).

second decade than in men in the third to sixth decades ($p < 0.01$). By contrast, females in the second decade show the highest LAP scores.

In some healthy subjects over 70 years of age, LAP scores in the range 14–20 were found, and in two patients, over 70 years of age, with untreated chronic myeloid leukaemia scores between II and III have been observed. In two other cases of chronic myeloid leukaemia, in a younger group scores between 2 and 14 were found. In spite of the wide range of normal, cases of polycythemia vera (3) disseminated carcinomatous (3) multiple myeloma (6) and reactive neutrophil leucocytosis (8) have all shown high LAP activity with scores in the range 200–300.

DISCUSSION

By the modified technique used here, the normal range for the LAP score tends to be higher than reported previously [4.5, 19–21]. Precipitation of substrate is increased by the more prolonged incubation at 37°C, and it may be that this heavier precipitation has emphasized the differences in LAP score with age and sex, differences which have not hitherto been appreciated.

The changes in LAP activity with the menstrual cycle, pregnancy and the use of oral contraceptives (as mentioned above) and the increase in LAP activity produced by pituitary and adrenal hormones in man [22] and by oestrogens, progesterones and testosterone in experimental animals [23] imply that hormonal factors influence the LAP. The variations with age and sex in LAP score reported here confirm the differences previously described employing an enzyme assay technique [17] and are in keeping with the hypothesis that the level of LAP activity is at least partly controlled by the sex hormones. The prevalence of oral contraception among the women studied here is not known. However it seems unlikely that these agents alone would be responsible for the difference observed between the sexes in the younger age groups (i.e. under 50 years) and especially in the 20 years and under group where the sex difference in LAP score is most obvious.

Levels of LAP activity have long been known to be low in chronic myeloid leukaemia [1, 2, 4–6] and the LAP score is occasionally employed in the laboratory diagnosis of this disorder particularly in atypical cases where diagnosis is difficult. This study indicates that a

low LAP score may be a manifestation of ageing and caution should be exercised in the interpretation of the result of this investigation in the elderly.

Authors' acknowledgements. We are grateful to Dr E. E. TIERMAN, of the Canadian Red Cross Society Blood Transfusion Service, for his co-operation and to Mr F. LANGRISH of the Department of Art as Applied to Medicine in the University of Toronto for the figure.

Summary

The leukocyte (neutrophil) alkaline phosphatase (LAP) has been determined in 389 males and 227 females, using histochemical method. Activity of this enzyme is significantly higher in females than in males from the second to the fifth decades; thereafter no significant difference is noted. In both the LAP score declines with age, and, in the elderly (over 70 years) overlap with patients of similar age with chronic myeloid leukaemia may be seen. The need for caution in interpreting low LAP scores in suspected chronic myeloid leukaemia in the elderly is stressed.

References

1. WACHSIEDER, M. Alkaline phosphatase activity in normal and abnormal human blood and bone marrow cells. *J. Lab. clin. Med.* 51: 1 (1946).
2. VALENTINE, W. N. and BECK, W. S. Biochemical studies on leucocytes. I. Phosphatase activity in health, leucocytosis and myelocytic leukaemia. *J. Lab. clin. Med.* 58: 29 (1951).
3. BECK, W. S. and VALENTINE, W. N. Biochemical studies on leucocytes. II. Phosphatase activity in chronic lymphatic leukaemia and miscellaneous haematologic conditions. *J. Lab. clin. Med.* 58: 245 (1951).
4. HAYMON, F. O. J. and QUAGLIARO, D. Cytochemical demonstration and measurement of leucocyte alkaline phosphatase activity in normal and pathological states by modified azo-dye coupling technique. *Brit. J. Haemat.* 4: 375 (1956).
5. LEONARD, B. J.; ISMAIL, M. C. G. and WILKINSON, J. F. Alkaline phosphatase in the white cells in leukaemia and leukaemoid reactions. *Lancet* i: 289 (1956).
6. MITTAL, W. J.; BILGORA, L. J.; MEDVEDOFF, I. B. and DAMMECH, W. Alkaline phosphatase of mature neutrophils in chronic forms of the myeloproliferative syndrome. *Amer. J. clin. Path.* 30: 285 (1958).
7. KOLIER, R. D.; SEAMAN, A. J.; OSGOOD, E. E. and VANBELLVORTER, H. Myeloproliferative diseases. Diagnostic value of the leucocyte alkaline phosphatase test. *Amer. J. clin. Path.* 30: 295 (1958).
8. HAYMON, F. O. J. *Leukaemia, research and clinical practice* (Churchill, London 1960).
9. RUTENFELD, A. M.; RONALD, C. L. and BURROTT, J. M. An improved histochemical method for the demonstration of leucocyte alkaline phosphatase activity: clinical application. *J. Lab. clin. Med.* 65: 696 (1965).
10. GORDON, S. and HURTIER, E. Re-evaluation of the leucocyte alkaline phosphatase test. *Med. J. Austr.* 52: 15 (1965).
11. MÜLLER, D. Zur Frage der endokrinen Beeinflussung der alkalischen Leukocyten-phosphatase. *Blut* 16: 273 (1967).

injected into baby mice a marked lymphocytosis was observed the degree of which correlated fairly well with the clinical assessment of the activity of the disorder. The effect reached its maximum intensity after 5 days and disappeared after 14 days. A search was made [2-3] for LSF in a number of other disorders including other forms of leukaemia. It was found only in CLL, lymphosarcoma and myelofibrosis.

Evidence for the presence of a feedback mechanism can be found in the work on LAP rats [1]. LAP treatment of the rats 8 times removed 50% more leucocytes than LAP treatment 6 times. This suggests that the leucocyte depletion had already begun to cause an increased LIF production. A lymphocytosis stimulating substance (LSS) has been found in both mouse and human thymus [4]. Both LSS and LSF have been shown to produce a lymphocytosis in baby mice and at the same time to inhibit LSS production in these mice [4]. This suggests a negative feedback mechanism is controlling LSS production.

Evidence is available from the literature, therefore, that humoral substances can be found in both animals and man which affect the numbers of circulating lymphocytes. For the hypothesis presented here it is necessary to show that lymphopoietin can cause an increase in the rate of mitosis. If the hypothesis is correct the serum of patients with CLL should contain a relatively large amount of lymphopoietin. This has been investigated by adding CLL serum to phytohaemagglutinin (PHA)-stimulated normal human lymphocytes in culture.

Materials and Methods

The CLL serum used was prepared as follows. After diagnosis but before treatment mouse blood was obtained and placed in sterile bottles and allowed to clot. The serum was removed and spun down at 5 000 rpm for 15 min to remove any cells present. The supernatant serum was then kept frozen at -20°C until used.

The cultures were set up as follows. Twenty ml of venous blood was obtained from healthy volunteers and immediately transferred to a sterile bottle containing anticoagulant (heparin or dextran). After allowing the erythrocytes to settle the supernatant plasma and cells were withdrawn. Each culture contained 1.5 ml of plasma and cells. The experimental cultures had 2.0, 1.0, 0.5 or 0.1 ml of CLL serum added. All cultures were made up to final volume of 10 ml with TC 199 culture medium. Experimental cultures were set up both with PHA, two drops of reconstituted PHA per culture and without PHA. All cultures were incubated for 72 h at 37°C at which time 0.2 ml of demecolcine (Colcemid®) at a concentration of 1 mg in 100 ml was added and the cultures were incubated at 37°C for further 6 hours. The cells were then spun down at 1 000 rpm for 10 min, resuspended in 3 ml of hypotonic saline for 15 min at 37°C and then fixed in acetic acid/alcohol (1:3) over-

night. They were then spun down and resuspended in 45% acetic acid, spread onto cold slides, air dried and stained with 10% Giemsa in pH 6.4 buffer. The mitotic index, here defined as the number of mitoses per 1,000 cells was determined by examination of at least 1,000 cells from each culture. The experiment was performed in triplicate.

Results

The average results of the experiments using PHA are given in table I and are expressed in the third column as a percentage of the control value. It will be seen that there was a definite and significant increase in the rate of mitosis in the cultures treated with CLL serum. In the cultures without PHA no transformation of the lymphocytes took place showing that the effect of the CLL serum was on the transformed cells capable of mitosis and that the increase in mitotic rate found was not due to antigenic stimulation of the lymphocytes by CLL serum.

Discussion

The suggestion made here is that LIF LSF LSS and the mitotic stimulator found in CLL serum are all lymphopoietin. It has been shown that humoral substances which increase the rate of lymphocyte production are formed in conditions of leucopenia [1] and are present in cases of lymphocytosis [2-3] and are found in thymus [4]. It is further shown here that at least one of these substances acts as a mitotic stimulator and thus all parts of the hypothesis have some supporting experimental evidence.

Table I. The effect of CLL serum on the mitotic index of normal human PHA-stimulated lymphocytes in culture (average of 3 experiments)

CLL serum per culture, ml	Mitoses per 1,000 cells	Percent of control
0.2	28	373.3
0.5	27	360.0
1.0	16.3	220.0
2.0	10	133.3
0.0	7.5	100.0
(control)		

It need hardly be emphasised that this hypothesis, if correct, raises a number of interesting questions. If, as a number of workers believe, there is more than one population of lymphocytes in the body does lymphopoietin occur in more than one form? Even more important is the question of the site of lymphopoietin production. From the available evidence [4] the thymus seems the most probable and this organ has long been implicated in lymphocyte production. If this hypothesis is supported by further investigations then different approaches to the treatment of lymphoproliferative disorders may become possible.

Acknowledgment. I wish to thank the Smith Kline and French Foundation for financial support.

Summary

Evidence is presented for the hypothesis that a humoral substance, lymphopoietin, which acts by controlling the rate of mitoses in the lymphocyte production pathway controls lymphopoiesis. It is suggested that the amount of lymphopoietin produced in the body possibly in the thymus, is controlled by a negative feedback mechanism and that a lymphocytosis may occur when this feedback mechanism fails.

References

1. GORDON, A. S., VICK, R. O.; SEIGEL, C. D.; DORRITY, B. S.; HAMBUR, E. S.; LORRE, J. and ESKER, M. Evidence for a circulating leucocytosis-inducing factor (LIF) *Acta haematol., Basel* 23: 323 (1960).
2. MITTAL, D. A lymphocytosis stimulating factor in the plasma of chronic lymphatic leukaemic patients. *Brit. J. Cancer* 19: 169 (1956).
3. MITTAL, D. Further studies on the plasma lymphocytosis stimulating factor in chronic lymphatic leukaemia and some other disease states. *Brit. J. Cancer* 19: 431 (1957).
4. MITTAL, D. The thymic origin of the plasma lymphocytosis stimulating factor. *Brit. J. Cancer* 19: 442 (1956).

Institut d'Hématologie, Service des Maladies du Sang et Centre Régional de Transfusion Sanguine de Strasbourg (Prof. R. WARTZ)

Le rôle des inhibiteurs faibles du facteur VIII

G. MAYER, GENEVIEVE NOEL et R. WARTZ

avec l'assistance technique de MARLENE WERNER

Nous avons relevé dans un ensemble de cas cliniques qui nous étaient adressés pour un syndrome hémorragique fruste peu inquiétant, ou pour une simple anomalie de la crase sanguine constatée dans d'autres laboratoires, une activité neutralisante faible mais incontestable du plasma vis-à-vis du facteur VIII. Comme le système des inhibiteurs de la coagulation reste assez mal connu et sa pathologie est plus étendue qu'elle n'apparaît aujourd'hui sur la foi d'exemples frappants mais très rares pour le praticien, nous avons cru utile de publier ces quelques observations. Ce sont des cas de routine qui concernent le plus souvent de petits malades, difficiles à tenir sous une analyse exhaustive et même des bien portants.

Matériels et méthodes

Pour les techniques de routine nous renvoyons aux ouvrages qui les exposent [4, 7]. La consommation de la prothrombine est donnée par la prothrombine résiduelle virale du sérum laissé quatre heures à 37° C. L'effet inhibiteur d'un plasma sur la mixture normale du test de génération de la thromboplastine (TGT) se manifeste lorsque ce plasma sert de substrat dans ce test.

Recherche d'un inhibiteur du facteur VIII. Du plasma citraté est agité deux fois pendant 20 min à la température du laboratoire avec 100 mg/ml de sulfate de baryum jusqu'à l'obtention d'un temps de QUITZ supérieur à 15 min (plasma Ba). Ce plasma Ba citraté que nous utilisons pour le TGT depuis plus de dix ans conserve mieux et plus longtemps son facteur VIII et son facteur V que le plasma Ba oxalaté. Le sérum provient de sang recueilli sur thromboplastine cérébrale humaine et laissé quatre heures à 37° C.

Un volume de plasma Ba à tester non dilué (ou parfois de sérum ou de fraction à tester) est incubé pendant 60 min (initialement 30 min) à 37° C avec 4 volumes d'un pool entier de plasmas Ba normaux, source de facteur VIII. Un autre mélange, où le tampon bicarbol-saline remplace le matériel à tester est mis en route parallèlement. A la fin de

L'incubation les mélanges sont dilués au 1/10^e en imidazol-saline. Le facteur VIII résiduel est déterminé dans le TGT.

Dans ce but nous y avons amené de légers changements de technique et une importante modification de lecture. Dans la mixture le plasma Ba est introduit dilué 1:10 le sérum 1/20. L'étalonnage est fait à 20, 10, 5 et 2,5% de plasma Ba normal dans le plasma Ba hémophile: les valeurs sont reportées sur papier bilogarithmique. Le matériel à tester 1:10 remplace ensuite à 20% dans le plasma Ba hémophile le plasma Ba normal. Son taux de facteur VIII se lit alors aisément sur la courbe d'étalonnage (= valeur lue \times 5).

Le paramètre que nous utilisons est le temps de coagulation minimum (TCm) de chaque mixture testée dans le TGT. Nous ne définissons jamais un point chronologique fixe où tester toutes nos mixtures, par exemple le moment du TCm d'une mixture normale. Au contraire, nous suivons chaque mixture pas à pas jusqu'à ce qu'elle ait passé son TCm. Le TGT est très complexe. Il renferme beaucoup d'éléments certainement très intéressants mais incontrôlés et non maniables. Le TCm seul est un paramètre remarquable. Il est stable, c'est-à-dire qu'il reste toujours dans le même rapport quantitatif avec les TCm des témoins. Il est sensible, car il se modifie proportionnellement aux corrections et de manière à engendrer une ligne droite sur un papier bilogarithmique. Il définit la mixture qui le donne. Par contre le moment où il se produit est très variable selon des circonstances que nous omissions mal. Nous avons bien souvent pu constater que pour un temps d'incubation strictement défini, les TC des diverses mixtures subissent une déviation et ne sont plus vraiment proportionnels entre eux. Aussi ne nous paraient-ils plus caractéristiques et préférons nous au prix d'un travail plus long, déterminer ce TCm qui n'est pas simplement un TC parmi d'autres, le plus faible, mais aussi un paramètre de signification particulière.

L'unité d'inhibiteur du facteur VII sera, selon Boos *et al.* [2, 15], la quantité capable de neutraliser 75% du facteur VIII contenu dans un ml de plasma.

Compte tenu de ce qui précède, la concentration I d'inhibiteur exprimée en unités/ml sera donnée par la formule:

$$I = \frac{100 - 100 \frac{C}{C_0}}{75} \times 5$$

où C est le taux du facteur VIII résiduel du mélange à tester. C₀ celui du mélange témoin à 20% de tampon représentant la valeur initiale du facteur VIII, 100 C/C₀ le taux du facteur VIII résiduel dans le mélange à tester exprimé en % de la valeur initiale et 100-100 C/C₀ le facteur VIII disparu en % de la valeur initiale.

Un manque de 15% du facteur VIII initial répond à l'unité d'inhibiteur mais ce mouvement est trop faible pour se dégager des erreurs d'appréciation. Nous estimons que l'inhibiteur n'est certain que pour les déficits après incubation supérieurs à 30% soit 2 unités. Nous retenons comme douzeuses les valeurs entre 1,5 et 2 unités.

La recherche d'un inhibiteur du facteur IX répond aux mêmes principes. Mais elle se fera sur le sérum méubé avec un pool de sérums normaux, le mélange étant ensuite dilué 1/20 et testé sur le sérum hémophile B dans le TGT. L'unité d'inhibiteur pourra être définie de manière analogue.

Résultats

Circonstances étiologiques (tableaux I et IV) Les femmes prédominent parmi nos malades ainsi que les sujets jeunes. Les deux tiers en ont moins de 20 ans, aucun n'atteint la soixantaine.

Tableau 1. Données cliniques et hématologiques

Cas N°	Sexe	Âge ans	Affection	Syndrome hémorragique	Données hématologiques	Hérédité	Remarques	
1	M	19	épistaxie	effluets épistaxie	transfusions	0		
2	F	11	hématuries	effluets hématuries	0	0		
3	F	23	syndrome hémorragique	frase coupure, avulsions dentaires, gingivorragies, épistaxie, ecchymoses, post-partum	2 grossesses (2 ^e hémorragique) transfusions	hémorragies chez le grand- père et l'arrière grand-père paternel et chez la fille. Laborateur du facteur VIII chez la cousine maternelle (Cas N° 5)	maladie héréditaire post- rhumatismale	
4	F	34	hémorragies	frase coupure, interven- tions, gingivorragies, épis- taxis, hémorragies, post-partum	4 grossesses transfusions	hémorragies chez 2 des 4 garçons, mais absence d'inhibiteur du facteur VIII	absence de Q ₁₀ -test	
5	F	18	-	0	0	cousine maternelle du cas N° 3		
6	M	9	maladie de von Willebrand	frase (modérée)	0	?		
7	F	10	hémorragies	frase coupure, avulsions dentaires, interventions, gin- givorragies, hémorragies	0	hémorragies chez la mère et les deux sœurs		
8	F	53	syndrome hémorragique	frase coupure, avulsions dentaires, gingivorragies, épistaxie, ecchymoses, pétéchies	3 grossesses	hémorragies chez les 3 filles et 1 des 2 garçons mais absence d'inhibiteur du facteur VIII	hémorragies de phlébites post- gravidiques	

Tableau I (suite)

Obs. No	Sex	Age ans	Affection	Syndromes hématologiques	Données hématologiques	Médicats	Remarques
9	F	36	hépatolymphonégatie chronique	0	transfusions	0	Altophosphite hémodysse adéquates d'hépatite virale
10	M	14	ophtalmogalabie bénigne	franc: hépatasie, hématomeres, corporeaux poireux pré- fals des membranes latérales	transfusions	hématogrammes clairs oncle maternel	
11	M	19	abcès sous-jacent rétine droit	0	transfusions	0	névrose hépa- tique inscra- tique récurrente hépatique portable
12	M	55	gastromyxome hépatite d'inscrup- raion	0	transfusions	0	
13	F	19	rhinorhagies, dou- leurs abdominales abdom	diarrées rectorragies mémorragies	pénicilline	0	
14	F	7	végétations aortiques	diarrées ecthymos	0	0	angines pharyn- geennes répétées

Un grand nombre avait reçu des transfusions de sang et un au moins de la pénicilline, avant que l'inhibiteur ait été découvert. De même, près de la moitié des femmes avaient eu des grossesses dont plusieurs multiples et les incidents de la délivrance avaient été souvent l'occasion de transfusions. L'effet d'une grossesse associé à celui des transfusions apparaît de manière frappante dans l'observation Wie. Cette jeune femme avait une concentration d'inhibiteur de 2,7 u/ml et un taux de facteur VIII de 32%. Après une grossesse interrompue au 3 mois, suivie de transfusions, l'inhibiteur était monté à 5,1 u/ml et le facteur VIII descendu à 13%. Transfusions et pénicilline sont administrées si largement que leur rôle étiologique est certainement très sous-estimé.

Les affections qui encadrent la découverte de l'inhibiteur sont assez dissemblables et comparables à celles qui se retrouvent chez les individus possédant un inhibiteur puissant. A noter cependant la maladie de von WILLEBRAND. Dans quatre de nos cas existait une atteinte hépatique, une fois au moins sévère.

Il est curieux de trouver chez plus d'un tiers de nos malades, une hérédité de la tendance hémorragique. Cependant tous les membres de ces fratries, à l'exception d'un seul, qui ont pu être examinés, ne montrent pas d'inhibiteur. Ce n'est donc pas ce dernier qui se transmet, mais un terrain hémorragique mal élucidé.

Clinique (tableaux I-IV et V) Dans un peu moins de la moitié des cas, un syndrome hémorragique, jamais menaçant, attire l'attention et amène la découverte de l'inhibiteur. Chez un nombre équivalent de sujets souffrant d'une maladie caractérisée, un examen systématique de la crase sanguine aboutit, pour des raisons diverses, à la recherche de l'inhibiteur. Parfois enfin ce dernier est décelé à la suite d'un contrôle systématique chez un individu présentant une incommodité banale ou bien portant. Le syndrome hémorragique existe chez les $\frac{1}{3}$ des malades pris dans leur ensemble et chez les $\frac{3}{4}$ de ceux dont l'inhibiteur est au dessus de 2 u/ml plus de la moitié présentent un saignement franc. Il n'est d'ailleurs jamais très inquiétant et consiste en épistaxis, gingivorragies, ecchymoses, hémorragies génitales, héorragies des diverses sortes de plaies.

Signes biologiques se rapportant à l'inhibiteur (tableaux II et V) L'hypo-coagulabilité est le signe le plus fréquent puisqu'elle se retrouve chez les trois quart du groupe d'ensemble et presque tous les sujets ayant un inhibiteur avéré. Elle se manifeste dans la coagulation du sang

Tabelle II: Troubles de la coagulation en rapport avec l'insuffisance

On	Concentration de la prothrombine malade (normal)	TC du rpp (N < 210 sec)	du sang ml/min (N < 12 min)	Facteur VIII (N = 70-120)	Inhibiteur du facteur VIII U/ml	Facteur IX % (N = 70-120)	Effet inhibi- teur du sub- strat dans le TCT	Particularités
1	28,5 (31,4)	850	12 30	80	0,6	100	+ à 90% de plasma du malade	Le rpp un effet inhibiteur à 10% dans le plasma normal
2	normale	normal	17-19	58	5,6	inhibiteur 0	+	
3	normale	370	14 30	13 75	5,1	70 52	0	2 mois après une pro- thèse lectronique sous le traitement l'inhibiteur mesuré de 2,7 à 5,1 u/ml et le facteur VIII tombe à 52 à 15%
4	normale	540	17	70	4,3	85	0	
5	normale	900	12 15	47-61	9,9		0	l'inhibiteur disparaît en même temps que le facteur VIII mesuré à 81%
6	normale	normal	normal	15	3,3		0	maladie de von Willebrand

Tableau II (suite)

Cas N°	Consommation de la prothrombine, ml/min (titrage) sec	TC du FFP sec (N < 240 sec)	du sang, ml/min-sec (N < 12 min)	Facteur VIII % (N = 70-120)	Inhibiteur du facteur VIII /ml	Facteur IX % (N = 70-120)	Effet inhibi- teur du sub- strat dans le TGT	Particularités
7	30,5 (31,5)	275	19-	25-26	3,1	95	0	l'inhibiteur disparaît en même temps que le facteur VIII monte à 100% et que la con- sommation se normalise
8	24,1 (31,5)	normal	13-15	11 100	3,0	85	+ puis 0	
9	thrombocytopénie	507	normal	60	2,7		0	pris adrénales 0,1 mg disparition de l'inhibiteur et facteur VIII 92%
10	normale	normal	16-15	75	2,0	90-90	+	
11	normale	normal	normal	100	2,0		0	
12	thrombocytopénie	300	normal	100	1,8		substrat défectueux	
13	normale	normal	12 30	75-100	1,7	35	0	
14	normale	normal	15-15	90	1,6		0	

en dehors des taux des facteurs VIII et IX, seuls les valeurs anormales sont portées

Tableau III. Troubles associés de la crase sanguine

Cas N°	Fragilité vasculaire	Altération plaquettaire (plaquettes $\times 10^9/\text{mm}^3$)	Hypoprothrombinémie	Fibrinogène mg/100 ml (N = 500-550)	Fibrinolyse Facteur X % (N = 70-120)	Anticoagulants circulants ATP: antithrombotiques AT antithrombotiques
1	0	0	0	278	0	0
2	0	0	0	256	0	0
3	+	TS 4 min 30 sec a.s.m. 45 pas normal	0	normal	(+) poids 0	0
4	(+)	plaquettes 108,0	0	normal	0	0
5	0	0	0	normal	0	0
6	+	0	0	normal	0	0
7	+	0	0	218	0	0
8	0	aggrégation plaquettaire 0,5 μmol 17% (32%) de la valeur initiale	0	normal	0	0
9	(+)	thrombocytopenie 23,3-60,0	temps facteurs VII et X 17,4 (13,7) sec, temps facteur II 16,1 (13,7) sec	282	0	0
10	0	a.s.m. 36-31	facteurs VII et X 16,8 (13,6) sec facteur II 13,9 (14,8) sec	264	(+)	présence d'une ATP
11	0	plaquettes 316,8	0	786	0	présence passagère d'ATP
12	+	plaquettes 57,2	facteurs VII et X 12,4 (13,3) sec facteur II 23,0 (13,0) sec	142	0	présence d'une AT
13	(+)	0	facteur V 26,3 (22,8) sec facteurs VII et X 16,4 (13,4) sec facteur II 13,8 (14,9) sec	III	0	présence d'une ATP
14	0	0	0	normal	0	0
					93	0

Tableau IV Circonstances étiologiques

Sexe	Hommes : 5	Femmes : 9	
Âge	< 20 ans : 9	20-39 ans : 2	40 59 ans : 3
Tendance hémorragique dans la famille	5		
	1 présence d'un inhibiteur faible du facteur VIII		
Grossesses	4		
Transfusions	7		
Pénicilline	1		
Mise en évidence de l'inhibiteur	par contrôle systématique : 2		
	par contrôle d'un syndrome hémorragique : 6		
	épistaxis (1), hémarthrose (1), métrorragies (2)		
	tendance hémorragique (2)		
	par contrôle au cours d'une affection caractérisée : 6		
	splénomégalies chroniques (2) avorts sous-péritonéaux sur		
	névrose hépatique post-traumatique rétrograde (1)		
	gammaglobulino avec hépatite d'association (1)		
	syndrome fibrilic-vasculariel et crises abdominales (1)		
	maladie de von WILLEBRAND (1)		

complet et un peu moins dans celle du plasma pauvre en plaquettes après récalcification.

La consommation de la prothrombine est mauvaise, une fois éliminée toute thrombocytopénie dans un peu moins d'un tiers des inhibiteurs avérés. Quoique inconstant, c'est là un signe intéressant, car en l'absence de toute autre cause, il attire l'attention sur l'inhibiteur. Les relations entre la consommation de la prothrombine et l'inhibiteur ainsi que l'effet inhibiteur du plasma dans le TGT sont illustrés par l'observation N° 3.

Le facteur VIII est le plus souvent abaissé pour l'ensemble des cas il l'est presque toujours chez les sujets à inhibiteur avéré. C'est là aussi un signe remarquable, qui fait soupçonner un inhibiteur du facteur VIII cependant inconstant l'observation N° 1 qui présente la plus forte concentration d'inhibiteur de notre série (6,6 u/ml) à un taux normal de facteur VIII (80%). Cependant le lien entre le facteur VIII et l'inhibiteur est indéniable l'un s'abaisse en même temps que l'autre s'accroît et inversement (cas N° 3, 5, 8).

La mise en évidence d'un effet inhibiteur en dehors du test d'incubation spécifique, est difficile avec un matériel aussi peu actif. Le

Tableau V Manifestations cliniques et biologiques de l'inhibiteur

	Total des cas	Cas à inhibiteur > 2 u/ml	Cas douteux (inhibiteur < 2 u/ml)
Syndrôme hémorragique :			
franc	10 : 14 cas	7 : 9 cas	3 : 5 cas
discret	6 : 14 cas	5 : 9 cas	1 : 5 cas
Hypocoagulabilité	4 : 14 cas	2 : 9 cas	2 : 5 cas
du plasma pauvre en			
plaquettes	11 : 14 cas	8 : 9 cas	3 : 5 cas
du sang complet	7 : 14 cas	6 : 9 cas	1 : 5 cas
10 : 14 cas	10 : 14 cas	7 : 9 cas	3 : 5 cas
Mauvaise consommation			
de la prothrombine	3 : 12 cas ¹	3 : 8 cas	0 : 5 cas
Facteur VIII			
abaissé (< 70%)	8 : 14 cas	8 : 9 cas	0 : 5 cas
taux moyen, % (N=90 ± 26)	56 ± 30	42 ± 27	88 ± 13
Effet inhibiteur du plasma			
dans le TGT	4 : 13 ²	3 : 9 cas	1 : 4 cas ³

Deux cas avec thrombocytopénie et mauvaise consommation de la prothrombine ont été éliminés.

Un cas avec substrat défectueux au temps de Quous éliminé.

plasma pauvre en plaquettes utilisé comme substrat d'une mixture normale dans le TGT ne s'est montré inhibiteur que dans un tiers de cas. Son temps de récalcification est rarement assez allongé pour permettre une recherche d'anticoagulant par mélange gradué à un plasma normal. Seule l'observation N° 1 avec ses 66 u/ml d'inhibiteur a permis cette épreuve, montrant un effet inhibiteur déjà manifeste au $\frac{1}{16}$ ainsi qu'une autre du même ordre avec le mélange des substrats dans le TGT positive au $\frac{1}{8}$.

Le facteur IX est abaissé dans un tiers des cas où il a été testé. Ce qui retient surtout l'attention est, dans l'observation N° 3 la coexistence d'un inhibiteur du facteur IX avec celui du facteur VIII et à un taux identique (2,7 u/ml) en même temps que le facteur IX était déprimé à 32 %. Au contraire, l'observation N° 1 avec 100% de facteur IX, ne montre pas trace d'inhibiteur anti facteur IX.

Signes biologiques associés à ceux de l'inhibiteur (tableaux III et VI)
Certains affectent également les cas douteux et ceux à inhibiteur avéré : fragilité vasculaire, abaissement du fibrinogène, fibrinolyse. D'autres prédominent dans les cas douteux : hypoprothrombinémies,

Tableau VI. Troubles associés de la crase sanguine

	Total des cas	Cas à inhibiteur > 2 u/ml	Cas douteux (inhibiteur < 2 u/ml)
Fragilité vasculaire	7 : 14 cas	5 : 9 cas	2 : 5 cas
Hypoprothrombinémie	4 : 14 cas	1 : 9 cas	3 : 5 cas
Atteintes plaquettaires	7 : 14 cas	4 : 9 cas	3 : 5 cas
Thrombocytopénies	3 : 14 cas	1 : 9 cas	2 : 5 cas
Atteintes fonctionnelles	3 : 14 cas	2 : 9 cas	1 : 5 cas
Abaissement du fibrinogène	7 : 14 cas (dont 1 hépa- tite grave)	4 : 9 cas	3 : 5 cas (dont 1 hépatite grave)
Fibrinolyse (arrêtée)			
paragènes	2 : 14 cas	1 : 9 cas	1 : 5 cas
Antithromboplastines	3 : 14 cas	0 : 9 cas	3 : 5 cas
Facteur IX < 70%	3 : 7 cas		
Facteur X < 70%	6 : 14 cas	3 : 9 cas	3 : 4 cas

Dans 3 cas, atteinte hépatique dont 1 hépatite grave avec hypoprothrombinémie, hypofibrinogénémie et présence d'une antithrombine.

thrombocytopénies, faible activité antithromboplastique du plasma. Les uns et les autres paraissent sans lien avec l'inhibiteur. Les atteintes fonctionnelles des plaquettes pourraient soulever la question d'un rapport de causalité, n'étant leur nombre infime.

Caractéristiques évolutives L'inhibiteur n'est pas constant. Nous le voyons augmenter après une grossesse suivie de transfusions (cas N° 3). Chez d'autres sujets, il disparaît, en même temps que certains signes s'évanouissent et que d'autres persistent.

Cas N° 8 TC 15 min 30 sec. Consommation de la prothrombine 24,1 (31,5) sec. Effet inhibiteur du plasma sur une mixture normale dans le TGT Facteur VIII 11%. Inhibiteur 3 u/ml. Après 10 jours, TC 15 min 45 sec. Consommation normale. Disparition de l'effet inhibiteur dans le TGT Facteur VIII 100%, plus d'inhibiteur.

Cas N° 5 TC 12 min 15 sec. Plasma pauvre en plaquettes recalcifié 360 sec. Facteur VIII 47%. Inhibiteur 3,3 u/ml. Après deux mois, TC et plasma pauvre en plaquettes recalcifié normaux. Facteur VIII 64%. Inhibiteur non appréciable.

La disparition de l'inhibiteur après une injection intraveineuse de 0,08 mg d'adrénaline dans un cas d'hépatosplénomégalie résulte sans doute de sa neutralisation par l'excès de facteur VIII libéré à la suite de cette épreuve.

Caractéristiques biochimiques Nos cas ne se prêtent guère à une analyse biochimique. Tous nos inhibiteurs ont résisté à une double

absorption par le sulfate de baryum. Le sérum du cas N° 1 était presque aussi actif que le plasma baryté (5,5 u/ml). Nous avons essayé de fractionner le plasma baryté du cas N° 3 par électrophorèse sur cellogel (méthode modifiée par expression des blocs à la place de l'élution). Nous avons retrouvé 5,7 u/ml d'inhibiteur dans les α -globulines et 2,4 u/ml dans les β -globulines.

Discussion

La littérature des inhibiteurs du facteur VIII est devenue considérable [17-26] depuis que LOZNER *et al.* [16] en publièrent le premier cas spontané et que MUNRO et JONES [19] les trouvèrent chez l'hémophile classique A. Aujourd'hui, la plupart des auteurs les considèrent comme des anticorps (29-14) 7 S γ -globulines [1-28] associés à des 19 S γ -M globulines [30]. Ig globulines à chaînes légères, semblables aux autoanticorps froids des anémies hémolytiques [27]. Cependant tous ne sont peut-être pas des γ -globulines [24-25]. De plus, des substances très différentes telles que l'hématoporphyrine, peuvent se comporter comme des inhibiteurs caractéristiques du facteur VIII [8]. Il n'est d'ailleurs pas certain que tous ces inhibiteurs soient des anticorps : au moins dans certains cas, ils fonctionnent comme des enzymes [6-22]. Les inhibiteurs du facteur VIII spontanés et ceux apparus chez des hémophiles sont considérés comme identiques et étudiés ensemble. Mais cela même n'est pas assuré puisque leur cinétique peut se montrer différente [12]. Ces divergences doivent nous faire réserver notre jugement sur l'unicité de ce groupe d'inhibiteurs.

Les conditions étiologiques qui entourent la production des inhibiteurs spontanés sont assez bigarrées. Cependant la grossesse [5-9, 16b, 20] même chez une primipare, la sensibilisation à la pénicilline [12] jouent un rôle manifeste. Tout un ensemble de malades est rassemblé sous l'appellation plutôt confuse de maladies immunologiques. Un groupe assez notable en est formé par divers rhumatismes, puis viennent les atteintes lymphoïdes, les dysprotéïnémies, des affections cutanées intestinales, hépatospléniques. Pour le reste, dans beaucoup d'observations, aucune étiologie ne se laisse déceler. Chez tous ces malades, la corticothérapie n'a guère donné de succès [13] et pourrait même être suspectée dans la genèse de l'inhibiteur [11]. Les immunosuppresseurs sont à l'essai [32].

Nous croyons que les inhibiteurs faibles du facteur VIII que nous avons détectés sont de même nature que ceux, puissants et spectaculaires, dont parle la littérature. Nous trouvons ici le même cadre étiologique, la grossesse surtout et les transfusions, suggérant une immunisation. Par ailleurs, nous avons recherché aussi cet inhibiteur faible chez les hémophiles. Nous l'avons trouvé (> 2 u/ml) chez plus d'un tiers de nos hémophiles graves (5/16) qui avaient reçu de nombreuses transfusions, mais chez aucun de nos hémophiles de la variété muts, peu transfusés (0/8). L'identité entre l'inhibiteur faible et le fort est donc vraisemblable, encore que le groupe d'ensemble puisse réunir des cas de pathogénie et de signification fort diverses.

Quelques remarques s'imposent cependant l'association d'un inhibiteur du facteur VIII avec un inhibiteur du facteur IX, comme chez le cas N° 3 a été signalée [25]. L'hérédité d'une tendance hémorragique, que nous relevons assez souvent parmi nos malades, n'est guère mentionnée que par quelques auteurs [21-33]. Nous sommes frappés par le jeune âge de notre population alors que l'inhibiteur classique touche souvent des sujets plus âgés et même des vieillards. Si ce fait se vérifiait, il pourrait signifier que, contrairement aux apparences, les inhibiteurs puissants ne naissent pas toujours ex abrupto mais qu'un certain nombre d'entre eux se développent à partir d'un état latent, muet ou discret en clinique, caractérisé par un faible taux d'inhibiteur et une médiocre tendance hémorragique. Chez les hémophiles, nous l'avons constaté, cette situation s'accompagne encore d'une très bonne réponse aux transfusions de sang et de plasma qui corrigent bien le temps de coagulation et même la consommation de la prothrombine. L'inhibiteur disparaît ou diminue passagèrement, pour réapparaître et remonter ensuite. Ce mauvais équilibre, gros de dangers futurs, peut brusquement, sous une stimulation énergique ou maintenue, antigénique ou autre, s'effondrer.

Si donc ce faible inhibiteur du facteur VIII n'a pas de grand rôle à jouer en clinique et s'il ne rend même pas son porteur vraiment malade, le mettre en évidence n'est pourtant pas inutile. Car les sujets qui en sont affligés, sont à surveiller de près. Les grossesses, les transfusions et la pénicilline dont on abuse, d'autres facteurs encore que nous ignorons risquent d'accroître cet inhibiteur et nous devons craindre, sans néanmoins pouvoir le prouver que parmi ces sujets, puisse naître un inhibiteur puissant ou pour le moins malfaisant.

Résumé

Certains sujets présentent un inhibiteur faible du facteur VIII, manifesté par une petite hypocoagulabilité, parfois par une mauvaise consommation de la prothrombine, et surtout un taux réduit du facteur VIII. Les grossesses, les transfusions, la pénicilline, une tendance héréditaire aux hémorragies jouent un rôle étiologique. Ces inhibiteurs faibles sont probablement de même nature que les grands inhibiteurs de la littérature et représentent un état presque latent mais qui pourrait se transformer brusquement un jour en inhibiteur puissant. D'où la nécessité chez de tels sujets de surveiller les grossesses et d'économiser transfusions et pénicilline.

Summary

Some individuals possess weak factor VIII inhibitor activity as shown by minor hypocoagulability sometimes by poor prothrombin consumption and especially by low factor VIII levels. Pregnancy transfusions, penicillin, hereditary haemorrhagic tendency all play a part in the aetiology. These inhibitors represent an almost latent state, which could, however, at some point be transformed into a powerful inhibitor. This makes it necessary in such patients for close supervision during pregnancy and caution in the use of transfusions and penicillin.

Bibliographie

1. ANDERSON, B. R. and TROTT, B. B. γ G antibody to human antihemophilic globulin (Factor VIII). *J. Immunol.* 100: 175-186 (1968).
2. BLOOM, R. and BOWELL, E.: A method for the study of antihemophilic globulin inhibitors, with reference to six cases. *Brit. J. Haemat.* 5: 379-395 (1959).
3. BLOOM, R. and DOUGLAS, A. F. The thromboplastin generation test. *J. clin. Path.* 6: 23-29 (1953).
4. BLOOM, R. and MACFARLANE, R. G. Human blood coagulation and its disorders; 3rd ed. (Blackwell, Oxford 1963).
5. BLOOM, A. L., DAVIES, A. and REED, J. K. A clinical and laboratory study of a patient with an unusual factor VIII inhibitor. *Thromb. Diath. haemorrh.* 15: 12-28 (1966).
6. BARNES, R. T. and RATNOFF, O. D. Studies on the nature of the circulating anticoagulant directed against antihemophilic factors with notes on a assay for antihemophilic factor. *Blood* 20: 137-149 (1962).
7. CAER, J., LARRIERE, M. J. et SAMAMA, M. L'hémophilie (Expansion Scientifique, Paris 1968).
8. DAVIS, R. B., BLOOM, R. and DAWSON, K. W. E.: 'Inhibitor like' effects of hemostatic physins on factor VIII (antihemophilic globulin). *Thromb. Diath. haemorrh.* 17: 299-306 (1967).
9. DUBOIS, J., ROUSSEL, L., LEBLANC, J., DURAFFOUR, P., FROM-WARTELLE, O. et CACHET, J. Anticoagulant circulant inhibiteur du facteur antihémophilique A, découvert dans les suites d'accidents de la toxicogénivulvique. Evolution vers la guérison. *Rev. franç. clin. biol.* 6: 1014-1033 (1961).
10. FAIR, F. G. Hemophilia like disease following pregnancy with transplacental transfer of an acquired circulating anticoagulant. *Blood* 8: 598-606 (1953).
11. GONDEMAUD, M. et HURT, A. Maladie hémorragique acquise par anticoagulant circulant inhibant la thromboplastinofornation. *Sang.* 30: 393-404 (1959).
12. GARROD, D. Spontaneous inhibitors of factor VIII. *Brit. J. Haemat.* 15: 57-73 (1968).
13. HARRISON, W. M. R. Treatment with cortisone of haemorrhagic disease due to a circulating anticoagulant. *Brit. med. J.* 4: 764-767 (1959).
14. HOUZAR, C. Studies on an acquired anticoagulant directed against factor VIII. *J. Lab. clin. Med.* 72: 384-392 (1967).

15. LEITCH, A.; BROWELL, E. and DICK, G. W. R. An antihæmophilic globulin (Factor VIII) inhibitor: purification, characterization and reaction kinetics. *Brit. J. Haemat.* 9: 245-258 (1963).
16. LORRER, E. L., JOLLIFFE, L. S. and TAYLOR, F. H. L. Hemorrhagic diathesis with prolonged coagulation time associated with circulating anticoagulant. *Amer. J. med. Sci.* 192: 318-327 (1940).
- 16b. MADDOX, F. W. and QUICK, A. J. Hemophilia like disease on the female with note on the clotting time of the recalcified plasma. *Amer. J. med. Sci.* 99: 443-447 (1915).
17. MARGOLIS, A., JACKSON, D. P. and RATNOFF, O. D. Circulating anticoagulants. A study of 40 cases and review of the literature. *Medicine* 40: 145-202 (1961).
18. MAYET, G., GODEL, M.; GERARD, J. M., LEVY, G. et MILLER, P. Présence d'une activité neutralisant la thromboplastine cérébrale humaine dans les plasma des ac couchées. *Bull. Fédér. Soc. Gynéc. Obstét. franç.* 19: 487-490 (1967).
19. MICKEL, F. L. and JORDA, H. W. The detrimental effect of frequent transfusions in the treatment of patient with hemophilia. *Amer. J. med. Sci.* 205: 710-713 (1945).
20. NILANOV, J. M., SEANER, B. and GYDELL, G. Circulating anticoagulant after pregnancy and its response to ACTH. *Acta haemat., Basel* 19: 40-50 (1958).
21. NILANOV, J. M. and WUNDERLICH, A. Hyperglobulinæmia as the cause of hemophilia like disease. *Blood* 2: 1067-1077 (1953).
22. OLLIGENDORF, P. and AMBER, C. J. A case of factor VIII inhibitor developed after electric shock therapy. *Scand. J. Haemat.* 4: 401-410 (1967).
23. PAOT, M. et COCHETVIEL, P. Microélectrophorèse des protéines du sérum sur arêtes de cellulose gelatinée. *Ann. Biol. clin.* 23: 1209-1219 (1965).
24. POKROVSKY, P. H., DAOQ, J. H. and TILSON, F. A circulating anticoagulant inhibiting antihemophilic globulin. *J. clin. Path.* 16: 334-338 (1963).
25. REICH, C., ALTMAN, R., ROYER, J. and MADDOX, R. Combined factor VIII and IX inhibitors in girl. *Thromb. Diath. Haemorrh.* 16: 349-356 (1966).
26. ROBERTS, H. R., SCALZI, M. B., MADDOX, J. T., WINTER, W. P. and PIERCE, G. D. A clinical and experimental study of acquired inhibitors to factor VIII. *Blood* 25: 805-818 (1965).
27. SERRANO, S. S. The immunologic character of acquired inhibitors of antihemophilic globulin (factor VIII) and the kinetic of their interaction with factor VIII. *J. clin. Invest.* 46: 147-156 (1967).
28. SEITZMAN, N. R.; MARDER, V. J. and LEITCH, A. Inactivation of factor VIII (AHF) by γ globulin anticoagulant. *J. clin. Invest.* 42: 980 (1963).
29. SPART, T. M. and KIRKILL, B. G. A circulating anticoagulant selectively active against human antihemophilic factor (autoimmune hemophilia). *Stanford med. Bull.* 12: 246-256 (1954).
30. SYNGAARD, A. Circulating anticoagulant in hemophilias (evidence for antibody nature). *Scand. J. Haemat.* 3: 227-235 (1966).
31. WHITFIELD, A. G. W., MEYRELL, M. J., FINNEY, B. M. and HEDDER, W. A. A circulating anticoagulant occurring after temporal arteritis and controlled by corticosteroid therapy. *J. clin. Path.* 15: 357-360 (1962).
32. WUNDERLICH, G.; BÖTTCHER, D. and GAOS, R. A circulating anticoagulant directed against antihemophilic globulin (factor VIII) combined with thrombocytopenia. *Thromb. Diath. haemorrh.* 20: 144-154 (1968).
33. WYCKEL, K. and MACKENROTH, S. Familial anomalous 2A globulin accompanied by disorders of blood coagulation and pathological immune phenomena. *Arch. intern. Med.* 116: 361-336 (1965).

Department of Anatomy University of Bristol, and University Department of Haematology Royal Infirmary Sheffield

Cell Degeneration Pattern in Bone Marrow and Blood of Guinea Pigs Following Administration of Cyclophosphamide

M. KAUL¹ and G. HUDSON

In a quantitative study of haemopoietic recovery over a period of 6-21 days following the injection of a sublethal dose of cyclophosphamide in the guinea pig [8] striking differences were found in the recovery pattern of different cell-lines in the bone marrow. These differences could be attributed to a complex interplay of factors, and in relation to this it seemed important to have more complete information about the pattern of degeneration following the use of this chemotherapeutic agent. In the investigation described here, quantitative cellular studies, supplemented by light and electron microscopic observations, have been made on guinea pigs at intervals of 6-72 h after the injection of a similar sublethal dose of cyclophosphamide. Some of the findings have been mentioned in a brief abstract elsewhere [7].

Material and Methods

All the observations were made on healthy male guinea pigs of the Dunkin-Hartley strain weighing approximately 400 g at the commencement of the experiment. A total of 42 animals was used, 21 in the test and 21 in the control series. Each animal in the test series was given a single i.p. injection of 350 mg/kg cyclophosphamide, and each control was injected with corresponding volume of sterile physiological saline. Pilot experiments in which animals were observed over a period of 3 months, have shown that this is not a lethal dose of cyclophosphamide. Over the period of 3 days studied here, the animals were a little off-colour and showed loss of body weight of about 10%. No intestinal disturbances were observed. Quantitative cellular studies of blood and bone marrow were made in 5 animals

per group: 16, 33 and 72 h. Specimens of marrow were examined with the light and electron microscope in two animals per group after the same time intervals.

The techniques used for quantitative study of blood and bone marrow were, except as mentioned below, identical with those used in the earlier study [8]. The animals were killed by exsanguination from the common carotid artery under ether anaesthesia. Routine counts were performed on the arterial blood, direct method of counting eosinophils [5] being employed. Using procedures described in detail by LOONEY [13], marrow suspension of known dilution was prepared, by shaking plug of marrow with autologous serum in small tube containing glass bead. Normal haemocytometric methods were used to count the number of nucleated cells in the suspension and the result was converted into total nucleated cells per unit volume of bone marrow. The procedure was carried out on humeral marrow of both sides and the results were averaged. Dry smears were prepared from the suspensions and stained with ALABEAL tetrachrome stain. Differential counts were made at right angles to the long axis of the smear at approximately its centre. By relating the percentages of the various cell types to the total nucleated cell counts, the results could finally be expressed as absolute numbers per mm^3 of the original marrow.

With our usual techniques, one can normally expect that between 5 and 15% of all the cells seen in the marrow smears will be damaged to such degree that accurate identification is impossible. The proportion of such damaged forms tends to be less in thicker smears. Preliminary observations on marrow smears at 24 and 72 h after cyclophosphamide indicated that much higher proportion of damaged forms - of the order of 40% - was present. It seemed possible that this difference might be related to the fact that the marrow was relatively acellular (see below) and that the concentration of cells in the suspension was correspondingly low. When more concentrated suspensions of marrow in serum, 1 in 5 or 1 in 6, instead of the usual 1 in 10 or 1 in 12, were used, the proportion of damaged forms was considerably less and usually lay within normal limits. Concentrations of this order were, therefore, employed in the main series of experiments described above.

The techniques used for obtaining specimens of bone marrow for light and electron microscopic study were essentially similar to those described previously [6]. Within 4 min of the demise of the animal, specimens of humeral marrow were placed in ice-cold 1% osmium tetroxide buffered at pH 7.3 and cut up into very small blocks. These were fixed for 1.5 h, washed, dehydrated through increasing strengths of alcohol and finally embedded in Araldite. Sections of about 1 μm thickness were stained with aqueous solutions of methylene blue and azur II in borax and examined with the light microscope. Ultra-thin sections were stained with either 1% uranyl acetate or 1% phosphotungstic acid for 5 min and examined in Hitachi HS 7 electron microscope.

Results

The quantitative data are summarized in table I and the principal findings seem self-evident. It should be noted that the absolute counts of some subgroups in the bone marrow and the blood (including basophil granulocytes, monocytes, plasmacytes, megakaryocytes, macrophages and unidentified cells) have not been separately itemized. In the case of very large cells such as megakaryocytes and macrophages, which show uneven distribution in marrow smears, the quantitative technique does not provide reliable estimates of their numbers.

Table 1 Quantitative data

	6 h		24 h		72 h	
	Test	Control	Test	Control	Test	Control
Marrow cells × 1000/mm ³						
Total nucleated	1 799 (98)	1,804 (93)	746 (136)	1,846 (60)	454 (80)	1,878 (69)
Total myeloid	615 (151)	687 (143)	434 (131)	561 (165)	244 (7*)	757 (95)
Myeloblasts	13 (8)	10 (8)	4 (5)	28 (8)	5 (2)	25 (7)
N. promyel + myel.	54 (35)	66 (39)	14 (9)	58 (16)	5 (4)	78 (22)
N. metamyel.	175 (46)	108 (44)	77 (27)	102 (96)	36 (10)	134 (45)
N. band + segm.	273 (111)	376 (105)	252 (129)	295 (114)	121 (58)	405 (96)
N. unidentified	41 (3)	50 (26)	38 (31)	22 (6)	36 (15)	52 (33)
Eosinophils	41 (14)	61 (15)	40 (16)	47 (23)	38 (15)	52 (19)
Total erythroid	448 (157)	481 (138)	70 (34)	609 (156)	46 (37)	507 (44)
Proerythrobl.	14 (5)	24 (12)	1 (1)	16 (9)	1 (1)	18 (10)
Basophilic	30 (23)	55 (10)	1 (1)	50 (28)	2 (2)	54 (18)
Poly + ortho.	381 (138)	389 (133)	62 (32)	535 (124)	40 (34)	427 (56)
Total lymphoc.	469 (168)	349 (46)	151 (79)	396 (74)	59 (25)	327 (157)
Small lymphoc.	386 (146)	220 (35)	134 (70)	309 (75)	45 (21)	245 (142)
Transitional	32 (13)	55 (15)	13 (12)	54 (15)	8 (6)	32 (11)
Total damaged	172 (29)	147 (31)	65 (22)	151 (50)	67 (15)	119 (42)
Blood cells 100/mm ³						
Total white	87 (25)	68 (15)	57 (9)	55 (10)	15 (6)	61 (8)
Total neutro.	61 (23)	36 (16)	28 (5)	23 (2)	4 (2)	31 (7)
Eosinophils	0.15 (0.11)	0.38 (0.18)	0.04 (0.04)	0.38 (0.06)	0.06 (0.02)	0.28 (0.15)
Total agranular	25 (6)	28 (3)	7 (3)	25 (9)	8 (6)	27 (6)
Spleen weight mg	570 (70)	570 (190)	400 (70)	670 (120)	380 (70)	740 (80)

Average values are given with standard deviations in brackets.

Difference between test and control values significant at the 0.01 level of probability

In the marrow smears, as well as in the electron microscopic preparations obtained from animals at 24 and 72 h after cyclophosphamide neutrophil granulocytes were encountered with certain abnormal features (fig 1 2). Typically these cells had the size and cytoplasmic characteristics of immature neutrophil leucocytes while the nucleus showed marked segmentation. The number of separate nuclear segments often exceeded 10. For purposes of classification we termed such cells segmented metamyelocytes. The average counts of these forms were 41 000 (± 22 000) at 24 h and 33 000 (± 10 000) at 72 h. A few



Fig 1 Segmented metamyelocyte in bone marrow smear 24 h after cyclophosphamide. The nucleus shows an advanced degree of segmentation: nine lobes could be identified. The cell is large, being about 17 μ m in diameter. The cytoplasm shows numerous (neutrophilic) granules as well as dense inclusion. In the original smear the cytoplasm appeared slightly basophilic ($\times 2,800$).

segmented metamyelocytes were seen in 3 of the experiments at 6 h after cyclophosphamide. One also gained the impression that at 24 and 72 h, the later forms of neutrophil showed an increased degree of nuclear segmentation, but this was not studied quantitatively.

In the blood smears, the neutrophil granulocytes of the 24 and 72 h test animals showed clear evidence of increased segmentation. Arneeth counts carried out on the 24 h specimens indicated that there was a marked 'shift to the right' in the cyclophosphamide injected group. In particular there was a highly significant increase in the percentage of neutrophils with 5 or more nuclear segments (51% as against 11% in the controls: $t=4.1$). Nuclei with up to 14 segments were noted. Some cells also showed cytoplasmic basophilia and were reminiscent of the segmented metamyelocytes observed in the marrow.

In sections examined with both the light and electron microscope, the bone marrow of the test animals showed little difference from that of the controls at 6 h, although macrophages containing degenerating cells seemed more frequent. At 24 h, the test marrows appeared rather acellular and macrophages containing the remains of degenerating cells were particularly prominent. At 72 h the test marrows were again




Fig. 2. Electron micrograph of segmented metamyelocyte 24 h after cyclophosphamide. The nuclear profiles (NN) show evidence of segmentation. The cytoplasm contains well-developed endoplasmic reticulum (ER) as well as a number of dense (neutrophilic) granules ($\times 7,300$).

less cellular than those of the controls fat vacuoles and large sinusoids appeared more numerous.

Discussion

The results show that following the administration of a sublethal dose of cyclophosphamide, there was a profound decrease in marrow cellularity. No significant change was observed in the total number of nucleated cells at 6 h, but at 24 and 72 h, striking changes were present. The three major cell-groups seemed to be affected somewhat differently. A very considerable reduction in the numbers of erythroid and lymphocytic cells was already present at 24 h, whereas no signif

ificant change was detected in the total number of myeloid cells at this interval. At 72 h, the average numbers of erythroid, lymphocytic and myeloid cells were reduced respectively to 9, 18 and 32% of the corresponding control values. A similar 'sensitivity' of erythroid precursor cells and lymphocyte-like cells to cyclophosphamide has been observed by Hoss [4] in the rat. In this connection it may also be relevant that by 24 h there was a significant reduction both in the counts of the mononuclear cells (lymphocytes, monocytes and blast cells) of the blood as well as in the weight of the spleen, whereas no significant change in blood neutrophil numbers was detected until 72 h. To what extent an early reduction in the size of a particular cell population reflected an actual destruction of cells is uncertain, although the prominence in the 24 h sections of macrophages containing degenerating cells would support such a concept. The suggestion that the myeloid series may have been less affected by cyclophosphamide in this respect, might also be correlated with the observation that during recovery from this drug [8] total myeloid numbers regained (and in fact overshoot) control levels approximately a week before the erythroid and lymphocyte numbers did. However attention must also be given to the rather complex changes in the myeloid sub-groups. It may be seen from table I that over half the normal myeloid cell-population consists of band and segmented neutrophils, and that at 24 h after cyclophosphamide the number of these later forms was virtually unaffected. In contrast, the early actively-dividing forms (myeloblasts, promyelocytes and myelocytes) showed a dramatic reduction in numbers at 24 h. By 72 h, the counts of the later forms of marrow neutrophil as well as the counts of neutrophils in the blood, showed a highly significant decrease. By 144 h [8] they had reached levels of less than 5% of the corresponding controls. These observations appear to be consistent with those of Hoss [4] who found that in the rat, the non-dividing myeloid cells reached minimum values two days later than the dividing myeloid cells, and with those of HARRIS [3] who reported that in guinea pigs following exposure to irradiation, the decline in the number of granulocytes in the early stages varied inversely with their degree of differentiation. The present finding that total myeloid numbers were not greatly reduced at 24 h after cyclophosphamide appears to have been due almost exclusively to a resistance of the later forms of neutrophil. It would also seem that the eventual reduction in the size of the marrow compartment of band and segmented neutrophils

reflected the fact that the earlier forms had either been destroyed or were failing to mature. Thus, very few new cells would enter the compartment of later forms to replace those being released into the blood stream.

The presence in the bone marrow of the cells which we have designated 'segmented metamyelocytes' (fig 1 2) may be very relevant to this interpretation. In smears, these usually appeared as large cells with basophilic cytoplasm containing neutrophil granules, and with a nucleus which showed a number of separate segments. It is of course, true that in normal marrow smears, one may infrequently encounter an immature neutrophil with two or more distinct nuclear segments. Studies in tissue culture have also shown that in maturing granulocytes, segmentation appears and disappears several times before it becomes a permanent morphological feature [1]. However the frequency with which segmented metamyelocytes were observed following cyclophosphamide and the degree of segmentation which was present in some of these cells seemed clearly to indicate that they were abnormal. Confirmation of this was found in a preliminary experiment which we carried out in collaboration with Dr E. S. MEEK. Measurements with an integrating microdensitometer indicated that segmented metamyelocytes contained double the normal amount of nuclear DNA. Large cells with abnormally large amounts of DNA (in most instances not exceeding the pre mitotic content) have been noted by a number of other investigators after the use of cytotoxic drugs, and the suggestion has been made that progression is blocked at the G2 stage of the cell-cycle (see the reviews of KUTLMAN [9] and WINKLER [12]). Whatever the precise mechanism by which segmented metamyelocytes were produced, it would eventually lead to a decreased production of the mature forms of neutrophil granulocyte.

The presence of increased nuclear segmentation in neutrophil granulocytes, which was seen here both in the blood and in the bone marrow has been reported by other investigators following the use of alkylating agents [2 10, 11]. The evidence of increased nuclear segmentation in the blood neutrophils at 24 h after cyclophosphamide suggests that this agent may have an effect on non-dividing as well as on dividing cells. The morphological appearances resemble those of a premature and rather exaggerated ageing process. The possibility that these appearances may parallel changes in cell-function might repay further investigation.

Acknowledgments. Thanks are due to Miss H. NEARS for help in preparing the manuscript, to Miss G. HARRISON for technical assistance and to Mrs. P. WATSON for preparing the illustrations.

Summary

Studies of bone marrow and blood were carried out following a single sublethal dose of cyclophosphamide in guinea pigs. At 24 h, there was a profound decrease in marrow cellularity and macrophages containing degenerating cells were prominent. Erythroid, lymphocytic and immature myeloid cells were reduced in numbers, while later forms of neutrophil granulocytes were virtually unaffected. There was reduction in the spleen weight and in the number of mononuclear cells in the blood. At 72 h later forms of marrow neutrophil and blood neutrophils were also significantly reduced.

The presence in the bone marrow of abnormal neutrophils, designated as 'segmented metamyelocytes' and nuclear hypersegmentation in the neutrophils of the blood seem particularly significant in relation to the mechanism of action of cyclophosphamide.

References

1. BOLL, I. and KERN, A. Granulocytopenia in human bone marrow cultures studied by means of kincinotography. *Blood* 25: 449 (1965)
2. ELSON, L. A., GALTON, D. A. G. and TULL, M. The action of chlorambucil (CB 1348) and busulphan (myeleran) on the haemopoietic organs of the rat. *Brit. J. Haemat.* 4: 335 (1958)
3. HARRIS, P. F. A comparison of cell depletion in irradiated guinea-pig bone marrow studied by quantitative techniques. *Acta haemat., Basel* 23: 293 (1960)
4. HART, H. Regeneration of bone marrow cells in rats following cyclophosphamide or total body irradiation. *Acta radiol.* 4: 337 (1966)
5. HUDSON, G. Eosinophil populations in blood and bone marrow of normal guinea pigs. *Amer. J. Physiol.* 196: 1171 (1960)
6. HUDSON, G. and YOFFEY, J. M. The passage of lymphocytes through the sinusoidal endothelium of guinea-pig bone marrow. *Proc. roy. Soc. B* 163: 486 (1966).
7. KAUL, M. and HUDSON, G. Effect of cyclophosphamide on the blood and bone marrow of the guinea pig (proceedings). *J. Anat., Lond.* 104: 190 (1969)
8. KAUL, M. and HUDSON, G. Recovery of haemopoiesis after cyclophosphamide. *Acta haemat., Basel* 41: 170 (1969)
9. KATLMAN, B. A. Actions of chemicals on dividing cells (Prentice-Hall, New Jersey 1966)
10. KOLLER, H. C. Comparative effects of alkylating agents on cellular morphology. *Ann. N.Y. Acad. Sci.* 68: 783 (1958).
11. WHEELER, A. G., DAVIES, D., HAWKINS, H. C., PATTIE, H. G. and WHEELER, J. H. A toxicologic and hematologic evaluation of cyclophosphamide (Cytosin 7) in experimental animals. *Toxicol. appl. Pharmacol.* 4: 324 (1962)
12. WHEELER, G. P. Some biochemical effects of alkylating agents. *Fed. Proc.* 26: 683 (1967).
13. YOFFEY, J. M. Bone marrow reactions (Arnold, London 1966)

Authors' addresses: Dr G. HUDSON, Faculty of Medicine, University of Sheffield, Sheffield, S10 2TA (England). Dr M. KAUL, Department of Anatomy, Lady Hardinge Medical College, New Delhi (India).

Departments of Medicine and Pathology Veterans Administration Hospital
and School of Medicine, University of Pittsburgh, Pittsburgh, Pa.

Histiocytic Medullary Reticulosis

Case Report with Electron Microscopic Study¹

Z. A. ZAWADZKI, C. E. PERA and E. R. FISHER

In 1939 SCOTT and ROBB-SMITH [1] described the clinical and pathological features of 4 patients which they considered to be unique from other forms of malignant lymphoma. The lesion which they designated as histiocytic medullary reticulosis was characterized by focal proliferations of histiocytic cells in medullary portions of hemopoietic organs. Erythrophagocytosis by the histiocytic cells represented a distinctive feature of the disorder. Thus, as well as the absence of involvement of the peripheral blood, distinguished histiocytic medullary reticulosis from monocytic and histiocytic leukemia.

Histiocytic medullary reticulosis is a rapidly progressive fatal disorder [2-16] with survival usually from only 1 to 15 months with a median duration of 5½ months following recognition [5-10]. No sex predilection has been noted and the age of patients with the disorder has ranged from 26 to 70 years with a mean of 48 years [5].

Recently we had the opportunity to study a patient in whom *intra vitam* diagnosis of this disorder was established. Electron microscopy of samples of bone marrow has allowed for the ultrastructural characterization of these neoplastic elements.

Case Report

A 45 year old white man entered the hospital complaining of intermittent pains in both gluteal and lumbar regions radiating to the medial aspects of both thighs. He also had experienced general malaise, anorexia and constipation for several months. He had lost

This investigation was supported by United States Public Health Service grant C-5183.

10 kg since the onset of his illness. His past medical history had disclosed that he was subjected to two craniotomies for brain tumor 6 years previously and had received cobalt therapy for this lesion 1 year ago. The liver edge was tender and palpable 3 cm below the right costal margin. The tip of the spleen was felt just below the left costal margin. Discrete small (1-1 cm) axillary lymph nodes were palpable bilaterally. There was striking bony tenderness over the sternum, rib cage, both clavicles, both scapulae, pelvis and the spinous processes of the vertebrae. Neurological examination was negative although symptoms of expressive aphasia were present. Hematocrit 32%, hemoglobin 10.8 g%, White cells 6,600/mm³ with 66% neutrophils, 1% myelocytes, 26% lymphocytes, 5% monocytes, 1% eosinophils and 1% basophils. Peripheral blood smear showed polychromatophilia, red cell stippling, spherocytes and a few nucleated red cells. Reticulocytes varied from 1.0 to 2.8%. Platelets 154,000/mm³. Sedimentation rate 72 mm/h (corrected to 18 mm/h). Total serum protein 6.6 g% (albumin 2.9 and globulin 3.7). Serum bilirubin 0.7 mg%, cholesterol 250 mg% and alkaline phosphatase 111 King-Armstrong units. Glutamic oxaloacetic transaminase (SGOT) 45 units, lactic dehydrogenase (LDH) 920 units. LE test, Coombs test and the serological examination for syphilis and rheumatoid factor were negative. The leukocyte alkaline phosphatase score was 76 (normal range 20-100). Serum electrophoretic pattern: moderate elevation of α_2 -globulin. Serum immuno-electrophoretic patterns were within normal limits.

Radiological skeletal survey showed an increased density of bones of the vertebral bodies and the pelvis in both sacroiliac regions. Aspiration of bone marrow was difficult due to the hardness of bone. Biopsies of bone marrow were performed.

Bone Marrow

Light microscopy The bone marrow smear was hypercellular and consisted almost exclusively of large reticulum cells whose average size was 30-40 μ m. Most of these cells contained 2 or 3 nuclei and a few nucleoli. Almost every cell contained one or more erythrocytes. Occasionally erythroblasts could be recognized within the cytoplasm of these large reticulum cells. Smears stained with Prussian blue revealed a moderately positive reaction for iron within the reticulum cells but an absence of extracellular iron stores.

A liver biopsy disclosed foci of extramedullary hematopoiesis and marked hemosiderosis.

Electron microscopy The cells comprising the lesion of histiocytic medullary reticulosis exhibited large nuclei which were frequently indented. Nuclear chromatin was evenly dispersed. Nucleoli were inconspicuous. The nucleus was surrounded by a double membrane. Cell cytoplasm was abundant and its surface was often irregular with pseudopodial extensions. Varying sized pinocytotic vesicles were also present beneath the cell membrane. Golgi structures appeared well developed and were observed in perinuclear areas. Coarse endoplasmic reticulum frequently appeared as relatively large, occasionally tortuous channels (fig. 1). Other vesicles and vacuoles were dispersed throughout the cytoplasm. Occasional dense bodies surrounded by a solitary membrane with homogeneous matrix (cytosome) or portions of other organelles within their confines (cytosomeosomes) were also present (fig. 2). Tetrads characteristic of ferritin could be discerned in some of the membrane-bound bodies. Mitochondria were relatively sparse and characteristically contained only a medium of cristae. The cytoplasm of some of these cells contained numerous homogeneous or multilaminated lipid droplets and/or myelin figures whereas others contained fine fibrils. Portions of intact forms of erythrocytes were encountered within the cytoplasm of some cells (fig. 3). In some instances, erythrocytes were encountered between the cell membranes of adjacent tumor cells. In such instances, they appeared distorted (fig. 4). Other erythrocytes appeared to indent the cell membrane of tumor cells and portions of phagocytized erythrocytes at the cell surface were often associated with large cytoplasmic vacuoles. A solitary membrane frequently was noted about intracytoplasmic portions of such erythrocytes.




Fig 1 Portions of two neoplastic cells in bone marrow. Endoplasmic reticulum (Er) is dilated and Golgi complex (G) is conspicuous. The nucleus is scalloped ($\times 12,000$)

Erythrokinetic Studies

The serum iron was $190 \mu\text{g}/100 \text{ ml}$. Total iron binding capacity was $253 \mu\text{g}/100 \text{ ml}$. The red cell survival half-time, determined by chromomycin¹¹ method was 28.5 days (normal range 25 to 57 days). Plasma clearance of radioactive iron was 67 min (normal range 60-90 min). Direct counts over spleen, liver, heart and marrow revealed progressive accumulation of radioactivity in the spleen, minor rise in the liver, the usual drop in the heart and essentially no uptake over the marrow. No essential difference in the radioactivity uptake over the marrow in comparison to the spleen and the liver was observed during the duration of study. Blood counts during this time showed platelet level from the 5th day on. The plateau of the curve and low level of radioactivity indicated poor incorporation of radioiron.

Clinical Course

The patient was observed in the outpatient clinic monthly intervals. The hematocrit ranged from 19 to 27 and the hemoglobin from 8.4 to 6.0 g%. H was readmitted to the hospital 7 months after the onset of his illness because of massive hematemesis from which he succumbed.




Fig. 2. Portion of neoplastic cell in bone marrow with cytoplasmic lipid droplets (L). Cytosomes (Cs) and cytosomes (C) are also present. The cytoplasmic border shows pseudopodial extensions (P) ($\times 9,900$). The insert reveals tetrads of ferritin in the cytosome indicated at C ($\times 350,000$).

Autopsy

Macroscopic description. The liver weighed 2,700 g. The parenchyma appeared mottled yellow-brown. The spleen weighed 300 g and was soft with a dark red cut surface. The para-aortic and cervical lymph nodes were moderately enlarged; the cut surface was white and homogeneous. Tumor nodules were in the left temporo-occipital area, frontal horns of both lateral ventricles and occluding the fourth ventricle of the brain.

Microscopic description. The liver and spleen contained numerous foci of hematopoiesis. Kupffer cells of the former contained intact red blood cells as well as hemosiderin within their cytoplasm. The bone marrow and lymph nodes revealed almost total replacement of their normal structure by sheets of histiocytes (fig. 5). These latter had abundant finely granular cytoplasm that was faintly reactive when stained by the periodic acid-Schiff technique and often contained oil red O positive lipid droplets and erythrocytes. Cell nuclei were for the most part eccentrically placed, ovoid and rounded and with finely granular chromatin. Focal infiltrates of these cells were also seen in the pancreas and bone marrow.



Fig 2. Erythrocyte (E) within cytoplasm of neoplastic cell. There are relatively few organelles in this area of the cytoplasm ($\times 16,500$).

Sections of tumor nodules in the brain showed a moderately well differentiated ependymoma with large areas of oligodendroglial and astrocytic differentiation as well as multiple ependymal neoplasms.

DISCUSSION

The clinical and pathological features encountered in this patient warrant the diagnosis of histiocytic medullary reticulosis [1, 5, 6, 10, 11, 16]. The etiology of this disorder has not been established [3, 6]. There is little evidence to implicate bacterial infection or autoimmunity in its pathogenesis, as has been suggested [2, 6]. On the other hand, most have agreed that it represents a neoplasm of histiocytic elements. Its distinction from so-called histiocytic leukemia or reticulum cell sarcoma is apparent since a leukemic phase of the disease has not




Fig 4 Distorted erythrocyte (E) between the cytoplasmic membranes of two adjacent neoplastic cells. A large vacuole is present in the cytoplasm of one of the cells and the erythrocyte markedly invaginates the cytoplasm of the other ($\times 21,000$)

been recognized and erythrophagocytosis is not recognized as a salient feature of these two diseases. The electron microscopic appearance of the tumor cells allows for their categorization as histiocytes, not only because of their overt phagocytic properties but also the presence of pseudopodal extensions, frequent intracytoplasmic cytosomes and cytosegresomes and quantity and appearance of other subcellular organelles. The sequential changes occurring in erythrophagocytosis as revealed by electron microscopy does not appear unique in this instance the findings do not explain why these histiocytic elements have such an avidity for erythrocytes. We have observed qualitatively similar erythrophagocytosis by electron microscopy in a few examples of Zieve's syndrome and other hemolytic anemias.



Fig. 5. Neoplastic cells replacing bone marrow in section of *post mortem* specimen stained by Weizmann's reticulum method ($\times 100$)

The results of the ferrokinetic studies as well as the presence of accumulations of ferritin within the cytoplasm of the tumor cells are consonant with the view that the anemia in patients with histiocytic medullary reticulosis may be due to the lack of iron stores as result of the excessive erythrophagocytosis. Estimates of erythrocyte survival time and iron clearance were within normal limits.

The cerebral neoplasm encountered in this patient appears to be coincidental. Although recent ultrastructural study of a so-called reticulum cell sarcoma (microglioma) of brain has revealed similarities between the tumor cells of histiocytic medullary reticulosis and this glioma [17] the appearance of the brain tumor in this patient was, unequivocally that of an ependymoma.

Recognition of this disorder *intra vitam* represents a unique diagnostic experience for histiocytic medullary reticulosis [4 6 16]

Summary

A diagnosis of histiocytic medullary reticulosis was established *histo riam* by bone marrow examination in 45-year-old white man with bone pain and anemia. Results of electron microscopy of the neoplastic histiocytes and ferrokinetic studies support the hypothesis that the anemia in patients with this disorder is due to the unavailability of iron stores resulting from the excessive erythrophagocytosis.

References

- 1 SCOTT R. B. and ROSS-SMITH, A. H. T. Histiocytic medullary reticulosis. *Lancet* **ii**, 194-198 (1959)
- 2 CRYST, H.; GOTO ALK, H. C. and OKAZAKI, K. Histiocytic medullary reticulosis. Report of two cases. *Arch. intern. Med.* **94**, 375-383 (1954)
- 3 MARRASALL, A. H. E. Histiocytic medullary reticulosis. *J. Path. Bact.* **71** 61-71 (1956)
- 4 CHEN-FEI, Y. CHENG-HANG, T.; HUAN-TEH, H. TUNG 'U'NG, T. HAN-LUNG, K.; CH'U 'T'ANG, Y. and CHEN, L. Histiocytic medullary reticulosis. *Chin. med. J.* **80**, 466-474 (1960)
- 5 ZAK, F. G. and REICH, E. Histiocytic medullary reticulosis. *Amer. J. Med.* **31**, 815-819 (1961)
- 6 GREENBERG, E. COOPER, D. M.; FRANK, G. L. and KYLE, R. A. Histiocytic medullary reticulosis. *Proc. May Clin.* **57**, 271-283 (1962)
- 7 HENRI, J.; UNGER, B.; JUNG, W. E. and LORNE, T. R. Histiocytic medullary reticulosis. A case report. *Amer. Ann. Med.* **73**, 269-274 (1964)
- 8 KAMEGA, A. K. and NAKATSU, H. Histiocytic medullary reticulosis (Reticuloendotheliosis with striking erythrophagocytosis). *Acta path. jap.* **14**, 231-237 (1964)
- 9 BOAKE, W. C.; CARD, W. H. and KENNEDY J. F. Histiocytic medullary reticulosis. Concomitance in father and son. *Arch. intern. Med.* **116**, 245-252 (1965)
- 10 FREEDMAN, R. M. and STODOLSKY, N. H. Histiocytic medullary reticulosis. *Amer. J. Med.* **38**, 130-133 (1965)
- 11 LYNN, E. C. and ALFREY C. P. J. Histiocytic medullary reticulosis. Hemolytic anemia due to erythrophagocytosis by histiocytes. *Ann. intern. Med.* **63**, 666-671 (1965)
- 12 MEDFORD, F. Histiocytic medullary reticulosis. Report of case. *Arch. intern. Med.* **116**, 589-593 (1965)
- 13 LUTMAN, G. R. and SCHWARTZ, B. A. Histiocytic medullary reticulosis. Report of a case with autopsy findings. *Brit. med. J.* **59**, 1345-1350 (1966)
- 14 PERLMAN, V. and WOOD, J. A. Histiocytic medullary reticulosis. Report of the first case in Jamaica. *Amer. J. clin. Path.* **48**, 396-400 (1966)
- 15 VAITHIANATHAN, T. FARRER, B. and GRUNY, J. G. Histiocytic medullary reticulosis. *Amer. J. clin. Path.* **47**, 160-166 (1967)
- 16 NATELSON, E. A. LYNN, E. C.; HETTING, R. A. and ALFREY C. P. J. Histiocytic medullary reticulosis. The role of phagocytosis in pancytopenia. *Arch. intern. Med.* **122**, 223-229 (1968)
- 17 HORVAT, B. PERA, C. and FISHER, E. R. Electron microscopic study of primary reticulum cell sarcoma (microglioma) of brain. *Arch. Path.* **47**, 609-616 (1969)

Author address: DR. ZBIGNIEW A. ZAWADZKI, CARLOS E. PERA, and EDWIN R. FISHER, Departments of Medicine and Pathology Veterans Administration Hospital, University Drive C, Pittsburgh, Pa. 15240 (USA)

Institute of Pathology University of Kiel
(Director Prof. Dr A. LÖNNERT)

A Case of Acute Leukemia with Pseudo-Pelger Cells Containing Auer Bodies

L. D. LEDER

Cytological, cytochemical, and electron microscopic studies have shown that Auer bodies are pathological azurophilic granules [1 4 5 6]. They do not occur in normal blood cells and hitherto have been described in acute and chronic myeloid leukemia, in myelo-monocytic leukemia, and in undifferentiated blasts of acute erythremic myelosis. They have never been found in cells of the lymphatic system. Therefore, Auer bodies prove a given hematological case to be neoplastic and of myeloid nature.

Pseudo-Pelger cells, on the other hand, are atypical granulocytes. They display rather dense and coarse chromatin and partial or complete lack of segmentation. In contrast to the true Pelger abnormality the pseudo-Pelger variety is not hereditary. Pseudo-Pelger cells have been reported in various forms of myeloproliferative disorders [19 18 21 2, 3 20 8 9]. GUNZ and BARRY [8] state that the presence of pseudo-Pelger cells is quite diagnostic for the myeloid variety of acute leukemia. Others, e.g. THIELE [21] assume this to be merely an incidental finding.

In the following report a case of acute leukemia is described. This case is well suited for a discussion of the diagnostic significance and the meaning of pseudo-Pelger cells in hematological disorders.

Case Report

Bone marrow and blood smears of a 23 years old male suffering from acute leukemia were studied. The marrow was highly cellular. There were predominantly small rounded blasts

with narrow cytoplasmatic rim. With Pappenheim stain these blasts could hardly be differentiated from lymphatic cells (fig. 1). Only few erythropoietic cells, megakaryocytes and granulocytic cells were present. The mature neutrophils partly displayed the pseudo-Pelger abnormality (fig. 2). Such cells together with blasts could also be observed in peripheral blood smears, but not during remission which excludes heredity.

In addition to Pappenheim stain, the naphthol AS-D chloroacetate esterase method was performed [10]. The smears were fixed for 30 min in formalin-methanol 1:9. Incubating medium: 1 drop of 4% pararosanilin in 2 M HCl was mixed with 1 drop of 4% sodium nitrite in distilled water. After 60 sec 30 ml of 0.1 M Michaelis buffer pH 7.62, were added. The pH was adjusted to 6.3 with 2 M HCl. 100 mg of naphthol AS-D chloroacetate, dissolved in 1 ml of N,N -dimethylformamide were added. The mixture was filtered. The smears were incubated for 30 min at room temperature, rinsed in tap water, counterstained with hemalum and mounted in glycerin jelly. Results: Nuclei blue, positive elements bright red.

A small percentage of the lymphoid blasts exhibited positive naphthol AS-D chloroacetate esterase reaction, showing various degrees of positivity. This finding allowed an easy and definite identification of the condition as acute myeloid leukemia, because this esterase reaction is specific for the neutrophilic cell series and for tissue mast cells, the latter being of no significance in our case [7, 10, 11, 17].

In addition, some of the cells contained Auer bodies (fig. 3). According to Fauci *et al.* [4] these bodies could be demonstrated quite distinctly by means of the naphthol AS-D chloroacetate esterase reaction. Some of the pseudo-Pelger cells also exhibited Auer rods (fig. 4).

Discussion

Our observation clearly shows that the NASDCl-esterase reaction can be used to great advantage for the classification of acute leukemia.




Fig. 1 Bone marrow smear. Predominantly small, lymphocyte-like cells. Naphthol AS-D chloroacetate esterase reaction ($\times 1400$).



Fig. 2. Pseudo-Pelger cells. Blood and bone marrow. Naphthol AS-D chloroacetate esterase reaction ($\times 1,400$)




Fig. 3. Immature cells with Auer bodies. Naphthol AS-D chloroacetate esterase reaction ($\times 1,400$)

[11 12, 14 15 16] Thus, in the present case any doubt about the myeloid character of the lymphocyte like blasts could easily be eliminated by the demonstration of various grades of this esterase activity in some of these cells. The presence of Auer bodies proved this conclusion to be correct.




Fig 1 Pseudo-Pelger cells containing Auer bodies. Naphthol AS-D chloroacetate esterase reaction ($\times 1400$)

Furthermore, the existence of Auer rods in the pseudo-Pelger cells furnishes some information about the meaning of this abnormality in leukemias. The Auer bodies prove the pseudo-Pelger abnormality to be closely related to the leukemic process. Indeed, they represent pelgeroid paraleukocytes in the sense of ROHR [19]. In our case both paramyeloblasts and paraleukocytes were found. This observation supports ROHR's view that in leukemia differentiation as well as dedifferentiation takes place in the proliferating cell lines. This implicates that a given cell line (e.g. promyelocytes and myelocytes) may be affected by the leukemic process at various stages of maturation. The neoplastic condition obviously is not limited to - or beginning at - the stage of the myeloblast, as is believed by some authors. In consequence, atypical blasts and paraleukocytes are both derived from the same, originally normal cells. In many cases dedifferentiation with increasing anaplasia parallels progression of the disease. Thus, as we know end stages frequently reveal almost pure populations of anaplastic blasts. In consequence, the appearance of blasts is a feature of the end stage, rather than of the initial stage of the leukemic process [19]. Detailed studies of myelo-monocytic leukemias have led us to the very same conclusion [13].

Finally the occurrence of Auer bodies in pseudo-Pelger cells supports the view of GUNZ and BARRY [8] who claim that the demon-

stration of pseudo-Pelger cells in acute leukemia is quite suggestive of the myeloid nature of a given case. The report of HAYHOR *et al* [9] is in good accordance with this interpretation. The latter authors described pseudo-Pelger cells in acute erythremic myelosis, acute granulocytic leukemia, and in acute myelo-monocytic leukemia. They never saw pseudo-Pelger cells in acute lymphatic leukemia. Due to his own observations this author also believes that the demonstration of pseudo-Pelger cells in hematological disorders, especially in unclassified acute leukemias, strongly supports the diagnosis of acute myeloid leukemia and almost with certainty excludes acute lymphatic leukemia.

Summary

A case of acute leukemia with pseudo-Pelger cells containing Auer bodies is reported. The significance of this observation and the diagnostic importance of pseudo-Pelger cells in hematological disorders are discussed. Some comments are given on the advantages of the naphthol-AS-D chloroacetate esterase reaction in relation to the classification of leukemias. The appearance of pseudo-Pelger cells in the blood of patients with unclassified hematological disorders may be first symptom of myeloid leukemia. The given case of acute leukemia the occurrence of pseudo-Pelger cells strongly supports the myeloid nature of the disease and almost definitely excludes lymphatic leukemia.

References

1. ACKERMAN, A. Microscopic and histochemical studies on the Auer bodies in leukemic cells. *Blood* 5: 847-863 (1950)
2. DARTZ, J. M., DARTZ, J. V. and MCSORLEY, J. G. A. Pelger-like leukocytes in chronic myeloid leukaemia. *Acta haemat., Basel* 12: 117-124 (1954)
3. DOLL, A. E. and MOSCOWITZ, W. C. Acquired pseudo-Pelger anomaly of granulocytic leukocytes. *New Engl. J. Med.* 261: 742-746 (1959)
4. FISCHER, R., HANSENKESTER, H. H. und KÄUPER, C. Der cytochemische Nachweis von Naphthol AS-D Chloroacetal Esterase in Auerstäbchen. *Klin. Wochr.* 44: 1401-1402 (1962)
5. FREEMAN, J. A. The ultrastructure and genesis of Auer-bodies. *Blood* 15: 449-465 (1960)
6. GOLDBLUM, A. F. Acid phosphatase activity in Auer bodies. *Blood* 24: 305-308 (1964)
7. GOMORI, G. Chloroacetyl esters as histochemical substrates. *J. Histochem. Cytochem.* 1: 469-470 (1953).
8. GUNZ, F. W. and BURN, A. F. Cellular types in acute leukaemia: diagnosis and significance. *J. clin. Path.* 16: 325-331 (1963)
9. HAYHOR, F. C. J., QUARLES, D. and DOLL, F. The cytology and cytochemistry of acute leukemia (Her Majesty Stationary Office, London 1964)
10. LEDER, L.-D. Über die selektiv fermentcytochemische Darstellung von neutrophilen myeloiden Zellen und Gewebestellen im Paraffinschnitt. *Klin. Wochr.* 42: 553 (1964)

11. LEIDER, L. D. Der Nachweis der Naphthol AS-D Chloracetat-Esterase und seine Bedeutung für die histologische Diagnostik. *Verh. dtsch. Ges. Path.* 48, 317-320 (1964)
12. LEIDER, L. D. Leukosedagnostik mit fermentcytochemischen Methoden. *Klin. Wochr.* 45, 55 (1967)
13. LEIDER, L.-D. *Der Blutzmonocyt* (Springer Berlin/Heidelberg/New York 1967)
14. LEIDER, L. D. 7th Int. Congr. Int. Acad. Path. Short Course 12: Histochemistry in Pathologic Diagnosis: Lymph nodes and bone marrow. Milan, Italy 5-11 September 1968.
15. LÖFFLER, H. Hinweise zur Unterscheidung unreiferer Leukämien mit cytochemischen Methoden. *Dtsch. med. Wochr.* 88, 1331-1332 (1963)
16. LÖFFLER, H. 7th Int. Congr. Int. Acad. Path. Short Course 12: Histochemistry in Pathologic Diagnosis: Blood. Milan, Italy 5-11 September 1968.
17. MOTOYU W. C.; MCPHERSON, K. and FLEISCHMAN, L. Esterase activity in leukocytes demonstrated by the use of Naphthol AS-D Chloracetate substrate. *J. Histochem. Cytochem.* 8, 200-207 (1960).
18. MOWERS, M., SARWICK, A. A. and LOWE, L. Dwarf cell (atypical myelogenous) leukemia. *Acta haemat., Basel* 2, 123-131 (1949)
19. RONA, K. Zum Problem der Differenzierungspotenzen der Leukozellen. *Schwiz. med. Wochr.* 78, 991-993 (1948)
20. SNAPE, E., COLLINS, Z. and MILLER, E. Acquired Pelger-Huet cells in blood dyscrasias. *Amer. J. med. Sci.* 240, 732-737 (1960)
21. TROILE, H. Pelger'sche Kernanomalie und akute myeloische Myelose. *Folia haemat., Lps.* 71, 250-256 (1952)

3rd International Transplantation Congress

The 3rd International Congress of the Transplantation Society will take place in the Netherlands Congress Centre, The Hague, from 7-11 September 1970. It will deal with the study of the different aspects of organ transplantation.

Organizing Committee: Prof. D. W. VAN BEEKUN, State University of Leiden; Prof. J. J. VAN LOONEN, University of Amsterdam; Prof. J. J. VAN ROON, State University of Leiden and Dr. H. BALZER, Radiobiological Institute of the Netherlands Organization for Applied Scientific Research (TNO).

Further information will be given by the secretariat, c/o Holland Organizing Centre, 16, Lange Voorhout, The Hague (The Netherlands).

XIII. Internationaler Kongress für Hämatologie, München 1970

Aus technischen Gründen musste der Termin für den XIII. internationalen Hämatologen-Kongress geändert werden. Der Kongress wird vom 2.-8. August 1970 stattfinden. All jene, die noch keine vorläufige Anmeldung übersandt haben, werden gebeten, ihre Adresse dem Kongressbüro XIII. Internationaler Hämatologen-Kongress, Postfach 200, D-8 München 12 mitzuteilen, damit ihnen die Unterlagen zugesandt werden können.

XIIIth International Congress of Hematology Munich 1970

For technical reasons, the date of the XIIIth International Congress of Hematology had to be changed. The Congress will take place from August 2-8, 1970. All those who have not yet registered provisionally are invited to inform the Congress Bureau, XIIIth International Congress of Hematology, P.O. Box 200, D-8 Munich 12 (Germany) of their address so that details can be sent to them.

German Academy of Sciences, Institute for Cancer Research, Experimental Section,
Berlin-Dach

Studies on the Pathogenesis and Mechanism of Hematologic Diversification by Re-Isolation of the Myeloid Leukemia Virus (Graffi)

F. FREY

Preliminary studies have shown that the diversification of Graffi virus-induced leukemias depends essentially upon the type of starting leukemia used as virus source [8, 12, 13-15]. This fact tends to a correlation between the marking of the various leukemia types and the cell form: the virus used for infection has been obtained from them.

Organ filtrate studies using virus obtained from myeloid leukemias for infecting newborn mice have given first evidence about the pathogenesis of this diversification [6, 9-14]. We started extensive experiments to determine the site of primary virus attack being important for the mechanism of diversification. Then the virus has been isolated from the place of formation at different intervals of time from the varying types of leukemia and was investigated for leukemogenic activity by bioassay.

Materials and Methods

Newborn random-bred mice of the inbred strain XVII Bn. were injected subcutaneously with the virus in form of cell-free filtrates from mature-cellular myeloid, paraneoplastic, lymphatic or reticular leukemia. Five, 10 and 20 days after inoculation spleen lymph nodes, bone marrow, thymus, liver and brain were removed from the treated young mice, cell-free preparation was made, and the filtrate diluted 1:100 in relation to fresh weight of the organ was re-administered to newborn XVII-mice. The treated mice remained with their mothers until puberty. Then they were separated according to sex. Control for the presence of leukemias followed at intervals. When leukemia occurred the mice were killed. The leukemia types were classified according to their blood picture and organ sections and, in some doubtful cases, according to criteria due to cytochemical reactions [10].

Results

Table I referring to myeloid starting leukemia shows the strong leukemogenic action of filtrates (except brain) prepared on the 5th day following infection. Strongest activity has been observed with spleen and liver filtrates having shortest latent periods, too. Organ filtrates (except brain) prepared 10 days after infection show already maximum leukemogenic action, the majority being myeloid leukemias. There is moderate diversification only the lymph node filtrate shows stronger diversification. The proportion of myeloid and reticular-mixed leukemias is high with 5 day filtrates and then continuously decreases with strongly leukemogenic organ filtrates of spleen and liver obtained 10 or 20 days following infection. Chloroleukemias increase in the same relation. In preparations made 20 days following infection, application of spleen filtrate induces 97 % myeloid leukemias, among them 77% chloroleukemias, whereas lymph node filtrates caused only 50% myeloid leukemias, among them 35 % chloroleukemias. Thus spleen filtrates from myeloid leukemias induce the strongest degree of identical reproduction.

Table II referring to a paramyeloblastic leukemia serving as virus source shows that only spleen filtrates have a distinct leukemogenic action at a relatively long latent period. Maximum leukemogenic activity is reached only by filtrates prepared 20 days after infection. Diversification is considerable almost all types of leukemias were induced. Myeloid and reticular mixed leukemias become strikingly rare. Spleen, bone marrow liver and lymph node filtrates cause predominantly myeloid leukemias. Thymus filtrates, however induce mainly lymphatic and reticular leukemias. The identical reproduction of the paramyeloblastic leukemia is as low as 10 %.

Table III presents the results of experiments with a lymphatic starting leukemia. In filtrates isolated 5 days after virus infection, a distinctly leukemogenic action of the thymus preparation becomes apparent which is expressed by a short latent period. In the same experiments a weaker activity is exhibited by spleen and bone marrow filtrates. Maximum inducing activity is caused by most of the organ filtrates produced 10 days after virus infection. This concerns predominantly thymus, spleen and lymph node filtrates. The diversification is strong so that almost all leukemia types were induced. Thymus and lymph node filtrates induce lymphatic and mixed forms by 50

Table 1. Leukemogenic effect of cell-free organ filtrate prepared from mice infected with virus of myeloid leukemia origin

Organ filtrate prepared from	Number of mice	Number Percent of leuk- emias	Latency days	Percent distribution of leukemia types										not det.
				ma. my leuk.	lm. my leuk.	chlo. leuk.	paucy bla. leuk.	my ret. leuk.	ret. leuk.	ret. ly leuk.	by leuk.	cy bla. leuk.	cy my leuk.	
Spleen	57	81	84	10	16	42	-	23	3	-	3	3	-	1
	20	20	100	10	15	53	-	13	-	-	5	-	-	-
	110	90	82	9	11	77	-	1	-	-	1	-	-	-
Lymph nodes	48	70	54	4	6	42	-	12	4	16	8	3	3	-
	32	30	93	-	17	57	7	7	3	3	-	3	3	-
	71	60	84	7	10	35	10	21	3	8	2	-	-	4
Bone marrow	12	5	42	(20)	(40)	-	-	(20)	-	(20)	-	-	-	-
	11	10	91	30	10	40	-	20	-	-	-	-	8	-
	70	51	73	18	20	41	2	10	2	-	-	-	-	5
Thymus	18	9	50	(11)	(33)	(33)	(11)	(11)	-	-	-	-	-	-
	6	6	(100)	-	-	(33)	-	(17)	(17)	(33)	-	-	-	-
	28	25	90	-	30	(33)	-	16	-	12	-	-	-	8
Liver	51	19	61	21	21	16	-	21	16	-	-	-	-	5
	13	13	100	18	51	23	-	15	8	3	-	-	-	-
	79	56	71	5	28	51	-	7	3	9	-	2	5	9
Brain	46	9	20	(44)	-	(11)	-	(22)	-	(11)	(11)	-	-	-
	7	3	(43)	-	-	(33)	-	-	-	-	-	-	(57)	-
	72	13	18	23	8	11	-	18	-	8	-	-	-	-

ma. my. leu. mature myeloid leukemia, im. my. leu. immature myeloid leukemia, chlo. leu. chloroblastoma,

paucy. bla. leu. paucerythroblastic leukemia, my. ret. leu. reticular type of myeloid a. reticular leukemia,

reticular leukemia (all leukemias originated in the RH3) ret. b. leu. mixed types of reticular and lymphatic leukemia,

ly. leu. lymphatic leukemia, my. Ma. leu. erythroblastic leukemia, my. my. leu. mixed types of erythroblastic and myeloid leukemia.

a) Filtrates prepared 5 days, b) 10 days, and c) 30 days after virus infection.

Table II Leukemogenic effect of cell-free organ filtrates prepared from mice infected with virus of paramyeloblastic leukemia origin

Organ filtrates prepared from	Number of mice	Number of leukemia	Percent	Latency days	Percent distribution of leukemia types									
					ma. my leuk.	lm. my leuk.	chlo. leuk.	pa. my blk. leuk.	my ret. leuk.	ret. leuk.	ly leuk.	cy blk. leuk.	cy my leuk.	not det.
Spleen	34	6	18	245	(33)	(35)	(17)	-	(17)	-	-	-	-	-
	b 29	21	72	169	-	10	48	14	10	-	10	-	4	-
	c 18	16	100	115	19	13	30	13	-	6	-	-	13	-
Lymph nodes	37	-	-	-	-	-	-	-	-	-	-	-	-	-
	b 33	20	61	172	-	5	70	3	5	5	-	-	-	-
	c 30	30	100	153	3	10	40	10	7	3	7	10	3	-
Bone marrow	28	-	-	-	-	-	-	-	-	-	-	-	-	-
	b 23	16	70	146	6	-	50	6	6	-	6	-	6	-
	c 27	32	82	168	4	14	45	4	-	-	-	14	14	-
Thymus	39	1	3	166	-	-	-	-	-	-	(100)	-	-	-
	b 28	24	86	129	-	4	25	8	4	17	4	29	8	-
	c 32	30	94	137	-	10	17	7	5	17	5	20	10	3
Liver	32	1	3	318	-	(100)	-	-	-	-	-	-	-	-
	b 33	23	66	194	4	4	63	-	4	9	4	9	-	-
	c 24	21	88	170	-	19	42	5	5	9	5	5	5	-
Brain	27	-	-	-	-	-	-	-	-	-	-	-	-	-
	b 32	9	27	183	-	(11)	(78)	-	-	-	-	-	-	-
	c 25	10	40	140	-	-	60	-	20	10	-	-	-	-

) Filtrates prepared 5 days, b) 10 days, and c) 20 days after virus infection.

Table III. Leukemogenic effect of cell-free organ filtrates prepared from mice infected with virus of lymphatic leukemia origin

Organ filtrate prepared from	Number of mice	Percent of leuk. mice	Latency days	Percent distribution of leukemia types										ery. bld. leuk.	ery my leuk.	not det.
				ana. my leuk.	lea. my leuk.	chlo. leuk.	panmy bld. leuk.	panmy my leuk.	ret. leuk.	ret. leuk.	ret. leuk.	by leuk.	by leuk.			
Spleen	29	4	201			(75)							(25)	-	-	-
	32	29	137	17	7	45		7	10	3	15	3	15	3	-	-
	53	29	120	7		48	-	13	3	7	10	3	10	3	3	3
Lymph nodes	99	2	260										(100)	-	-	-
	54	30	149	7	7	57		17	3	10	20	-	10	-	-	6
	51	28	111	7	4	11	4	7	11	18	36	-	18	-	3	3
Bone marrow	55	3	203			(35)	-				(35)		(35)	-	-	-
	52	25	150	24	4	36		4	4	12	20		12	-	-	-
	24	21	116	28	24	19		24	5	8	9		8	9	-	-
Thymus	48	16	164	-	-	19		13	6	13	43		13	-	6	-
	41	36	199	11	11	28		5	8	17	22		17	5	3	3
	51	26	116	19	19	19	-	12	4	19	27		19	-	-	-
Liver	17						-							-	-	-
	54	25	152	20	20	36		-	8	4	28		4	-	4	-
	53	28	144	11	11	32	4	11	4	17	14		17	-	7	-
Brain	51	1	240										(100)	-	-	-
	27	15	148	7	13	40	-	7	-	13	13		13	-	-	7
	26	6	170			(15)					(37)		(15)	(15)	-	-

a) Filtrates prepared 5 days, b) 19 days, and c) 20 days after virus infection.

Table 1) Leukemogenic effect of cell-free organ filtrates prepared from mice infected with virus of reticular leukemia origin

Organ filtrates prepared from	Number of mice	Number of leukemic	Percent	Latency days	Percent distribution of leukemia types									
					mye. leuk.	lin. my leuk.	chlo. leuk.	parmy bla. leuk.	mye. ret. leuk.	ret. leuk.	ly leuk.	ly leuk.	ery bla. leuk.	ery leuk.
Spleen	a	26	3	4	-	-	-	-	(100)	-	-	-	-	not det.
	b	33	7	21	-	-	(28)	-	(45)	(28)	-	-	-	-
	c	32	14	44	-	-	37	-	21	21	-	-	-	-
Lymph nodes	a	31	9	35	-	-	-	-	-	-	-	-	-	-
	b	26	11	48	-	-	(56)	-	(22)	(11)	(11)	-	-	-
	c	24	11	48	-	-	35	-	18	8	9	-	-	9
Bone marrow	a	36	3	8	-	-	(33)	-	(33)	(35)	-	-	-	-
	b	37	13	35	-	8	38	-	8	38	8	-	-	-
	c	27	9	33	-	-	(33)	-	(56)	(11)	-	-	-	-
Thymus	a	27	-	-	-	-	-	-	-	-	-	-	-	-
	b	40	28	70	-	-	43	-	7	28	-	-	4	4
	c	46	38	83	-	-	34	-	11	45	5	-	-	14
Liver	a	46	-	-	-	-	-	-	-	-	-	-	-	5
	b	52	15	47	-	-	60	-	7	53	-	-	-	-
	c	23	12	48	-	-	33	-	-	50	17	-	-	-
Brain	a	52	2	6	-	-	(50)	-	(50)	-	-	-	-	-
	b	29	-	-	-	-	-	-	-	-	-	-	-	-
	c	27	3	11	-	-	(100)	-	-	-	-	-	-	-

) Filtrates prepared 3 days, b) 10 days, and c) 30 days after virus infection.

whereas only 20% of these types were produced by myeloid organs. The identical reproduction in these target organs is 30-40%.

Table IV shows the results of organ filtrate experiments with a reticular starting leukemia. The primary leukemogenic action is weak and does not become manifest with filtrates produced 5 days after infection. Only thymus filtrates produced 10 days after virus infection have a strong leukemogenic action. Diversification is strikingly low. Lymphatic leukemias did not occur. It is astonishing that chloro-leukemias are induced almost exclusively in the myeloid series. Reproduction of reticular leukemias is up to 50 % in liver and thymus.

Discussion

As distinctly shown by the experiments, organ filtrates of animals inoculated with virus of a myeloid leukemia show maximum leukemogenic activity. Those animals treated with virus from a lymphatic leukemia follow in the second place. The lowest effect is obtained with organ filtrates of mice infected by virus of paramyeloblastic and reticular leukemias. The primary site of virus attack can be determined by the parameters of leukemia induction quota and latent period in series of experiments using virus re isolated shortly after infection. The strongest primary action with virus prepared 5 days after infection is shown by filtrates of mice treated with virus of myeloid and paramyeloblastic leukemias and thymus filtrates of mice treated with virus of lymphatic leukemias. The primary effect of the virus in reticular leukemia in the bioassay becomes manifest only in thymus filtrates produced 10 days after infection. If the leukemogenic action is in direct proportion to the amount of active virus those organs showing the strongest primary leukemogenic action in the filtrate experiment should also contain the greatest amount of virus. Re-isolation of the virus shortly after infection exclusively comprises the newly formed virus at the primary sites of its formation. Target cells being preferentially infected and having first replication are different for viruses isolated from the hematologically different leukemia forms. Our studies have shown that target cells for the virus from myeloid and paramyeloblastic leukemias are localized preferentially in spleen, for the viruses from lymphatic leukemias in thymus, and for the virus from reticular leukemias predominantly in thymus and liver. Whereas the

primary replication proceeds in the specific target cells subsequent multiplication of virus may take place in a number of other cells of the organism. Megakaryocytes are of special importance in this regard. They are considered as essential sites of multiplication of murine leukemia viruses [1 4 5 17]. A fundamental difference exists between specific target cells and all other cells in which a multiplication of viruses takes place. Only the target cells can be induced by the leukemogenic virus to undergo malignant transformation. Thus the viral leukemogenesis requires for its manifestation the active leukemogenic virus on the one hand and the specific sensitive target cell, on the other.

In connection with splenectomy experiments [6] we referred to the role of the spleen in the pathogenesis of virus-induced myeloid leukemias. An extirpation of the spleen up to 5 days following virus application from mature cell myeloid leukemia reduces the leukemogenic incidence to about 20% as compared with shamoperated control mice. It is probable that splenectomy removes target cells in which primary replication of the virus occurs within the first 5 days and which, by the action of the virus, undergo transformation into malignant leukemia cells. Splenectomy after the 5th day following infection and virus administration from immature-cell myeloid leukemia induces a weaker effect and remains without any effect when using virus from reticular and lymphatic leukemias [6]. These aspects have not been duly considered in splenectomy experiments made by other authors [11] so that their results cannot be compared with ours. As to irradiation induced myeloid leukemias of RF mice significant changes of the leukemia incidence after splenectomy have been also observed by Upton *et al.* [18].

According to our findings our virus strain is inclined basically to induction of myeloid leukemias. This is manifested not only by the highest rate of identical reproduction, but is distinctly shown by the high proportion of myeloid leukemias induced by virus from hematologically different types. The identical reproduction of a given type of leukemia is induced, to a great extent, by the virus isolated from organs containing target cells sensitive to that virus. This conclusion is reasonably drawn by our findings using virus preparations from mature-cell myeloid leukemias. The fact that the virus re isolated from target organs induced only a low hematological diversification in bioassays in contrast to the virus formed outside of the target cell is an

essential finding in elucidating the mechanism of diversification. A further factor for the increased diversification and the correspondingly less identical reproduction is the use of virus from immature-cell leukemia, in our case paramyeloblastic leukemia. On the basis of our tentative hypothesis [8, 14] we assume that the virus produced in immature leukemia cells has less receptors from the mother cell due to the weaker specific character of the cell. This might be the reason of the reduced histotropy of the virus and the intense diversification of the leukemia types induced.

PASTERNAK and PASTERNAK [16] using MAP test were able to demonstrate Graft virus indirectly 1 day following infection in spleen, liver and brain and 3 days after infection in thymus and lymph nodes, too. Spleen and liver homogenates were most active in producing antibodies. Least activity was found in thymus and brain. This suggests that the induction of antibody formation by the virus and the leukemogenic action of the virus are closely correlated. A marked leukemogenic activity of brain filtrates has been observed in our experiments only after infection with virus from lymphatic or paramyeloblastic leukemias. In experiments of BEFFERT *et al.* [2] brain filtrates prepared 1-2 weeks after administration of Ha/JCR virus had a leukemogenic action by 1 log lower as compared with filtrates from spleen, liver and kidney.

A part of leukemias occurring in our investigations represented mixed forms. The presence of a mixed form can be diagnosed easily by the different mode of infiltration of the leukemia component. CHIECO-BLANCHI [3] who administered Graft virus to C57 Bl mice described the simultaneous occurrence of myeloid and lymphatic leukemias in an individual mouse. We could not confirm this observation, although we used much a greater experimental material.

Acknowledgment. We are indebted to Miss BARBETTE ZELAN, Mrs. DAOMAR RUCHTER, and Mrs. CHRISTINE GUTERMAN for their technical assistance.

Summary

Virus from hematologically different forms of GRAFT virus-induced leukemia was re-isolated from the sites of formation at different intervals after application in newborn mice. By bioassay it was investigated for its leukemogenic activity. Organ filtrates of mice inoculated with virus from myeloid leukemia show highest leukemogenic activity followed by virus from lymphatic leukemia. Most intense primary action was found in spleen filtrates

of mice treated with virus from myeloid and paramyeloblastic leukemias as well as thymus filtrates from mice treated with virus from lymphatic and reticular leukemias. An identical reproduction of given leukemia type is preferentially induced by virus isolated from organs containing target cells specific for the virus. The particular role of the spleen in myeloid leukemogenesis is discussed.

References

1. BEISWOLF D. Electron microscopic information on organ distribution of Graff's leukemia virus in leukemic and preleukemic mice. Proc. 3rd Int. Symp. comp. Leukemia Res., Paris 1967 *Bibl. haemat.*, vol. 31 pp. 57-60 (Karger Basel/New York 1968)
2. BERRYETT R. F. GRACE, J. T. DEMARAZO, L. A. and MIZUKI, E. A.: Recovery of murine leukemia virus prior to development of leukemia. Growth curve and dose response. *Cancer Res.* 26: 364-369 (1966)
3. CRIZZO-BIANCHI, L.; FIORE-DONATI, L. TERRYER, G. and PERVELLI, N. Lymphatic neoplastic transformation of thymus in mice with myeloid virus-induced leukemia. *Nature, Lond.* 208: 697-698 (1965)
4. DALTON, A. F. Microscopology of murine tumor viruses and of affected cells. *Fed. Proc.* 21: 936-941 (1962)
5. DEHAARD, E. and FRIBO, C. Electron microscope study of cell-free induced leukemias of the mouse. A preliminary report. *J. biophys. biochem. Cytol.* 4: 151-156 (1958)
6. FEY F. Tierexperimentelle Untersuchungen nach Reisolierung des Virus der myelischen Leukämie der Maus (Graff). *Folia haemat.*, Lpz (im Druck)
7. FEY F. und GRAFFI, A. Beeinflussung der myelischen Filtrleukämien der Maus durch Splenektomie. *Naturwissenschaften* 45: 471-472 (1958)
8. FEY F. und GRAFFI, A. Untersuchungen zur hämatologischen Aufspaltung der durch das Virus der myelischen Leukämie der Maus induzierten Leukosen. *Acta haemat.*, Basel 33: 139-159 (1963)
9. FEY F. und GRAFFI, A. Untersuchungen zur Pathogenese der durch das Virus der myelischen Leukämie der Maus induzierten Leukosen mittels selektiver Organfiltrate. *Krebsforsch. Krebsbekämpfung*, vol. 6, pp. 38-41 (Urban & Schwarzenberg, München/Berlin/Wien 1967)
10. FEY F. und SCHRAMM, E. J. Alkalische Phosphatase bei virusinduzierten Leukämien der Maus. *Acta biol. med. germ.* 11: 264-273 (1963)
11. FIORE DONATI, L. and CRIZZO-BIANCHI, L. Influence of host factors on development and type of leukemia induced in mice by Graff's virus. *J. nat. Cancer Inst.* 32: 1083-1107 (1964)
12. GRAFFI, A. BELKA, H. und FEY F. Leukämieerregung durch ein filtrierbares Agens aus malignen Tumoren. *Acta haemat.*, Basel 25: 143-174 (1963)
13. GRAFFI, A. and FEY F. Studies on the action of the myeloid virus of the mouse. *Comp. Leukemia Res., Proc. 1st Wenner Green Symp.*, Stockholm, pp. 51-54 (Pergamon, London 1965)
14. GRAFFI, A. FEY F. and SCHRAMM, T. Experiments on the hematologic differentiation of viral mouse leukemia. *J. nat. Cancer Inst., Monogr.* 27: 21-31 (1966)
15. KÄRCHER, W. und GRAFFI, A. Über das Vorkommen der myelischen Leukämie der Maus in verschiedenen Organen und zu verschiedenen Zeitpunkten nach künstlicher Infektion. *Acta biol. med. germ.* 5: 409-412 (1960)

16. PASTERNAK, G. and PASTERNAK, L.: Demonstration of Graft leukemia virus and virus-induced antigens in leukemic and nonleukemic tissues of mice. *J. nat. Cancer Inst.* **32**, 157-168 (1968)
17. PRINDELLI, N., CATECO-BIANCHI, L., TRIDENTE, G. and FIORA DONATI, L.: Virus particles in bone marrow megakaryocytes and susceptibility of mice to virus-induced leukemia. *Int. J. Cancer* **3**: 990-998 (1968)
18. UPTON, A.C., WOLFF, F.F., FURTH, J. and LIVERALL, A.W.: A comparison of the induction of myeloid and lymphoid leukemias in X-irradiated RF mice. *Cancer Res.* **18**: 842-848 (1958)

Department of Internal Medicine, University of Pavia, Pavia

Chronology of the Mitotic Cycle of Acute Leukemia Cells

E. G. ROYDANELLI, E. MAGLIULO, G. PILLA, F. FALCINI and
G. M. BARIGAZZI

Since the demonstration by the stathmokinetic test of ASTALDI and MAURI [1] that acute leukemia cells in the overall proliferate at a lower rate than normal granuloblasts, many other reports, based on radioisotopic techniques [2, 3, 4, 5, 6, 7, 8, 9, 10] have shown that in the majority of cases the production of acute leukemia cells may be inferior to that of normal granulocytopenias.

The purpose of this paper is to present some chronological values obtained by phase-contrast cine micrographic studies on proliferating acute leukemia cells.

Materials and Methods

Acute leukemia cells were obtained from bone marrow and peripheral blood of 10 acute (paraneoplastic) leukemia patients. Only those individuals were chosen in which the illness was diagnosed for the first instance. No previous specific treatment had been given. Only results obtained in those patients in which the leukemic process approximated steady condition were employed. This was stated by the number of blasts circulating in peripheral blood remaining constant for at least one week after the study.

A part of bone marrow and peripheral blood samples was smeared and stained with May-Griewald-Giemsa. The remaining particles of bone-marrow tissue were cultivated *in vitro* for 24 h and studied by phase-contrast cine-micrography according to technique already described [11].

Mitotic indices (mitoses/1000 cells) were determined on bone marrow and peripheral blood smears by counting 10,000 cells for patient. Each 1000 bone marrow acute leukemia cells were further divided in two classes according to size: "large cells with diameter $> 13 \mu\text{m}$, and small" cells with diameter $< 13 \mu\text{m}$.

Results

The results of studies on panoptically stained smears of acute leukemia (AL) bone marrow and peripheral blood are reported in

Table I. Cytological studies on smears of bone marrow and peripheral blood from AL patients

Patients	1	2	3	4	5	6	7	8	9	10	Average ± S.D.
Mitotic indices (mitoses/1,000 cells) in bone marrow AL cells	1.0	6.5	1.3	4.6	2.4	0.5	2.8	3.9	3.5	5.2	3.17 ± 1.94
Mitotic indices (mitoses/1,000 cells) in periph. blood AL cells	0.0	0.1	0.0	0.2	0.1	0.0	0.0	0.1	0.0	0.3	0.07 ± 0.11
Large cells/ 1,000 AL cells in bone marrow	33	301	77	395	164	250	433	163	138	320	220.5 ± 120.3
"Small" cells/ 1,000 AL cells in bone marrow	917	629	923	705	836	741	567	835	862	680	779 ± 120.5
Mitotic indices of AL cells cor- rected for the presence of 'small' cells	18.8	21.3	16.8	15.5	14.6	1.9	6.4	23.6	25.3	16.2	16.06 ± 7.27

Table II. Distribution according to mitotic phase of 517 karyokinesis counted in acute leukemia bone marrow smears

Mitotic phase	Prophase	Metaphase	Anaphase	Telophase
Absolute values	34	190	29	64
Percent values	10.72	59.93	9.14	20.18

tables I and II. The morphological development of AL cell mitosis is illustrated in figures 1 and 2.

The chronological values obtained by the phase-contrast cinematographic study of 20 AL cell divisions in the living state are reported in table III. As shown in table I, AL cells display a very low mitotic index in bone marrow. Furthermore, values very near to 0 are approached in peripheral blood. No mitoses were seen in 'small




Fig. 1. Morphological aspects of mitosis in an acute leukemia paraneurocytoblast. Frames from phase-contrast micro-record on living cells *in vitro*. 1 and 2 prophase. 3-5 metaphase. 6 and 7 profile view of the equatorial plate. 8-16 anaphase migration of daughter chromosomes toward the poles, with some cytoplasmic bubbling on 14-16.



Fig. 2. Same cell as seen in figure 1 in the course of telophase. The photos show the development and deepening of cytoplasmic furrow until cleavage of the cell in two separated daughter units. The cell exhibits emissions of cytoplasmic bubbles along its contour. Note the bilobed aspect of the nucleus in one daughter cell.

blasts so that a correction was afforded to mitotic indices, due to the presence of this non proliferating or at least very slowly proliferating fraction of cell population. Consequently a marked increase in mitotic indices resulted in the majority of cases, with an average

Table III. Duration of mitosis and its phases (min/sec) in AL cells studied *in vitro* by phase contrast cinematography

Mitosis No.	Prophase	Metaphase	Anaphase	Telophase	Total mitotic time
1	9'32	38'40	5'19	13'42	67'33
2	9'36	30'06	11'08	22'14	73'04
3	4'28	53'10	5'03	16'78	81'11
4	9'19	37'01	5'22	19'50	71'32
5	8'50	40'20	7'41	16'11	73'02
6	9'26	44'13	4'22	11'38	69'41
7	10'11	52'06	9'12	22'02	93'31
8	8'00	37'15	2'70	12'39	60'14
9	9'36	43'58	8'37	20'40	83'11
10	10'31	49'19	10'20	13'40	83'50
11	5'38	48'36	7'09	20'02	81'25
12	7'22	40'49	5'56	21'34	75'41
13	9'02	54'16	6'16	12'03	81'37
14	8'33	38'54	8'59	10'34	67'20
15	11'50	42'39	10'50	20'43	86'04
16	7'43	33'08	4'41	22'59	68'33
17	7'34	48'00	7'06	17'78	80'58
18	4'20	35'31	6'48	19'54	67'33
19	12'27	47'00	5'24	21'43	86'34
20	12'46	36'33	8'46	16'00	74'05
Mean	8'53	43'46	7'07	17'38	77'25
SD	1'11	7'39	2'21	4'04	7'38

value being approximately fivefold the mean of mitotic indices of the whole leukemic cell population (proliferating + non proliferating cells). A large proportion (59.93 %) of mitotic figures was in metaphase (table II). A minor number (20.18%) were in telophase followed by prophase (10.72 %) and anaphase (9.14 %).

Mitosis in leukemia cells studied by phase-contrast cinematography had a mean duration of 77 min 25 sec \pm 7 min 38 sec (table III). The major part of average karyokinetic time was spent in metaphase (about 56 % of mitotic time) and at a lesser degree in telophase (22 %) and then in prophase (11 %) and anaphase (9 %). For each mitotic phase the percent fraction of mitotic duration appeared well correlated with the relative incidence among mitotic figures in bone marrow smears.

Discussion

Evidence is being accumulated that acute leukemia cells are not provided of high proliferative potentials [1-10]. In such an instance, the comparison is made with normal granulocytopoietic cells, so that more extensive informations on time parameters of mitotic cycle of both normal and leukemic cells are urgently needed.

In a previous report [11] we made an attempt to characterize the chronology of normal granulocytopoietic proliferation. The time estimates were performed by combining informations derived from mitotic indices in bone marrow smears and mitotic durations directly determined on living cells.

A similar series of data on acute leukemia cells is presented in this paper basing on the assumption that possible influences due to the *in vitro* environment would exert their action to the same extent on both normal and leukemic cells. Furthermore the chronological data previously presented fit well with kinetic data obtained by radioisotopic techniques. Thus it is assumed that our chronological data were approaching the *in vivo* situation more closely than those obtained by other *in vitro* methods.

In the present report the low mitotic index of acute leukemia cells [1 12 13 14 15] is confirmed. Extremely rare mitoses were found in peripheral blood, so that, for sake of simplicity circulating AL cells were considered non proliferating elements and AL cells were assumed to be produced almost exclusively in bone marrow. The great majority of mitoses in bone marrow were confined to large blasts.

As the mitotic index is given by the ratio mitoses/cells capable of division mitotic indices were corrected for the presence, in the denominator of the 'small' cells not capable of division. It is interesting enough that the corrected mitotic indices ranged from a minimum of 1.9‰ and a maximum of 25.3‰ with an average of $16.06 \pm 7.27\%$ thus approaching in the majority of cases that of normal myeloblasts (23.64 ‰) and being even higher than that of normal promyelocytes (13.28‰). If we could make a further correction of mitotic indices for the presence of non proliferating cells also in the 'large blast' population, probably values superposable to those of normal myeloblasts would be attained.

It is well known that the mitotic index is a measure not only of cell production, but also of relative mitotic duration [1]. The chrono-

logical studies performed in the living afforded values of AL cell mitotic time (77 min 25 sec) much higher than those previously obtained in normal granulocytopoietic cells (44 min 47 sec in myeloblasts, 53 min 59 sec in promyelocytes and 65 min 23 sec in myelocytes) thus confirming also the reports by BOLL *et al* [14-15]

As already mentioned [16, 17] mitosis in undifferentiated stem cells lasts longer than in differentiated parenchymal cells. This fact shows that AL cells behave as an undifferentiated population also at the level of mitotic duration. Furthermore the emission of cytoplasmic bubbles during AL cell cytokinesis (fig 2) constitutes an almost exclusive morphological characteristic of undifferentiated hemopoietic cells [17]. A good correlation was found between the fraction of mitotic time attributable to each karyokinetic phase and the frequency (over 100 mitoses) of karyokinetic figures pertaining to the same phases in bone marrow smears, the latter frequency thus being a good marker of relative mitotic phase duration.

The finding of a mitotic time longer than normal may be discussed in terms of the overall proliferative potentials of AL cells. However as HILLMANN recently pointed out [9-10-18] a great many assumption must be made in order to compare normal and leukemic hemopoiesis on the basis of mitotic (or labeling) indices and durations of mitosis (or of other phases of mitotic cycle)

First of all AL cell proliferation is characterized neither by a steady-state condition nor presumably by an 'orderly' timed progression. The proliferative potentials are very variable in relation to different patients and to different phases of the illness in the same patient [19-20-21]. Cell death rates and the exact proportion of cells maturing without division, or of cells dividing in extramedullary sites, are unknown. Furthermore the nature (multiplicative or stem cell) of proliferating compartments has not yet been defined though GAVOSTO [19] recently suggested the existence of an unrecognized stem cell compartment feeding into the multiplicative blast line. It is not known whether apparently non dividing cells are able to resume proliferative activity under certain stimuli.

We may accept that in the patients studied by us a steady condition was approached at least for the relatively brief duration of the experiments, and that AL cell production was almost exclusively or prevalently confined to 'large' blasts in bone marrow. Small blasts could well constitute a non proliferating maturative-like subpool.

If 'large' blasts were the stem-cells of the system or at least cell entry from other unrecognized compartments in small AL cell proliferation could be approached to that of a proliferating pool initiated by a stem cell and terminated by a heteromorphogenetic division [18] i.e. the last division of 'large' blasts giving rise to two cells ('small' blasts) morphologically different from their mother-cell. This could be the case in figure 2 where one of daughter cells is provided with a bilobed nucleus.

This is a very hypothetical construction which obviously does not correspond exactly to the real conditions, but it is the only one which allows to make some computations on the bases of mitotic indices and mitotic times, even if the latter though rather physiological were obtained *in vitro*. For a full discussion of the limits to the application of such indices for estimating proliferative time parameters the paper of KILLMANN *et al* may be consulted [18]. Suffice it to say that the computed weighted average generation time for the 'large' blast compartment should be 80 h. Such a generation time might correspond to transit time if AL 'large' blasts undergo only one division and phase transition ('large' becoming 'small') corresponds to mitosis. This does not seem to happen in real conditions [21]. Otherwise only a maximum transit time could be computed by $N/K_{exit} = N/K_M$ where N = cell number in the population, K_{exit} cell exit rate and K_M = mitotic rate, the latter being computed in 12.44/1 000 'large' blasts. The maximum transit time should then correspond to 284 h, that is 11 days. In a previous report we presented some time estimates for normal granuloblasts [11]. The weighted average generation time for all granulocytic precursors capable of division was less than 90 h and probably very near to 60 h. The transit time of myeloblasts was 31 h with a total transit time of granulocytopoietic cells of 127-240 h. These values are rather shorter than those computed for AL cells.

We may not state that the structure of the proliferating pools of normal granuloblast and acute leukemia cells is comparable. However such data prompt us to consider that generation time and transit times of 'large' leukemia blasts are longer than those of normal granuloblasts considered in the whole. If the comparison was to be made between AL 'large' blasts and their nearest normal counterparts, the myeloblasts, or between the total blast population ('large' + 'small') and the total normal granulocytopoietic population an even lower than normal proliferative potential could be assessed for AL.

cells. Our assumptions are in good agreement with the concepts recently expressed by KILLMANN [10] in a review on AL cell proliferation. The data of previous authors show that at least in the majority of adult cases the generation time of leukemic blasts is not only longer than that of normal myeloblasts but also than that of the whole normal granulocytopoietic precursors. This confirms what has been previously stated by early investigations by the stathmokinetic test [1]

Summary

Samples of bone marrow and peripheral blood from 10 patients with acute paraneoplastic leukemia were studied by determining mitotic indices, relative phase frequencies, *in vivo* duration of mitosis and its phases, and by computing the average generation time and transit time. The results are in accord with the thesis that the proliferative activity of acute leukemia cells is lower than that of normal granulocytopoietic cells.

References

1. ATTALDI, G. et MAURI, G. Recherches sur l'activité proliférative de l'hémocytoblaste de la leucémie aiguë. *Rev. belge Path.* 23, 69 (1953)
2. LAJTHA, L. J. On DNA labeling in the study of the dynamics of bone marrow cell population; in *The kinetics of cellular proliferation*, p. 173 (Grune & Stratton, New York/London, 1959)
3. GAVOTTO, F., MARADEI, G. and PILERI, A. Nucleic acids and protein metabolism in acute leukemia cells. *Blood* 16, 1555 (1960)
4. GAVOTTO, F.; PILERI, A.; BACCI, C. and PROSSATO, L. Proliferation and maturation defect in acute leukemia cells. *Nature, Lond.* 203, 22 (1964)
5. MAUER, A. M. and FISHER, V. Comparison of the proliferative activity of acute leukemia cells in bone marrow and blood. *Nature, Lond.* 193, 1066 (1962)
6. CRADDOCK, C. G. and NAKAI, G. S. Leukemic cell proliferation as determined by *in vivo* deoxyribonucleic acid synthesis. *J. clin. Invest.* 41, 360 (1962)
7. PILERI, A. et al. Cytochemical and proliferative characteristics of acute promyelocytic leukemia cells. *Europ. J. Cancer* 2, 189 (1966)
8. STORTI, E. and TORRELLI, E. RNA and protein metabolism in normal and leukemic leukocytes as studied by autoradiography; in HAYTHOR, *Current research in leukaemia*, p. 108 (University Press, Cambridge 1963)
9. KILLMANN, S. A. Acute leukemia. The kinetics of leukemic blast cells in man. An analytical review. *Ser. haemat.* 1, 28 (1968)
10. KILLMANN, S. A. Acute leukemia. Development, remission/relapse pattern, relationship between normal and leukemic hemopoiesis and the 'deeper-to-further' stem cell hypothesis. *Ser. haemat.* 1, 103 (1968)
11. RONDANELLI, E. G., MAGGIULO, E., CAROÙ, F. P. and GIRALDI, A. The chronology of the mitotic cycle of human granulocytopoietic cells. Phase-contrast studies on living cells *in vivo*. *Blood* 30, 537 (1967)
12. ATTALDI, G., RAVETTA, A. Studio anatomico-funzionale del midollo osseo nella leucemia acuta. *Haematologica* 26, 637 (1942)

13. SALERA, U and TANCHINO, E: The proliferative activity of leukemic cells. A quantitative study of the mitotic rate and the average mitotic time. *Sci. med. ital.* 4: 425 (1956)
14. BOLL, I. und GAMER, O: Die Mitosedauer der Parakleukoblasten. *Acta haemat., Basel* 27: 229 (1962).
15. BOLL, I.: Granulocytopenie unter physiologischen und pathologischen Bedingungen, pp. 67-93 (Springer Berlin/Heidelberg/New York 1966).
16. RONDANELLI, E. G., GORDA, P. and PECORARI, D.: Influence of differentiation and maturation upon the time cycle of mitosis in normal hemopoietic cells cultivated *in vivo*. *Haemat. ital.* 2: 35 (1959)
17. RONDANELLI, E. G., GORDA, P., GORDA, G., MAGGIOLIO, E.: La ciclofasi delle cellule emopoietiche normali e patologiche. *Bibl. haemat.*, vol. 41 (Viscontini, Pavia 1968).
18. KILMARX, S. A.; CROWTHER, E. B.; FLEISCHER, T. M.; BORN, V. P. and BERNARD, G.: Mitotic indices of human bone marrow cells. II. Considerations on the use of mitotic index data for estimate of time parameters in proliferating cell systems with particular reference to serially connected multiplicative compartments. *Blood* 21: 241 (1963).
19. GAVOTTO, F. and FILLI, A.: Proceedings of IAEA Symposium on the Effect of Radiation on Cellular Proliferation and Differentiation, Monaco 1968.
20. MAIER, A. M. and FERRA, V.: Characteristics of cell proliferation in four patients with untreated acute leukaemia. *Blood* 28: 428 (1966)
21. CLARSON, B.; OKITA, T.; OTA, K. and FAIR, J.: Studies of cellular proliferation in human leukemia. I. Estimation of growth rate of leukemic and normal hemopoietic cells in two adults with acute leukemia given single injections of tritiated thymidine. *J. clin. Invest.* 46: 506 (1967)

Department of Clinical Pathology Royal Victoria Hospital, Belfast

Distribution of Amino Acids in Urine, Plasma, Leucocytes and Erythrocytes of Leukaemic and Normal Subjects

MAUREEN B. LEE, C. DENTIE BOLGER and J. M. BRIDGES

A variety of regimes, based on modification of the dietary amino acid content, has been advocated in the management of acute leukaemia. ALLAN *et al.* [1] gave supplements of phenylalanine and tyrosine to 5 children including one in whom it was the only therapy and in whom the total white and blast cell counts fell. HALIKOWSKI *et al.* [6-7] and HILSON [8] gave diets with low purine and low animal protein content in addition to conventional therapy and they felt that these were associated with better responses. The relative value of these various regimes, as all the authors emphasise must await further larger and more rigorously controlled clinical trial. Evaluation of this type of therapeutic approach would be helped if there was knowledge of how the leukaemic subjects differed from normal with regard to their amino acid metabolism.

In a previous study [11] we reported on the urinary amino acid pattern in leukaemic and normal subjects and in this report we extend these studies to an analysis of the amino acid composition of normal and leukaemic plasma, red and white cells.

Materials and Methods

Fifty healthy hospital staff served as controls and 36 patients with leukaemia (20 acute, 8 chronic lymphatic and 8 chronic granulocytic) were studied. In all patients the clinical, peripheral blood and bone marrow findings were typical of the respective types. Patients were at various stages of their illness and were receiving treatment with steroids and cytotoxic agents. Blood and urine samples were taken without reference to previous protein intake and at least 2 sets of specimens were obtained from each patient. Subconized glassware was used throughout the preparation of blood specimens.

Blood samples (10 ml) were anticoagulated by the addition to diaminocethane-tetraacetate (2.0 mg/ml EDTA). After centrifugation at 900 g for 10 min, 2 ml of plasma was removed and replaced by 2 ml Intradex (Glaxo Laboratories). This caused rapid sedimentation of the red cells and some 30 to 60 min later the supernatant plasma containing many white cells, but only a few red cells was removed. The cells were deposited by centrifugation at 100 g for 10 min and the supernatant discarded. By the addition of 5 ml of ice cold water remaining in contact with the cells for not more than 30 sec, the red cells were lysed. Then 5 ml of 1 percent solution of EDTA in hypotonic saline buffered with glycylglycine (pH 7.0) was added [7]. The cells were resuspended and washed twice in isotonic buffered saline (1% EDTA, pH 7.0) and finally resuspended in 1 ml. The white cell count was carried out and the suspension was homogenised by sonication for 2 min.

Red cell haemolysates were prepared from red cells washed three times in normal saline and then made up to give final PCV of 55% with distilled water. Haemolysis was completed by 3 cycles of freezing and thawing. Plasma, the red cell and the white cell homogenates, were filtered to dryness in a Sartorius membrane filter over an ice bath and the free amino acids were collected in the filtrate. Urine and the filtrates were desalted by electro dialysis, using the Baird & Tatlock ion exchange apparatus [19-22]. 150 μ l of plasma and red cell homogenates, volumes of white cell homogenate to correspond to an extract from 10,000 cells (60-150 μ l) and a volume of urine corresponding to a total non-protein nitrogen of 250 mg (50-200 μ l) were used for chromatography.

The chromatographic method was as previously described [11]; 8 mm chromatography paper No. 541 placed on racks [4] were developed in 25% phenol solution with ammonium added. The second solvent, run at right angles to the first, was saturated 2,4,5 trichlorobenzene (Yorkshire Tar Distillers). The amino acid spots were identified by comparison with pre-constructed map of known amino acids. Spot densities were scored from 1-10 by comparison with 5 μ l of α -amino-octanoic acid (scored 5) which was run with each batch of papers. The score, assessed by the same person throughout the study was presented as the average obtained by dividing the total value for each of the amino acids by the number of specimens in each group. The numbers thus obtained for each of the 16 amino acids in the leukaemic group and in the control group were compared.

Results

The results of the urine, plasma, white cell and red cell chromatograms from the control and leukaemic subjects are shown in tables I-IV.

In the urinary chromatograms the leukaemic groups show very similar patterns, apart from the low methyl histidine in chronic granulocytic leukaemia and the low serine in chronic lymphatic and chronic granulocytic leukaemia. Comparison of all leukaemic subjects with the controls showed that in the former glutamic acid and methionine were increased, whereas valine was decreased.

The amino acid levels in the plasma from the leukaemic patients were very similar the only exception being the serine level which was lower in the chronic granulocytic and lymphatic groups. Compar

Table 1 Amino acid distribution in urine

	Arg Lys Orn	Pro	Meth Hist	Gln NH ₂	Asp	Glu acid	Gly	Ser	Ala	Threo Meth	Val	Leu	Tau	Tyr	Try	Cys
Control	0.3		0.32	1.6	2.4	2.0	0.9	3.1	2.3	0.1	0.1	0.8	0.9	2.4	0.7	-
Acute hepatoma	0.78	0.06	0.50	1.3	2.6	2.0	2.3	3.3	2.9	0.63	1.4	0.4	0.63	2.1	0.9	0.1
Chronic granulocytic hepatoma	0.63	0.01	0.09	1.2	2.9	1.9	2.0	2.9	1.1	2.4	0.3	1.4	0.8	1.3	0.3	-
Chronic lymphatic hepatoma	0.4	0.03	0.3	1.1	2.3	1.8	1.9	2.6	0.63	2.8	0.23	2.6	0.4	1.8	0.2	-

Table 2 Amino acid distribution in plasma

	Arg Lys Orn	Pro	Meth Hist	Gln NH ₂	Asp	Glu acid	Gly	Ser	Ala	Threo Meth	Val	Leu	Tau	Tyr	Try	Cys
Control	1.16	2.9		3.6	1.1	2.1	3.1	1.8	3.3	2.83	1.2	4.3	3.8	1.1	0.34	-
Acute hepatoma	1.3	1.7		0.12	4.8	1.6	1.7	2.2	1.4	4.0	0.73	1.1	3.7	0.23	0.74	-
Chronic granulocytic hepatoma	1.8	2.1		0.04	3.1	1.7	2.4	2.6	0.7	4.8	0.9	0.8	4.1	0.3	0.9	-
Chronic lymphatic hepatoma	1.99	1.9		0.04	3.8	1.4	2.1	2.3	4.1	1.0	0.9	3.2	3.2	0.2	0.7	-

Table III. Amino acid distribution in white cells

Arg Lys Orn	Pro	Meth Hist	Hist	Glut NH ₂	Asp	Glu acid	Gly	Ser	Ala	Threo	Meth	Val	Leuc	Iso	Tyr	Trp	Cys
		-		2.0	2.2	2.1	1.7	1.4	2.3	0.1	0.13	1.2	1.5	2.0	-	-	-
0.64	0.3		0.08	1.5	2.2	2.7	1.7	1.1	3.0	0.04	0.4	1.7	2.3	3.4	0.16	-	-
0.91	0.28		0.41	1.46	1.7	1.5	2.4	2.2	3.5	1.2	0.25	2.3	3.5	2.2	1.0	-	-
1.3	0.08	-	0.21	0.91	1.5	2.5	2.2	1.8	2.8	0.68	0.33	1.4	2.3	2.4	0.20	-	0.12

Table IV. Amino acid distribution in red cells

	Arg Lys Orn	Pro	Met	1Het	Gln NH ₂	Asp	Glu acid	Gly	Ser	Ala	Threo	Met	Val	Leuc	Ten	Tyr	Try	Cys
Control	0.08	0.08	-		3.0	3.5	4.0	2.2	2.3	3.0	0.58	0.08	1.3	1.2	0.83	-	-	-
Acetic																		
Acetic	0.35	0.1		0.2	2.2	3.1	2.5	1.8	1.0	2.1	1.5	-	0.71	0.95	0.11	-	-	-
Chronic																		
Chronic	0.22		-		2.2	3.1	2.5	1.3	1.0	2.1	0.5	-	0.85	0.9	0.5	-	-	-
Chronic																		
Chronic	0.26				2.1	4.6	2.4	2.0	0.8	1.3	0.2	0.06	0.8	0.9	0.46	-	-	-

ed with the normal, the leukaemic plasma had less threonine and taurine and apart from traces of histidine not found in the controls, no significant increase in any amino acid was noted.

Analysis of the chromatograms prepared from the white cell homogenates showed that within the leukaemic groups there was a great deal of variation and no overall pattern could be deduced. All leukaemic groups showed an increased threonine and a decreased taurine whilst small amounts of arginine, lysine, proline, histidine and tyrosine were present which were not seen in the controls. In the chronic lymphatic group glutamine and aspartic acid were low whilst in the chronic granulocytic group serine, valine and leucine were increased relative both to the other types of leukaemia and the controls.

The amino acid patterns from red cells in the leukaemic groups were very similar except that in acute leukaemia the threonine level was elevated. Comparison of the leukaemic with normal red cells showed increased arginine and lysine, whereas the glutamic acid, serine and taurine values were decreased.

Discussion

The finding of high urinary methionine and decreased valine in leukaemic subjects is similar to that of a previous study [11]. The reason for this is not clear but it does not follow from changes in the plasma, which in the leukaemic subjects showed that the methionine and valine levels were similar to the control values. In the material here studied the levels of plasma taurine and threonine were decreased, but the other amino acids were normal. KELLY and WATMAN [10] in a study of the plasma amino acids of leukaemic subjects also found threonine to be lower than normal. In all types of leukaemia they found glutamic acid to be elevated, a finding also reported by other workers [20-21]. ROUSER [16] found glutamine levels to be very low in the plasma of leukaemic patients.

The red cells of our leukaemic patients showed a decreased level of glutamic acid, serine and taurine. ROUSER *et al* [18] found red cell glutamic acid to be low in all leukaemic patients and in some cases glutamine and aspartic acid were increased. McMENAMY *et al* [13] found the glutamic acid and serine content of red cells from leukaemic patients to be increased.

As would be expected, the most striking changes in this study were found in the amino acid content of the white cells. We found the arginine lysine proline, histidine and threonine increased and the taurine level decreased in all leukaemic groups, whereas only with the chronic myeloid leukaemic was the aspartic acid content low. decreased taurine was also found in the leukaemic plasma and red cells. Nour Eldin and Wilkinson [14] reported the taurine content of leukaemic cells to be lower than normal, whereas Iyer [9] found this amino acid to be significantly elevated in leukaemic leucocytes.

In this type of study as with many involving leukaemic white cells, it is not possible to obtain satisfactory control material and thus one is comparing primitive leukaemic cells with normal mature cells. In our method we studied the extract from the same number of white cells in each subject, but for the leukaemic this probably represented a greater cellular volume, and the influence of this cannot be ascertained. From our results, and those of other workers, no discernible patterns involving any particular amino acid emerges for any specific type of leukaemia. It is interesting to note that many of the changes were similar for the various types of leukaemia and this has also been noted by other workers. The interpretation of this type of material is hindered by the fact that the level of plasma amino acids may vary throughout the day [23]. Changes in amino acid patterns may also depend on protein intake [5 12] and certain complications of the disease and therapies may of themselves, cause changes [3 15 17 24]. Some of our patients were on steroid therapy were having blood transfusions or a variety of cytotoxic agents. If material is limited to patients examined prior to therapy then the numbers available would be very low. A further difficulty is in the method of separation of amino acids by chromatography and the recording of the results as minor variations in techniques may lead to substantial changes in the results obtained. It would seem that the limitations of this type of study are such that it is unlikely that our understanding of the nature of the leukaemic process will be enhanced by them.

Summary

Amino acid distribution in urine, plasma, white cell homogenate and red cell haemolysate from 36 patients with various types of leukaemia was compared with 50 control subjects. The patterns within the leukaemic groups were rather similar and, as between control and leukaemic groups, there were only minor differences.

References

1. ALLAN, J. D., IRELAND, J. T., MILNER, J. and MOSS, A. D.: Treatment of leukaemia by amino acid imbalance. *Lancet* **i**: 302 (1963).
2. ARCHER, R. K.: Isolation of eosinophils from the blood. The eosinophil leucocytes, p. 117 (Blackwell, London/Oxford 1963).
3. BLUM, E. L., SANDERCO, A. A., NELSON, D. H. and ENGLISH, R.: Normal levels of 17 hydroxy corticosteroids in peripheral blood of man. *J. clin. Invest.* **32**: 818 (1953).
4. DATTA, S. P., DEUT, C. E. and HAKER, H.: An apparatus for the simultaneous development of many two dimensional paper chromatograms. *Science* **112**: 621 (1950).
5. FRANK, E. G.: The levels of individual amino acids in the plasma of normal man at various intervals after a high protein meal. *J. clin. Invest.* **37**: 1710 (1958).
6. HALIKOWSKI, B., ARMATA, J. and GARWICK, S.: Low-protein purine-free diet in treatment of acute leukaemia in children. Preliminary communication. *Brit. med. J.* **i**: 519 (1966).
7. HALIKOWSKI, B., ARMATA, J. and GARWICK, S.: Low-protein and purine free diet in acute leukaemia in children. *Polish med. J.* **5**: 556 (1966).
8. HIRAO, D.: Low protein diet in leukaemia. *Brit. med. J.* **i**: 979 (1966).
9. IYER, G. Y. N.: Free amino acids in leucocytes from normal and leukaemic subjects. *J. Lab. clin. Med.* **54**: 229 (1959).
10. KELLY, J. S. and WAMMAN, H. A.: Quantitative plasma amino acid values in leukaemic blood. *J.* **633** (1957).
11. LEX, M. B., NELL, D. W. and BANDERS, J. M.: Urinary amino acid excretion in subjects with leukaemia. *J. clin. Path.* **20**: 70 (1967).
12. McLACHLAN, J. M., VOGL, F. S., MORRISON, A. B. and CASARELLI, J. A.: Blood amino acid studies. IV. Some factors affecting plasma amino acid levels in human subjects. *Canad. J. Biochem.* **41**: 191 (1963).
13. McMENAMY, R. H., LEWIS, C. H. and WALLACE, D. F. H.: Unbound amino acid concentrations in plasma, erythrocytes, leucocytes and urine of patients with leukaemia. *J. Lab. clin. Invest.* **37**: 1683 (1960).
14. VOGL-ELDER, F. and WILKINSON, J. F.: Amino acid content of white blood cells in human leukaemia. *Brit. J. Haemat.* **7**: 338 (1955).
15. RUTLER, R. S. and MELNICK, K. L.: Cortisone-provoked depression of plasma-tyrosine concentration. Relation to enzyme induction in man. *J. clin. Invest.* **44**: 1690 (1963).
16. ROUSSER, G.: Free or easily extractable amino acids in blood cells and body fluids in leukaemia. BETHUNE and MORTO. The leukaemias. Henry Ford Hosp. Symp., p. 371 (Academic Press, New York 1957).
17. ROUSSER, G., KELLY, K., JELDER, B. and HELLER, D.: Free amino acids in the blood of man and animals. V. Effects of nyloran, dimethyl nyloran and related compounds in chronic granulocytic leukaemia. In HOLDEN. The amino acid pools, p. 413 (Elsevier Amsterdam 1961).

18. ROOPER, G.; KELLY ; SAMUELS, A. J ; JELDKER, B. and HELLER, D : Free amino acids in the blood of man and animals. II. Normal individuals and patients with chronic granulocytic leukaemia and polycythaemia; in HOLDEN, The amino acid pools, p. 373 (Elsevier Amsterdam 1961)
19. SMITH, I : Dialysis and related techniques. Electrodialysis, chromatographic and electrophoretic techniques. 2nd ed., p. 51 (Heinemann, London 1960)
20. WALKER, D. G.; PRASAD, A. and SADRUK, J : Free amino acid levels in ultrafiltrates of human blood plasma. *J. Lab. clin. Med.* **59**: 110 (1962).
21. WHITE, J. M.; OZAWA, G., ROM, A. L. and McILHENRY E. W. An effect of acoplasm on glutamic acid metabolism in the host. *Cancer Res.* **14**: 508 (1954).
22. WOOD, T : Desalting of urine by electrodialysis. *Nature, Lond.* **186**: 634 (1960).
23. WURTMAN, R. J : ROSE, C. M., CARMAN CHOU, M. S. and LARIN F. F. Daily rhythms in the concentration of various amino acids in human plasma. *New Engl. J. Med.* **279**: 172 (1968).
24. WURTMAN, R. J : ROSE, C. M.; ROSE, L.; WILLIAMS, G. and LUTLER, D. Diurnal amino acid rhythms in endocrine diseases. *Clin. Res.* **16**: 335 (1968).

Hematology Division, University of Nebraska Medical Center Omaha, NE

Suppression by RNA of Human Lymphocyte Transformation

P. G. RIGBY and D. M. JOHNSON

RNA from yeast added to normal human lymphocyte cultures has been shown previously to inhibit cell proliferation of phytohemagglutinin (PHA) stimulated cells [1-3]. The mechanism by which this suppression takes place and the potential sources and kinds of RNA concerned have not been determined [1-4]. A considerable amount of literature is available regarding the nature and action of RNA, including the kinetic study of RNA metabolism in lymphocyte-type cells as well as other biological systems [5-11]. The purpose of this paper is to investigate further the amounts and types of RNA which will produce suppression of human lymphocyte transformation (HLT).

Materials and Methods

The method of lymphocyte culture is based on that reported by BAIRD and HENNINGSON [12] and later by JOHNSON *et al.* [1-3] from this laboratory. Heparinized human blood was allowed to sediment at 37° C in screw cap glass tubes for 3 h. Supernatant plasma was removed and 1-2 million cells in plasma were pipetted into flint glass prescription bottles containing 3 ml of medium (MEM 1 Spinner media, supplemented with 20% fetal calf serum, penicillin, streptomycin, and L-Glutamine). The basic suspension was varied by the addition of phytohemagglutinin (PHA) 0.02 ml/ml culture medium (General Biochemicals, Lot No. 661601).

Yeast RNA at varying concentrations from 0.03 to 30.0 mg/culture (Mann Research Laboratories, Inc., Lot No. L-1941) was utilized. Polyuridylic acid (Mann Research Laboratory Inc. Lot No. T 3135) was obtained and utilized in the tissue cultures as indicated.

The suppression of lymphocyte growth and transformation was observed by cell counts on the 1st, 4th, and 7th days, using Cetrinide (1:10 dilution in 1% acetic acid concentration, 5 mg/ml) to avoid the clumped lymphocytes seen with the PHA incubation [13]. Cell cultures were done in triplicate and counts in duplicate. Transformation was suppressed

Table I. HLT suppression with RNA titration and effect of retyophillization (all cultures have phytohemagglutinin)

Exp.	Test materials	Amount of RNA mg/culture	Cell No. Mean \pm SE $\times 10^4$	P
A	Control	none	1.55 \pm 0.12	
	Yeast RNA	30.0	0.11 \pm 0.04	< 0.01
		0.3	0.70 \pm 0.03	< 0.05
		0.03	1.28 \pm 0.1	> 0.05
		0.003	2.15 \pm 0.31	< 0.01 (increased)
B	Control	none	1.93 \pm 0.47	
	Yeast RNA	3.0	0.06 \pm 0.03	< 0.01
		0.9	0.49 \pm 0.08	< 0.01
C	Control	none	1.89 \pm 0.06	
	Yeast RNA	0.9	1.07 \pm 0.10	< 0.01
		0.3	0.64 \pm 0.05	< 0.01
D	Control	none	2.89 \pm 0.29	
	Retiophillized yeast RNA	3.0	0.48 \pm 0.09	< 0.01
	Yeast RNA	3.0	0.26 \pm 0.02	< 0.01
E	Control	none	3.96 \pm 0.29	
	Yeast RNA	3.0	2.50 \pm 0.06	< 0.01
	Retiophillized yeast RNA	3.0	2.25 \pm 0.18	< 0.01

when the counts of all cells in the culture on the 7th day were significantly reduced from control levels (table I). The morphological evaluations using Wright's and/or Acridine Orange staining were entirely consistent with the suppression of HLT noted on the basis of cell counts, showing consistently lower percentage of transformed cells with fewer counts as previously reported [1-3].

Results

(1) Suppressed HLT occurred with yeast RNA in amounts of 0.3 0.9 3.0 and 30.0 mg of RNA/culture as seen in table I.

(2) Suppressed HLT occurred with yeast RNA after retyophillization (table I).

(3) Polyuridylic acid, simulating artificial messenger RNA, did not suppress HLT in PHA stimulated cultures in doses of 0.01 to 2.0 mg/culture. However a significant reduction in cell numbers was observed with polyuridylic acid alone (table II).

Table II. The effect of polyuridylic acid on HLT

Exp.	Test material	Amount of RNA mg/culture	Cell No. Mean \pm SE $\times 10^4$	P
A	Polyuridylic acid (without PHA)	none	0.60 \pm 0.01	
		1.33	0.41 \pm 0.03	< 0.01
		0.5	0.35 \pm 0.11	0.02
		0.05	0.52 \pm 0.04	> 0.05
		0.005	0.75 \pm 0.06	< 0.01 (increased)
B	Polyuridylic acid (with PHA)	none	2.18 \pm 0.61	
		1.33	3.09 \pm 0.21	> 0.05
		0.5	2.16 \pm 0.16	> 0.05
		0.05	1.35 \pm 0.16	> 0.05
		0.005	2.67 \pm 0.39	> 0.05

(4) The finding of a significant increase in cell numbers when small doses of RNA or polyuridylic acid were utilized may indicate a possible additional stimulating effect.

Discussion

RNA from yeast, before and after rehyophilization, has been shown to decrease the transformation of lymphocytes in tissue culture stimulated by PHA. The possibility that a contaminant is responsible for this effect is reduced by the observations that rehyophilized RNA is effective and that increasing doses of RNA give increasing suppression. Polyuridylic acid, simulating an artificial messenger RNA, did not suppress PHA stimulated HLT though a reduction in cell count was observed without PHA. Further study may show whether the suppressive effect is encountered with other kinds or fractions of RNA.

An understanding of the specificity of PHA and its action on the human lymphocyte has not been fully elaborated at this time. The site of RNA action in these studies is unknown. RNA has been reported to be on the surface of human cells, as well as in the cytoplasm and nucleus [14-16]. RNA is known to be incorporated into living cells in a number of experimental systems [2, 17]. The effect of RNA on

lymphocytes when PHA is not added is not as dramatic, but may show some suppression [9]. In the present study polyuridylic acid showed some effect without PHA. The apparent stimulation of HLT by small amounts of yeast RNA (with PHA) or poly U (without PHA) requires further study for satisfactory explanation.

The relationship between suppressed HLT by RNA and altered lymphocyte function can be correlated with *in vivo* transfer experiments using RNA in animals [18, 19]. RNA extracted from Ehrlich ascites tumor given at a dose of 4 mg/day for 8 days, as well as that extracted from white Swiss mouse liver (same dosage) have been shown to delay skin allograft rejection in mice (as well as yeast RNA) [18, 19]. The allografts were from C57/Black mice given to white Swiss mice; the normal rejection time was 9.5 days and the delays were to 12.5 and 11.4 days ($p < 0.01$) respectively [18, 19].

The findings of suppressed human lymphocyte transformation *in vitro* and delayed skin allograft rejection *in vivo* support the hypothesis that biological interference with immunologic function is possible with RNA [20].

Summary

Human lymphocyte transformation (HLT) with PHA was suppressed by the addition of RNA in tissue culture. Polyuridylic acid, simulating artificial RNA, did not suppress HLT in similar dosages in PHA stimulated cultures. The relationship between suppressed HLT by RNA and altered lymphocyte function has been correlated with *in vivo* transfer experiments using RNA in animals.

References

1. JOHNSON, D., PRATT, P. T. and RIGBY, P. G. Lymphocyte nuclear RNA and immune competence. 11th Congr. Int. Soc. Hemat. (Bilgite, Sydney 1966).
2. JOHNSON, D. M., PRATT, P. T. and RIGBY, P. G. An evaluation of human lymphocyte nuclear RNA with Acridine Orange. *Blood* 29: 800 (1967).
3. RIGBY, P. G., JOHNSON, D. M. and SHAMAM, A. R. Serial studies of human lymphocyte nuclear RNA in tissue culture. *Clin. Res.* 16: 323 (1968).
4. HOLLOUTCH, V., FARMER, L. and CHOCKER, T. T. The inhibition of nuclear RNA synthesis by added RNA. *Exp. Cell Res.* 44: 362-374 (1966).
5. KILLANDER, D. and RIGBY, P. G. Initial changes of deoxyribonucleoprotein and synthesis of nucleic acid in phytohemagglutinin-stimulated human leucocytes *in vitro*. *Exp. Cell Res.* 35: 701-704 (1965).
6. COOPER, H. L. and RIGBY, A. D. RNA metabolism in lymphocytes stimulated by phytohemagglutinin. Initial responses to phytohemagglutinin. *Blood* 25: 1014-1027 (1965).

- 7 COOPER, H. L. and RIGBY, A. D. Synthesis of nonribosomal RNA by lymphocytes response of phytohemagglutinin treatment. *Science* 152: 516 (1966).
- 8 HENRY P. RIGBY, P.; KAKOV, M. and WEISBERG, S. M. Characteristics of RNA synthesized *in vivo* by lymphocytes of chronic lymphocytic leukemia. *J. lab. clin. Med.* 69: 42-61 (1967).
- 9 TORRELLI, U. L. HENRY P. H. and WEISBERG, S. M. Characteristics of the RNA synthesized *in vivo* by the normal human small lymphocyte and the changes induced by phytohemagglutinin stimulation. *J. clin. Invest.* 47: 1083-1093 (1968).
- 10 SCHUTOV, J. LOHRMANN, R. OZGA, I. E. and MOLES, H. T. Specificity of oligonucleotide synthesis directed by polynucleic acid. *Proc. nat. Acad. Sci., Wash.* 69: 409-415 (1968).
- 11 RANGLER, D. H. DELK, A. and ABELL, C. W. The stability of polynucleic acid in acid solution. *Biochemistry* 4: 2002-2009 (1965).
- 12 HIRASAKAWA, K. BACOT, F. KALODNY, R. L. FRAMBERT, L. R. and HADLOCK, A. Immune response and mitosis of human peripheral blood lymphocytes *in vivo*. *Science* 122: 1185-1187 (1963).
- 13 STEWART, C. G. and ISOMAN, M. A method for counting phytohemagglutinin-stimulated lymphocytes. *Blood* 28: 628 (1967).
- 14 WISE, L. and MAYER, E. Ribonucleic acid with the cellular peripheral zone and the binding of calcium to ionogenic sites. *J. Cell. Physiol.* 29: 281-292 (1976).
- 15 MAYER, E. and WISE, L. Ribonucleic acid at the periphery of different cell types, and the effect of growth rate on ionogenic groups in the periphery of cultured cells. *Exp. Cell Res.* 50: 441-453 (1968).
- 16 WISE, L. and MAYER, E. The presence of ribonucleic acid within the peripheral zones of two types of mammalian cells. *J. Cell Physiol.* 62: 343-360 (1966).
- 17 MAYER, J. A. and EDWARDS, R. H. Transfer of heightened immunity to skin homografts by lymphoid RNA. *J. clin. Invest.* 43: 2166 (1964).
- 18 RIGBY, P. G. The inhibition of transplantation immunity to skin homografts. *Res. 15: 432 (1967)*.
- 19 RIGBY, P. G. The delay of allograft rejection by malignant RNA. *Transplantation* 7: 142-146 (1969).
- 20 BACOT, C. BOUT, A. M. BURTON, S. VERONIA, F. and FALLO, M. Delay of human lymphocyte 'blast' transformation by homologous RNA. *Acta haemat., Basel* 39: 270-273 (1968).

Institute of Medical Pathology (Director: Prof. A. BARRETT APOSTOLLA) University of Turin, Turin

The Starch Gel Quantitative Electrophoresis of Haemoglobin as Screening in the Thalassaemia Syndromes

G. RISCO, E. GALLO, U. MAZZA, G. BIANCO and V. PRATO

The diagnosis of Cooley's anaemia does not present any difficulties, as the illness develops with clear clinical symptoms and typical haematological and biochemical characteristics. On the contrary, in some thalassaemia trait carriers the diagnosis cannot be easy, i.e. when striking haematological and clinical features are absent. In these cases several tests, which are often linked to subjective interpretation, are required. The authors who have dealt with the problem of the screening of thalassaemia agree in recognizing that none of these tests by itself enables one to detect unmistakably all the carriers [2, 3, 5, 9]. A simple method has recently been perfected which allows one to dose accurately all the haemoglobin fractions obtained by starch gel electrophoresis [6]. By this method the value of each haemoglobin fraction in a sufficiently large number of thalassaemia heterozygous patients has been determined; these values were compared with those drawn from a large number of clinically and haematologically normal subjects and with those of subjects suffering from haematological disorders of different kinds, in order to establish whether the quantitation of the haemoglobin fractions obtained by means of starch gel electrophoresis can profitably be used, even alone, in the screening of thalassaemia.

Materials and Methods

The investigation was carried out on the following subjects: (1) 200 healthy and haematologically normal subjects of ages varying between 15 and 75 years; (2) 195 heterozygous

carriers of β - and $\beta\delta$ -thalassaemia with microcytic anaemia and characteristic osmotic stigmata. These patients of ages varying between 7 and 68 years came from the Po delta, from Southern Italy and the Italian islands: only two of them originated from Piedmont; (3) 25 genetically certain carriers of thalassaemia trait: these did not present thalassaemic osmotic stigmata, but thalassaemia was present in their families and was transmitted by them to their children. Their mean haematological data were as follows: Hb 13.9% (± 0.83) RBC $4.70 (\pm 0.26) \times 10^6/\text{mm}^3$ MCH 29.62 pg (± 2.15) PCV 42.48% (± 1.57) MCV $91.32 \mu\text{m}^3 (\pm 1.35)$. There was no increase of bilirubin and red blood cell osmotic fragility was in most cases in the normal range. (4) 4 subjects suffering from sickle-cell thalassaemia; (5) 67 subjects suffering from anaemias of different types.

Haemoglobin, erythrocyte count and hematocrit were determined in all the subjects from these values mean corpuscular haemoglobin concentration and mean corpuscular volume were calculated. In the thalassaemic patients and in their relatives red blood cell osmotic fragility in hypotonic solutions was determined by means of the method of PRATO *et al.* [4] which enables one to determine the quantitative fragility curve. In the cases where the diagnosis was doubtful reticulocyte count and sideremia were also determined.

Haemoglobin electrophoresis was performed on critical starch gel, according to SERTUSI [8] in a discontinuous buffer system tris - EDTA borate pH 8.1 - borate pH 9.0. The quantitation of each fraction was carried out according to RUCCO *et al.* [6]. For electrophoresis, fresh haemoglobin, treated with potassium cyanide immediately before use, was utilized, to avoid the formation of slow moving components which tend to migrate into the same position as normal foetal haemoglobin. Foetal haemoglobin was also determined in all the cases by the method of BERKE [1].

Results

The summary of the results is illustrated in figures 1 and 2.

Normal subjects. In this group the mean value of Hb A_2 has been found to be 2.32% (± 0.38) the mean value of Hb F 0.80% (± 0.74). The value of Hb F is higher than those obtained by means of alkali-denaturation according to BERKE: by this method the mean value has been found to be 0.59% (± 0.19).

The higher values of Hb F on starch gel electrophoresis could be due to a slight contamination of Hb F by Hb A: this cannot happen in the case of Hb $A_{2\delta}$ since its separation both from the other normal haemoglobin components and from the carbonic anhydrase is very clear. For this work the mean values with a tolerance of 2σ are considered as still normal. The highest normal value of Hb A_2 is therefore 3.10% and that of Hb F 1.30%.

Heterozygous thalassaemia. In relation to the electrophoretic picture the subjects examined can be divided into three groups: the first with an isolated increase of Hb $A_{2\delta}$, the second with a simultaneous increase of Hb A_2 and Hb F and the third with an isolated increase of Hb F. We should mention that all the thalassaemic subjects examined belong to one or to another of these groups, that is, in every case a patho-




Fig. 1 Distribution of Hb A₂ (left) and Hb F (right) in patients suffering from heterozygous β - and $\delta\beta$ -thalassaemia, compared with normal subjects. Abscissa: percent of haemoglobin; ordinate: number of cases.

logical electrophoretic picture was present. 111 thalassaemic subjects fall into the first group: the Hb A₂ values vary between 3.48 and 5.23% and those of Hb F between 0.52 and 1.30%. The second group contains 68 subjects: the Hb A₂ values range between 3.42 and 5.85%. Some cases in this group present very high values of Hb A₂, the highest we met in our screening. The Hb F values range between 1.38 and




Fig. 2. Distribution of Hb A₂ (left) and Hb F (right) in healthy genetically certain carriers of thalassaemia trait and in patients suffering from non-thalassaemic anaemia, compared with normal subjects. Abscissa: percent of haemoglobin; ordinate: number of cases.

12.55%. In this group most of the cases showed relatively low values of Hb F: in only about 25% of the cases the value of Hb F is higher and comparable to those observed in the third group which presents an isolated increase of Hb F. The third group consists of 18 subjects belonging to 9 families. In these the variation of the electrophoretic pattern is due to an isolated increase of Hb F. This fraction even reaches very high values, varying between 4.04 and 16.73%, while the Hb A₂ ranges between 1.77 and 3.03%. Some subjects in this group are certainly affected by $\beta\delta$ -thalassaemia, for the others we are as yet unable to give reliable data, as the family study has not yet been completed.

Genetically certain carriers of thalassaemia trait. The haemoglobin picture was found to be pathological in all the 25 carriers of thalassaemia trait. They were suspected to be such during the family investigation, but they were clinically and haematologically normal. As can be seen in figure 3 they all show a raised Hb A₂ level which ranges between 3.38 and 5.37. In 11 cases there is also an increased Hb F.

Subjects suffering from sickle-cell thalassaemia. In these subjects we observed two different electrophoretic patterns (fig. 3). The most common (3 cases) is characterized by Hb A (11–14%) Hb S (74–84%) Hb F (5–11%) and Hb A₂ (3.5–4.5%). The second pattern (1 case) shows a normal level of Hb A₂ (2.87%) a high level of Hb F (9.4%) and Hb S (87.73%). Hb A was absent.

Anaemias of different types. The haemoglobin picture was found to be normal in 64 out of 67 patients. The Hb A₂ level in 3 cases was a little higher than our normal value; these patients belonged to non thalassaemic families and their anaemia was not microcytic. In 4 cases we have also found a slight isolated increase in Hb F.




Fig. 3. Search gel electrophoresis *trans*-EDTA-borax pH 8.1 of: (1) A-S heterozygote; (2) Cooley's anaemia with small amount of Hb A and high Hb A₂; (3) sickle-cell thalassaemia some Hb A is present, Hb A₂ and Hb F are consistently increased; (4) heterozygous β -thalassaemia Hb A₂ is raised, small amount of Hb F is present; (5) sickle-cell thalassaemia in this case Hb A is absent, Hb F is highly increased and Hb A₂ is in the normal limits; (6) heterozygous β -thalassaemia with an isolated increase of Hb A₂; (7) normal subject; (8) heterozygous β -thalassaemia with simultaneous increase of Hb A₂ and Hb F; (9) $\beta\beta$ -heterozygous thalassaemia Hb A₂ is in the normal limits, while Hb F is clearly raised; (10) Cooley's anaemia Hb A₂ increased and Hb A is nearly absent; (11) non-thalassaemic.

Discussion

The results obtained in healthy subjects are similar to those described by other authors and confirm that these values range within narrow limits. In all the cases of heterozygous β - and $\beta\delta$ -thalassaemia one or more than one fraction showed a statistically significant variation. In 57% of our patients we observed an isolated increase in Hb A₂ in 34% a simultaneous increase in Hb A₂ and Hb F and in 9% an isolated increase in Hb F.

The first two patterns, according to WEATHERALL [10] are typical for the heterozygous β -thalassaemia the difference between these two pictures, however, does not exclude the possibility that they may be two distinct forms of thalassaemia [7]. We shall return to this subject when we have studied a sufficiently large number of families. However we can say that the haemoglobin picture does not seem to have any relation with the seriousness of the clinical picture and the degree of anaemia. The isolated increase of Hb F is characteristic of $\beta\delta$ -thalassaemia however an isolated increase in Hb F has been found in members of families with typical β -thalassaemia.

Apart from any genetical interpretation which might be formulated on the bases of our results, we must point out that all the thalassaemic subjects examined, showed characteristic alterations of their haemoglobin picture. These results seem to point to the fact that the quantitation of the haemoglobin fractions obtained by starch gel electrophoresis is enough, by itself, to recognise with certainty all the cases of heterozygous β - and $\beta\delta$ -thalassaemia. The study concerning the carriers of non thalassaemic anaemias confirms the validity of the method: in fact only in 4.5% of the cases an abnormal electrophoretic picture, characterised by a modest rise of Hb A₂ was obtained: these patients were certainly not suffering from thalassaemia, and affected by normocromic anaemia. The modest rise in Hb F observed in some cases does not allow us to make a diagnosis of thalassaemia, and the thalassaemic subjects presenting an isolated increase on Hb F show values not inferior to 4%. For this condition WEATHERALL gives values of 5% or more.

Quantitative starch gel electrophoresis allows us to detect only some cases of double heterozygotes for the β -thalassaemia gene and for a gene for an abnormal β -chain variant of Hb A. In these cases diagnosis is possible when Hb A₂ is raised: in all other cases only a

family study can provide a sure diagnosis. In cases of double heterozygotes for β -thalassaemia gene and for a gene for an abnormal α -chain variant of Hb A₁, the diagnosis can be easier but we must point out that a rise in Hb A₂ can be hidden as the Hb A₂ fraction carrying the α -chain abnormality has an abnormal mobility. On the other hand, we have observed that the method is quite useless for the diagnosis of heterozygous carriers of α -thalassaemia I and β -thalassaemia II unless haemoglobin H or haemoglobin Bart's is present.

Nevertheless, our results on the whole seem to indicate that the quantitation of haemoglobin fractions obtained by starch gel electrophoresis is a sufficiently foolproof method in the screening of the thalassaemia syndromes.

Summary

The authors have analysed on starch gel electrophoresis 195 heterozygotes for β - and $\delta\beta$ -thalassaemia with clinical and haematological abnormalities, 25 certain carriers of the thalassaemia gene, without any pathological findings and 4 patients suffering from sickle cell-thalassaemia. The results have been compared with those obtained from 200 normal subjects and from 67 patients with various non thalassaemic anaemias. In all the thalassaemic subjects an abnormal haemoglobin pattern was observed. Only 4.5% of the non thalassaemic anaemias showed a slight increase of Hb A₂ and in 4 cases out of 67 the level of Hb F was higher than normal.

References

1. BETKE, K.; MARTI, H. R. and SCHLICHT, I. Estimation of small percentages of foetal haemoglobin. *Nature, Lond.* 184: 1877 (1932)
2. FERAS, P. Il problema del riconoscimento della stigmata talassemica in Grecia. *Atti G. Stud. «Il Problema sociale della microcitemia» del m. di Cooley's Ist. ital. med. Soc. Roma* 2: 171 (1962)
3. LEEMAN, H. and HINTHMAN, R. G. *Man haemoglobin* (North-Holland Publishing, Amsterdam 1966)
4. PRATO, V.; FLORIDA, L.; MAZZA, U. Comportamento osmotico dell'eritrocita umano. I. L'eritrocita normale. *Minerva med.* 118: 225 (1964).
5. QUATTRO, N.; DIOS, E.; VENTURATO, V. Le emoglobinopatie in Campania. *Ann. Sciav.* 6: 3 (1964)
6. RICCO, G.; GALLO, E.; FLORIDA, L. and PRATO, V. A simple method for the quantitation of haemoglobin fractions obtained by starch gel electrophoresis. *Acta haemat., Basel* 30: 316 (1967)
7. SCHROEDER, R. C.; WYATT, L. N. and BOK, J. A new genetic variant of β -thalassaemia. *Nature, Lond.* 209: 44 (1966)
8. SETHURAI, O. An improved procedure for starch-gel electrophoresis. Further variation in the serum protein of normal individuals. *Biochem. J.* 71: 585 (1959)
9. WEATHERALL, D. J. *The thalassaemia syndromes* (Blackwell, Oxford 1963)
10. WEATHERALL, D. J. The genetics of the thalassaemias. *Brit. med. Bull.* 25: 24 (1969).

Authors' address: Drs. G. RICCO, E. GALLO, U. MAZZA, G. BRANCO and V. PRATO, Istituto di Patologia Speciale Medica, Via Genova 3, 10126 Torino (Italy)

Effect of Lysolecithin on Bovine Erythrocyte Osmotic Fragility¹

S. R. GARFIN, M. A. SHEA and E. F. BERNSTEIN

Department of Surgery, University of Minnesota Medical School, Minneapolis, Minn. and
University of California, San Diego

A constant decrease in erythrocyte osmotic fragility was observed by SHEA [1-2] during studies concerning the effects of *in situ* blood pumping and subsequent reinfusion into the donor animal. In these canine experiments, and other experiments involving 24 and 48-hour partial arteriovenous bypass in dogs [3] the erythrocyte osmotic fragility gradually decreased during the perfusions and over the five days following the experiments, and returned to normal over the subsequent 14 days. Reported observations of experimental or clinical conditions involving a decrease in osmotic fragility are not common, but one substance reported to cause such an effect is lysolecithin [4-5]. COLLIER and PONDOR have described an increased resistance to hypotonic hemolysis following the addition of red blood cells to sublytic concentrations of lysolecithin. However to our knowledge, the data documenting these observations has not been published. The present experiment was designed to quantitate the effect of varying sublytic concentrations of lysolecithin on the osmotic fragility of bovine erythrocytes.

Method

Blood was drawn under sterile conditions in ACD solution from fasted calves on the day of the experiment. After centrifugation for 20 min at 2,500 rpm the plasma was separated from the red blood cells.

A stock solution of lysolecithin was prepared from commercially available material obtained from cobra venom (Mann Research Laboratories, Inc., New York, N.Y.) by adding 20 mg of crystalline lysolecithin to 10 ml saline. On the day of the experiment the solution

was sonified to increase the effective solubility of lysolecithin. Stock lysolecithin solution was added to saline to obtain final concentrations ranging from 0 to 5.1×10^{-11} μ mol lysolecithin/RBC prior to the addition of red blood cells. Erythrocytes were added to obtain final hematocrit between 30 and 40%, gently mixed, and incubated for 30 min at 37°C. Following incubation, the osmotic fragility of the erythrocytes was determined by exposing them to progressively decreasing concentrations of sodium chloride solutions [6]. RBC osmotic fragility was also determined with the Fragilgraph Osmotic Test Recorder Model D2 (Kalmecic Instruments, Inc., New York, N.Y.) measuring the time for 50% hemolysis. The Fragilgraph was maintained at constant temperature of 37°C by Haake Model F water bath, and its output was recorded on Texas Servo-riter II potentiometric recorder. The hematocrit and plasma hemoglobin concentrations of the incubated solution were determined by the methods of WATSON [7] and FLAOK and WATSON [8], respectively.

Results

The osmotic fragility of the erythrocytes exposed to concentrations of lysolecithin less than 1.68×10^{-11} μ moles lysolecithin/RBC did not




Fig 1 Plot of RBC osmotic fragility (determined by manual method) versus lysolecithin concentration, with standard error of the mean indicated for each concentration. A modest and statistically insignificant decrease in osmotic fragility is noted at lysolecithin concentrations in the range of 2.5×10^{-12} μ mol lysolecithin/RBC. Significant changes, however are not seen until concentrations exceeding 20×10^{-12} μ mol lysolecithin/RBC were examined and these are in the direction of increasing fragility.

demonstrate any significant change from the controls (fig 1). There was no consistent decrease in osmotic fragility in any of the 12 experiments. At higher concentrations of lysolecithin, ranging from 1.68 to 5.08×10^{-11} μM lysolecithin/RBC, there was a gradual INCREASE in osmotic fragility. Duplicate measurements performed in the Donon Fragiligraph (fig 2) demonstrate similar changes, but the magnitude of the changes and statistical significance of the data are not as great.

DISCUSSION

In continuing studies concerning the mechanism of mechanically induced hemolysis, our laboratory has focused its attention on several of the late effects observed following the exposure of canine, human and bovine blood to various forms of mechanical stress. One of these effects




Fig. 2 Erythrocyte osmotic fragility as determined by the time for 50% hemolysis in the Donon Fragiligraph, is plotted against lysolecithin concentration. There appears to be slight decrease in fragility at low concentrations, but this is statistically insignificant. At higher concentrations, again, an increase in osmotic fragility was observed.

has been the peculiar and consistent finding of an increase in resistance to osmotic stress, or decrease in osmotic fragility after approximately $\frac{1}{4}$ of the blood volume of dogs was pumped *ex vitro* and then reinfused into the donor animal [1]. Of interest is the additional observation that when only a fraction of the animal's cells have been exposed to trauma, not only these, but all of the animal's cells, subsequently demonstrate alterations in osmotic fragility [1]. Additional experiments failed to demonstrate any consistent changes in erythrocyte volume which might help explain these observations [2].

One substance which has been suggested as participating in both the normal lysis of aged red cells and in the damage observed following exposure to artificial surfaces is lysolecithin. This substance has been reported to cause a decrease in erythrocyte osmotic fragility in sublytic concentrations [4-5]. Inasmuch as the literature concerning this aspect of the effects of lysolecithin appeared scanty, an appropriate experiment to evaluate the osmotic effects of lysolecithin in sublytic concentrations was performed.

In observing the effects of similar concentrations of lysolecithin upon rabbit RBC morphology WATTERS¹ has observed an initial stage of crenation at lysolecithin concentrations of 5×10^{-12} μM LL/RBC, followed by sphering at lysolecithin concentrations approximating 2×10^{-11} μM LL/RBC, and finally by lysis at concentrations greater than 5×10^{-11} μM LL/RBC. This sequence can be reversed by the addition of bovine serum albumin prior to hemolysis. Albumin is known to actively bind lysolecithin. It therefore appeared logical that, at the stage of crenation, cells exposed to appropriate concentrations of lysolecithin might well have an increased resistance to osmotic stress. That such results were not observed casts doubt upon the role of lysolecithin as a significant participant in the effects of mechanically induced hemolysis. Furthermore, experiments directed at measuring the release or appearance of significant amounts of lysolecithin during or following the exposure of bovine, canine, human and mouse blood to mechanical stress have failed to demonstrate an increase in the concentration of lysolecithin in either red blood cells or plasma.² These observations, when coupled with the results of the present experiment, make the proposed lysolecithin hemolytic mechanism unlikely.

¹ Unpublished data.

² BRAWLEY, E. F. unpublished data.

demonstrate any significant change from the controls (fig 1). There was no consistent *decrease* in osmotic fragility in any of the 12 experiments. At higher concentrations of lysolecithin ranging from 1.68 to 5.08×10^{-11} μM lysolecithin/RBC, there was a gradual *increase* in osmotic fragility. Duplicate measurements performed in the Danon Fragilgraph (fig 2) demonstrate similar changes, but the magnitude of the changes and statistical significance of the data are not as great.

Discussion

In continuing studies concerning the mechanism of mechanically-induced hemolysis, our laboratory has focused its attention on several of the late effects observed following the exposure of canine, human and bovine blood to various forms of mechanical stress. One of these effects




Fig 2. Erythrocyte osmotic fragility as determined by the time for 50% hemolysis in the Danon Fragilgraph, is plotted against lysolecithin concentration. There appears to be slight decrease in fragility at low concentrations, but this is statistically insignificant. At higher concentrations, again, an increase in osmotic fragility was observed.

Department of Chemical Pathology, Government Hospital and Tel-Aviv University Medical School, Tel-Hashomer and Department of Pediatrics, Government Hospital, Hadera

Hereditary Deficiency of Adenylate Kinase in Red Blood Cells

A. SZKINBERG, D. KAHANA, SLAVA GAVENDO¹, J. ZAIMAN and JUDITH BEN EZZER

Adenylate kinase (ATP-AMP phosphotransferase, EC 2.7.4.3) catalyses the interconversion of adenine nucleotides according to the following equation $2 \text{ ADP} \rightleftharpoons \text{ATP} + \text{AMP}$. High activity of this enzyme has been found in red blood cells and in some other tissues [1]. In 1966 FIELDS and HARRIS [2] described a genetic polymorphism of this enzyme in human red cells. Several accounts on relative frequency of the genes governing this polymorphism in different populations have been recently published [3-8].

Within the frame of an investigation of this genetic trait in different population groups in Israel a blood sample demonstrating a deficiency of adenylate kinase (AK) in red cells was encountered. Family investigations demonstrated a hereditary transmission of this deficiency. In the same family an additional genetic defect has been detected, namely glucose-6-phosphate dehydrogenase (G6PD) deficiency due to an electrophoretically fast mutant. These investigations are described in the present report. A preliminary report has been published [9].

Methods

Preparation of hemolysates. Heparinized blood was centrifuged for 5 min at 1,200 *g* in a refrigerated centrifuge (4°C). Plasma and buffy coat were removed. The red cells were washed three times in cold saline and centrifuged each time for 5 min at 2,000 *g*. Hemolysates for starch gel electrophoresis for adenylate kinase and phosphoglucomutase (PGM) were prepared by freezing and thawing in a mixture of dry-ice acetone. Hemolysates for starch gel electrophoresis for G6PD were prepared according to the recommendations of WHO Scientific Group [10].

Work performed in partial requirement for M.Sc. degree at the Department of Microbiology, Tel-Aviv University.

Hemolysates for quantitative enzyme assays were prepared by lysis of packed red cells in 3 volumes of distilled water. All the examinations were carried out on stream free hemolysates prepared by centrifuging at 41,000 *g* for 20 min at 4 °C.

Starch gel electrophoresis. Examination for AK was carried out by the horizontal method of FILMS and HARRIS [2], in cold room (4 °C), but at 5.5 V/cm for 17 h. PGAM was examined by the horizontal method of SZENDERG *et al.* [11], in cold room (4 °C) but at 6.5 V/cm for 24 h. The staining mixture was prepared according to MOORE [12].

Starch gel electrophoresis for G6PD was performed in the following systems: tris chloride buffer [10], EDTA-boric acid-tris [10] and phosphate buffer [13]. The staining was carried out with solutions containing MTT tetrazolium and phenazine methosulphate [10] or nitro-blue tetrazolium and methylene blue [14].

Quantitative Enzymatic Assays

Adenylate kinase. AK activity in the forward direction was determined by measuring the production of ATP with the aid of auxiliary enzymatic reactions involving hexokinase (HK) and G6PD [15] in a system coupled with the reduction of NADP to NADPH. The assay mixture (3 ml) contained the following final concentrations of reagents: 0.1 M tris HCl buffer pH 8.0, 10 mM glucose, 1 mM ADP, 0.4 mM NADP, 20 mM MgCl₂, 0.12 U/3 ml G6PD, 0.24 U/3 ml HK, 0.01 ml/3 ml hemolysate. The reduction of NADP was followed at 340 nm at 26°C in Zeiss Spectrophotometer. Before the addition of the hemolysate there was rise of extinction during few minutes probably due to residual traces of ATP in the ADP. When no more change in optical density was observed, 0.01 ml of hemolysate containing 1.5–2.5 g% Hb was added. There was usually a lag period of about 5 min before the reaction became linear with time. The enzymatic activity was calculated from the rate of reaction observed after the lag period.

AK activity in the backward reaction was determined by measuring the production of ADP with the aid of auxiliary reactions involving pyruvate kinase (PK) and lactic dehydrogenase (LDH) in a system coupled with the oxidation of NADH to NAD [15]. The assay mixture (3 ml) contained the following final concentrations of reagents: 0.073 M triethanolamine-HCl (TRA) buffer pH 7.6, 1.33 mM AMP, 1.1 mM ATP, 0.36 mM phosphoenol pyruvate, 0.52 mM MgSO₄, 133 mM KCl, 0.25 mM NADH, 3 U/3 ml PK, 36 U/3 ml LDH, hemolysate (1.5–2.5 g% Hb) 0.01 ml/3 ml. The assay mixture with hemolysate but without ATP did not show any change in optical density. On the other hand the mixture without AMP but with ATP produced a gradual decrease of extinction at 340 nm lasting for several minutes. Consequently all the assays were started without AMP which was added only after stabilization of optical density. Also in this reaction there was an initial lag period of several minutes and the calculations were based on activity observed after this period.

The reproducibility of adenylate kinase assays in blood samples from normal subjects examined in duplicates simultaneously or on consecutive days was within 10% range.

Iodoacetate was assayed in a system coupled with glycerol-1-phosphate dehydrogenase (GDH) and triosephosphate isomerase (TIM) [16]. The assay mixture (3 ml) contained the following final concentrations of reagents: 0.045 M TRA buffer pH 7.5 containing 2.6×10^{-4} M iodoacetate, 0.25 mM NADH, 0.75 U/3 ml GDH, 4.5 U/3 ml TIM and 0.1 ml/3 ml hemolysate (about 4 g% Hb). The reaction was started with fructose 1,6 diphosphate (4.0 mM final concentration).

Glucose-6-phosphate dehydrogenase was assayed by the slightly modified [17] method of KOSCHICKO and HORACEK [18].

Glutathione reductase [19]. The assay mixture (3 ml) contained the following final concentrations of reagents: 0.045 M tris-HCl buffer pH 7.6, 33 mM EDTA, 0.15 mM NADPH, 0.03 ml/3 ml hemolysate (about 4 g% hemoglobin). The reaction was started with oxidized glutathione (GSSG) (0.22 mM final concentration).

Hexokinase was assayed in system coupled with G6PD [20]. The assay mixture (3 ml) contained the following final concentrations of reagents: TRA-EDTA buffer (triethanolamine 0.025 M, pH 7.4 and EDTA 0.1%) 2 mM NaF, 8 mM $MgCl_2$, 2 mM glucose, 0.06 mM NADP, 0.024 U/3 ml G6PD, and 0.1 ml/3 ml hemolysate (about 4 g% Hb). The reaction was started with ATP (1.5 mM final concentration).

Lactic dehydrogenase [21]. The assay mixture (3 ml) contained the following final concentrations of reagents: 0.05 M phosphate buffer pH 7.5, 0.31 mM sodium pyruvate, 0.002 ml/3 ml hemolysate (about 4 g% Hb). The reaction was started by addition of NADH (0.15 mM final concentration).

Pyruvate kinase [22] was assayed in system coupled with LDH. The assay mixture (3 ml) contained the following final concentrations of reagents: TRA-HCl buffer 0.030 M pH 7.5, 1.5 mM phosphoenolpyruvate, 12 mM $MgSO_4$, 110 mM KCl, 0.15 mM NADH, 111 U/3 ml LDH, 0.030 ml/3 ml hemolysate (about 4 g% Hb). The reaction was started by the addition of ADP (3.4 mM final concentration).

The auxiliary enzymes, coenzymes and substrates used in the above spectrophotometric assays were purchased from Boehringer Co., Mannheim. The results of the enzyme activities were expressed as μ moles/min/g Hb at 26°C.

Catalase was determined by the method of FERTY [23] as modified by TARLOV and JELLIKOVSKA [24] with incubation time of 1 min.

Adenosine nucleotides. ATP, ADP and AMP were measured enzymatically with appropriate assay kits of Boehringer Co., Mannheim (TC-J No. 15979 TAAC and TC-K, No. 15980 TAAB). The determinations were carried out on whole blood heparinized and deproteinized with cold perchloric acid immediately after removal from the vein. The results were calculated per 100 ml of packed cells, representing therefore the content of all the cellular elements of blood, and not of red cells only.

Osmotic fragility, autohemolysis (24 h at 37°C) and Heinz bodies were examined according to DACE [25].



Fig 1 Adenylate kinase in hemolysates. Starch gel electrophoresis examined by the method of FINE and HARRIS [2]. 2 = proband, 1 = normal subject, AK phenotype 1. 3 and 4 = normal subjects, AK phenotype 2. The lowest spot in each sample is hemoglobin.

Case History

During an investigation of genetic polymorphism of AK among various populations groups in Israel, one blood sample showed an almost complete absence of AK activity on examination by starch gel electrophoresis (fig 1). The main isoenzyme components of AK were practically missing and only one minor anodic component was observed on the electropherograms. The mobility of this fraction was slightly different from those of the two minor components observed in normal blood controls. The sample was obtained from an Arab boy aged 5 months with the following family history (table I); his older brother was hospitalized several times in 3 hospitals since the age of 2 years. His hemoglobin values fluctuated between 3.7 and 8.6 g%, erythrocyte counts between 1,200,000 and 2,620,000, the reticulocytes between 2.9 and 33%. Some degree of hyperbilirubinemia was always present (2.3–9.4 mg%). No abnormal hemoglobins were found. The half life of erythrocytes measured with ^{51}Cr was considerably shortened. He was found to have G6PD deficiency but the enzyme values fluctuated between 0 and 1.8 U/g Hb (normal values 4.0–7.2). The condition of the boy was diagnosed as non spherocytic hemolytic anemia with G6PD deficiency. The boy died at home at the age of 7 years with cause of death unknown and before any studies on the type of G6PD deficiency could be carried out.

In view of this family history when the proband was born, the parents were advised to bring him for examination at the age of 2 weeks. It was found then that he had hepatomegaly, severe anemia (6.6 g% Hb), slight jaundice and no detectable activity of G6PD in red cells. He was given blood transfusion. Four months later again severe anemia with reticulocytosis of 5.5% and normal serum iron was observed. Physical examinations demonstrated hepatosplenomegaly. A blood sample obtained at that time showed an absence of G6PD and revealed the deficiency of AK on starch gel electrophoresis. One day after this blood sample was collected the child received again blood transfusion and further investigations were postponed for several months.

Table I Summary of observations on the proband (up to the time of diagnosis of adenylosuccinate kinase deficiency) and his deceased brother

	Proband age 2 weeks	Proband age 5 months	Brother (deceased) exami- nations at ages 2–7 years
Hb, g%	6.6	5.1–5.6	3.7–8.6
Hematocrit, %			13–30
RBC, 10^6	2.50		1.20–2.62
Reticulocytes, %		5.5	2.9–34
RBC survival (^{51}Cr)			half life 7 days
Serum bilirubin, mg%	3.3		2.3–9.4
Serum iron, $\mu\text{g}\%$		120	45–140
Fecal sterobilin			24–130 mg/24 h
G6PD, U/g Hb	0	0	0–1.8
Adenylosuccinate kinase		deficient by electrophoresis	not tested
Clinical notes	hepatomegaly blood transfusion	hepatosplenomegaly blood transfusion	hepatosplenomegaly multiple blood transfusions

Results

AK and G6PD were determined in red cells of both parents, the propositus (120 and 160 days after the last transfusion) and his 7 living sibs. The same samples were examined also by starch gel electrophoresis for determination of AK and PGM phenotypes. The results are summarized in table II.

AK activity Examinations of the blood of the propositus obtained on several occasions suggested some variability in the degree of the deficiency of this enzyme. As previously mentioned, the blood taken at the age of 5 months demonstrated only one minor band of activity on starch gel electrophoresis. A second blood sample obtained at the age of 9 months (120 days after the last transfusion) showed in quantitative assays about 10% of mean normal AK activity and on starch gel electrophoresis a faint pattern corresponding to the phenotype AK 1. In another blood sample obtained 40 days later about 4% of mean normal activity was present and on starch gel electrophoresis again only one minor band was seen. The family investigation revealed that a sister of the propositus (F I V/3) aged 4 years, also showed an almost complete absence of AK activity. In quantitative assays 0.5-4% of mean normal AK values were found and on the starch gel electrophoresis only the minor component was observed. All the other members of the family showed a partial deficiency of AK. The enzyme activities in their red cells measured in the 2 directions were below 2 standard deviations from the means of control groups. However considerable variation in expression was observed and the enzyme activity in various members ranged between 22 and 72% of mean normal values. We interpret the above data as being compatible with a single factor autosomal inheritance of AK deficiency with a variable expressivity in heterozygotes.

Additional investigations of AK The hemolysate prepared from red cells of the AK deficient girl did not show any inhibitory activity upon addition to normal hemolysates in the assay mixture for AK. Some experiments were performed to prove that the minor band of activity seen on electropherograms of the enzyme deficient subjects was indeed due to AK and not to secondary reactions. The colour development of this band did not require more time than the specific pattern of AK in normal subjects. Omission of glucose, ADP hexokinase or G6PD prevented the staining of this minor component.

Table II Family investigation enzyme data

Subjects	Relation to proband	Age (years)	AK activity direction brother sister	% of mean normal value	AK activity direction brother sister	% of mean normal value	G6PD activity ^a	AK phenotype	PGM phenotype	Blood group
I/1 ELI	Father	38	44.2	33.3	49.3-59.4	58.6-69.0	5.0-5.7	1	2 1	D, Rh pos.
I/2 ELI	Mother	35	25.6-31.1	20.3-24.7	25.9-33.4	22.3-31.1	1.4-3.0	1	1	AB, Rh pos.
I/1 RJ	Proband	11/12	9.4	10.5	4.4-8.8	3.8-7.6	0-1.6	1	2 1	B, Rh pos.
I/2 RJ	Sister	2	41.1	46.2	42.4	37.3	3.2	1	1	AB, Rh pos.
I/3 RJ	Sister	4	0.5-1.3	0.56-1.4	1.9-4.7	1.7-4.2	3.0	?	2 1	AB, Rh pos.
I/4 MJ	Sister	5	64.3	71.7	64.3	50.6	3.0	1	2 1	AB, Rh pos.
I/5 MJ	Sister	7	53.8	60.0	64.9	57.1	4.7	1	1	AB, Rh pos.
I/7 GJ	Brother	10	64.9	72.4	82.0	72.1	3.0	1	2 1	B, Rh pos.
I/8 GJ	Brother	12	61.0	68.0	79.5	69.9	4.4	1	1	B, Rh pos.
I/9 NJ	Brother	14	72.4-100.1	59.0	78.8	67.3	4.0	1	1	B, Rh pos.
Normal range			72.4-100.1		97.9-132.3		4.0-7.2			
Normal mean \pm SD			80.7 \pm 10.0		113.7 \pm 10.6					

Numbers according to the family tree (Fig. 3).

Expressed in pmol/min/g Hb at 37°C. When range of activities is given, the figures represent results obtained on examination of several samples (some months intervals); in other cases (no figures represent mean values of duplicate examinations of one blood sample).

12 subjects examined.

11 subjects examined.

G6PD activity The first 2 samples obtained from the propositus at the age of 2 weeks and 3 months did not show any G6PD activity while in samples obtained at the age of 9 months (120 days after transfusion) and 10 months (160 days after transfusion) activities of 1.6 and 0.9 units respectively were observed. These fluctuations will be discussed later but for the sake of description of the phenotype the case will be regarded as severe G6PD deficiency.

Crude hemolysates prepared from blood samples obtained at the ages of 9 and 10 months were examined by starch gel electrophoresis. In the three buffer systems used (see Methods) the mobility of G6PD of the propositus was more rapid than the normal G6PD type II (fig. 2). This observation suggested that the G6PD deficiency of the propositus was not of the usual Mediterranean type prevalent in our population.

Examination of the family demonstrated intermediate G6PD deficiency in the red cells of the mother and one of the sisters of the propositus (A.I. V/2). The father of the family the sister with A.K. deficiency and 6 other sibs of the propositus showed normal G6PD



Fig. 2. G6PD in hemolysates. Starch gel electrophoresis on tris-EDTA buffer [10]. 1 and 4 = normal subjects, G6PD type B. 2 = propositus. 3 = adenylate kinase deficient sister of the propositus (F.I. V/3). The origin is at the bottom of the figure. The lower bands represent hemoglobin and the upper bands G6PD. The hemolysate of the propositus contained 3.2 g% hemoglobin, the other hemolysates 1.6 g% hemoglobin. A similar separation but much fainter bands were obtained with hemolysates containing 0.4 g% (controls) and 0.8 g% (propositus) hemoglobin.

Table III Hematologic data obtained at the time of enzyme studies in the patient and his family

	Propositus (age 9-11 months)	Sister (P I V/9)	F ther (HLI IV/11)	Mother (HLI IV/2)	Normal range
Hb, g%	6.5-7.1	8.9-9.9	14.2	10.7-11.0	
RBC, 10^9	2.6-2.87	2.97-3.40	5.10	3.71-3.78	
Hematocrit, %	25-27	27-29	46	34-38	
Reticulocytes, %	3.4-12	2.0-3.2	0.5	0.5-0.8	
Serum bilirubin, mg%	1.9/0.1-2.4/0.5	1.4/0.3-1.7/0.3	-	0.9/0.5	
(total/direct)					
Serum iron, μ g %	141	120	-	50	
Osmotic fragility	normal	normal	normal	normal	
Autohemolysis, without glucose	3.6	2.1	0.9	1.5	0.2-1.0
%24 h/37°C with glucose	5.9	0.7	0.6	0.5	0.1-0.8
MCV, μ m ³	93.6-103.8	83.5-90.9	90.2	91.6-101.9	76-96
MCH, pg	24.5-27.5	28.5-28.6	27.8	28.8-29.1	27-32
MCHC, %	23.8-26.0	31.0-31.5	30.9	28.6-31.5	32-36
Blood film	macrocytes	few macrocytes	normal	normal	
	anisocytosis	slight anisocytosis			
	poikilocytosis				
	polychromasia				
	occasional				
	normoblasts				




Fig. 2. Family tree.

activity The family observations are summarized in figure 3 demonstrating that the probandus had a severe deficiency of both AK and G6PD his sister (F I V/3) severe deficiency of AK alone, 2 members of the family (S I IV/2 and A.I V/2) partial deficiency of the two enzymes, while the remaining members of the family partial deficiency of AK alone.

Hematologic observations (table III) The blood examinations of the probandus performed at the age of 9-11 months showed a hypochromic anemia (Hb 6.5-7.1 g%) with marked reticulocytosis (8.4-12 %) and moderate hyperbilirubinemia. The serum iron and osmotic fragility were normal, while autohemolysis was increased (5.6%) and not corrected by glucose. These results suggested that most probably the child suffered from chronic non spherocytic hemolytic anemia.

The sister (F I V/3) which had severe AK deficiency but normal G6PD also showed an anemia (normocytic, normochromic) though in somewhat milder degree. Her Hb was about 9 g % and RBC about 3 000 000 She had only slight reticulocytosis (2-3.2 %) and slight hyperbilirubinemia (1.4-1.7 mg %) Serum iron and osmotic fragility were normal. Autohemolysis in the absence of glucose was slightly above the normal range observed by us in control subjects. It is of interest to note that the finding of anemia in this child was rather unexpected. The girl (4 years old) was not considered by the parents to be ill and as far as it is known to us she was never brought for medical examination When the anemia has been detected in the present investigation, physical examination revealed a pale and apathetic child without enlargement of liver or spleen and without any other particular findings

A mild degree of anemia without reticulocytosis or hyperbilirubinemia was also observed in the mother with partial deficiency of G6PD and AK, while the hematologic findings in the father were normal. The WBC and platelets counts were normal in both parents and the two AK deficient children. Heinz bodies were not found in any of these subjects.

Activity of other enzymes in red cells (table IV) The activity of several enzymes has been measured in the blood of these 4 members of the family The probandus showed markedly increased activity of pyruvate kinase, aldolase glutathione reductase and hexokinase, reflecting most probably the presence of a high proportion of young cell population Increased activity of hexokinase and glutathione reductase was also

Table IV Activity of some red cell enzymes in the AK deficient children and their parents

Enzyme	Progenitus	Mother (P.J. V/3)	Father (H.I. IV/1)	Mother (S.I. IV/1)	Control values Normal subjects = 14	GSFD def. subjects = 10
Aldolase	5.65	2.62	2.56	2.98	2.96 ± 0.98	5.71 ± 0.46
Glutathione reductase	7.1	4.1	3.6	3.57	3.57 ± 0.58	5.52 ± 0.81
Hemokinasin	6.52	6.62	0.37	0.36	0.51 ± 0.03	0.46 ± 0.01
Lactic acid dehydrogenase	125.0	101.0	108.0	96.0	102.0 ± 11.0	106.0 ± 10.10
Pyruvate kinase	17.8	11.2	9.8	11.0	9.7 ± 0.77	10.7 ± 1.20
Catalase	0.23	0.24	0.26	0.22	0.2 ± 0.035	0.19 ± 0.000

Catalase activity in Erythrocytes units other enzymes expressed in $\mu\text{mole}/\text{min}/\text{g}$ Hb.

Data on rubens dehydrogenase activity also 2 standard deviations from the mean of control normal subjects.

Table V Adenine nucleotides content of blood cells (μ moles/100 ml cells)

	ATP	ADP	AMP	Percent ADP ^a
Propositus	131.4	39.8	7.6	20.0
Sister (F I 1/3)	141.0	38.9	6.9	20.5
Father (H I 1V/1)	111.0	24.8	3.4	17.8
Mother (S I IV/2)	113.8	31.0	4.4	20.8
Controls with reticulocytosis				
Case 1 (retic. 13%)	180.3	29.2	5.8	13.6
Case 2 (retic. 3.5%)	126.8	18.0	2.2	12.2
Case 3 (retic. 2.6%)	147.1	14.3	6.9	8.6
Normal range (n = 16)	88.5-137.0	14.7-24.8	1.2-5.2	10.0-18.9
Normal mean \pm SD	108.4 \pm 13.6	17.9 \pm 2.9	3.3 \pm 1.0	14.0 \pm 2.8

Percent ADP was calculated by the formula
$$\frac{\text{ADP} \times 100}{\text{ATP} + \text{ADP} + \text{AMP}}$$

observed in the red cells of the sister with severe AK deficiency while the mother showed an increased activity of glutathione reductase only.

Adenine nucleotides content of blood (table V) In comparison with normal subjects elevated concentrations of ATP, ADP and AMP were observed in the cells of the propositus and his AK deficient sister. However the relative increase of the ADP seemed to be higher than that of ATP and AMP. In both AK deficient subjects and their mother ADP constituted about 20% of the sum of adenine nucleotides, while the mean value observed in normal controls was $14.0 \pm 2.8\%$. In one control subject with marked reticulocytosis and 2 subjects with mild reticulocytosis the relative content of ADP was only 8.6-13.6%.

Discussion

In this family two genetic enzymatic defects of red cells have been detected, namely a deficiency of AK and a deficiency of G6PD due to a non-Mediterranean variant. The genes for those two abnormalities segregated independently and different combinations have been observed in various members of the family. The results suggested that the AK deficiency was transmitted by an autosomal gene with a partial and variable expressivity in heterozygotes. The G6PD deficiency was

not due to the Mediterranean variant prevalent in our area, as a mutant enzyme with an electrophoretic mobility faster than G6PD type B was found in the red cells of the propositus (the parents were not yet examined in this respect). No detailed characterization studies of the mutant enzyme have yet been performed and thus its identity remains to be determined. The most common variant with increased electrophoretic mobility is the A- (African) type leading to drug sensitive hemolysis. Other fast variants have been described in cases with or without non spherocytic hemolytic anemia [10, 26, 27].

In the red cells of the propositus marked fluctuations of both G6PD and AK activity were observed in samples obtained at different times. Their cause is at present not clear. It does not seem probable that they were due to remnants of transfused blood, as the samples were obtained always at least 120 days after transfusion. The fluctuations did not show a correlation with reticulocyte counts, and thus could not be explained on the basis of changes in relative proportions of a younger cell population.

The nature of the metabolic burden imposed by the AK deficiency has not yet been elucidated. The physiological function of this enzyme is not exactly known. HARRIS *et al* [28] suggested that it probably plays a specific role in maintaining cellular ATP content. According to MILLS *et al* [29] AK is essential for the conversion of AMP to ADP. Several other investigators demonstrated that AK is efficient in regulating the equilibrium of adenine nucleotides in tissues even when the energy charge varies rapidly and thus it plays an important role in regulation of the energy metabolism and of the activity of many enzymatic systems [30, 31, 32, 33]. We thought that the analysis of adenine nucleotide content of blood of AK deficient subjects would throw some light on the metabolic importance of this enzyme and the direction in which the equilibrium represented by AK reactions is favored in the body. We presumed that a metabolic block due to the enzyme deficiency would result in accumulation of the products at one side of the equilibrium with a deficiency at the other side. However the results of the analysis of the 2 AK deficient subjects did not bear out this expectation. All the three adenine nucleotides were found in increased concentrations. The only clue to the possible effect of enzymatic abnormality was the finding that the relative content of ADP was higher in the enzyme deficient cells than in most normal controls or control subjects with slight or moderate reticulocytosis. In recently

published observations of MILLS *et al.* [29] elevated levels of ATP and AMP were found in cases with young cell population. However they were not accompanied by a parallel increase of the ADP levels. The mean relative ADP content of red cells of normal subjects studied by these investigators was 12.4%, while in a heterogenous group of subjects with a younger cell population it was 11.1%. Our finding of a relatively increased ADP content of the AK deficient cells suggests a possibility that in normal red cells the enzyme acts mainly in the direction of the conversion of ADP to ATP and AMP. However the data are limited and additional investigations are required before drawing definite conclusions.

The hematological data obtained in the girl with AK deficiency suggest the presence of a mild non-spherocytic hemolytic anemia, conforming to the type 1 of SZLWYN and DACIE [34]. On several examinations a moderate anemia has been observed with normal serum iron and osmotic fragility slightly increased autohemolysis correctable by glucose, slight hyperbilirubinemia and slight reticulocytosis. However obvious relationship between the enzyme deficiency and the anemia has not been established with certainty. The investigation of this case has been hampered by the fact, that the family was quite unco-operative. The parents do not consider the girl to be ill and they refuse to give consent to hospitalization or any investigative procedures beyond the donation of a few samples of venous blood.

The probandus showed a severe anemia with pronounced reticulocytosis and hyperbilirubinemia. His autohemolysis was markedly increased and not corrected by glucose. These findings resemble the type 2 of non-spherocytic hemolytic anemia [34]. It is tempting to suggest that the severe clinical condition resulted from an interaction of the two enzymatic defects coexisting in his red cells. A possibility of a potentiating detrimental effect of a double enzymatic abnormality has been suggested by OAKI *et al.* [35] who described a mild hemolytic anemia and abnormal autohemolysis in a woman heterozygous for G6PD and pyruvate kinase deficiency.

Summary

A new genetic defect of red cells, namely deficiency of adenylate kinase, has been detected in an Arab family with coexistent deficiency of glucose-6-phosphate dehydrogenase due to an electrophoretically fast mutant. The adenylate kinase deficiency was transmitted most

probably by an autosomal gene with partial and variable expressivity in heterozygotes. The proband with deficiency of both enzymes presented a congenital non-spherocytic hemolytic anemia with marked reticulocytosis and increased autohemolysis not correctable by glucose. His older sister with adenylate kinase deficiency only showed moderate anemia with very slight reticulocytosis, mild hyperbilirubinemia and slightly increased autohemolysis corrected by glucose. A causative relationship between the adenylate kinase deficiency and the anemia has not been yet established with certainty.

References

1. TODD, J. A.; BELL, J. L. and BARON, D. N. Assay and distribution of adenylate kinase in human tissues. *Biochem. J.* 90: 7P (1964)
2. FIDLER, R. A. and HARRIS, H. Genetically determined variation of adenylate kinase in man. *Nature, Lond.* 202: 261 (1966)
3. RAPLEY, S.; ROMON, E. B. and HARRIS, H. Data on the incidence, segregation and linkage relations of the adenylate kinase (AK) polymorphism. *Ann. hum. Genet.* 31: 237 (1967)
4. BOWMAN, J. E., FRISCHER, H., APGAR, F., CARSON, P. E. and HARRY GOWER, M. Population, family and biochemical investigation of human adenylate kinase polymorphism. *Nature, Lond.* 214: 1156 (1967)
5. SEIN, L. Y.; HEE, D. Y. Y.; BOWMAN, J. E.; SEIN, B. C. and SEIN, P. L. The electrophoretic phenotypes of red cell 6-phosphogluconate dehydrogenase and adenylate kinase in Chinese populations. *Amer. J. hum. Genet.* 20: 474 (1968)
6. GORDON, H.; VOORPS, M. L. and KIRKMAN, M. M. Genetical relation in some basian red cell enzymes. An interracial study. *Brit. J. med.* 60: 1031 (1966)
7. BREWER, E. J., BOWMAN, J. E. and TASHIR, R. E. The electrophoretic phenotypes of red cell phosphogluconate, adenylate kinase, and acid phosphatase in the American Negro. *Acta genet., Basel* 17: 97 (1967)
8. WILLE, B. and RITTER, H. Zur Populationsgenetik der Adenylatkinase. Genhäufigkeit in einer suchts-estereichen Stichprobe. *Humangenetik* 5: 278 (1968)
9. SZERENHO, A., GAVENDO, M. and CARASE, D. Hereditary adenylate kinase deficiency of red blood cells. *Lancet* 315 (1969)
10. World Health Organization. Standardization of procedures for the study of glucose-6-phosphate dehydrogenase. *Techn. Rep. Ser.* 366, pp. 30, 39-41 (Genev. 1967)
11. SEINCE, N., HOPKINSON, D. A. and HARRIS, H. Phosphogluconate polymorphisms in man. *Nature, Lond.* 204: 742 (1964)
12. MORRIS, E. A new red cell phosphogluconate phenotype in man. *Acta genet., Basel* 18: 123 (1968)
13. MATIAS, C. K., OWEN, B. and BEUTLER, E. Sex linkage of the glucose-6-phosphate dehydrogenase gene in Equidae. *Nature, Lond.* 210: 115 (1966)
14. KIRKMAN, H. N. and HOPKINSON, D. A. Sex-linked electrophoretic difference in glucose-6-phosphate dehydrogenase. *Amer. J. hum. Genet.* 15: 241 (1963)
15. HARRIS, R. J. and MILLER, D. C. R. The adenylate kinase of human plasma, erythrocytes and platelets in relation to the degradation of adenosine diphosphate in plasma. *Biochem. J.* 103: 773 (1967)
16. LÖNN, G. W.; WALLER, H. B. and KARLSSON, O. Quantitative Fermentbestimmungen in roten Blutzellen. *Klin. Wochs.* 35: 871 (1957)
17. SZERENHO, A. and CRUJAN, L. Sulfhydryl groups in the red cells of normal and glucose-6-phosphate dehydrogenase deficient subjects. *Biochim. biophys. Acta* 23: 564 (1964).

18. KORNBERG, A. and HORWICKER, B. Glucose-6-phosphate dehydrogenase; in COLOWICK and KAPLAN *Methods in enzymology* vol. 1 p. 323 (Academic Press, New York 1955)
19. RACKER, E. Glutathione-reductase (liver and yeast) in COLOWICK and KAPLAN *Methods in enzymology* vol. 2, p. 722 (Academic Press, New York 1955).
20. SLEDE, M. W. COLE, G. T. and COLE, C. F.: Comparative study of hexokinase from yeast and animal tissues. *J. biol. Chem.* **186**: 763 (1950)
21. WROBLEWICK, F. and LAIDL, J. S. Lactic dehydrogenase activity in blood. *Proc. Soc. exp. Biol., N.Y.* **20**: 210 (1955)
22. BUCKER, T. and FLEISHER, G. Pyruvate kinase from muscle in COLOWICK and KAPLAN *Methods in enzymology* vol. 1 p. 433 (Academic Press, New York 1955)
23. FIDWYER, B. N. Perborate as substrate in: new assay of catalase. *J. biol. Chem.* **180**: 1197 (1949)
24. TARLOW, A. R. and KELLERMEYER, R. W. The hemolytic effect of primaquine. XI. Decreased catalase activity in primaquine-sensitive erythrocytes. *J. Lab. clin. Med.* **58**: 204 (1961)
25. DACE, J. V. and LEWIS, S. M. *Practical haematology*; 3rd ed., pp. 135-144 146 (Churchill, London 1963)
26. BOVET, P. and GALARD, C. Nouvelles variantes de la glucose-6-phosphate déhydrogénase érythrocytaire. *Rev. franç. Et. clin. biol.* **13**: 90 (1968)
27. KIRKMAN, H. N. KIRSON, C. and KENNEDY, M. Variants of human glucose-6-phosphate dehydrogenase: studies of samples from New Guinea. in BEUTLER *Hereditary disorders of erythrocyte metabolism* (Grune & Stratton, New York 1968)
28. HARRIS, H. HOPKINSON, D. A. and LUTTMAN, J. Enzyme diversity in human populations. *Ann. N.Y. Acad. Sci.* **157**: 232 (1968)
29. MILLS, G. C. LEVIN, W. C. and ALPERT, J. B. Hemolytic anemia associated with low erythrocyte ATP. *Blood* **32**: 15 (1968)
30. ATKINSON, D. E. Biological feedback control: at the molecular level. *Science* **150**: 851 (1965)
31. ATKINSON, D. E. and WALTON, G. M. Adenosine triphosphate conservation in metabolic regulation. *J. biol. Chem.* **242**: 3239 (1967)
32. BOWELL, J. L. and PRADET, A. Study of adenosine 5'-mono di- and triphosphates in plant tissues. IV. Regulation of the level of nucleotides, *in vivo*, by adenylic kinase: theoretical and experimental study. *Biochim. biophys. Acta* **162**: 230 (1968)
33. PRADET, A. et BOWELL, J. L. Contrôle *in vivo* des nucléotides adéniques par l'adenylique kinase. *C.R. Acad. Sci., Paris* **285**: 2416 (1968)
34. SELWYK, J. G. and DACE, J. V. Autohemolysis and other changes resulting from the incubation *in vitro* of red cells from patients with congenital hemolytic anemia. *Blood* **9**: 414 (1954)
35. ORSI, F. A. NATRAN, D. G.; SOREL, V. W. and DIAMOND, L. K. Extreme hemolysis and red-cell distortion in erythrocyte pyruvate kinase deficiency. I. Morphology, erythrokinetics and family enzyme studies. *New Engl. J. Med.* **290**: 1023 (1964)

Authors' address: Prof. Dr ARON SEIDENBERG, BSc & GAVIENDO, M. Sc., JACOB ZAITMAN, M. Sc., JUDITH BEN-EEZER, M. Sc., Department of Chemical Pathology, Government Hospital, Tel-Hadassah (Israel) Dr DAVID KAJIARA, Department of Pediatrics, Government Hospital, Hadassah (Israel)

V. CRINA, L. BONOMO and C. SESTORI: *Proceedings of the International Symposium on Gammapathies, Infections, Cancer and Immunity* Carlo Erba, Milano 1968. 94 p.

Auf Einladung der Carlo Erba-Foundation fand am 30. September 1967 in Bari ein Symposium statt, an welchem 18 Autoren die leischichtigsten Beziehungen der Immunreaktionen zu Infektionen, Autoimmunität und maligner Entartung diskutierten. Die im vorliegenden Band zusammengefaßten 12 Vorträge geben denn auch einen Einblick in die Komplexität der Grundfunktionen des immunologisch aktiven Zellsystems. Der schmale Band vermittelt auch dem erfahrenen Immunbiologen so zahlreiche Anregungen, dass seine Anschaffung als dringend empfohlen sei.

A. HÄMÖ, *Beri*

Actes du VI^e Congrès National de Transfusion Sanguine: Tours, 28-26 Juin 1966: tome I et II; supplément au tome II, No 3 de la Revue de Médecine de Tours, mai-juin 1968. La Sennart, Tours (France). 873 p.

Der unter E. CHATELAIN herausgegebene Bericht des VI. französischen Transfusionskongresses, organisiert von der französischen Gesellschaft für Bluttransfusionen unter Mitwirkung der nationalen Gesellschaften für Hämatologie und Pädiatrie sowie des französischen Roten Kreuzes umfasst im ersten Teil Referate über folgende Gebiete: 1. Zelluläre und humorale Immunität inkl. Transplantationsimmunität mit Übersichten sowie experimentellen Arbeiten über die γ C-Immunglobulinstruktur und die Immunglobuline des Nektars; 2. Präparation von Immunglobulinen, speziell von Hyperimmunglobulinen und i. pflanzbaren Präparaten und deren klinische Verwendung sowie Methoden zur Titrierbestimmung antibakterieller und antiviraler Antikörper in diesen Produkten; 3. Immunglobulinopathien mit ausgewählten klinischen Fällen von speziellen Dys- und Para-proteinkämien sowie hereditäre und erworbene Immunglobulinmangelzustände, sowie Vorschläge für quantitative Immunglobulinbestimmungen (passiv. Hämagglutination); 4. Therapeutische Verwendung von Immunglobulinpräparaten bei bakteriellen Infektionen und Prophylaxe von Viruskrankheiten sowie die Möglichkeit der Unterdrückung allergischer (anaphylaktischer) Reaktionen durch unspezifische Immunglobuline der Reagin-klassen; 5. Organisatorische Probleme im Transfusionswesen mit Beschreibungen von Organisations- und Datenverarbeitungssystemen in einer Reihe von französischen Blutspendencentren; 6. Probleme der Blutgruppenserologie, namentlich experimentelle Arbeiten über seltene Phänotypen im ABO-System, seltene Erythrozytenantikörper Leukozyten- und Thrombozytenantikörper sowie eine immunologisch interessante Beobachtung über ABO-Blutgruppenabweichen und Immunglobulinantigene im allergischen Exztrakt von Hamstern. Im zweiten Teil wird über die folgenden 8 Kolloquien berichtet: 1. Serumgruppen und Enzym polymorphismen; 2. Konservierung von Blut und Blutprodukten, speziell von Problemen des Überlebens von Zellelementen; 3. Hämodynamik und Metabolismus von Blutkomponenten, insbesondere Fragen der Messung dieser physiologischen Prozesse; 4. Antikörper im Blutspendenzentrum (Automaten für Blutgruppenbestimmungen, Locus-Screening, Transaminase-Screening); 5. Hämatologische Erkrankung des Neugeborenen, namentlich Fragen der Diagnose dieser Krankheit in der Antikörperaktivität und Probleme der intrauterinen Transfusion; 6. Hämorrhagischer Schock, seine Pathogenese und Therapie; 7. Überlebensstudien an Thrombozyten mit einer Reihe von experimentellen Befragungen zur Ausarbeitung standardisierbarer Kriterien und 8. Probleme der Spenderwerbung. Leider wird das Orientierung in den beiden Bänden durch das Fehlen eines Index erheblich erschwert. Einige ausgezeichnete Übersichtsreferate sowie eine Reihe von experimentellen Originalarbeiten machen jedoch das Studium dieses Kongressberichts empfehlenswert.

BUTLER, *Beri*

We have had the opportunity to evaluate blood proliferocytes during human malaria. Increased numbers of proliferocytes were found in blood from 5 malaria patients. This result led us to carry out experimental studies on blood proliferocytes in experimental animals.

Materials and Methods

Blood labeling, micromethod. Peripheral blood was obtained from patients' fingertips. Animal studies utilized blood from the excised tail tip or from cardiac puncture. White cell counts and stained blood smears were routinely obtained. All blood specimens (each about 0.2 ml total volume) were drawn into heparinized hematocrit microtubes and mixed with 0.01 ml ^3H -thymidine in saline (100 $\mu\text{Ci}/\text{ml}$, 15 mCi/mmole , New England Nuclear). The blood tubes were then incubated for 1 h at 37°C to permit DNA labeling. After brief centrifugation to sediment the leukocytes, the segment of each microtube containing the column of buffy coat with part of the upper layer of red cells was cut away. The contents of each leukocyte rich segment was delivered into a siliconized spot plate and mixed with a drop of normal saline to resuspend the cells. This buffy coat mixture was then loaded into a fresh microtube. The loaded end of the tube was rapidly drawn across a clean glass slide so that a narrow linear smear of the leukocyte suspension was obtained. The slide smears were processed for autoradiography (ARG) exposed for one week, then developed and stained as previously described [7] except that Kodak NTB-2 emulsion diluted 1:1 with water was used here. At least 1,000 mononuclear cells were examined in each slide and the number of proliferocytes found was recorded. All proliferocytes had 10 or more grains overlying their nuclei. ARG background was always much less than 3 grains per equivalent cell area. Many proliferocytes were heavily labeled so that fine detail was obscured. Partial classification of less labeled blood proliferocytes was attempted. The percent proliferocytes found per total mononuclear cells examined was calculated. The results were expressed as the proliferocytes index, i.e., the calculated number of proliferocytes per 10,000 mononuclears.

Adult male mice, HA/ICR strain, weighing about 20-25 g were infected with *P. Berghei* by i.p. injection of 0.5 ml malarial mouse blood on day 6 which had been diluted 1/200 with normal saline. This dose routinely transmits malaria and kills 95 to 98 % of 1-month old mice by the sixth day¹. Mice were sacrificed each day after inoculation and blood obtained for proliferocyte studies. Another group of mice received 0.5 ml of 1:10 saline dilution of malarial blood which had first been refrigerated for 3 days to kill all organisms.

Adult Fisher strain rats were used in other experiments. Splenectomy was carried out in both rats and mice following ether anesthesia. Sham splenectomy was performed in some animals by merely removing parts of omentum.

Results

Blood proliferocyte levels of 10 healthy human adults (ages 21 to 45) ranged from less than 10 to 20 proliferocytes per 10,000 mononuclear cells with a mean value of 5. The labeled cells seen in their

blood consisted mostly of large lymphocytes and monocytes with clear or pale cytoplasm. Other rarer proliferocytes resembled young lymphocytoid, monocytoïd, and plasmacytoid cells with deeply basophilic cytoplasm. No small lymphocytes were found labeled.

Five recent veterans of Vietnam (ages 21-25) were seen when they were febrile and in the midst of an attack of *Vivax* malaria. All had positive blood smears for malaria and were promptly treated after diagnosis. None remained febrile more than 3 days. Distinctly increased numbers of proliferocytes as much as 20-fold greater than normal were seen in blood from these malaria patients at the onset. Only one of the patients had a palpable spleen. None manifested prominent hemolysis or anemia. After clinical response to therapy within 3 to 4 days, blood proliferocyte levels rapidly declined. The types of blood proliferocytes seen during their illness included all cell types seen in normal blood. No small lymphocytes were seen labeled.




Fig 1 Blood proliferocytes during mouse malaria. Group A: 4 weeks old mice; group B: 10 weeks old splenectomized mice; group C: 10 weeks old sham splenectomized mice; group D: 10 weeks old non-operated mice.




Fig. 2. Autoradiograph of mouse peripheral blood on day 6 after malaria inoculation. Note the labeled small lymphocyte (proliferocyte) in center and high degree of red cell partial-thrombocytopenia.

Studies of blood proliferocytes in normal and malarial mice were carried out. Blood proliferocyte levels in normal mice were higher than in normal humans. In a group of 59 normal mice the mean blood proliferocyte index was 38 with a standard deviation of 22. Labeled cells seen in normal mouse blood appeared to be both small and large lymphocytes, as well as monocytes.

Thirty-six young mice were inoculated with malarial mouse blood. Blood proliferocyte levels were monitored daily thereafter. The result of this experiment is shown in figure 1 (group A). Two hours after inoculation with malarial blood, proliferocyte levels remained within control limits. Subsequently proliferocytes increased during days 1-3. Maximal blood proliferocyte levels were seen on day 4 in all mice.

when more than a 10-fold rise was noted (mean value 490). This high blood proliferocyte was not entirely sustained for on days 5 and 6 blood proliferocyte levels were 300 and 225 respectively. All animals were severely anemic on days 5 and 6 with hematocrits ranging from 12 to 32 % and were barely alive when sacrificed. Red cell parasitism in the infected mice on day 4 was 9 %. By day 5 50 % of the red cells and at the day of death, 98 % were parasitized with organisms. An autoradiograph prepared from mouse blood on the sixth day after inoculation with malaria is shown in figure 2. A high degree of red cell parasitism is seen. A mouse blood proliferocyte is shown which by its size, nuclear shape and scant pale cytoplasm, most closely resembles a lymphocyte.

The mean blood leukocyte count during experimental malaria in these mice initially was 15 000/mm³ but declined to the lowest value on day 3 when the mean WBC count was 5 500/mm³. Afterwards, the WBC count gradually recovered. Splenic hypertrophy consistently occurred during the malarial infection and was distinct on day 3. At day 6, all malarial mouse spleens had enlarged to approximately twice normal size.

In another experiment, mouse malarial blood containing large numbers of killed parasites was injected into 4 mice. Proliferocyte levels in tail vein blood remained within normal limits throughout 10 days after inoculation and all mice remained healthy. Splenomegaly did not occur.

The role of the spleen on blood proliferocyte levels during murine malaria was also evaluated in a group of somewhat older mice (10 weeks old). These results are depicted in figure 1. These older animals had either undergone splenectomy (group B) or sham splenectomy (group C) 3 weeks prior to malaria inoculation. A third group was intact (group D). All animals were infected with murine malaria blood as before. Older mice with intact spleens given malaria (group D) were slightly more resistant to the usual inoculum; these animals survived for 9-10 days. Blood proliferocytes were also increased with a peak on day 5 during their infection. When 10 pre-splenectomized mice were given malaria (group B) the course of the infection was distinctly milder and the mice lived for 12 days. Blood proliferocytes barely increased in this group and no peak levels were seen. A third group of 5 mice (group C) who had been previously sham splenectomized, responded to malaria in a fashion similar to the older intact group.

The previous results have shown that malarial infection is associated with increases in blood proliferocytes. The effect of splenectomy alone on blood proliferocyte levels in mice and rats without interaction of malaria was studied. These results are shown in figure 3. Twenty mice were splenectomized and the proliferocytes in the blood serially evaluated. Splenectomy resulted in a rise in blood proliferocytes to a peak at 14 days post operation. The blood proliferocyte levels remained elevated for 2 weeks then gradually fell to normal levels by 6 weeks. Sham splenectomy in 10 mice did not perturb their blood proliferocyte levels.

A group of 10 rats also underwent splenectomy and blood proliferocytes were monitored post operation. These results are also shown in figure 3. These animals, like the mice showed a gradual rise in blood proliferocytes with distinct elevated levels on day 7 which rose further at day 14 to a mean of 125 then gradually declined. In contrast, blood proliferocyte levels in normal intact rats had a mean value of 55.




Fig. 3. Blood proliferocytes following splenectomy and sham splenectomy in mice and rats (no malaria).

Since anemia is an important aspect of murine malaria the possibility that the blood proliferocyte response was mediated by the anemia, *per se* was explored. Two adult rabbits were acutely bled via cardiac puncture so that their hematocrits fell to 50% pre-treatment values. Daily blood proliferocyte levels did not show any significant change occurred in spite of subsequent reticulocyte responses as high as 20%. A group of rats were made severely anemic after receiving phenylhydrazine. In spite of normal reticulocyte responses, blood proliferocyte levels failed to increase.

Discussion

The present report is a quantitative study of DNA synthesizing cells of the blood. These cells are here named proliferocytes. A proliferocyte is any cell having the capacity of promptly utilize ^3H -thymidine for its ongoing DNA synthesis so that it labels promptly and is seen in prepared ARG. Excluded from this definition are unlabeled but otherwise identical appearing cells of any tissue or fluid which are in other phases of their cell cycle at the time of labeling and which may or may not also proliferate eventually. The present definition permits the detection and quantitation of proliferocytes in tissues or fluids at the time of testing. While numerous studies of cell proliferation and kinetics have utilized ^3H -thymidine to study proliferocytes and their progeny in generative compartments, few workers have evaluated proliferocytes in non-generative and transit compartments such as blood, urine and various secretions. The presence of proliferocytes in these areas in health and disease deserves further study.

The present study shows that blood proliferocytes are increased when human beings and mice are infected with malaria. The types of blood cells seen labeled here do not seem to differ from those seen in viral and bacterial infections previously reported to show increased blood proliferocytes. The rarity yet diversity of blood proliferocytes makes their morphological classification difficult. JANDL has shown that splenic cell proliferation is stimulated by splenic work either due to increase cell trapping or induced immunologic challenge [9]. Blood proliferocytes during malaria may thus represent spillage from the hyperplastic spleen during stimulation by work. Recently, however, CHAN *et al.* [10] reported that the number of ^3H -thymidine labeled

cells (proliferocytes) detected in normal rat blood increased as much as 4.5 fold 7 days after splenectomy. Increased blood proliferocytes persisted in their splenectomized rats for as long as 23 days. Our results in mice and rats confirm and extend their findings. Compensatory hypertrophy of remaining lymphoid organs after splenectomy was suggested as a cause for the results seen. Presumably proliferocytes are shed into the blood during this process. This hypothesis is quite compatible with splenic hypertrophy as a source of increased blood proliferocytes in malaria. Our data suggest overall that blood proliferocytes arise from stimulation of diverse lymphoid tissues. No specific splenic role is envisioned in blood proliferocyte production except that the spleen is a major source of lymphoreticular tissue. In splenectomized animals, compensatory lymphoreticular hyperplasia with increased blood proliferocytes could ensue.

Summary

Trilabeled thymidine labeling of blood leukocytes *in vivo* was used to detect circulating mononuclear blood cells capable of proliferation. Blood proliferocytes were found to be markedly elevated acutely in 5 patients with malaria. Mice infected with murine malaria demonstrated maximally increased numbers of blood proliferocytes 4 to 5 days after inoculation. Prior splenectomy in mice prevented the usual proliferocyte increase of malaria. Splenectomy alone in mice and rats yielded increased numbers of blood proliferocytes in the absence of malaria. Blood proliferocytes seem to represent 'spillage' from lymphoreticular tissues stimulated by immunologic or reticuloendothelial work.

References

1. BOYD, V. P., CROOKER, E. P., FLEISHER, T. M. and SCHORE, P. K. DNA synthesizing cells in the peripheral blood of normal human beings. *Science* 128: 202 (1958).
2. BOYD, V. P., FLEISHER, T. M., CROOKER, E. P., RUBIN, J. R., BRECHER, G. and SCHORE, P. K. Proliferative potentials of bone marrow and blood cells studied by *in vivo* uptake of ³H-thymidine. *Acta haemat., Basel* 21: 1 (1959).
3. BOYD, V. P., FLEISHER, T. M., CROOKER, E. P., RUBIN, J. R., BRECHER, G. and SCHORE, P. K. Autoradiographic studies on DNA synthesizing cells in the peripheral blood. *Haemat. in Milano* 2: 103 (1959).
4. GARTO, F., PILERI, A. and MARANI, G. Incorporation of thymidine labeled with tritium by circulating cells of infectious mononucleosis. *Nature, Lond.* 183: 1671 (1959).
5. EPSTEIN, L. C. and BRECHER, G. DNA and RNA synthesis of circulating atypical lymphocytes in infectious mononucleosis. *Blood* 25: 2 (1965).
6. SCHWED, J. R., OLSEN, R. J. and MORSCHER, S. Infectious mononucleosis and autoradiographic study of DNA and RNA synthesis. *Scand. J. Haemat.* 2: 18 (1965).

7. RUTHER, J. R.; BOND, V. P.; KELLER, S., FLEISHER, T. M. and CROWTHER, E. P. DNA synthesis in circulating blood leukocytes labeled *in vivo* with ^3H -thymidine. *J. Lab. clin. Med.* 58, 751 (1961)
8. GUMP, H. W. and FREEDY, F. R. The relationship of infection and DNA synthesizing cells in human blood. *J. Lab. clin. Med.* 69, 428 (1967)
9. JONES, J. H.; FILER, N. M.; BARNETT, S. B. and MACDONALD, R. A. Proliferative response of the spleen and liver to hemolysis. *J. exp. Med.* 122, 299 (1965)
10. CHAN, PO-CHUEN; JOHNSON, L. L.; MOSSETTE, F. C.; LOBCK, J. and GORDON, A. S. Trilabeled-thymidine incorporating cells in the peripheral blood of normal and splenectomized rats. *Proc. Soc. exp. Biol. N.Y.* 125, 614 (1967)

The Clinical Laboratories, Section of Cytochemistry Meir Hospital, Kfar-Saba, and
Department of Microbiology Bar Ilan University Ramat-Gan

Enzymatic and Chemical Changes in Human Lymphocyte Cultures

L. A. ROZENKZAJN and DINA FISCHER

The normal population of lymphocytes in human blood consists predominantly of small cells, a few large lymphocytes and occasional atypical mononuclear cells [1]. Phytohemagglutinin (PHA) an extract of *Phaseolus vulgaris* causes agglutination of the red cells in peripheral blood cultures [2] and stimulates the transformation and mitosis of the lymphocytes [3]. Neutrophils and monocytes show signs of degeneration while eosinophils retain their morphological characteristics. There is a difference of opinion as to the origin of macrophages. Some authors believe that macrophages originate from lymphocytes [4, 5, 6] while others, that they are derived from monocytes [7]. Cytochemical investigations of cells in blood cultures during the process of transformation have been reported by various authors [6, 8-14].

In the present study we tried to examine and estimate both qualitatively and quantitatively the activity of various enzymes and chemical constituents in human blood cell cultures (BCC). We were especially interested in the biochemical changes taking place during the transformation of lymphocytes stimulated by PHA.

Materials and Methods

Using the method of MOOREHEAD *et al.* [15] with slight modification [16] BCC were made from peripheral blood of 14 healthy subjects. Using the same method pure lymphocyte cultures were made after the lymphocytes had been separated on glass columns [7].

Light and phase contrast microscopy were used. Fluorescent microscopic studies were done with acridine orange (AO) for RNA and DNA while neutral red (NR) was used for neutral fats [17].

Cytochemical examinations were performed on the cells after 24, 48, and 72 h of culture. As control, blood cells cultured without PHA were used. The cytochemical staining was done immediately after the smears were prepared from the BCC.

The rate of transformation of lymphocytes was determined by counting 200 cells in smears which were stained with MGG staining. Small lymphocytes, intermediate cells and blast-like cells, were counted.

Staining methods used included May-Grünwald-Giemsa (MGG) peroxidase for general diagnosis [18] azo-dye coupling method for acid phosphatase (AP) [19] and for alkaline phosphatase activity [20]. Esterases were determined by using alpha-naphthyl acetate, naphthol AS-D chloroacetate and naphthol AS-D acetate as substrates [21]. Dehydrogenases: glucose-6-phosphate dehydrogenase (G-6-PDH), lactic dehydrogenase (LDH), succinic dehydrogenase (SDH) [22] and dihydroorotate dehydrogenase (DHO.DH) [23]. The latter was demonstrated using the same technique as for G-6-PDH, the incubating solution containing equal amounts of dihydroorotate 1 mg/ml and Nitro BT 0.5 mg/ml of Sörensen buffer pH 7.4. Diaphorases: dihydronicotinamide-adenine dinucleotide diaphorase (NADH diaphorase) and dihydronicotinamide-adenine dinucleotide phosphate diaphorase (NADPH diaphorase) [22].

For the study of DNA metabolism ^3H -thymidine was used, concentration of 1 $\mu\text{Ci}/\text{ml}$. Autoradiograms were prepared using Ilford K 5 emulsion. The exposure period was 7 days. Methyl-Green-Pyronin (MGP) staining for DNA and RNA was used with the adaptation of Krawiec method [24]. Soda Black B [25], Sudan III [17], Oil Red O [26] were used for investigation of lipids. Periodic acid Schiff (PAS) reaction was carried out with and without ptyalase digestion [27]. PAS staining was also done on smears which were prepared from heparinized cross blood of 9 healthy subjects. The blood was incubated in sterile glass tubes for 24, 48 and 72 h with the sole addition of glucose to make up 100, 500 and 1000 mg % solutions, no other constituents being added. A control cross blood was incubated without glucose.

The activity of the acid phosphatase, dehydrogenases, diaphorases and the glycogen content in the lymphocytes was estimated in semiquantitative way [19, 22, 28].

The glycogen content and the acid phosphatase activity were determined by counting 100 small lymphocytes and 100 transformed lymphocytes (intermediate and blast-like cells). The glycogen content of lymphocytes incubated with glucose, the rate of DNA synthesis and the enzymatic activity of dehydrogenases and diaphorases were determined by evaluating the score in 100 lymphocytes.

The grading for DNA synthesis (^3H -thymidine) was done according to the number of grains present in the nucleus of the cell. 0 = nucleus containing no grains, 1+ = nucleus containing isolated groups of grains, 2+ = nucleus rich in grains but with certain areas void of them, 3+ = nucleus overcrowded with grains.

Results

Morphology

Phase contrast microscopy After 24 h of culture, intermediate cells with reticular nuclei and a more abundant cytoplasm replaced the small lymphocytes. A few cells had visible nucleoli, and some exhibited movement. After 48 h the cells were large with nuclei which contained

a nucleolus. Mitochondria and round shiny bodies $1\text{ }\mu\text{m}$ in diameter were distinguished in the cytoplasm. After 72 h the majority of cells looked like blasts, some being large, others smaller while mitotic figures were also observed. Macrophages and remnants of neutrophils were already noted after 24 h. The eosinophils retained their morphological characteristics. In the culture of pure isolated lymphocytes no macrophages were seen.

May-Grünwald-Giemsa staining The cytoplasm of the transformed cells stained pale to dark blue. Vacuoles which correspond to the shiny round bodies observed under phase microscopy were found in many cells. Nucleoli could be distinguished in the nuclei of blasts.




Fig. 1




Fig. 2

Fig. 1 Differential count in leukocyte culture, stimulated by PHA. — Small lymphocytes, intermediate lymphocytes, blast-like cells.

Fig. 2 The score of the acid phosphatase activity in lymphocytes, in PHA-treated cultures, and in control cultures without PHA.

There was no difference between the rate of transformation of lymphocytes in the pure lymphocyte culture and in the blood cell culture (fig 1)

AO fluorescence The nuclei emitted a green fluorescence. In the cytoplasm of the majority of lymphocytes small bodies of red fluorescence could be distinguished. The number of these fluorescent bodies was greater in transformed cells. In the macrophages the cytoplasm emitted a strong red fluorescence.

AR fluorescence The spherical cytoplasmic inclusion bodies emitted a light green fluorescence while the nuclei and the cytoplasm showed an orange fluorescence. The identity of the spherical refractile inclusion and fluorescent bodies could be demonstrated by staining with NR and examining the same cell both by phase contrast and fluorescent microscopy.

Cytochemical Studies

Peroxidase staining Only neutrophils and macrophages showed enzymatic activity.

Acid phosphatase Azo-dye staining was positive in lymphocytes in all stages of their transformation. The enzymatic activity increased progressively and reached a peak after 72 h. The small lymphocytes that did not undergo transformation in the culture with PHA showed a stronger enzymatic activity than the lymphocytes cultured without PHA (fig 2). The vacuoles stained brown in a different way from the specific stain of the enzyme (fig 3). The staining took place also when the media did not contain the specific substrate. The enzymatic activity was very strong in macrophages.

Alkaline phosphatase No enzymatic activity was observed in the lymphocytes.

Esterase activity Using alpha naphthyl acetate as substrate the enzymatic activity in the small lymphocytes was in the form of small brown bodies in the cytoplasm or small scattered granules. In the blasts many small cytoplasmic granules were seen while in the monocytes and macrophages the enzymatic activity was strong taking the form of aggregates and numerous granules. Using naphthol AS-D chloroacetate as substrate the neutrophils exhibited strong enzymatic activity in the form of purplish-red clumps scattered in the cytoplasm. Lymphocytes were not stained and in the macrophages a few large



Fig 3

Fig 3. Acid phosphatase activity in PHA-induced lymphocytic cells. The activity is demonstrated by the scattered granules in the cytoplasm. Some acrotes are stained as round bodies with the azo-dye.



Fig 4

Fig 4. Transformed lymphocytes after 72 h in culture, showing strong activity of NADH dehydrogenase.

clumps could be distinguished. Using naphthol AS-D acetate as substrate the activity was observed in the lymphocytes in all stages of their transformation. In macrophages and neutrophils it took the form of reddish cytoplasmic granules.

Dehydrogenases (DHO DH SHD LDH G-6-P DH) and **diaphorases** (NADPH NADH) The enzymatic activity was observed in the form of diffuse cytoplasmic staining and/or bluish granules. Blasts and intermediate cells showed stronger activity than the small lymphocytes (fig 4 5)

Autoradiography The incorporation of thymidine ^3H corresponds to the synthesis of DNA and increases with the transformation of the lymphocytes (fig 6)

Methyl green pyronin The presence of RNA was made evident by a red staining which was stronger in the intermediate lymphocytes and strongest in the blasts.

With **Sudan III** and **Oil Red O** the cytoplasmic vacuoles stained red. By staining with **Sudan Black B** only a few black granules were seen in the cytoplasm in some small or transformed lymphocytes. Neutrophils and macrophages stained black.

Periodic acid Schiff In lymphocytes the staining increased in intensity in the first 24 h, and subsequently there was a reduction in staining intensity (fig 7). In some cultures there was a further increase in glycogen content in the second 24 h. In venous blood samples incubated with glucose only there was a progressive increase in the glycogen content during the 72 h of culture. The glycogen content of cells depends on the amount of glucose present in the media (fig 7). In the smears that were treated with pyraline PAS staining was negative.

In the pure lymphocyte cultures, cells showed the same cytochemical characteristics as the lymphocytes cultured from whole blood.




Fig 5




Fig 6

Fig 5. The score of dehydrogenases and diaphorases in the lymphocytes in PHA-treated cultures (—) and in control cultures without PHA (---).

Fig 6. The score of DNA synthesis demonstrated by ^3H -thymidine incorporation (autoradiography) in lymphocytes from leukocyte culture treated with PHA.




Fig. 7 The score of the glycogen content of lymphocytes in PHA-treated BCC, of lymphocytes from blood incubated without PHA, and from blood incubated without culture medium and PHA, but with the addition of different amounts of glucose.

DISCUSSION

The present study of the cytochemical changes accompanying morphological development, reveals in part the biochemical processes occurring in the transformation of lymphocytes.

One of these processes, the metabolism of sugars expresses itself firstly in the accumulation of glycogen in the culture during the first 24–48 h followed by its decay during an additional day (fig. 7) and secondly in an increase in the activities of the dehydrogenases and diaphorases involved in glycolysis (fig. 5). The utilization of glycogen as an energy pool is higher in the cultures with blast transformation than in the lymphocytes from blood incubated without culture medium, because the increased metabolic activity of the first requires more energy.

Examination of the glycogen synthesis in lymphocytes from blood incubated in glucose solutions without PHA indicated that the high level of glycogen synthesis is independent of the lymphocyte transformation and the degree of synthesis depends on the amount of sugar provided to the incubating blood. There are differences in the degree of synthesis of glycogen in lymphocytes from different donors, both when the blood is incubated with sugar only and when it is incubated in cultures in the presence of PHA. The rate of transformation is perhaps better when the synthesis of glycogen is higher.

An increase in the activity of DHO.DH which participates in pyrimidines synthesis indicates that synthesis of nucleic acids takes place (fig 5). This was corroborated by the demonstration of increased DNA synthesis (fig 6) and RNA content (MGP) in the cytoplasm of lymphocytic cells.

With the cytochemical staining method used we could not detect any signs of transformation of lymphocytes into cells of other series.

Similar to the findings reported in the normal hemopoietic cells, AP activity was stronger in the intermediate and blast like cells than in the small lymphocytes [19]. The increase in AP activity in the small lymphocytes as compared with its activity in the cells cultured without PHA (fig 2) is probably due to the effect of PHA on the permeability of the lysosomal membrane [29].

The vacuoles seen in the transforming cells are probably the products of lysosomal autodigestion. We believe that the vacuoles are an early sign of cellular damage in the same way that the presence of lipid inclusions occurring in leukocytes in synovial fluid is evidence of white cell degenerative changes [30]. These vacuoles which have been described as containing neutral fats [10] stained selectively with Sudan III, Oil Red O and exhibit fluorescence with NR, thus showing the cytochemical characteristics of lipids presumably neutral fats. The faint staining of the vacuoles by the azo dye technique for AP both with and without substrate, indicates a false reaction resulting from the solubility of Fast Garnet dye in lipids.

The macrophages which are not present in the pure lymphocyte cultures, appear in BCC as of monocytogenous origin. Similarly to the blood monocytes they show the same strong activity of AP and esterase alpha naphthyl acetate, a positive staining of peroxidase and Sudan Black B. The strong AO fluorescence is probably due to its own lysosomes and that of the phagocytosed cytoplasm of the neutro-

phils. The phagocytic activity of macrophages was demonstrated also by the finding within them of the remnants of cytoplasm of the neutrophils, made evident by the positive reaction of naphthol AS-D chloroacetate esterase. This enzyme is found only in the cytoplasm of granulocytes.

Acknowledgments. We are grateful to Mr J. ESSERT, M.Sc., from the hematological laboratory for his valuable help and wish to thank Mr. M. MEYER, B.Sc., and Mr. M. FALK for the illustrations.

Summary

In lymphocytes from healthy subjects, cultured *in vitro* in the presence of phytohemagglutinin, qualitative and semiquantitative evaluations of enzymatic activity and chemical constituents were made. The metabolism of sugars expresses itself by the accumulation of glycogen and by an increase of the dehydrogenases and diaphorases involved in glycolysis. DNA and RNA synthesis was made evident. The activity of acid phosphatase increased with the transformation of the lymphocytes, being stronger in the transformed lymphocytes than in the small ones. The vacuoles which appeared as shining bodies when examined under phase contrast microscopy appeared to contain neutral fats.

References

1. EFRATI, P. and ROZINSZAJN, L. The morphology of buffy coat in normal human adults. *Blood* 16: 1012 (1960).
2. LI, J. G. and OSGOOD, E. E. A method for the rapid separation of leukocytes and nucleated erythrocytes from blood or bone marrow with phytohemagglutinin from red beans (*Phaseolus vulgaris*). *Blood* 4: 670 (1949).
3. NOWELL, P. C. Phytohemagglutinin. An initiator of mitosis in cultures of normal human leukocytes. *Cancer Res.* 20: 462 (1960).
4. TROWELL, O. A. Cells and tissues in culture, vol. 2, p. 122 (Academic Press, London/New York 1963).
5. BIRMAN, L. Lymphocytes and macrophages *in vitro*. *Lab. Invest.* 15: 1084 (1966).
6. QUAGLIARO, M. and HAYMON, F. G. J. Metabolic changes in short term *in vitro* culture of normal and leukemic cells. Studies with cytochemistry and autoradiography. In HAYMON Current research in leukaemia, p. 124 (University Press, Cambridge 1965).
7. RANDOWITZ, Y. Separation of lymphocytes, polymorphonuclear leukocytes and monocytes on glass columns, including tissue culture observations. *Blood* 23: 811 (1964).
8. GOCCE, J. and ELVIA, M. W. Studies of lymphocytes and their derivative cells *in vitro*. I. Biochemical constituents. *Acta haemat., Basel* 36: 344 (1966).
9. GOCCE, J. and ELVIA, M. W. Studies of lymphocytes and their derivative cells *in vitro*. II. Enzyme cytochemistry. *Acta haemat., Basel* 37: 42 (1967).
10. TAMAKA, Y. and LEBOY, T. J. Lipids and acid phosphatase in cultured lymphocytes of peripheral blood. *Lab. Invest.* 15: 433 (1966).

11. QUAGLIRO, D., HAYNOR, F. G. J. and FLEDMAN, R. J. Cytochemical observation on the effect of phytohemagglutinin in short-term tissue culture. *Nature, Lond.* 196: 338 (1962).
12. COOPER, E. H.; BARRHAM, F. and HALE, A. J. Observations on the proliferation of human leukocytes cultured with phytohemagglutinin. *Brit. J. Haemat.* 9: 101 (1963).
13. BARKER, B. E. and FARNES, P. Histochemistry of blood cells treated with pokeweed mitogen. *Nature, Lond.* 214: 787 (1967).
14. YOFFEY, J. M., WINTER, G. C. B.; OSMUND, D. G. and MITCH, E. S. Morphological studies in the culture of human leukocytes with phytohemagglutinin. *Brit. J. Haemat.* 11: 483 (1965).
15. MOOREHEAD, P. S.; NOWELL, P. C.; MILLMAN, W. J.; BAFFES, D. M. and HICKMANFORD, D. A. Chromosome preparations of leukocytes cultured from human peripheral blood. *Exp. Cell Res.* 20: 613 (1960).
16. MILLMAN, W. J. Human peripheral blood leukocyte cultures in *Yates Human chromosome methodology* (Academic Press, New York/London 1963).
17. ROZENCZAJC, L.; ALAJMAN, A.; YAFFE, D. and ERRATI, P. Jordan's anomaly in white blood cells. Report of case. *Blood* 26: 258 (1966).
18. CARTWRIGHT, G. E. *Diagnostic laboratory hematology* p. 91 (Grune & Stratton, New York 1956).
19. ROZENCZAJC, L.; MARSHAK, G. and ERRATI, P. Acid phosphatase activity in normal human blood and bone marrow cells as demonstrated by the azo-dye method. *Acta haemat., Basel* 30: 310 (1963).
20. KAPLOW, L. S. A histochemical procedure for localizing and evaluating leukocyte alkaline phosphatase activity in smears of blood and bone marrow. *Blood* 10: 1023 (1955).
21. ROZENCZAJC, L.; LEBROVICH, M.; SWOMAN, D. and EPPSTEIN, J. The esterase activity in megakaryoblasts, leukaemic and normal hemopoietic cells. *Brit. J. Haematol.* 14: 605 (1968).
22. ROZENCZAJC, L. and SWOMAN, D. The demonstration of dehydrogenases and diaphorases in cells of peripheral blood and bone marrow. *Blood* 29: 737 (1967).
23. ROZENCZAJC, L.; FISCHER, D.; SARAB, J.; EPPSTEIN, J. and KOOBY, B. Cytochemical findings in lymphocytes in blood culture. *Harefesh* 73: 193 (1967).
24. KROCHOK, N. B. Histochemical staining with Methyl-Green-Pyronin. *Stain Technol.* 37: 233 (1962).
25. SEIDEMAN, H. L. and STOLIFY, G. W. An improved method of staining leukocyte granules with sodan black. *J. Path. Bact.* 59: 336 (1947).
26. PRANK, A. G. E. *Histochemistry theoretical and applied*; 2nd ed., p. 854 (Little, Brown, Boston 1961).
27. HAYNOR, F. G. J.; QUAGLIRO, D. and FLEDMAN, R. J. Consecutive use of Romanowsky and Periodic-Acid-Schiff techniques in study of blood and bone marrow cells. *Brit. J. Haematol.* 6: 23 (1960).
28. MITCH, W. J.; BERGHA, L. J.; MENDOZOFF, I. B. and DANKERHOFF, W. Cytochemical studies of glycogen content of lymphocytes in lymphocytic proliferations. *Blood* 13: 748 (1958).
29. ALLROY, A. C. and MALLUCCI, L. Lysozymes in dividing cells with special reference to lymphocytes. *Lancet* ii: 1571 (1964).
30. HENRO, C.; MICHAELI, D.; SHIBOLEY, S.; MERIDER, H. J. and ROZENCZAJC, L. The nature of refractile inclusions in leukocytes of synovial effusions. *Israel. J. med. Sci.* 3: 838 (1967).

Authors' addresses: L. A. ROZENCZAJC, Ph. D. Head of Clinical Laboratories, Dora Frenkel, M. Sc., Laboratory of Hematology, Meir Hospital, Kfar-Saba (Israel).

Departments of Medicine (Head: Prof. P. BRUNNEN), Medical Microbiology (Head: Prof. E. MONTAKALLIO) and Pediatrics (Head: Prof. T. PELTONEN) University of Turku, and the Central Geriatric Hospital of Tampere (Head: R. HILTUNEN)

Transketolase Activity of Red Blood Cells from Infancy to Old Age

T. MARKKANEN, R. HEIKINHEIMO and M. DAHL

On the basis of current knowledge, the transketolase activity (TKA) of the red cells falls in thiamine deficiency [3-13, 15, 16, 22-24, 27] and increases in megaloblastic anemia caused by vitamin B₁₂ deficiency [19, 20]. During experimental hemolysis the TKA of the red cells tends to increase, apparently due to the presence of numerous young forms of red cells [1, 14]. The TKA of foetal red cells has been found to exceed that of the maternal cells [26].

The present study was carried out to investigate the TKA changes in man in different age groups from birth to late old age.

Material and Methods

The series comprised 414 subjects. Detailed information concerning them is given in table I, which carries the same group numbers as figure 1.

The series was composed and initially examined in hospital conditions. The children of the series were found in the Department of Obstetrics and/or Pediatrics where they were under observation. They were all in an excellent physical condition and had no diseases which current opinion might hold to affect the transketolase activity of the red cells. The adult series was composed from the University Department of Medicine and from the Geriatric Hospital. The young and middle-aged patients were under observation for some minor internal complaints and had no deficiency diseases, or disorders which according to current opinion might affect the TKA of red cells. The geriatric series contained the following diagnoses: arthrosis, chronic rheumatoid arthritis and mainly cardiovascular diseases. All these patients were in an excellent nutritional condition.

All specimens were taken from venous blood and collected during the same season of the year (autumn) from the whole series. The specimens were analyzed as a large series immediately after they had been drawn, by a method described previously [15]. The TKA unit chosen for the present study was μmol sedoheptulose-7-phosphate/ ml cellular mass/30 min, 37°C, pH 7.4 (international unit).

Table I. Presentation of the total series studied

Group	Age	Men	Women	Total	Weight, kg mean \pm SD	Hb, g/100 ml mean \pm SD
1	0- 7 days	10	12	21	3.450 \pm 1.05	16.4 \pm 2.8
2	8- 30 days	4	6	10	3.380 \pm 0.28	16.3 \pm 2.4
3	31-364 days	5	3	8	5.400 \pm 1.48	12.5 \pm 1.0
4	1- 9 years	5	9	14	20.1 \pm 8.1	12.2 \pm 1.5
5	10- 19 years	8	11	19	50.6 \pm 19.2	13.6 \pm 1.1
6	20- 29 years	13	8	21	66.9 \pm 12.6	13.7 \pm 2.3
7	30- 39 years	12	6	18	73.0 \pm 13.6	14.2 \pm 1.3
8	40- 49 years	15	11	26	74.5 \pm 14.0	14.6 \pm 1.8
9	50- 59 years	8	13	21	73.0 \pm 12.3	13.7 \pm 0.9
10	60- 69 years	10	22	32	65.0 \pm 13.7	12.9 \pm 2.7
11	70- 79 years	20	79	99	58.0 \pm 13.3	13.4 \pm 1.8
12	80- 89 years	10	85	95	52.0 \pm 9.0	13.6 \pm 1.1
13	90- 99 years	2	19	21	48.0 \pm 10.4	13.7 \pm 1.5

Table II. TKA (units) in red blood cells in the whole series, men and women separately

Group	Whole material mean \pm SD	Men mean \pm SD	Women mean \pm SD
1	5.31 \pm 0.98	5.26 \pm 1.08	5.39 \pm 0.83
2	5.31 \pm 1.17	5.70 \pm 1.44	5.05 \pm 1.00
3	5.14 \pm 0.80	5.22 \pm 0.97	5.00 \pm 0.53
4	4.92 \pm 0.53	5.23 \pm 0.49	4.78 \pm 0.52
5	4.88 \pm 0.68	4.86 \pm 0.67	4.90 \pm 0.72
6	4.60 \pm 1.15	4.31 \pm 0.80	5.07 \pm 1.50
7	4.88 \pm 1.09	4.87 \pm 1.02	4.90 \pm 1.28
8	4.84 \pm 0.85	5.07 \pm 0.77	4.54 \pm 0.90
9	5.09 \pm 0.93	5.07 \pm 0.60	5.09 \pm 1.11
10	4.72 \pm 0.98	5.06 \pm 0.98	4.57 \pm 0.96
11	4.61 \pm 0.87	4.73 \pm 0.86	4.57 \pm 0.87
12	4.57 \pm 0.93	4.64 \pm 0.87	4.57 \pm 0.94
13	4.43 \pm 1.11	5.45 \pm 0.49	4.32 \pm 1.11

The statistical differences between the two sexes are not significant.

The results were treated by computer (Institute for Applied Mathematics, University of Turku). The overall mean and standard deviation (SD) of TKA were calculated by age groups (groups 1-13). The same values were calculated separately for both sexes by age groups (table II). In addition, regression analysis of all the data was carried out (fig. 1), the caption giving all the relevant details. The confidence limits taken for the regression analysis were \pm 5.0%.


TKA units
80

Fig 1 Regression analysis of the TKA data of the total series. The group numbers are the same as in table I. The solid line is the line of regression, the thin lines indicate the 95 percent confidence region. The individual results for the test subjects are indicated by points, the group means by crosses, while the triangles indicate the upper and lower limits. Notice that the scale of the axis changes at the age of 10 years (group 3). The correlation coefficient is 0.2197 the F-value 0.7634. The hypothesis that the regression line runs horizontally leads to the T-value of -4.572.

Results

The results are presented in table II and figure 1. Table II shows that the red cell TKA was at its maximum in the newborn and exceeded on the average, the 50 unit limit up to the age of one year. Subsequently the TKA gradually began to fall and was at its lowest in the last group aged 90-99 years. No statistically significant difference could be shown between the sexes. The regression analysis of all the data revealed that the regression curve was slightly declining throughout (fig 1). The T value obtained was -4.572. Accordingly the regression declines significantly towards the older age groups. Details of the statistical mathematics are presented in the table captions.

Discussion

The statistical and mathematical treatment of the results showed that the red cell TKA gradually decreases from birth towards late old

age. The variation of individual values within the age groups is large and numerous reading on either side of the mean are noted. It may be concluded from figure 1 that the differences really are on the statistico-mathematical level and although as such they are clearly significant ($T = -4.573$) from practical clinical work point of view the TKA differences between young and old age groups are relatively small.

The general view is that low TKA of the red cells indicates the absence of the co-enzyme in the patient. For this reason TKA determinations have been used to prove thiamine deficiency. All the members of the present series were in a good nutritional condition and had no symptoms which might have suggested a deficiency state. It may be asserted that in the geriatric groups (groups 11-13) spontaneous intake of food may be reduced, as is also indicated by the mean weight loss. All the members of these groups were, however treated in a geriatric hospital, where their adequate nutrition could be actively controlled.

When the red cell ages the activity of its enzyme systems may fall [1 17 18, 21 25]. The present study in fact disregarded the ageing of the red cell itself. The point is rather the ageing of the red cell's parent cell, and its effect on the quality of the red cells circulating in the blood. The question of interest was, therefore the general effect of ageing on the biochemical life of the cell. The TKA of red cells seems to fall with advancing age. This is in agreement with the findings concerning some other enzymes of the hexose monophosphate shunt.

Summary

The transketolase activity (TKA) of the red cells was studied in 414 test subjects from birth to advanced old age. The mean red cell TKA was highest in the newborn group (5.91 ± 0.98 units) and lowest in the oldest age group (4.43 ± 1.11 units). The other mean values fall between these extreme values. A statistico-mathematical regression analysis resulted in a TKA curve declining significantly from the young age groups towards old age ($T = -4.573$). No significant difference in the TKA of red cells was noted between the sexes in any of the age groups.

References

1. BERNTSEN, R. E. Alterations in metabolic energetics and cation transport during aging of red cells. *J. clin. Invest.* 38: 1572 (1959).
2. BOESCHORS, A., FORNARD, G., FANTON, A., LEONARD, G. and SEGER, P. Relationship between age and enzymatic activities in human erythrocytes from normal and F₁ vs. B₁₂-sensitive subjects. *J. clin. Invest.* 43: 834 (1964).

3. BAIR, M.: Dietary protein, riboflavin, pyridoxine, and thiamine and rat erythrocyte transketolase. *Fed. Proc.* 20: 228 (1961).
4. BAIR, M.: Erythrocyte transketolase in early thiamine deficiency. *Ann. N.Y. Acad. Sci.* 98: 528 (1962).
5. BAIR, M.: Effects of thiamine deficiency and of oxythiamine on rat tissue transketolase. *J. Nutr.* 78: 179 (1962).
6. BAIR, M.: Erythrocyte as biopsy tissue for functional evaluation of thiamine adequacy. *J. Amer. med. Ass.* 197: 186 (1964).
7. BAIR, M.; SMOCK, S. S. and DAVIDSON, C. S.: Effect of thiamine deficiency on mammalian erythrocyte metabolism. *Fed. Proc.* 15: 224 (1956).
8. BAIR, M., SMOCK, S. and DAVIDSON, C. S.: The effect of thiamine deficiency on the glucose oxidative pathway of rat erythrocytes. *J. Biol. Chem.* 230: 319 (1958).
9. BAIR, M., TAI, M. and OSTASHEVER, A. S.: Thiamine deficiency and erythrocyte hemolytic metabolism. *Fed. Proc.* 18: 518 (1959).
10. BAIR, M. and OWSEN, B.: The relationship between vitamin deficiency and certain blood enzymes in rats. *Fed. Proc.* 19: 321 (1960).
11. BAIR, M.; TAI, M., OSTASHEVER, A. S. and HALDERY, H.: The effect of thiamine deficiency on the activity of erythrocyte hemolytic transketolase. *J. Nutr.* 71: 273 (1960).
12. BAIR, M., OSTASHEVER, A. S.; TAI, M. and KALDERY, H.: Effect of feeding V-irradiated pork to rats on their thiamine nutrition as reflected in the activity of erythrocyte transketolase. *J. Nutr.* 75: 29 (1961).
13. BAIR, M., VERNIER, W. and WATSON, J.: Human thiamine deficiency and erythrocyte transketolase. *Fed. Proc.* 21: 468 (1962).
14. COLTORTI, M.; DE SMOCK, A. e BUDDELOW, G.: Attività enzimatiche del ciclo del pentosofosfato negli eritrociti in corso di anemia emolitica sperimentale. *Attività transchetolastica*. *Soc. Ital. Biol. sper.* 36: 1059 (1960).
15. DUFFY, P. M.: Clinical application of blood transketolase determinations. *New Engl. J. Med.* 267: 596 (1962).
16. LEVY, C. M., CARL, L., FRANK, O., GELBERG, R. and BAKER, H.: Incidence and significance of hypovitaminemia in randomly selected municipal hospital population. *Amer. J. clin. Nutr.* 17: 259 (1965).
17. LÖTTER, G. W. und WALLER, H. D.: Hämolitische Erythropathie durch Fehlen von Glucose-6-Phosphat-Dehydrogenase in roten Blutzellen als dominant vererbliche Krankheit. *Klin. Wochschr.* 35: 885 (1958).
18. LÖTTER, G. W. und WALLER, H. D.: Biochemie und Pathogenese der erythropenischen hämolitischen Anämien. *Dtsch. med. Wochschr.* 86: 27 (1961).
19. MARKEANEN, T.: Transketolase activity of red blood cells in conditions of hematological interest. *Acta haemat., Basel* 30: 321 (1968).
20. MARKEANEN, T. and KALLIONIEMI, L.: Transketolase activity of blood cells in various clinical conditions. *Amer. J. med. Sci.* 252: 564 (1966).
21. MARKE, P. A.: Red cell glucose-6-phosphate and 6-phosphogluconic dehydrogenase and nucleoside phosphorylase. *Science* 127: 1338 (1958).
22. SCHOUTER, H., AN EPE, L. W., S. ADER, B. and STUYVER, A. M.: Transketolase in blood. *Clin. chim. Acta* 18: 474 (1964).
23. SIX, H. G.: Heptulose phosphate formation in thiamine deficiency and other physiological states. *Proc. Soc. exp. Biol., N.Y.* 113: 733 (1963).
24. SIX, H. G., NYOM, V. N. and FAHRMAN, W. H.: Capacity of rat tissues to form heptulose phosphates in thiamine deficiency. *Biochem. biophys. Acta* 58: 277 (1961).
25. SYLLÉN-RAPOPORT, I.; SCHMIDT, D. und HORMANN, E. G. G.: Über die *in-vitro* Alterung transfundierter Erythrozyten bei einem Fall von kongenitaler Erythroblastopoenie (Diamond-Blackfan). *Folia haemat., Lpz.* 72: 429 (1961).

26. TAN TAY K.: Erythrocyte transketolase activity and thiamine transfer across human placenta. *Amer J clin. Nutr* 21 739 (1968).
27. WOLFE, S. J. BERK, M. L. and DAVENPORT, C. S. The effect of thiamine deficiency on human erythrocyte metabolism. *J. clin. Invest.* 37 1476 (1958).

Institut de Biochimie, Université de Lausanne, Lausanne

Etude de la fixation non spécifique des immunoglobulines G sur les érythrocytes

L'Influence de la variation de différents paramètres

D. DES GOUTTES et H. ISLIXER

Les immunoglobulines G (IgG) [7] se fixent non spécifiquement à la surface de cellules telles que les érythrocytes [1, 2, 4, 11, 12, 14, 16, 23] et de particules inertes telles que le latex [6].

Plusieurs hypothèses ont été émises concernant la fonction physiologique que possèdent les immunoglobulines adsorbées *in situ* à la surface cellulaire [3]. Les travaux d'OVARY [22] et HALPERN [13] ont permis de conférer à cette fixation non spécifique un rôle dans les processus de désensibilisation. Chez l'homme, JEANNET et coll. [16] ont observé une négativation du test de COOMBS après l'injection de γ G-globulines standard ou traitées à pH 4 chez un patient hypogammaglobulinémique souffrant d'une anémie hémolytique. Des expériences faites chez le chien et chez l'homme montrent la présence, à la surface des érythrocytes, d'une fraction d'IgG augmentant la viabilité de la cellule [10, 27]. Les mêmes auteurs observent qu'une autre fraction d'IgG fixée sur les leucocytes humains, augmente l'activité phagocytaire de ces cellules vis-à-vis du staphylocoque doré [10]. Enfin, l'étude de la fixation des macrophages et des monocytes sur les érythrocytes recouverts d'IgG permet de constater la transformation des érythrocytes en sphérocytes, ce qui favorise ainsi l'élimination de la cellule antigénique [18].

La nature de la fixation non spécifique des immunoglobulines à la surface cellulaire n'est pas encore connue, mais selon CRUCIAND et coll. [8] la présence du fragment Fc serait nécessaire à la fixation cellulaire des γ G-globulines. Pourtant, des expériences montrent que les

fragments Fab et Fc de l'IgG marquée à l' ^{125}I se fixent non spécifiquement à la cellule en quantité égale, sur une base pondérale, à l'IgG native [12].

Le présent travail étudie *in vitro* les caractéristiques de la fixation non spécifique de l'IgG sur les érythrocytes lors de la variation successive de différents paramètres que comporte le système nombre d'érythrocytes, quantité d'IgG mis en présence, conditions et mode d'incubation. L'existence d'une importante fixation de l'IgG sur le verre a conduit à mesurer parallèlement et à comparer la fixation de l'IgG sur le verre et sur les érythrocytes.

Matériel et méthodes

Préparation des érythrocytes. Les érythrocytes de lapin sont prélevés à raison de 10 à 20 ml par saignée à l'oreille. Le sang est recueilli dans un égal volume de solution d'Alsever stérile dont le pH est ajusté à 7.4 avec une solution d'acide citrique saturé. Sauf indication spéciale, les érythrocytes sont utilisés dès 24 h ou jusqu'à 8 jours après leur prélèvement. Les érythrocytes humains sont prélevés chez les donneurs O Rh+ et traités de la même façon que les érythrocytes de lapin. Avant chaque expérience, les érythrocytes sont lavés 3 fois dans un volume de tampon égal à 15 fois celui des érythrocytes. La composition de la solution tampon, appelée tampon ordinaire, est la suivante: un volume de tampon phosphate 0,15 M, pH 7.4 de conductivité égale à 8,52 mmoles, mesurée à l'aide d'un conductimètre Radiometer type Cdm 2d, et 9 volumes d'une solution NaCl 0,15 M. La force ionique finale calculée est de 0,175. Le comptage des cellules est fait à l'aide d'un Coulter Counter Modèle A (Coulter Electronics Ltd., St. Albans, Herts, Angleterre) et l'on vérifie au microscope l'homogénéité de la suspension, l'absence de cellules leucocytaires et l'aspect des érythrocytes. Le degré d'hémolyse observé en cours d'expérience influence peu de façon significative la mesure de radioactivité des culots d'érythrocytes. Ainsi, on négligera d'y porter une correction en rapport avec le degré d'hémolyse.

Préparation des IgG. Un mélange de sérums provenant de plusieurs lapins est précipité et lavé avec du sulfate d'ammonium saturé (concentration finale 40%). Les γ G-globulines ainsi obtenues sont ensuite passées sur une colonne de DEAE-cellulose élaste avec un tampon phosphate 0,01 M, pH 7.4. Une préparation d'IgG hautement purifiée provenant de la Croix Rouge Hollandaise nous a été utilisée. L'ultracentrifugation analytique de l'IgG faite à l'aide d'une ultracentrifugeuse Spinco modèle E. Beckman donne les caractéristiques de l'IgG suivantes:

$n_{20}^{20} = 6,7$; $D_{20}^{20} = 4,2 \cdot 10^{-7}$; $\bar{v} = 0,745$ P.M. = 155.400. Les préparations d'IgG utilisées contiennent moins de 3% d'agréga.

L'iodation des IgG est faite selon la méthode de BOOTS [3] modifiée par MCCORMACK [20]. Le rendement du marquage varie de 20 à 50%, il diminue avec l'âge de la solution d'iode et dépend de la concentration en protéine. Les solutions d'IgG utilisées pour le marquage à l'iode radioactif ont une concentration variant de 0,1 à 3%. L'iode radioactif (^{125}I ou ^{131}I) stérile et sans entraineur provient du Radiochemical Centre, Amersham (Angleterre) et de l'Institut fédéral de recherches en matière de réacteur Würenlingen (Suisse). Après dialyse de la solution d'IgG marquée contre le tampon pendant 72 h, la quantité d'iode libre restant non fixée à l'IgG représente 1 à 2% de la quantité fixée à l'IgG. La radio-

activité est mesurée à l'aide d'un compteur à cristal Nuclear Chicago (modèle Q 120-1). La concentration de l'IgG après le marquage est déterminée par la micro-méthode de HAJDASZL selon la technique rapportée par KARAT et MAYER [17] qui permet d'établir l'activité spécifique (cpm/ μ g de protéine) de l'IgG utilisée dans les expériences.

Les données numériques sont exprimées en moyenne \pm l'erreur moyenne de la moyenne (\pm SE). Les significations de différences entre les moyennes sont calculées en utilisant le test t selon les méthodes statistiques habituelles [23].

La fixation non spécifique de l'IgG aux érythrocytes est effectuée en incubant pendant 60 min à 37°C l'IgG marquée à l'ode radioactif avec les érythrocytes préalablement lavés 3 fois dans un large excès de tampon ordinaire. Après l'incubation, le mélange est centrifugé à 2000 rpm pendant 10 min et le culot d'érythrocytes est lavé 3 fois dans 2 ml de tampon ordinaire. Dans certains cas, le lavage est fait avec une solution isotonique de glucose tamponnée avec le tampon ordinaire afin de diminuer l'élution de l'IgG fixée non spécifiquement. La quantité d'IgG fixée aux érythrocytes est mesurée par la radioactivité du culot d'érythrocytes lavés. La fixation de l'IgG sur le verre est évaluée en transvasant au cours du troisième lavage le culot d'érythrocytes dans un autre tube. La perte d'hématic au cours du transvasage est négligeable. La fixation non spécifique de l'IgG aux érythrocytes est exprimée en μ g par culot ou en molécules d'IgG fixées par culot ou par érythrocyte. La fixation de l'IgG sur le verre est exprimée en μ g d'IgG fixés sur la surface de verre en contact avec le volume constant d'incubation.

Résultats

Des expériences ayant pour but d'évaluer la reproductibilité du système montrent qu'il n'y a pas de variation significative de la fixation non spécifique de l'IgG avec différentes populations d'érythrocytes ou avec des érythrocytes dont le temps de conservation diffère. Au cours du temps de conservation, l'IgG de lapin, contrairement à l'IgG humaine [11] ne se fixe pas significativement plus sur les cellules.

Influence de la concentration des érythrocytes La variation de la fixation de l'IgG-¹²⁵I en fonction du nombre d'érythrocytes a été étudiée en diminuant progressivement jusqu'à un facteur de 10 fois le nombre d'érythrocytes mis en présence d'une même quantité d'IgG. La figure 1 montre une augmentation significative du nombre de molécules d'IgG fixées par érythrocyte à mesure que le nombre d'érythrocytes diminue. Une semblable expérience a été faite en diminuant d'un facteur de 100 le nombre d'érythrocytes. Les résultats présentés dans le tableau I montrent que le nombre de molécules d'IgG par érythrocyte augmente de façon exponentielle à mesure que la quantité d'érythrocytes incubés diminue.

Influence de la concentration de l'IgG Des quantités croissantes d'IgG-¹²⁵I ont été incubées avec un nombre constant d'érythrocytes. L'ex




Fig 1 Variation de la quantité d'IgG-¹²⁵I fixé par érythrocyte en fonction du nombre d'érythrocytes incubés. Une quantité constante de 318 μ g d'IgG-¹²⁵I est incubée avec un nombre croissant d'érythrocytes. Les μ g d'IgG fixés par érythrocyte sont convertis en molécules en estimant le P.M.I. de l'IgG à $1,5 \cdot 10^5$. Le lavage des érythrocytes est fait avec une solution de glucose isotonique tamponnée avec le tampon ordinaire. Chaque point représente la moyenne de 5 valeurs \pm l'erreur moyenne de la moyenne ($\bar{x} \pm SE$).




Fig 2 Variation de la fixation de l'IgG-¹²⁵I aux culots d'érythrocytes en fonction de quantités croissantes d'IgG-¹²⁵I. L'expérience est faite avec deux concentrations d'érythrocytes différentes auxquelles on ajoute des quantités croissantes d'IgG-¹²⁵I. La quantité d'IgG-¹²⁵I fixée est exprimée en μ g par culot d'érythrocytes. Chaque point représente la moyenne de 5 valeurs \pm l'erreur moyenne de la moyenne ($\bar{x} \pm SE$).

présence a été faite avec deux concentrations d'érythrocytes différentes. La fixation cellulaire de l'IgG est mesurée en fonction de la concentration de l'IgG-¹²⁵I ajoutée (fig 2). La quantité d'IgG en su-

Influence de la force ionique. L'adjonction, au tampon ordinaire, d'une quantité croissante de glucose isotonique (6.7%) permet de faire varier la conductivité du tampon en gardant constante l'osmolarité le pH et le volume d'incubation. La force ionique est exprimée en unités de conductivité (mmho). Une même expérience a été faite avec du glucose hypertonique (20%). La figure 4 montre que la fixation de l'IgG aux érythrocytes augmente de façon exponentielle à mesure que la conductivité du milieu d'incubation diminue: la fixation cellulaire de l'IgG est moindre avec l'adjonction d'une solution hypertonique de glucose. La fixation de l'IgG sur le verre n'est pas influencée par la force ionique.

Influence de la température. La fixation de l'IgG-¹²⁵I aux érythrocytes est mesurée en fonction d'une variation de la température du milieu d'incubation de 4°C à 37°C (fig. 5). La fixation de l'IgG-¹²⁵I sur le verre est mesurée parallèlement. On voit que la fixation de l'IgG-¹²⁵I aux érythrocytes est dépendante de la température et diminue très significativement ($p < 0.001$) lorsque la température augmente. Par contre la fixation de l'IgG au verre, en présence d'érythrocytes, augmente significativement ($p < 0.01$) avec la température. En l'absence d'érythrocytes, la fixation de l'IgG au verre reste constante lors de la variation de la température. Ces résultats montrent l'existence d'une compétition entre les érythrocytes et le verre pour la fixation non spécifique de l'IgG-¹²⁵I.

Influence du temps d'incubation. Afin d'étudier la cinétique du processus de fixation de l'IgG-¹²⁵I aux érythrocytes, on fait varier le temps d'incubation d'abord de 5 min à 60 min (tableau II) puis de 30 min à 10 h (tableau III). On constate que la fixation de l'IgG-¹²⁵I reste constante au cours des différents temps d'incubation observés: la fixation non spécifique de l'IgG aux érythrocytes est un processus qui s'effectue dans les minutes qui suivent l'adjonction de l'IgG-¹²⁵I aux cellules. L'équilibre de cette fixation est rapidement atteint et reste constant. Il en est de même pour la fixation de l'IgG-¹²⁵I sur le verre.

Influence du lavage des érythrocytes après l'incubation. Après l'incubation, les érythrocytes sont lavés avec différentes solutions de même pH mais de force ionique variable. Dans le tableau IV les résultats sont comparés avec ceux obtenus par le lavage avec le tampon ordinaire. Un contrôle de la fixation sur le verre est fait parallèlement. Les résultats montrent que l'élution de l'IgG-¹²⁵I fixée aux érythrocytes

Tableau II. Fixation de l'IgG aux érythrocytes et au verre en fonction du temps d'incubation (de 5 min à 60 min)

Durée d'incubation min	μg d'IgG- ^{125}I fixés par culot	μg d'IgG- ^{125}I fixés sur le verre
5	$1,89 \pm 0,13$	$1,26 \pm 0,12$
10	$2,08 \pm 0,12$	$1,23 \pm 0,10$
20	$1,72 \pm 0,23$	$1,93 \pm 0,22$
30	$1,57 \pm 0,14$	$2,13 \pm 0,20$
60	$2,36 \pm 0,19$	$1,66 \pm 0,11$

200 μg d'IgG- ^{125}I ont été incubés avec $32,4 \cdot 10^8$ érythrocytes. Valeurs $\bar{x} \pm \text{SE}$, nombre d'essais = 3.

Tableau III. Fixation de l'IgG aux érythrocytes et au verre en fonction du temps d'incubation (de 30 min à 10 h)

Temps d'incubation	μg d'IgG- ^{125}I fixés par culot	μg d'IgG- ^{125}I fixés sur le verre
30 min	$1,00 \pm 0,16$	$1,96 \pm 0,13$
60 min	$1,19 \pm 0,12$	$2,05 \pm 0,07$
3 h	$0,81 \pm 0,13$	$2,16 \pm 0,17$
10 h	$1,07 \pm 0,09$	$2,17 \pm 0,16$

150 μg d'IgG- ^{125}I ont été incubés avec $32,4 \cdot 10^8$ érythrocytes. Valeurs $\bar{x} \pm \text{SE}$, nombre d'essais $n = 3$.

varie suivant le tampon de lavage utilisé après l'incubation. Elle est d'autant plus importante que la force ionique du tampon de lavage est grande. La fixation de l'IgG- ^{125}I sur le verre reste, par ailleurs, constante. La quantité d'IgG- ^{125}I fixée aux érythrocytes dépend du nombre de lavages (avec le tampon ordinaire) faits après l'incubation (tableau V). Dans cette expérience, la fixation de l'IgG- ^{125}I sur le verre est incluse dans les valeurs obtenues pour le culot. On constate une faible diminution à chaque lavage de la quantité d'IgG- ^{125}I fixée aux érythrocytes la quantité d'IgG- ^{125}I éluée à chaque lavage diminue et tend à devenir constante.

Tableau II Fixation de l'IgG-¹²⁵I aux érythrocytes et verre en fonction de différentes solutions de lavage

Solution de lavage	$\mu\text{g d'IgG-}^{125}\text{I}$ fixés par culot	$\mu\text{g d'IgG-}^{125}\text{I}$ fixés sur le verre
Tampon phosphate 0,15 M	$0,20 \pm 0,01$ $m < 0,01$	$0,98 \pm 0,03$
NaCl 0,15 M tamponné avec le tampon ordinaire	$0,28 \pm 0,016$ $m < 0,02$	$1,03 \pm 0,06$
Tampon ordinaire	$0,40 \pm 0,03$	$0,98 \pm 0,11$
Solution isotonique de glucose tamponnée avec le tampon ordinaire	$0,77 \pm 0,03$ $p < 0,001$	$0,99 \pm 0,07$
Solution isotonique de glucose non tamponnée	$0,88 \pm 0,08$ $p < 0,001$	$1,15 \pm 0,03$

126 $\mu\text{g d'IgG-}^{125}\text{I}$ ont été incubés avec $32,4 \cdot 10^6$ érythrocytes. Le lavage des érythrocytes après l'incubation a été fait avec les différentes solutions indiquées. La valeur de p indique une différence statistiquement significative par rapport à la valeur obtenue par lavage avec le tampon ordinaire. Valeurs $\bar{x} \pm \text{SE}$, nombre d'essais = 5.

Tableau I Fixation de l'IgG-¹²⁵I aux érythrocytes en fonction du nombre de lavages après incubation

Nombre de lavages	$\mu\text{g d'IgG-}^{125}\text{I}$ fixés/culot + verre
2	$3,04 \pm 0,25$
3	$2,42 \pm 0,18$
4	$2,23 \pm 0,20$
5	$2,13 \pm 0,14$
6	$1,97 \pm 0,07$

100 $\mu\text{g d'IgG-}^{125}\text{I}$ ont été incubés avec $32,4 \cdot 10^6$ érythrocytes. Valeurs $\bar{x} \pm \text{SE}$, nombre d'essais = 5.

Comparaison de la fixation de l'IgG-¹²⁵I sur le verre et sur les érythrocytes
L'étude parallèle de la fixation de l'IgG sur le verre et sur les érythrocytes permet de comparer l'importance de l'une de ces fixations par rapport à l'autre. Le tableau VI donne une comparaison de la fixation de l'IgG-¹²⁵I aux érythrocytes et au verre rapportée à une unité de surface égale à celle d'un érythrocyte ($140 \mu\text{m}^2$). Cette comparaison a été faite avec différentes concentrations d'érythrocytes. Le rapport de la surface du verre en contact avec l'IgG-¹²⁵I sur celle d'un

Tableau 17 Comparaison de la fixation d'IgG-¹²⁵I sur le verre et sur les érythrocytes

Erythrocytes incubés 10 ⁶	Molécules d'IgG- ¹²⁵ I fixées par érythrocyte 10 ⁶	Molécules d'IgG- ¹²⁵ I fixées par 140 µm ² de verre 10 ⁶
81,0	0,66 ± 0,03	47,43 ± 6,28
8,1	4,72 ± 0,14	55,56 ± 4,82
0,81	125,67 ± 9,0	190,0 ± 6,07

400 µg d'IgG-¹²⁵I ont été incubés avec un nombre variable d'érythrocytes. Les µg sont convertis en molécules d'IgG en estimant le poids moléculaire de l'IgG à $1,5 \cdot 10^6$. Le lavage des érythrocytes est fait avec une solution de glucose isotonique tamponnée avec le tampon ordinaire, la valeur $\bar{x} \pm SE$, nombre d'essais = 5.

Les valeurs dans la troisième colonne sont rapportées à une unité de surface égale à celle d'un érythrocyte (140 µm²).




Fig. 6. Fixation de l'IgG-¹²⁵I sur le verre en fonction du nombre de lavages. L'incubation met en présence 482 µg d'IgG-¹²⁵I avec $8,1 \cdot 10^6$ érythrocytes. Chaque point représente la moyenne de 2 valeurs \pm l'erreur moyenne de la moyenne ($\bar{x} \pm SE$). Le témoin indique la valeur de la fixation sur le verre sans érythrocyte après le 3^e lavage.

érythrocyte est de $2,6 \cdot 10^6$. Le nombre de molécules d'IgG-¹²⁵I fixées sur le verre est divisé par $2,6 \cdot 10^6$ pour obtenir le nombre de molécules d'IgG fixées sur une surface de verre égale à celle d'un érythrocyte. Ces résultats indiquent que la fixation de l'IgG-¹²⁵I sur le verre

augmente à mesure que le nombre d'érythrocytes incubés diminue cette augmentation est toutefois moins prononcée que pour la fixation cellulaire de l'IgG ¹²⁵I. En présence d'un nombre minimum d'érythrocytes, la fixation de l'IgG ¹²⁵I au verre et aux érythrocytes est égale pour une même unité de surface (140 μm^2). L'influence du nombre de lavages sur la fixation de l'IgG-¹²⁵I au verre est aussi étudiée (fig 6). Un témoin, en l'absence d'érythrocytes, indique la valeur de la fixation de l'IgG ¹²⁵I sur le verre après 3 lavages. On voit que la fixation de l'IgG-¹²⁵I sur le verre diminue de façon exponentielle avec le nombre de lavages. Différentes expériences étudiant la fixation de l'IgG-¹²⁵I sur le verre montrent qu'elle est proportionnelle à la surface du verre et qu'elle dépend de la nature du verre. La fixation de l'IgG-¹²⁵I sur divers tubes de matière plastique est plus importante que celle mesurée sur le verre.

Discussion

Nos résultats montrent que, dans les conditions étudiées, la fixation non spécifique d'IgG aux érythrocytes varie de 0,5 à 1 % de la quantité totale d'IgG incubée. Les nombreux constituants cytophiles du sérum peuvent, en contaminant l'IgG, majorer le pourcentage de fixation non spécifique obtenu par différents auteurs [13-23]. Dans ce travail les critères de pureté de l'IgG permettent d'exclure la présence de contaminants sériques cytophiles et d'affirmer que la radioactivité mesurée représente l'IgG. D'après les travaux de FROMMEL et GROS [11] la présence d'agréats augmente aussi la fixation cellulaire non spécifique de l'IgG. La formation d'agréats étant un processus continu la présence d'agréats ne peut être éliminée par les méthodes habituelles dans les préparations d'IgG utilisées. On sait, par ailleurs, que les IgG agrégées à 63°C se fixent près de 15 fois plus sur les érythrocytes que les IgG non agrégées [15]. La persistance de la radioactivité dans le culot, après lavage, prouve que l'IgG est fixée aux érythrocytes. La fixation de l'IgG se fait sur la membrane cellulaire et une pénétration de l'IgG dans la cellule est exclue puisque, après centrifugation des érythrocytes hémolysés, la radioactivité du surnageant est égale à celle du back-ground. La réaction de fixation de l'IgG aux érythrocytes est très rapide et n'est pas modifiée par une incubation prolongée. En diminuant le nombre d'érythrocytes in-

cubés en présence d'une quantité constante d'IgG la quantité d'IgG fixée par érythrocyte augmente. Ceci indique que la surface de l'érythrocyte ne limite pas la fixation non spécifique de l'IgG comme c'est le cas pour la fixation spécifique. D'autre part, lors de l'adjonction de quantités croissantes d'IgG aux érythrocytes, la fixation cellulaire de l'IgG augmente et la surface érythrocytaire n'est pas saturée par une quantité bien définie d'IgG bien que le pourcentage de fixation cellulaire diminue progressivement. Ceci suggère qu'une association de molécules d'IgG entre elles pourrait favoriser la fixation cellulaire non spécifique de l'IgG. De même les propriétés cytophiles des complexes antigènes-anticorps solubles ont été utilisées pour la sensibilisation passive de différentes cellules [28]. Selon ces auteurs, les complexes antigènes-anticorps stabiliseraient la fixation cellulaire en diminuant la dissociation spontanée des molécules à la surface de la membrane. L'association des molécules d'IgG entre elles facilitée par une forte concentration d'IgG pourrait agir de façon semblable lors de la fixation non spécifique.

La fixation non spécifique de l'IgG aux érythrocytes et au verre diminue lorsque le pH du milieu d'incubation augmente de 5.5 à 7.8. Ce fait indique que les forces électrostatiques interviennent dans la fixation non spécifique. Nos résultats sont en accord avec ceux obtenus par MOLLISON et coll. [21] alors que GROS et coll. [19] décrivent un optimum de fixation non spécifique à un pH de 7.0 comme pour la fixation spécifique [19].

Un accroissement de la *force ionique* du milieu d'incubation ou du tampon de lavage après l'incubation produit une diminution de la fixation non spécifique de l'IgG. Le même phénomène a été décrit pour la fixation spécifique [19]. Dans un milieu de faible force ionique, l'association des molécules de protéine entre elles est plus grande, ce qui permettrait d'expliquer en partie l'effet de la force ionique sur la fixation cellulaire de l'IgG. D'après les travaux de POLLACK et coll. [24] l'abaissement de la force ionique influence aussi la membrane érythrocytaire en diminuant son potentiel électro-négatif «zeta» ce qui favorise la fixation spécifique des hémagglutinines.

L'augmentation de la *température* du milieu d'incubation diminue la quantité d'IgG fixée non spécifiquement aux érythrocytes. Ces résultats sont en accord avec les travaux de SPURIO et coll. [26]. La diminution de la fixation non spécifique de l'IgG à 37°C montre que les forces qui maintiennent l'IgG à la surface de l'érythrocyte sont faibles et

diminuent lorsque l'énergie cinétique des molécules d'IgG s'accroît. Le fait que les IgG fixées non spécifiquement aux érythrocytes ou au verre puissent être éluées en grande partie par des lavages répétés, indique aussi que l'IgG fixée non spécifiquement est moins fortement liée à la membrane érythrocytaire qu'elle ne l'est lors de la fixation spécifique. La variation de la fixation de l'IgG en fonction du nombre d'érythrocytes et l'existence d'une compétition entre la surface du verre et celle de l'érythrocyte indiquent que la fixation non spécifique de l'IgG a lieu sur la surface cellulaire ou non cellulaire mise à disposition.

Nos remerciements vont à feu le Dr T. WISS pour ses conseils de valeur ainsi qu'au Dr M. WALDENHUT. Nous remercions aussi Mesdemoiselles H. WULF et B. FILLOUX pour leur assistance technique précieuse.

Ce travail fut rendu possible grâce à des subides du Fonds National Suisse de la Recherche Scientifique et à une contribution de la Maison F. Hoffmann-La Roche.

Résumé

La fixation non spécifique des IgG aux érythrocytes est étudiée *in vitro* chez le lapin en modifiant successivement la concentration d'érythrocytes, d'IgG ainsi que le mode d'incubation. Les IgG ne se fixent pas seulement sur les érythrocytes, mais encore sur des supports non cellulaires. Le mécanisme de fixation de l'IgG sur le verre semble différer de celui observé sur les érythrocytes. Une saturation de la surface érythrocytaire n'est atteinte qu'avec des quantités très importantes d'IgG. En présence de concentrations croissantes d'IgG, le pourcentage de fixation diminue mais la quantité totale fixée par cellule augmente progressivement, probablement en raison d'un phénomène d'association des molécules d'IgG.

Summary

The non specific *in vitro* fixation of IgG to red blood cells has been studied by varying successively the concentrations of erythrocytes, IgG and also the mode of incubation. The results show that IgG fixes not only to red cells but also to any supporting material. In the case of glass the mode of fixation appears to differ from that observed in erythrocytes. A slow saturation of the red blood cell surface is approached only with large quantities of IgG. Although the percentage of fixation diminishes with increasing amounts of IgG the absolute amount fixed per cell increases progressively probably due to association of IgG molecules.

Bibliographie

1. ALLERAND, C. D. and YARD, M. D. γ -Globulin affinity for normal human tissue of the central nervous system. *Science* 144: 1141-1142 (1964).

2. AMERSON, R. E. and WALFORD, R. L. Detection of leucocyte antibodies by means of 125 I labelled and purified antihuman-globulin antibody problems of non-specific adsorption of globulin by leucocytes. *Blood* 16: 1523-1534 (1960)
3. BOCCI, V. Efficient labelling of serum proteins with 125 I using chloramin T. *Int. J. appl. Radiat.* 15: 449-456 (1964)
4. BOOTHILL, J. C., COOPER, R. R. A. and REZK, V. Studies with marked antisera, quantitative studies with antisera marked with 125 I isotope and their corresponding red cell antigens. *Biochem. J.* 55: 745-757 (1953)
5. BOYD, W. C. Fundamentals of immunology 3rd ed. (Interscience, New York 1956)
6. CABEL, Y., VAN OM, and SEVIER, Y. M. The binding of immune globulins and other proteins by polystyrene latex particles. *J. reticulo-endothel. Soc.* 3: 29-40 (1966)
7. GEFPELLER, R., DRAY, S. and EDLIMAN, C. Nomenclature for human immunoglobulins. *Bull. Org. mond. Santé* 30: 447-450 (1964)
8. GROSSMANN, S.; FREI, P.; ISLER, H. et VAUGHN, A. Recherches concernant les propriétés cytophiles des γ -globulines humaines in SCHWABE, 5^e Congr. europ. Allergie, Bâle 1962, pp. 379-382 (Schwabe, Basel/Stuttgart 1963)
9. FIDALGO, B. V.; KAYAMA, Y. and NAJJAR, V. A. The physiological role of the lymphoid system. The binding of autologous (erythrophilic) γ -globulin to human red blood cells. *Biochemistry* 6: 3378-3385 (1967)
10. FIDALGO, B. V. and NAJJAR, V. A. The physiological role of the lymphoid system. Leucophilic γ -globulin and the phagocytic activity of the polymorphonuclear leucocytes. *Proc. nat. Acad. Sci., Wash. D.C.* 37: 937-964 (1967)
11. FROMMELT, D.; GROS, P. J.; MAQUEDEN, S. D. and ISLER, H. Studies on the mechanism of immunoglobulin binding to red cells. *Immunology Lond.* 11: 501-507 (1967)
12. GROS, P. J.; FROMMELT, D.; ISLER, H. and MAQUEDEN, S. P. Interaction of IgG and its fragments with red cells. *Immunology Lond.* 11: 489 (1967)
13. HALPERN, B. and FRICK, O. Protection against anaphylactic shock with γ -globulin in guinea pig and mice. *J. Immunol.* 88: 683-689 (1962)
14. ISLER, H.; CZERNITZ, J.-C.; J. TOE, J. C. and MAQUEDEN, G. Specific and non-specific fixation of plasma proteins in tumor in PLATTNER *Chemotherapy of cancer* (Elsevier Amsterdam 1964)
15. ISLER, H.; JACOT-GUTHRIE, H.; WALDENHORN, M.; FELLERSHOE, R. and CZERNITZ, J.-C. Complement fixation by different IgG preparations and fragments; in MAQUEDEN and GROSSER *Immunopathology* 5th int. Symp. Punta Ala 1967 (Schwabe, Basel)
16. JEANPOY, M.; BARADON, S. et HANCO, A. Fixation de γ -anticorps sur les érythrocytes de souris. *Vox Sang.* 9: 43-51 (1964)
17. KABAT, E. A. and MAYER, M. M. Kjeldahl nitrogen determination. *Experimental immunochemistry* 2nd ed., p. 476 (Thomas, Springfield 1961)
18. LO BOUQUÉ, A. F.; CUTRAN, R. S. and JAMES, J. H. Red cells coated with immunoglobulin G binding and sphering by mononuclear cells in man. *Science* 152: 1562-1565 (1967)
19. MAQUEDEN, S. P. Quantitative isotopic immunohematology *Transfusion* 4: 69-76 (1964).
20. MCCORMACK, W. and DEKOR, F. J. A method of trace lodination of proteins for immunologic studies. *Int. Arch. Allergy* 29: 185-189 (1966)
21. MOLLISON, P. L. and POLLEY, M. J. Uptake of γ -globulin and complement by red cells exposed to serum at low ionic strength. *Nature, Lond.* 203: 535-536 (1964).
22. OVAR, Z. et BOER, G. Action empêchant du sérum normal de lapin sur anaphylaxie cutanée passive du cobaye. *Ann. Inst. Pasteur* 44: 443-445 (1953)
23. PROFFER, B.; CORDONA, M. S. and INCE, T. L. The non-immunologic reaction of globulin molecules with the erythrocyte surface. *Vox Sang.* 7: 334-347 (1962)

24. POLLACK, W. HAGER, H. J.; RECKEL, N. TORIK, D. A. and SOMMER, H. O. A study of the forces involved in the second stage of hemagglutination. *Transfusion, Philad.* 5. 158-163 (1965)
25. SVENSSON, G. W. Statistical methods applied to experiments in agriculture and in biology (Iowa State College Press, Ames 1950)
26. SPRING, I. BLOCH, K. J. and ATTEN, R. F. Effect of non-specific γ -globulin on passive sensitization *in vitro* at different temperatures. *J. Allergy* 37 75-83 (1966).
27. THOMAS, T. S. FIDALCO, B. V. HARTMAN, S. and NAJJAR, V. A. The physiological role of the lysozyme system. The separation of γ -globulin into physiologically active components by cellulose phosphate chromatography *Biochemistry* 6. 11 3369-3377 (1967)
28. UICK, J. W. Passive sensitization of lymphocytes and macrophages by antigen-antibody complexes. *Proc. Nat. Acad. Sci., Wash.* 54 1599-1606 (1963)

Haemoglobin L Persian Gulf: $\alpha 57$ (E6) Glycine \rightarrow Arginine

§ RAJIBAR, JUDITH L. KENDERLERER and H. LEIMANN

Department of Immunology University of Tehran, and Medical Research Council Abnormal Haemoglobin Unit, Department of Biochemistry University of Cambridge, Cambridge

The haemoglobins of 3,200 patients at Tehran University Hospitals were screened for variants by electrophoresis. A number of known and unknown variants of haemoglobin A were found and we wish to report the identification of one of these. Its electrophoretic properties were identical to those of haemoglobin L [1]. No anaemia was detected, the morphology of the red cells was normal, there were no inclusion bodies, no evidence of increased methaemoglobin formation nor was any decrease in haem binding found. This is of some relevance as the substitution was shown to be next to the distal haem linked histidine of the α -chain.

As the amino acid substitution in haemoglobin L has not yet been identified it is quite possible that the new variant and haemoglobin L previously described [1] in a Hindu Punjabi family and in 3 Gujarati speaking Lohana families in Bombay [15] are not the same. The present haemoglobin was found in a woman from an area bordering the Persian Gulf, and we have called it haemoglobin L Persian Gulf. Unfortunately only one other member of the family a son, was available for screening and he did not have the variant.

On electrophoresis at alkaline pH on paper or starch, the variant moved slightly faster than haemoglobin S but more slowly than haemoglobin G (fig. 1). On agar gel electrophoresis at pH 8 [12] there was no clear separation from haemoglobin A. On chromatography at pH 6 the variant moved between haemoglobins E and C [8]. On starch gel electrophoresis [11] a second haemoglobin A₂ was noted, and this together with the fact that the proportion of the abnormal variant, though not unstable, was only 18% suggested that the variant




Fig. 1 Paper electrophoresis (pH 8.5) Left: Hb A and Hb L₁; right: Hb A and Hb S. Hb L₁ moves slightly faster than Hb S towards the positive pole. The position of the Hb A₂ fractions is indicated. — line of application.

was abnormal in the α -chain [10]. This was confirmed by examining the whole haemolysate by electrophoresis after treatment with para-mercuribenzoate [3] after electrophoresis of the isolated abnormal variant in 6 M urea [4] and by its hybridisation with canine haemoglobin [6].

Methods

The electrophoretic studies and the isolation of the variant, its digestion with trypsin, the preparation of fingerprints (peptide chromatograms) and the staining of the peptides were all carried out according to the techniques summarised by Sexl *et al.* [13] except that in addition to paper electrophoresis, ion exchange chromatography on DEAE Sephadex was used for the isolation of this variant [7].

Results

Figure 2 shows a fingerprint of the whole globin in which two differences from normal globin were observed. The first occurred in

Hb L whole globin




Fig. 2. Fingerprint (peptide chromatogram) of the isolated Hb L Persian Gulf.

Table I. The amino acid residues and their sequential numbers in the tryptic peptides (Tp) α VII and β VII of human haemoglobin

Chain	Number in helical sequence	E6	E7	E8	E9
α	Number in chain	57	58	59	60
	Residue of	glycine	histidine	glycine	lysine
β	Number in chain	62	63	64	65
	Residue of	alanine	histidine	glycine	lysine

the overlap of two peptides, α TpVII containing the amino acid residues $\alpha 57$ –60 and $\beta 62$ –66 (α and β E6–E10) which failed to show the transient yellow colour on treatment with ninhydrin which normally indicates the presence of the N-terminal glycine residue in α TpVII (Gly His-Gly Lys). The two peptides include the distal haem linked histidine residues of the α - and β -chain respectively (table I). The second abnormality was a positive staining for arginine observed slightly behind and above the lysine of $\alpha \beta$ TpVIII ($\alpha 61$ Lys and $\beta 66$ Lys). To eliminate the peptides from the β -chain for subsequent determination of the change the α - and β -chains were separated [5] and aminoethylated [9]. Figure 3 shows the fingerprint of the amino-

Hb L α -chain

Fig 3. Fingerprint (peptide chromatogram) of the N-methylated α -chain of Hb L. Free arginine (TpVII) and lysine (TpVIIb) were found together with peptide containing histidine, glycine and lysine (TpVIIb, see table II)

Table II Amino acid analysis of TpVIIb in figure 3

Amino acid	μ mol	Residues found	Residues expected in haemoglobin A
Histidine	0.00785	0.9	1
Glycine	0.01063	1.2	2
Lysine	0.00883	1.0	1
Total		3.1	4

ethylated α -chain and gives the position of three ninhydrin positive spots, which on amino acid analysis were shown to consist of free lysine free arginine, and of a peptide containing histidine glycine and lysine respectively. The electrophoretic mobility of haemoglobin L indicates the acquisition of one positive charge per α -chain. The finding of free arginine locates the substitution at the N terminal of a tryptic peptide of the α -chain by arginine or substitution by lysine or arginine of the penultimate residue of a tryptic peptide with a carboxy C-terminal arginine. There are only five positions in the

α -chain where a single point mutation could give rise to free arginine after tryptic digestion and where this would result in a haemoglobin which has one additional positive charge per α -chain. These are the N-terminal residues of threonine in α TpII and α TpVI, methionine in α TpV, glycine in α TpVII and leucine in α TpXII. Of these α TpII, V and VI are clearly present in their expected positions, and where applicable, with the expected staining reactions in the fingerprint of the whole globin (fig. 2). Peptide α TpXII is part of the insoluble core and cannot be demonstrated in the fingerprint of the whole globin, but α TpXIIa is present, and gives the expected reaction for histidine and sulphur in the fingerprint of the aminoethylated chain (fig. 3).

In the fingerprint of the whole globin, α TpVII, however, failed to show the expected yellow reaction on treatment with ninhydrin which indicated the absence of an N-terminal glycine residue in position $\alpha 57$. In the fingerprint of the isolated α -chain the yellow reaction with ninhydrin for the N-terminal glycine residue of α TpVII was not observed, and α TpVII was not in the expected position but had a slight decrease in positive charge and a lower chromatographic mobility compared with α TpVII in haemoglobin A.

This peptide was isolated by electrophoresis at pH 2 from the aminoethylated α -chain. On amino acid analysis one residue each of glycine, histidine and lysine was found (table II). As this peptide is formed after hydrolysis by trypsin from the α -chain, the lysine residue would be C-terminal and the glycine could not be N-terminal due to the failure to give the yellow colour with ninhydrin, thus the N-terminal residue would be histidine at $\alpha 58$. This peptide is therefore α TpVIIb accounting for residue $\alpha 58-60$; the free arginine in this case would arise from a substitution of $\alpha 57$ (E6) glycine to arginine. From the sequence of α TpVII and VI given in table III it can be

Table III. Sequence of TpVI and TpVII from haemoglobin L. Persian Gulf

Sequential numbers		TpVII					
41	42	55	56	57	58	59	60
Thr	Tyr	Val	Lys	Arg	His	Gly	Lys
				↑	↑		↑
				VIIa		VIIb	

↑ = position of hydrolysis by trypsin.

seen that tryptic hydrolysis would take place at the lysine residue $\alpha 56$ giving rise to α TPVI and the arginine residue $\alpha 57$ giving free arginine of α TPVIIa and at the lysine residue $\alpha 60$ giving α TPVIIb. Thus haemoglobin L Persian Gulf can be defined as $\alpha 57$ (E6) glycine \rightarrow arginine

Discussion

The glycine residue E6 is next to the distal haem linked histidine residue $\alpha 58$ (E7) and it is perhaps surprising that a change from glycine to arginine at this position should not cause some abnormality at least in the haem binding or in the tendency to methaemoglobin formation. However it must be noted that this residue varies greatly in known globins and indeed haemoglobin Norfolk with substitution $\alpha 57$ glycine to aspartic acid at the same position [2] does not show any pathological effect. In this connection we have re-examined haemoglobin Norfolk and found its susceptibility to oxidation to be normal.

It will be of interest to find out whether the haemoglobin L found sporadically in Indians is identical with haemoglobin L Persian Gulf. The variant observed in Bombay has been investigated [14] but these preliminary findings do not support the suggestion that these haemoglobins are the same.

Summary

A new haemoglobin has been identified from an Iranian woman. It has been designated haemoglobin L Persian Gulf, $\alpha 57$ (E6) glycine \rightarrow arginine. This variant of adult haemoglobin was not associated with any pathological conditions.

Acknowledgment. One of us (S.R.) is grateful to Dr M. Sadr, Secretary of CENIT Scientific Treaty in Tehran, for providing him with the equipment used in this survey.

Reference

1. AGRA, J. A. M. and LEHMANN, H. Haemoglobin L—new variant haemoglobin found in Punjab India. *Brit. med. J.* 142 143 (1957)
2. BAGLIONI, C. A chemical study of haemoglobin Norfolk. *J. Biol. Chem.* 237 6 4 (1962)
3. BUZZI, E. and FROSTICKER, C. A new method for the preparation of α and β subunits of human haemoglobin. *J. Biol. Chem.* 240 Pt. 3 1 352 (1965)

4. CARMICHAEL, A. I. and PETTIT, A. M. The amino acid composition of haemoglobin. III. A quantitative method for identifying abnormalities of the polypeptide chains of haemoglobin. *Blood* 24: 750-756 (1963)
5. CLEGG, J. B.; NACHTSON, M. A. and WEATHERALL, D. J. Abnormal human haemoglobins: separation and characterization of the α - and β -chains by chromatography and the determination of two new variants, Hb Chesapeake and Hb J Bangkok. *J. molec. Biol.* 19: 91-108 (1966)
6. HUGHES, E. R.; SHOOTER, E. M. and BEAVER, G. H. On the recombination of canine and human haemoglobins. *J. molec. Biol.* 4: 323-328 (1962)
7. HUBMAN, T. H. J. and DORY, A. M. Studies on the heterogeneity of haemoglobin. IX. The use of triis (hydroxymethyl) aminoethane-HCl buffers in the anion exchange chromatography on haemoglobins. *J. Chromatogr.* 19: 160-169 (B61) (1965)
8. HUBMAN, T. H. J. and PERC, H. A. The chromatographic behaviour of different human haemoglobins on the cation exchanger Amberlite IRC 50. *Clin. chim. Acta* 2: 307-311 (1957)
9. JONES, R. T. Structural studies of aminoethylated haemoglobins by automatic peptide chromatography. *Cold Spr. Harb. Symp. quant. Biol.* 29: 297-308 (1964)
10. LEIDMAN, H. and CARRELL, R. W. Differences between α - and β -chain mutants of human haemoglobin and between α - and β -thalassaemia. Possible duplication of the α -chain gene. *Brit. med. J.* 4: 748-750 (1968)
11. POULIN, M. D. Search gel electrophoresis in a discontinuous system of buffers. *Nature, Lond.* 180: 1477-1479 (1957)
12. ROBINSON, A. R.; ROBINSON, M.; HARRISON, A. R. and ZAVLIER, W. W. A new technique of differentiation of haemoglobin. *J. Lab. clin. Med.* 50: 743-752 (1957)
13. SECK, J.; BEALE, D.; VICE, D.; LEIDMAN, H.; GOODALL, P. T. and MACDONALD, S. Haemoglobin G Copenhagen and Haemoglobin J Cambridge. Two new β -chain variants of haemoglobin A. *Biochem. biophys. Acta* 140: 231-242 (1967)
14. SUDHAKARAN, P. K. and PILL, C. Some observations on Haemoglobin L Bombay. *Biochim. biophys. Acta* 70: 290-292 (1965)
15. SUDHAKARAN, P. K.; SANGHVI, L. D.; AGAR, J. A. M. and LEIDMAN, H. Haemoglobin L in Bombay: Findings in three Gujarati speaking Lohana families. *Acta. genet. stat. med.* 9: 202-206 (1959).

Authors' addresses: Dr S. RAHVAR, Department of Immunology University of Tehran, Tehran (Iran); Mrs. JUDITH L. KIMBERLIN and Prof. Dr H. LEIDMAN, MRC Abnormal Haemoglobin Unit, University of Cambridge, Department of Biochemistry Tennis Court Road, Cambridge (England)

Research Institute of Child Health, Hacettepe Children's Hospital, Ankara

Haptoglobin in Thalassemia

B. YAMAK and S. ÖZBOYLU

The term haptoglobin (Hp) was introduced by POLOVOVSKI and JAYLE to describe a group of serum glycoproteins specifically capable of binding hemoglobin *in vitro* and *in vivo* by forming complexes with it [1]. These haptoglobin hemoglobin (Hp-Hb) complexes *in vivo* are taken up by the reticuloendothelial cells from the circulation where Hb degradation occurs. If intra vascular hemolysis increases, plasma Hp concentration decreases [2-3]. By starch-gel electrophoresis, different kinds of Hp have been shown in the α_2 -fraction of the serum which are inherited genetically [4] and there is substantial evidence that its type is somewhat related to D chromosomes [5].

The absence of this protein is well documented in sickle-cell anemia [6] but Hp in thalassemia has been determined in only a few cases [8-10]. For this reason we looked for Hp in thalassemia major and minor.

Materials and Methods

In this study 33 cases of β -thalassemia major are presented in which the diagnosis was made clear by early developing hypochromic anemia, marked hepatosplenomegaly, increased serum iron and fetal hemoglobin, decreased erythrocyte osmotic resistance because of abnormal hemoglobin, and the presence of nucleated red blood cells (NRBC) on the peripheral smear. The patients' ages ranged from 6 months to 15 years and only 13 of them were girls. Forty-two β -thalassemia trait cases were found in either the parents (1) or the siblings (10) of the patients.

In all the patients, hemoglobin (Hb), hematocrit (Hct), white blood cells, reticulocytes, peripheral smear, sickling and Coombs test were determined by the standard methods. In all the homozygous cases bone marrow was also examined. The alkaline-resistant Hb levels were

determined by the method of SINGER *et al.* [11]. Starch-gel (pH 8.6) and agar-gel (pH 6.45) electrophoresis were performed by the techniques of SARRIS [12] and ROSEWALT *et al.* [13] respectively. Red blood cell osmotic fragility was done according to DACEY's methods [14] following 18 hours incubation at 37°C. For the detection of Hp, serum samples obtained just prior to transfusion were subjected to horizontal starch-gel electrophoresis at pH 8.6 (tris-citric acid) [12]. Before electrophoresis, sufficient Hb was added to the serum to saturate completely any Hp present. One half of each resulting gel pattern was stained with amido-black for the detection of protein bands, and the other half with benzidine stain to indicate the Hp-Hb complexes. These were compared with the serum of normal subjects. Three of the patients with thalassemia major had infection (cases 3, 26, 33) at the time when blood samples were drawn for Hp determination.

Results

The laboratory findings of the homozygous patients are shown in table I. In 23 patients, minimal Hb A component was observed by agar-gel electrophoresis. In 11 of these 23 cases Hb A could also be shown by starch-gel electrophoresis. Hb A₂ was not measured but estimated according to normal control Hb separation. Hp could not be shown in 26 of the 35 thalassemia major cases (74%). It was present in the normal amount in 7 of the cases (20%) and barely present in 2. In general, the spleen was more markedly enlarged than the liver. Splenectomy was performed in 7 cases when the transfusion intervals had become less than a month, causing some improvement. Five out of 35 patients with thalassemia major had previously had jaundice. In 2 cases (14 and 17) where it occurred in the neonatal period, it was accepted as a physiologic jaundice. In case 21 jaundice was noticed at 6 months of age for a month's duration, and in 2 (8 and 32) it occurred at 7 and 14 years of age respectively for which serum hepatitis was the most likely diagnosis.

Hp, Hb electrophoresis and Hb F values in patients with thalassemia trait are summarized in table II. In all but 7 cases Hp was found. Four of the ahaptogloblinemic thalassemia minor cases belonged to one family and 2 to another family which indicates the possibility of familial ahaptogloblinemia.

Discussion

Hp is synthesized by the liver and taken up by the reticuloendothelial cells when in combination with Hb *in vivo*. This protein in-

Table I Laboratory findings of the thalassemia major cases

Case No.	Age Sex	Hp	Hb g%	Ret %	Hb F %	Hb electrophoresis				
						Starch gel A ₂	F	A	Agar gel F	A
1	12 F	A	4.95	2.2	62	+	+	-	+	-
2	3 M	1 2	3.50	2.8	47.3	+	+	-	+	+
3	8/12 M	1 2	6.65	2.2	81	+	+	-	+	+
4	2 M	1 2	4.07	0.6	32	+	+	+	+	+
5	11/12 F	2 2	2.90	3.2	76	+	+	-	+	-
6	6 M	A	2.34	1.2	30	+	+	-	+	+
7	3.5 M	A	2.17	0.3	69.4	-	+	-	+	-
8	14 F	A	7.34	1.4	57.4	+	+	-		
9	4.5 M	A	3.85	11	12	+	+	+	+	+
10	3.5 F	A	4.80	0.4	19	+	+	+	+	+
11	5 M	A	6.20	0.8	19	+	+	+	+	+
12	18 M	A	7.05	3.8	51	+	+	+	+	+
13	8/12 F	A	4.71	5.4	74	+	+	-	+	+
14	2 M	A	3.15	1.6	81	+	+	-	+	-
15	7 M	2 2 VB	8.60	3.6	87	+	+	-	+	-
16	1.5 M	A	7.82	3	88	+	+	-	+	+
17	2.5 M	A	6.20	3.6	73	+	+	-	+	-
18	4/12 M	A	7.25	3.2	80	+	+	+	+	+
19	1 F	1-2	3.15	9.2	70	-	+	-	+	-
20	6/12 F	1 2	5.54	4.4	82	-	+	-	+	+
21	4 M	A	2.57	0.6	39	+	+	+	+	+
22	1.5 M	2 VB	4.71	3.2	68	+	+	-	+	+
23	1.5 F	A	3.16	4.8	95	+	+	-	+	-
24	4 M	A	2.98	2.6	54	+	+	-		
25	3 F	A	2.85	7	92	+	+	-	+	-
26	6 1 F	A	7.05	51	66	+	+	-	+	+
27	7/12 M	A	5.48	9.8	54.4	+	+	-	+	+
28	8 M	A	4.53	5.4	86	+	+	-	+	+
29	4.5 M	A	3.91	9.2	72	+	+	+	+	+
30	22 12 F	2 2	2.82	3	75	+	+	+	+	+
31	6 F	A	4.07	1.8	57	+	+	-	+	+
32	10 F	A	7.05	4	63	-	+	+	+	+
33	2 M	A	4.26	3.2	99	+	+	-	+	-
34	3 M	A	4.87	1.6	60	+	+	+	+	+
35	20 12 M	A	3.75	13.2	50	+	+	-	+	+

1-3 Very slight, A absent, Hb F alkali-resistant hemoglobin, Ret reticulocytes
Splenectomy

creases in inflammatory, neoplastic, degenerative processes, and following steroid treatment [15-17]. Its level is found to be low in the newborn period [18, 19] and in liver diseases [17-20] and to have the effect of estrogens [21]. Although genetically determined absence of

Table II Laboratory findings of thalassemia trait cases

Family No.	Hp	Hb Electrophoresis					Hb F %
		Starch gel A ₂	F	A	Agar gel F	A	
1 F	1 2	+	-	+	+	+	
2 M	2-2	+	-	+			
B-I	1 2	+	-	+	+	+	
B-II	1 2	+	-	+	+	+	
4 B-III	1 2	+	-	+	+	+	
B-IV	1 2	+	-	+	+	+	
6 F	1 2	+	-	+			
7 M	1 2	+	-	+	+	+	11
F	1 2	+	-	+	+	+	2.5
8 M	A	+	-	+	+	+	
S-I	A	-	-	+	+	+	
S-II	A	+	+	+	+	+	
B-I	A	+	-	+	+	+	
B-II	1 1 VS	-	-	+	+	+	
9 M	1 2	+	-	+	+	+	
F	2-2	+	-	+	+	+	
S	1 2	+	+	+	+	+	
10 S	1 1 VS	+	-	+	+	+	
14 M	A	+	-	+	+	+	6
F	A	+	-	+	+	+	4
15 M	1 2	+	-	+	+	+	6
F	1 2	+	-	+	+	+	7
16 M	1 1 S	+	-	+	+	+	6
F	1 1	+	-	+	+	+	4.5
17 M	1-2	+	-	+	+	+	8
F	1 2	+	-	+	+	+	6
21 M	1-2	+	-	+	+	+	4.5
22 M	1 2	+	-	+	+	+	1.5
F	2-2	+	-	+	+	+	2
23 M	1 2	+	-	+	+	+	5
F	1 2	+	-	+	+	+	3
26 M	2-2	+	-	+	+	+	2
27 M	1 2	+	-	+	+	+	1
F	2 2	+	-	+	+	+	2.2
29 M	A	+	-	+	+	+	5
F	1-2	+	-	+	+	+	2
30 M	2 2						
F	2 2						
31 M	1-2	+	+	+	+	+	5
F	1 2	+	-	+	+	+	5
35 M	1 2	+	-	+	+	+	2.8
F	1-2	+	-	+	+	+	5

B Brother S sister M mother F father A absent, VS very slight, S slight

this protein is well known [22-23] in general, decrease or absence of serum Hp has been observed in chronic or acquired types of hemolytic anemias in which the Hb turnover may be more than doubled, which indicates the severity of hemolysis [1-7].

Searches for Hp were made by JUNYARKAR [8] BADR EL DIN *et al.* [9] and MÜLLER EBERHARD *et al.* [10] in 5, 7 and 3 patients with thalassemia major respectively, but none could be shown in any of them. Neither did we find Hp in the serum of 74, of our 35 thalassemia major cases. Nine cases where Hp was present in the serum appeared to be no different in any respect from the other cases. They were not on steroids, did not have jaundice and their transfusion requirement was no less than that of the others. Their age, NRBC, reticulocyte counts, the size of the liver and spleen, Hb level, Hb F and the presence or absence of Hb A were no different from that in the rest of our patients.

Seven of the patients were splenectomized. In 2 of them, Hp was checked before and after splenectomy (4 and 10). In one Hp was shown before and after splenectomy but in the other it was not present in either determination. In one case Hp was determined only after splenectomy and in the rest only before splenectomy. The 2 patients of BADR EL DIN *et al.* [9] were splenectomized without any rise in the Hp level due to this procedure although it was stated that the Hb level was significantly raised in both. Since the hemolytic state persists after splenectomy in thalassemia major this finding is not at all surprising. When the rate of Hp utilization exceeds that of production or release of this protein, the Hp concentration falls to levels too low to be measured. Because this glucoprotein was shown in one patient of BADR EL DIN *et al.* [9] following infection, in 2 after milk injection and in our 9 cases, it is strongly suggested that ahaptoglobinemia in thalassemia is not due to the inability of the synthesis in general, but to increased consumption as is usual in hemolytic anemia.

In 7 of the 42 thalassemia trait cases, Hp was absent. Six of these patients were from 2 families. A high incidence of ahaptoglobinemia is also reported in children with sickle cell trait [6-25]. In our two families there were 3 and 3 patients with ahaptoglobinemia (including thalassemia major). Congenital ahaptoglobinemia may also be considered, since hemolysis is not a prominent finding in the thalassemia trait. If this holds true some correlation should be postulated between the thalassemia and Hp genes.

Hp was searched for in only 2 cases of thalassemia trait in the literature, and was not found in any which would also raise questions about the high incidence of ahaptoglobinemia in thalassemia [7-8]. In addition to COOLEY's anemia cases, we examined the serum of more than 200 subjects and with only one exception, whose family could not be studied, we were unable to find any ahaptoglobinemia without hemolytic anemia. Neither did EDELMAN *et al.* [26] find any ahaptoglobinemia cases out of 300 people whose serum was examined in this country. That again might indicate that the high incidence of ahaptoglobinemia in thalassemia in this country may be related to the disease in some way.

Because thalassemia is a hemolytic anemia, the absence of Hp in the serum of most cases is not unexpected.

Summary

The type and presence of haptoglobins were determined in the serum of 33 and 42 patients with thalassemia major and minor respectively. Haptoglobins could not be shown in the starch gel electrophoresis in 74 and 17% of these groups of patients respectively. No correlation was found between the age, hemoglobin concentrations, transfusion frequency, size of spleen, liver reticulocyte count, nucleated red blood cells and the presence or absence of Hb A electrophoretically in thalassemia major cases. It is pointed out that the incidence of ahaptoglobinemia among thalassemia trait cases seems to be more frequent.

References

1. WINTROBE, M. M. Clinical hematology 6th ed., p. 167 (Lea & Febiger Philadelphia 1967).
2. ALLISON, A. C. and REID, W. The binding of haemoglobin by plasma proteins (haptoglobins). Its bearing on the renal threshold for haemoglobin and the aetiology of haemoglobinaemia. *Brit. med. J.* **44**: 1137 (1957).
3. MURRAY, R. K.; COVOKEL, G. E. and FERT, J. H. The role of haptoglobin in the clearance and distribution of extracorporeal hemoglobin. *Blood* **17**: 43 (1961).
4. BRIDGES, O. and WALKER, N. F. Notation for serum-protein groups and the genes controlling their inheritance. *Nature, Lond.* **178**: 694 (1956).
5. GERALD, P. S.; WARDER, S.; SINGER, J. D.; COMORAN, P. A. and UHARSKY, L. A ring D chromosome and anomalous inheritance of haptoglobin type. *J. Pediat.* **70**: 172 (1967).
6. WITTEN, C. F. Studies on serum haptoglobin. A functional inquiry. *New Engl. J. Med.* **268**: 529 (1962).
7. BRIS, I. and LEVIN, S. M. The haptoglobin content of serum in hemolytic anemia. *Brit. J. Haemat.* **5**: 348 (1959).
8. JUSWALKAR, R. V. Haptoglobin in sickle cell anemia and thalassemia, *Indian J. med. Sci.* **16**: 311 (1964).

9. BADE EL-DEY, M. K., KHALIL, M. and KASHEM, A. S.: Haptoglobin level in some diseases of infancy and childhood. *Acta paediat. scand.* **55**: 584 (1966).
10. MILLER-ESPERARD, U., JAYE, J., LEE, H. H., HANSTEIN, A. and HANCA, M.: Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. *Blood* **27**: 811 (1966).
11. SEWELL, K., CZEKOWSKI, A. I. and SEWELL, L.: Studies on abnormal hemoglobins. I. Their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. *Blood* **6**: 413 (1931).
12. SMITH, O.: Zone electrophoresis in starch gels. Group variations in the serum proteins of normal human adults. *Biochem. J.* **61**: 629 (1957).
13. ROBINSON, A. R., ROMAN, M., HARRISON, A. P. and ZETLER, W. W.: A new technique for differentiation of hemoglobin. *J. Lab. clin. Med.* **50**: 743 (1957).
14. DACEY, J. V. and LEWIS, S. M.: *Practical haematology*. 3rd ed., p. 135 (Churchill, London 1963).
15. NYMAN, M.: Serum haptoglobin. Methodological and clinical studies. *Scand. J. clin. Lab. Invest.* **11**: 1 (1959).
16. STEDTKE, W. von and NYMAN, M.: Effect of androgens on α_2 -globulins in women. *J. clin. Endocrin.* **17**: 910 (1957).
17. OWAN, J. A., MACRAE J. R. and GOT, C.: Serum haptoglobins in hepatobiliary disease. *Brit. med. J.* **i**: 1454 (1959).
18. RACER, A. R., GERALD, P. S. and DIAMOND, L. K.: Haptoglobin patterns in cord blood sera. *Nature Lond.* **191**: 717 (1961).
19. ÖZSOYLU, S. and TANTERİ, G.: Plasma hemoglobin and haptoglobin levels in the newborn period. *Turk. J. Pediat.* **10**: 9 (1968).
20. HAYE, O. and YAMAK, G.: Haptoglobin in children with infectious hepatitis. *J. Pediat.* **67**: 116 (1963).
21. BOGREN, N. E. and NYMAN, M.: Effect of estrogens on the haptoglobin level in the blood. *Scand. J. clin. Lab. Invest.* **13**: 107 (1961).
22. ALLMON, A. C., BURROUGHS, B. S. and BARR, W.: Haptoglobin types in British, Spanish, Basque and Nigerian African populations. *Nature Lond.* **181**: 824 (1958).
23. GOTTLIEB, A., WICH, N. and ROSE, J.: Familial hypohaptoglobinemia. A genetically determined trait segregating from glucose 6-phosphate dehydrogenase deficiency. *Blood* **21**: 129 (1963).
24. OWEN, J. A., GREGORY, G. C. and SMITH, H.: Serum haptoglobins in haemolytic states. *J. clin. Path.* **13**: 478 (1960).
25. MANTA, S. R. and JENSEN, W. N.: Haptoglobins in haemoglobinopathy. Genetic and clinical study. *Brit. J. Haemat.* **6**: 240 (1960).
26. EDEM, S., ARAY, M. and CEMRAN, A. I.: Distribution of haptoglobin types in Turkish people. *Nature, Lond.* **210**: 915 (1966).

Clinical Pathology Laboratories, Royal Victoria Hospital, Belfast

Evaluation of a Dual Radioisotope Urinary Excretion Test in the Diagnosis of Pernicious Anaemia

T. K. BELL and D. LEE

A rapid procedure for differentiating between patients with intrinsic factor deficiency and other causes of vitamin B₁₂ malabsorption, which combined the two parts of the urinary excretion test introduced by SCHILLING [6] was reported by KATZ *et al.* [4]. These workers simultaneously administered ⁵⁸CoB₁₂ bound to human gastric juice and free ⁵⁸CoB₁₂ followed by a large flushing intramuscular dose of non-radioactive B₁₂ and assayed the quantities of the two radioisotopes in the following 24 hour urine collection.

In a preliminary communication, BELL *et al.* [2] described a modification of this double isotope technique using ⁵⁷CoB₁₂ bound to human gastric juice and free ⁵⁸CoB₁₂ which replaced ⁵⁸Co resulting in a lower radiation dose to the patient. This dual radioisotope test for investigation of vitamin B₁₂ absorption has been further evaluated and the results are now described.

Methods

Preparation of human gastric juice. Human gastric juice was obtained from normal subjects following maximal histamine stimulation [5] and, following the method of KATZ *et al.* [4], was immediately brought to pH 10 with 10% NaOH, and after 20 min neutralised to pH 7 with 1.0 N HCl. The juice was filtered to remove mucus and other deposits and the intrinsic factor content determined by the method of GORTLER *et al.* [3]. Human gastric juice having concentration of active intrinsic factor less than 80% of the total B₁₂ binding capacity was discarded. Bile-stained gastric juice was also rejected.

Preparation of radioactive B₁₂ doses. Freeze dried ampoules of vitamin B₁₂ labelled with ⁵⁸Co and with ⁵⁷Co each with specific activity of 1 µCi/µg B₁₂ were obtained from the Radiochemical Centre, Amersham. Oral doses of ⁵⁸CoB₁₂ and ⁵⁷CoB₁₂ bound to human

gastric juices ($^{57}\text{CoB}_{12}\text{HCl}$) each with concentrations of $0.25 \mu\text{g B}_{12}$ in 20 ml water were prepared as described previously [2]. Usually 12 radioactive doses, and appropriate standards, of the unbound and bound B_{12} were prepared at a time and these were stored at -15°C until required.

Dose administration. All subjects were fasted overnight. A dose of $^{57}\text{CoB}_{12}$ and a dose of $^{58}\text{CoB}_{12}$ bound to human gastric juices were simultaneously administered orally followed immediately by an intramuscular injection of $1,000 \mu\text{g}$ of non-radioactive B_{12} . No food was allowed until 2 h later and all urine excreted in the 24 h after giving the doses was collected.

Measurement of the radioactive urine. Four hundred ml of the urine collection were assayed using an annular cell technique on a sodium iodide well type scintillation counter [1]. Since ^{57}Co emits γ rays with energies of 0.12 MeV compared with ^{58}Co which emits γ rays with energies of 0.81 MeV the amount of each isotope in the total urine collection can be readily determined by altering the discriminator bias settings on an associated scaler and solving the simultaneous equations described by V. KALL and VETTER [7], for the assay of liquid containing a mixture of two radioisotopes.

Patients

One hundred patients have been included in the present retrospective study reflecting the use made of this dual isotope urinary excretion test by the clinical staff of this hospital, in the investigation of possible cases of B_{12} deficiency. Patients in the following categories have been excluded: (a) those who have had gastric surgery; (b) those with renal failure; (c) those with biochemical parameters supporting a diagnosis of 'malabsorption syndrome'.

The series includes 29 patients whose results were previously published [2].

The patients included in the pernicious anaemia group showed a clinical picture consistent with the diagnosis supported by the finding of most of the following abnormalities: a macrocytic peripheral blood picture, megaloblastic bone marrow, low serum B_{12} level, histamine fast achlorhydria or a satisfactory response to B_{12} therapy.

Results

The pattern of results obtained is displayed in figure 1 and summarised in table I. Of the 62 control subjects only 4 gave $^{58}\text{CoB}_{12}$ excretions of less than 7% of the free $^{58}\text{CoB}_{12}$ dose. Only one control excreted less than 6% of this dose. All patients with pernicious anaemia (PA) excreted less than 6% of the $^{58}\text{CoB}_{12}$ dose. One patient with PA gave a $^{57}\text{Co}/^{58}\text{Co}$ ratio of 1.7 (which lies in the normal range of 0.8 to 1.8 for this series) and 2 patients gave a ratio of 1.9. In all other PA patients the $^{57}\text{Co}/^{58}\text{Co}$ ratio was greater than 2.0. A ratio of 35.7 was found in one PA patient but this result has not been included in the range and mean values for the ratio of ^{57}Co to ^{58}Co in the PA group.

Table I. Summary of results

Subjects		Percentage of dose excreted		Ratio $\frac{^{57}\text{Co}}{^{58}\text{Co}}$
		$^{57}\text{CoB}_{12}$ HGJ	$^{58}\text{CoB}_{12}$	
62 Controls	mean	18.2 ± 6.4	16.2 ± 6.5	1.2 ± 0.3
	range	(5.7-33.0)	(4.0-32.1)	(0.8-1.8)
38 PA	mean	7.0 ± 2.9	2.2 ± 1.4	3.7 ± 2.0^1
	range	(1.8-16.8)	(0.3-5.7)	(1.7-9.6)

Based on 37 results i.e. leaving out the high ratio of 33.7




Fig. 1. Diagram illustrating the percentage of the two radioactive doses excreted and the ratio $\frac{^{57}\text{Co}}{^{58}\text{Co}}$ in the 24 h urine collections from 62 controls and 38 PA subjects.

Discussion

The present retrospective study has confirmed the accuracy and reliability of this test in the detection of deficiency of intrinsic factor in

Addisonian PA. In the previous study [2] all normals indicated a $^{57}\text{Co}/^{58}\text{Co}$ ratio of less than 1.6 while all those with PA, gave a ratio greater than 2.0. The results of studying a larger group of patients seem to indicate a slight overlap between the normal and pathological ranges, the range for patients with PA being 1.7 to 9.6, and for the control group 0.8 to 1.8. The result of the test agreed with the diagnosis made on other criteria in over 90% of the patients examined.

An attempt has been made to assess the possibility that high levels of intrinsic factor antibody present in serum and body fluids might inactivate the administered intrinsic factor and prevent its taking part in the absorption of B_{12} . Anti-intrinsic factor was sought in 36 patients in the present series including 12 subjects with PA and was demonstrated in 6 patients. All of these had PA, and had a $^{57}\text{Co}/^{58}\text{Co}$ ratio in the PA range (values 2.1–5.5). Thus the presence of intrinsic factor antibody does not appear to interfere significantly with the test.

The simultaneous administration of $^{58}\text{CoB}_{12}$ and $^{57}\text{CoB}_{12}$ bound to intrinsic factor is advantageous to the patient, the clinician and the laboratory staff. Carried out in this way the test involves only one 24 hour collection of urine and the result can be available within 48 h of commencing the test. Recently the Radiochemical Centre, Amersham has set out to simplify the test further by presenting the bound and unbound radioactive B_{12} in the form of two capsules ready for administration thereby reducing the preparations for the test in the laboratory to a minimum. Preliminary studies with this preparation, which will soon be available commercially are promising.

Acknowledgments. We wish to express our thanks to Dr M.O. NISLOW for his helpful advice and encouragement. Thanks are also accorded to Dr J.M. BARNES for his interest, Sister K. FARRELL and Mr S.J. TODD for nursing and technical assistance, and Mr A. LAMONT for preparing the diagram.

Summary

A retrospective study of the use of a urinary excretion test following the simultaneous oral administration of free $^{58}\text{CoB}_{12}$ and $^{57}\text{CoB}_{12}$ bound to human gastric juice in 100 patients is reported. The test provides an accurate evaluation of the intrinsic factor status in over 90% of the patients studied.

References

1. BELL, T. K. Annular counting of radioisotopes in large liquid volumes on a well type scintillation crystal of sodium iodide. *Brit. J. Radiol.* 38: 886 (1965).
2. BELL, T. K.; BURGESS, J. M. and NELSON, M. G. Simultaneous free and bound radioactive vitamin B₁₂ urinary excretion test. *J. clin. Path.* 18: 611 (1965).
3. GOTTLIEB, C.; LAU, K. S.; WASSERMAN, L. R. and HENBERT, V. Rapid charcoal assay for intrinsic factor (IF) gastric juice unsaturated B₁₂ binding capacity antibody to IF and serum unsaturated B₁₂ binding capacity. *Blood* 25: 875 (1965).
4. KATZ, J. H.; DYKES, J. and DONALDSON, R. M.: Simultaneous administration of gastric juice-bound and free radioisotopic cyanocobalamin. Rapid procedure for differentiating between intrinsic factor deficiency and other causes of vitamin B₁₂ malabsorption. *J. Lab. clin. Med.* 67: 266 (1963).
5. KAY, A. W. Effect of large doses of histamine on gastric secretion of HCl and augmented histamine test. *Brit. med. J.* 4: 77 (1953).
6. SCHILLING, R. F. Intrinsic factor studies. II. *J. Lab. clin. Med.* 42: 860 (1953).
7. VEALL, N. and VETTER, H. *Radioisotope techniques in clinical research and diagnosis*, p. 103 (Butterworth, London 1958).

Libri

Cell Kinetics in Human Leukemia. Series Haematologica, vol. 1 No. 3. Munksgaard, Copenhagen 1968. 128 p.

Among the most interesting trends of modern hematology is certainly the study of the kinetics of leukopoiesis in normal and pathologic conditions. The availability of new investigatory methods such as the use of tritiated precursors of the nucleic acids synthesis and radioactive inorganic substances applied either through research *in vitro* or *in vivo*, has furnished data of great interest on the proliferative and maturative activities of the normal and leukemic leukocytes. It will be enough to emphasize that it has been definitely proven that in acute leukemia two clones of blastic cells do exist. One is proliferative and the other is temporarily or completely incapable of further divisions (sterile clone). This fully confirms the observation made in 1950-1953, using the stathmokinetic test, that the cell population of acute leukemia is endowed with low proliferative activity.

The last issue of the well-known *Series Haematologica* deals exactly with the topic "Cell Kinetics in Human Leukemia". This publication is selling-out, complete set-up written by particularly qualified authors on the problems of leukocyte kinetics. There are contributed collections dedicated to the kinetics of chronic lymphocytic leukemia (L. M. SCARFIA), chronic granulocytic leukemia (P. A. CASSAVERIO and D. R. BOONE), and of acute leukemia (S. A. KILLMAN). This chapter dedicated to kinetics of the leukemic clones is especially ample, this field that has shown itself, more than any other, rich in results and new prospects. A stimulating contribution by S. A. KILLMAN offers an interesting hypothesis on the mechanism with which the normal hemopoiesis is suppressed by the abnormal blastic population in acute leukemia. These articles review and discuss the most recent acquisitions and they serve as a very useful aid both to those who study this subject and to those who want to keep up to date on the rapid progress being made in this area. All parts of the issue have quite numerous and accurate bibliographical references. This issue certainly contributes favorably to holding the prestige of *Series Haematologica* high. A periodical that continues to be more and more successful. G. ARZALLI, Torino

A. GALINDETTI, G. RIGGIO. *Lo studio del cromosoma umano*. Capelli, 1966. 199 p. Preis L. 4.500.

Dieses Buch gibt in 150 Druck- und Bildseiten eine Einführung in die menschliche Zytogenetik. Es enthält Kapitel über Chromosomenverteilung, Strukturnormalen, über klinische und zytogenetische Fakten der Trisomiesyndrome, Geschlechtsanomalien und Mibildungssyndrome, wie auch eine Besprechung der Chromosomenbefunde bei Neoplasien und hämatologischen Erkrankungen. Neben erklärenden Darstellungen, die stark vereinfacht sind, besteht dieses Buch vor allem aus einer weitreichenden Dokumentation der zytogenetischen Literatur bis 1964 wobei Wichtiges und Unwichtiges, Bewiesenes und Unbewiesenes nebeneinander stehen. Das Bildmaterial ist leider von schlechter Qualität. Methodische Einzelheiten sind zugehend angeführt, jedoch sind die Originalarbeiten nicht zitiert. Neue Techniken, wie Mibromethode oder Autoradiographie, fehlen. Da das Buch heute veraltet ist, sind naturgemäß noch Zusammenhänge aufgesprochen, die bereits wieder fallengelassen worden sind. Positiv zu erwähnen ist die Bibliographie von ungefähr 1000 Autoren. Leider ist sie nicht gegliedert und bezieht sich a.T. nicht auf den Text, so dass erwünschte Stellen eines Autors unter Umständen nicht gefunden werden können. Druckfehler und Fehler substantieller Art dürften den Anfänger verwirren, so dass man sich fragt, wenn man das Buch empfehlen soll. Der italienischen medizinischen Literatur wäre wohl mit der Übersetzung eines guten ausländischen Autors mehr gedient gewesen.

U. LOCHMANN, Bad

M. FRANÇOIS: *Einführung in die neueren Methoden der Lichtmikroskopie*. Übersetzt von LEONIE ALBERT G. BRAUN, Karlsruhe 1967. XI + 332 p., 340 fig. Preis: DM 56.-.

Der mikroskopischen Verfahren sind in den letzten Jahrzehnten um eine Reihe von sehr wesentlichen neuen Arbeitsmethoden bereichert worden. Diese neuen Mittel, wie Phasenkontrast- oder Interferenz-Mikroskopie, sind nur erfolgreich anzuwenden, wenn die theoretischen Grundlagen bekannt sind. Zur Einführung in diese Grundlagen veröffentlichte M. FRANÇOIS 1961 einen Fortschrittsbericht *Progress in Microscopy* (Pergamon Press). Diese Monographie fand eine sehr gute Aufnahme, und dies veranlaßte 1967 eine ergänzte deutsche Übersetzung.

Das vorliegende Werk ist keine Anleitung für die praktische Mikroskopie: es vermittelt nur die Theorie. Da eigentlich alle neuen mikroskopischen Methoden nur mittels wellenoptischer Betrachtungen erfassbar sind, so bringt das einleitende Kapitel in klarer, jede Umständlichkeit vermeidender Weise die Grundlagen der Bildentstehung im Mikroskop. Damit ein solches Bild – besonders von sehr kleinen Objekten – richtig interpretiert werden kann, muss absolute Klarheit vorhanden sein über das Wesen eines derartigen Bildes und ebenso auch über die Faktoren (Beleuchtungsprinzip, Wellenlänge des Lichtes, Optikeigenschaften) welche die Bildqualität beeinflussen oder gar verfälschen können. Leider begegnet man in der Praxis immer wieder „Normalverbrechern“ mikroskopischer Geräte, die infolge ihres oft erschreckenden „Nichtwissens“ um die Zusammenhänge ihre Apparaturen falsch einsetzen oder das Resultate falsch deuten.

Im zweiten Kapitel werden die Grundlagen und die Anwendungsmöglichkeiten der Phasenkontrastmikroskopie dargestellt. Da dieses Verfahren in seiner landläufigen Anwendung schon lange bekannt ist und deshalb in den Standardwerken der Mikroskopliteratur gebührend berücksichtigt wird, hat sich der Autor hier etwas kürzer gefaßt. Hingegen geht er im folgenden dritten Abschnitt ausführlich auf die Interferenzmikroskopie ein. Nach einer kurzen, aber wiederum klar formulierten Einführung in das Prinzip werden die diversen technischen Ausführungen für die Interferenzmikroskopie vorgestellt. Das Kapitel schließt mit einem Hinweis auf die Empfindlichkeit dieser Methoden.

Unter dem Sammelbegriff „Auflichtmikroskopie“ bringt der nächste Teil alle Methoden, bei denen das Licht senkrecht oder leicht schräg durch das Objektiv auf das Präparat geführt wird. Nach der Erläuterung der verschiedenen Beleuchtungsrichtungen und der korrespondierenden Hilfsmittel folgt die Auflicht-Phasenkontrastmikroskopie, wobei wiederum die verschiedenen technischen Lösungen verglichen und erklärt werden. Ein weiterer Teil dieses Kapitels befaßt sich mit der schiefen Beleuchtung. Darunter ist nicht die gewöhnliche Epibeleuchtung mit der senklich neben der Optik einstrahlenden Lichtquelle verstanden, sondern die Leuchtverfahren nach SCHMALZ und nach MINOZZI. Auch hier wird auf die praktischen Anwendungsmöglichkeiten hingewiesen; so können z. B. diese Methoden wertvolle Ergänzungen zu Phasenkontrast- oder Interferenz-Untersuchungen von Oberflächenstrukturen sein. FRANÇOIS bemerkt übrigens im Zusammenhang mit den einleitenden Betrachtungen über die Bildinterpretation, dass diese sehr erleichtert und gesichert werden kann, wenn die mikroskopische Untersuchung eines Präparats nach Möglichkeit mit verschiedenen Verfahren vorgenommen wird. Weitere Bestandteile dieses Kapitels bilden die Auflicht-Dunkelfeldmethode (mit dem Hinweis auf das Bestimmen von Neigungswinkeln) und das Auflicht-Interferenzverfahren. Wiederrum werden die einleitenden Geräte beschrieben und abschließend zeigt der Autor welche Probleme damit gelöst werden können. Wie in den anderen Teilen des Buches erfolgt das auch hier durch übersichtliche Schemata sowie durch Abbildungen von Geräten und Resultaten. Das Kapitel endet mit der Darstellung der Auflichtbeobachtung anisotroper Objekte im polarisierten Licht und mit einer Skizze über die Hochtemperaturmikroskopie.

In den folgenden Kapiteln werden verschiedene Messmethoden und die dabei zu erzielende Genauigkeit (Kapitel 5) besprochen, die Brechzahlbestimmung mit dem Zweistrahl-Interferenzmikroskop (Kapitel 6) die Möglichkeiten des Polarisations-Interferenz-

mikroskope (Kapitel 7) sowie im Kapitel 8 Dicken-, Rauheits- bzw. Winkelbestimmungen. Biologisch interessieren dürfte in diesem Abschnitt die Interferenzmikroskopische Bestimmung des Trockensubstanzgehaltes von lebenden Zellen.

Während in den zuvor kurz referierten Kapiteln 3-8 der Mediziner nur verhältnismäßig wenig Anwendungsmöglichkeiten findet, dürfte der nächste Abschnitt über die mikroskopischen Methoden mit Infrarot- und ultravioletter Strahlung wieder von erheblicher praktischer Bedeutung sein. Auf die Skizzierung der technischen Voraussetzungen, wie Spezialoptik oder Kondensor für UV folgen die Aufzeichnungs- und Beobachtungsmittel, in erster Linie der Bildwandler, der Leuchtschirm und die Fernsehkamera. Den Abschluss dieses Kapitels bildet die Erläuterung von verschiedenen Möglichkeiten der Fluoreszenzmikroskopie, besonders interessieren könnte hier der Hinweis auf die Phasenkontrast-Fluoreszenzverfahren.

Wieder mehr dem Chemiker und den Physiker werden die im nächsten Kapitel aufgeführten Gebiete der Mikrospektrometrie und der Mikrophotometrie anprechen. Von allgemeinem Interesse sind dafür die im nächsten Teil erklärten Methoden des Flying Spot (Scanning)- und des Laser-Mikroskops. Das Buch verfügt zwar über ein sehr umfangreiches Verzeichnis von einschlägiger Literatur, doch wäre hier zur Einführung in die sicher noch längst nicht ausgeschöpften Möglichkeiten eine ausführlichere Darstellung erwünscht. Ebenso wäre auch eine reichere Behinderung des Kapitels am Platz gewesen, um die Resultate dieser wirklich neuartigen Verfahren zu dokumentieren.

Das letzte Kapitel ist mikroskopischen Untersuchungsmethoden in der Chemie reserviert; selbstverständlich findet man darunter auch Anwendungsmöglichkeiten für die physiologische Chemie. Den Schluss des Buches bilden das 46 Seiten umfassende, kapitelweise gegliederte Literaturverzeichnis sowie die üblichen Register.

In verdienstvoller Arbeit haben der Autor und ebenso der ausgezeichnete Übersetzer LUDWIG ALBERT ein Werk geschaffen, das vorzüglich zur Förderung des Wissens um die verschiedenen neuen Verfahren geeignet ist. Selbstverständlich konnten unmöglich alle denkbaren Anwendungen in ausführlicher Weise beschrieben werden, es wäre sonst aus dem handlichen Buch ein unübersichtlicher Wälzer entstanden. Deshalb muss man sich beim Lesen immer wieder daran erinnern, dass das Werk eine Einführung darstellen soll. Diesen Zweck des Einführens hat FRANKOW sicher erreicht, denn wie schon bemerkt, vermeidet er jeden überflüssigen Ballast und beschränkt sich auf knappe Formulierung der Prinzipien. Gelegentlich wird allerdings mathematisches Denken vorausgesetzt. L. JACOB BOM

Actualités hématologiques. 2^e Série. Publiée sous la direction de JEAN BERNARD. Masson, Paris 1968. 258 p., 55 fig. 60 Tab. Prix 50 NF

Die zweite Serie der *Actualités hématologiques*, die wiederum unter der Leitung von Prof. JEAN BERNARD und unter Mitwirkung zahlreicher namhafter Kliniker und Forscher der französischen Hämatologie erschien, stellt sich dieselbe Aufgabe wie die erste Serie, eine Übersicht zu geben über einige wichtige und aktuelle Gebiete der Hämatologie. Das erste vorwiegend klassisch orientierte Kapitel ist der akuten Leukämie und der Makroglukulinämie Waldenström gewidmet. JEAN BERNARD gibt aufgrund eines grossen eigenen Materials eine Übersicht über das Rubikomyon (Dexamethan), dessen therapeutischen Wert er vor allem bei unreifen Myelomen sieht. Mit seiner hohen Aktivität und Toxizität eignet sich das Medikament vor allem für die Einleitung einer Behandlung. Auf die Möglichkeit einer Verlangsamung der Remission unreifer lymphatischer Leukämien durch die Methode der Remission (vorwiegend kindliche Fälle!) weisen JACQUELINE WITZ und BOSTON hin. Weitere Abschnitte dieses Kapitels befassen sich mit der Miesingod leukemia und mit symptomatischen therapeutischen Massnahmen bei akuten Leukämien. Aus dem Gebiet der Makroglukulinämien werden immunologische, cytologische, radiologische und therapeutische Gesichtspunkte dargestellt. Das zweite Kapitel befasst sich

der Zytologie der Lymphadenitis. Funktionelle Untersuchungen der Erythropoese, der Thrombocyten und der immunologischen Defekte bei malignen Lymphomen sind die Themen des dritten Kapitels. Ergebnisse neuerer hämatologischer Forschungen werden im letzten Kapitel zusammengefasst: Säugtierleukämien, Feline und Hybridisierung von Säugtierzellen, Isotopenuntersuchungen über die Lymphosystemzirkulation bei chronischer lymphatischer Leukämie, Gewebegruppen und schließlich die Beeinflussung der Gerinnung durch Fibrinogenprodukte.

Auch diese zweite Folge der *Actualités hématologiques* wird ihrem Titel gerecht, indem sie zahlreiche aktuelle Probleme zur Darstellung bringt. Dabei liegt das Hauptgewicht auf der klinischen Hämatologie, und es werden wie schon im ersten Band zahlreiche praktischen Fragen berücksichtigt. Das Buch vermag daher allen hämatologisch interessierten Ärzten wertvolle Informationen zu vermitteln. H. LÖNN, Basel

U. WILKENROCK. Zur Physiologie und Pathologie des Phosphatstoffwechsels unter besonderer Berücksichtigung der Phosphatverbindungen des kindlichen Blutes. Mit Gedächtniswort von Prof. F. Liebermann. Bdheft 60 zu Arch. Kinderheilk. Ferd. Enke, Stuttgart 1969. XI+109 p., 11 fig. 28 Tab. Preis DM 90.

In einer Einleitung, Physiologie des Phosphatstoffwechsels, gibt der Verfasser eine Übersicht über Phosphorverbindungen in der Nahrung, Phosphatresorption und Verteilung der Phosphate im Organismus, besonders im menschlichen Blut (Erythrocyten, Leukozyten, Thrombocyten und im Plasma). Hierauf wird die eigene Methodik geschildert. Der eigene Beitrag liegt hier vor allem in der säulenchromatographischen Trennung und Bestimmung freier Nukleotide und phosphathaltiger Metaboliten im Blut bei Kindern. Danach werden die Normwerte der Ausscheidung der Phosphate im Stuhl und im Urin, der Phosphatbedarf und die Regulation des Phosphatstoffwechsels besprochen.

Etwa zwei Drittel der Monographie sind der Pathologie des Phosphatstoffwechsels gewidmet, wobei folgende Kapitel besprochen werden: Rachitis und Osteomalazie, Tetanie, Hyperkalzämie-Syndrome und Störung der Knochenmatrix sowie das Verhalten der Phosphatasen im Blut bei anderen Krankheitszuständen. Bei den meisten der besprochenen Störungen berichtet der Verfasser über die mit seiner Methodik erhaltenen eigenen Resultate und kommentiert sie im Vergleich mit den schon bekannten Daten, insbesondere bei der Vitamin-D-Mangelrachitis, bei Zytosom-, verschiedenen renal- Störungen, nachfolgender Tetanie und Frühparathyreopathie. M. VIRT, Basel

C. J. D. ZARAFONETS (editor) Proceedings of the International Conference on Leukemia Lymphoma. Len & Febiger Philadelphia 1969. 519 p. Price US \$ 15.00.

The conference held in Ann Arbor 1967 gives an excellent cross section about the present state and problems of leukemia and lymphoma. Several of the papers and panel discussions have as topic the viral etiology of leukemia (R. W. MÜLLER, A. C. UPTON, W. R. BRYAN, L. DRACOWSKI, J. T. GRACE, W. R. MURPHY, C. ZARAFONETS and SARA E. STEWART). Very instructive is the presentation of MARCEL BROSS on the ultrastructure of normal and leukemic granulocytes. W. S. DECK reviewing the biochemical properties of normal and leukemic leukocytes, is very sceptical whether assaying the leukocyte enzymes will contribute much to the knowledge of the nature of leukemia; in his opinion the basic problem remains the physiological mechanism which regulates leukopoiesis. Of particular interest is the paper of DAVID P. BOHRETT on the African lymphoma, its epidemiological and therapeutic aspects. One section of the book contains papers and panel discussions of the present-day treatment methods in leukemia and lymphoma. These proceedings are of great interest for all haematologists, clinicians and experimental pathologists. G. ROSENBERG, New York, NY

L. G. Koss: *Diagnostic Cytology and Its Histopathologic Basis*. 2. Aufl. Pitman, London/Lippincott, Philadelphia 1969 633 S. mit fast 1200 Abb. Preis £ 10.-

Bereits die 1961 erschienene 1. Auflage dieses Buches war ein Standardbuch der diagnostischen Zytologie. Die jetzt nach 7 Jahren erschienene 2. Auflage ist gegenüber der ersten gründlich überarbeitet und vor allem im Kapitel über den weiblichen Genitaltrakt stark erweitert worden. Auch neuere Erkenntnisse der allgemeinen Zytologie wurden einbezogen.

Das Werk gliedert sich in zwei Hauptteile: «Allgemeine Zytologie» und «Diagnostische Zytologie der Organe». Im ersten Teil werden kurz, aber übersichtlich die Grundstrukturen der Säugetierzelle dargestellt, wobei entsprechend der heutigen Bedeutung die Lysosomen allerdings relativ kurz berücksichtigt werden. Neben einer Darstellung der Aktivitäts- und Degenerationserscheinungen der Zelle, die für die Beurteilung von Ausstrichpräparaten besonders wichtig sind, werden auch andere pathologische Prozesse der Zellen etwa bei Entzündungen oder bei Hyperplasien und Metaplasien berücksichtigt. Die Teile über die Chromosomenstruktur -dynamik und -pathologie sind mehr für den allgemein zytologisch interessierten Leser und weniger für den Zytodiagnostiker wichtig. Im zweiten Teil wird eine ausgezeichnete Darstellung der verschiedenen zytologischen Befunde im weiblichen Genitaltrakt, im Respirationssystem, im Nieren-Harnbläsensystem und im ganz intestinalen System gegeben. Ein besonderes Kapitel ist der Krebszytodiagnostik im Körper gewidmet. Auch die Tumorzellen, die durch Aspirations-Biopsie gewonnen werden können, sowie die in Blut und Lymphe zirkulierenden Tumorzellen werden ausführlich beschrieben. Für den diagnostisch tätigen Pathologen ist der jeweilige Bezug der Histologie auf die Ausstrich-Zytologie von besonderem Wert. Durch diese Gegenüberstellung und den ausführlichen, gut gegliederten und leicht lesbaren Text unterscheidet sich dieses Buch wohl-tuend von anderen Büchern des gleichen Themas. Bei den Darstellungen der Vaginal-Ausstriche und der Zervix-Abstriche sind die Spiegelungsbeefunde an der Portio und für histologische und zytologische Bezug berücksichtigt. Die Abhängigkeit des histologischen und zytologischen Bildes vom weiblichen Zyklus könnte bei Vergleich der anderen Kapitel etwas ausführlicher sein, da die Zyklusdiagnostik in der Praxis eine bevorzugte Rolle spielt. Bei den einzelnen Krankheiten werden die morphologischen Befunde starkvoll durch Häufigkeitswertangaben - z.T. unter Einfluss der Therapie - ergänzt. Besonders ist auch der Einbezug von Nebenfunden, z.B. von Nematothen oder Filarien im Sputum. Der Wert der Zytologie für die klinische Diagnostik ist in mehreren Tabellen klar belegt, wobei auch vielfach Verlaufbeobachtungen aufgeführt werden. Ein Abschnitt über die zytologischen Techniken enthält alle für die Praxis notwendigen Methoden einschl. Hinweisen für die zytologische Berichterstattung und für die skizzierte Organisation zytodiagnostischer Laboratorien.

Das Buch gehört in die Hand aller Pathologen und Kliniker die sich täglich mit der histologischen und zytologischen Tumordiagnostik befassen. Es enthält aber außerdem viele für die spezielle Pathologie der Tumoren wichtigen Einzelheiten, besonders in den Abschnitten über die Tumoren des weiblichen Genitaltraktes. Wer allerdings als Student oder als Anfänger die Zytodiagnostik lernen will, ist durch dieses Buch überfordert. Da die Reproduktionen der Mikrophotos kontrastarm sind, ersetzt das Buch bei der täglichen Arbeit nicht die vielfach in Bestdruck vorliegenden zytologischen Atlanten anderer Autoren. Es handelt sich also um ein Nachschlagewerk für den Fachmann. Ein gründlich bearbeitetes Sachregister ermöglicht ihm die Benutzung dieses starkvoll gestalteten Buches.

E. GRIMMACK, Wuppertal

Department of Haematology St. Georg General Hospital, Hamburg Data Processing Center University of Hamburg, and Division of Medical Biochemistry Institute of Physiological Chemistry of the University of Hamburg

Inter Relations between Iron Stores, General Factors and Intestinal Iron Absorption

K. HAUFMANN R. KUEZ, O. W. SONNENBERG H. BARTELS and
H. G. HEINRICH

Iron stores, rate of erythropoiesis, anaemia hypoxaemia, transferrin saturation, gastric secretion pancreatic secretion and dietary constituents have been reported to influence intestinal iron absorption [5]

For several decades routine measurement of ^{59}Fe retention after oral iron administration has been prevented by technical difficulties which have been overcome during the last years by ^{59}Fe whole body counting but experience is still limited. The purpose of this paper is to summarize the results of studies on the correlation between the diagnostic criteria of iron metabolism reported preliminarily elsewhere [11-17 21] In 780 subjects including normal controls, patients with blood liver and neoplastic diseases or infections three cytochemically different types of non haemic iron in bone marrow reticuloendothelial cells, sideroblasts, serum iron: total iron binding capacity (TIBC) transferrin saturation, haematocrit, haemoglobin red blood cells, and the ^{59}Fe absorption whole body retention test (^{59}Fe AWBRT) (4 x large volume radioactivity detector with liquid organic scintillator) [16 17] after administration of 0.558 mg Fe^{++} + 17.5 mg ascorbic acid in a strictly fasting state have been compared.

Subjects

Totally 843 individuals have been examined, in part several times. The 780 subjects with comparable findings have been classified into the following groups: normal controls with normoiderms (see definitions) 74 (males 36, females 38) Iron deficiency: prelatent iron deficiency 109 latent iron deficiency 27 iron deficiency anaemia 66, pregnancy with hypoiderms 33. Gastrectomy: partial 19 (with hypoiderms 12) total 3. Polycythaemia 34 (with hypoiderms 28).

Different types of anaemia: hypoplastic anaemia 23, pure red cell anaemia 4, sideroachrestic anaemia 14 (with hypoiderms due to treatment or bleeding 2, with prelatent or latent iron-overload 8, with manifest iron-overload 4) untreated megaloblastic anaemia 10 (examined during reticulocytosis 7) haemolytic anaemia 11 (hypoiderms 2) renal anaemia 1.

Malignant diseases: epithelial cancer 8 (hypoiderms 1), Hodgkin's disease 72 (hypoiderms 7) reticulum cell sarcoma or reticulosis 15 (hypoiderms 2), acute leukaemia in adults 18 (hypoiderms 1) lymphocytic leukaemia 47 (see table IV) myelocytic leukaemia 17 (see table IV).

Chronic infections: 28 (hypoiderms 1). Collagen diseases: 15 (hypoiderms 5) Liver diseases: fatty liver 21 (hypoiderms 1) liver cirrhosis 43 (hypoiderms 15) chronic hepatitis 3, haemochromatosis 7 fibrosarcomas: 47 (with hypoiderms 10) Not included into the comparison: osteomyelofibrosis 10, without evaluable bone marrow iron 53.

Methods

Bone marrow smears with thick squash preparations of larger fragments aspirated from the sternum or the iliac crest were fixed in the vapour of neutralized formaldehyde 35% for 3 min. The slides were stained with 100 ml potassium ferrocyanide 1% + 1 ml hydrochloric acid 25% at room temperature for 15 min. About 50 oil immersion fields (microscopic magnification 10×40) of at least two preparations were examined by two independent observers. Cytochemical grading of the Prussian blue reaction was performed separately for the following three types of non haemos iron in bone marrow reticuloendothelial cells.

1. Diffuse cytoplasmatic iron staining of different intensity already described in the histochemical and cytochemical literature [see 4, 22, 24] was seen in isolated cells (fig. 1) cytoplasmic backlogs, and separated cell fragments of well preserved thinner areas of the squash preparations in specimens of subjects with normoiderms and hyperiderms. These elements could be followed easily as the thicker layers which appear spotted of diffuse blue to greenish. Cytochemical grading considered the colour scale and the number of positive cells in relation to the thickness of the area examined.

- | | |
|----------|--|
| 0 | iron staining completely absent |
| (+) | traces, single faint blue cells in less than one quarter [(+)] two quarters (+) or three quarters (+)/+ of thick areas |
| 1+ | faint blue staining in nearly every appropriate field |
| 2+ to 4+ | increasing number of distinctly blue cells |
| 5+ to 6+ | numerous dark blue cells |

2. Polymorphous haemosiderin particles were recorded 0 to 6+ according to their number and size in similar way as described above. These aggregates occurred frequently in cells with and rarely in cells without the diffuse iron (fig. 1). They could be seen already




Fig 1 Thin area of bone marrow squash preparation (Prussian blue staining) with two iron containing macrophages surrounded by erythroblasts. Left cell diffuse cytoplasmic iron with two small haemosiderin particles. Right cell haemosiderin particles of different size without diffuse iron. Single post-thyroid cell fragments.

in unstained preparations [28, 30] and seem to be identical with the haemosiderin granules of other authors [10, 23, 27, 30, 33].

3. Small uniform sized Prussian blue granules 0 to 6+ were observed after parenteral therapy with colloidal iron [4, 10] and in more refractory states in haemochromatosis [4, 22], pernicious anaemia [31], and single cases of transfusional hyperferritinosis in pure red cell anaemia after busulfan treatment of myelocytic leukaemia and single cases of sideroachroic anaemia [own unpublished observations].

The report of LEADER *et al* [25] that histochemical iron grading in sections is equivalent to cytochemical grading in well preserved squash preparations is in accordance with own studies.

Sideroblasts were counted in 50–200 cells of the red cell series in thinner areas of the squash preparations. Only when identification of iron free immature erythroblasts was difficult slight counterstaining with aqueous eosin 0.1% (1 min) was performed.

Plasma iron was determined using bathophenanthroline [26] and total iron binding capacity according to CARAWAY [6] in fasting subjects. The serum haematocrit was measured in microhaematocrit centrifuge. Haemoglobin was estimated as cyanhaemoglobin in an Eppendorf photometer using commercially available standard. Erythrocytes were counted with the Coulter counter model A, B and F.

Intestinal iron absorption was determined by means of the ^{59}Fe absorption whole body retention test (^{59}Fe -AWBRT) using a large volume radioactivity detector with liquid organic scintillator [16]. An oral test dose of $0.556 \text{ mg } ^{59}\text{Fe}^{++}$ ($10 \mu\text{Ci} = 0.05\text{--}0.20 \mu\text{Ci}$) + 17.6 mg ($\approx 100 \text{ Mol}$) L- (+) ascorbic acid was given in strictly fasting state (see results and discussion). The retained radioactivity was measured 14 and 21 days later.

Statistical analysis included conventional methods and non parametric tests, such as the Mann-Whitney U-Test for comparison of arithmetic means in different groups [29]. In correlation analysis computation of the Spearman rank correlation coefficients and the

product moment correlation coefficients gave corresponding results in smaller groups. In larger series the latter test was used only. The correlation matrices were subjected in the rotaplot program of factor analysis [19]. Details are reported elsewhere.

Definitions

In organizing data it has been found useful to classify the subjects examined into the following main groups defined by cytochemical grading of reticuloendothelial iron supplemented by the corresponding examination of liver iron, when iron overload is suspected.

Hypsiderosis	diffuse iron 0 to (+)/+ haemosiderin particles 0 to (+)
Normsiderosis	diffuse iron 1+ to 4+ haemosiderin particles (+) to 3+
Hypersiderosis	diffuse iron 5+ to 6+ haemosiderin particles 4+ to 6+

The term hypsiderosis includes every type and degree of symptomatic, co-morbid and co-normal iron deficiency independent of diagnostic criteria of iron metabolism other than exhausted iron stores. In the majority of cases iron deficiency can be subdivided by combination of different diagnostic ranges of at least three variables.

Prelatent iron deficiency	hypsiderosis, normal plasma iron ($> 60 \mu\text{g}\%$), normal red cell indices haematocrit $> 38\%$, haemoglobin $> 12 \text{ g}\%$, erythrocytes $> 4.0 \text{ million}/\text{mm}^3$
Latent iron deficiency	hypsiderosis, plasma iron $< 60 \mu\text{g}$, normal red cell indices
Manifest iron deficiency	hypsiderosis, plasma iron and red cell indices reduced

In corresponding way stages of reticuloendothelial and parenchymal iron overload are defined.

Prelatent iron overload	increased RES or parenchymal iron stores with normal plasma iron $< 180 \mu\text{g}\%$ or transferrin saturation $< 60\%$, no tissue damage
Latent iron overload	hypersiderosis, increased plasma iron and transferrin saturation, no tissue damage
Manifest iron overload	hypersiderosis with increased plasma iron, transferrin saturation, and tissue damage

Results

During the initial period of this study measurement of ^{59}Fe retention in otherwise healthy young women and male blood donors with exhausted iron stores gave frequently far too low values in comparison with corresponding groups of in-patients. Such irregular effects could be considerably reduced in number when the subjects examined were asked repeatedly to remain completely fasting for 10 to 12 h before and 2 h after the administration of the test dose. Only some tap water was allowed. Iron loading before, during or after uncontrolled intake of little food or drinks diminished the arithmetic mean of intestinal

Table I. Effect of uncontrolled intake of food (or drinks) and iron therapy on intestinal iron absorption in the same subjects

	n	AM %	SD \pm %	Range %
A. Prelatent and latent iron deficiency				
Fasting subjects	27	75.0	13.0	32.0-97.0
Subjects not completely fasting	27	32.9	16.6	6.2-57.0
B. Different stages of iron deficiency Oral iron therapy 6.0-12.0 g Fe ⁺				
Before therapy	18	91.7	9.3	71.0-100.0
After therapy (diffuse iron $\geq 1+$)	18	32.0	9.3	8.5-48.0
C. Iron deficiency anaemia Parenteral iron therapy* 1.0-3.5 g Fe ⁺⁺⁺				
Before therapy	16	88.2	5.8	80.1-98.2
After therapy (see text)	16	19.1	11.2	6.0-46.8
Relapse despite of residual bodies 1+ to 4+ (only in part the same subjects)	11	88.2	10.3	63.5-100.0
D. Prelatent and latent iron deficiency Parenteral iron therapy				
Before therapy	11	72.4	12.9	48.6-92.5
After therapy	13	19.4	10.3	7.5-48.1

*number of subjects examined, AM arithmetic mean of iron absorption values, SD standard deviation.

iron absorption by the factor 2.3 in the same individuals with prelatent and latent iron deficiency serving as their own controls when they were strictly fasting during the critical period (table I A $P < 0.01$). Similar observations were made in few subjects with different diseases.

In single cases with severe iron deficiency anaemia excluded from this study heavy blood losses after the administration of the test dose reduced the ⁵⁵Fe retention by about 20-30% as estimated by the subsequent determination of the ⁵⁵Fe whole body turnover rate.

The first group of table II ($n = 780$) consisted of subjects with comparable results. The second series ($n = 646$ table II table III B, fig 2) excluded all groups totally in which irregular results were observed (see also table IV).

A close negative correlation has been computed between the diffuse Prussian blue reaction of bone marrow RE cells and the ⁵⁵Fe AWBRT

Table II Correlations

Correlations between	All cases		Without dysregulation	
	n = 780	± CI	n = 646	± CI
Diff. F - ⁵⁹ Fe-AWBRT	-0.76	0.04	-0.88	0.03
Diff. Fe - haemosiderin	+0.64	0.06	+0.63	0.07
Diff. F - TIBC	-0.60	0.06	-0.66	0.06
Diff. Fe - UIBC	-0.64	0.06	-0.68	0.06
Diff. Fe - plasma iron	+0.35	0.06	+0.35	0.08
Diff. F - sideroblasts	+0.30	0.07	+0.30	0.08
⁵⁹ Fe-AWBRT - haemosiderin	-0.49	0.07	-0.57	0.08
⁵⁹ Fe-AWBRT - TIBC	+0.39	0.06	+0.36	0.06
⁵⁹ Fe-AWBRT - UIBC	+0.37	0.07	+0.37	0.06
⁵⁹ Fe-AWBRT - sideroblasts	-0.35	0.09	-0.45	0.09
⁵⁹ Fe-AWBRT - plasma iron	-0.24		-0.32	0.10
⁵⁹ Fe-AWBRT - haemoglobin	+0.07		+0.06	
Plasma iron - sideroblasts	+0.33	0.07	+0.32	0.08
Transferrin-sat. - sideroblasts	+0.60	0.06	+0.50	0.07

⁵⁹ = correlation coefficient, CI = confidence interval of the correlation coefficient ($P < 0.01$) Diff. F = diffuse Prussian-blue reaction of bone marrow RE cells, Haemosiderin = polymorphous haemosiderin aggregates in bone marrow RE cells, ⁵⁹Fe-AWBRT = ⁵⁹Fe-absorption whole body retention test, TIBC = total iron binding capacity, UIBC = unsaturated iron binding capacity

in both groups of table II. Significantly lower correlation coefficients were obtained in the comparison of the haemosiderin aggregates, the ⁵⁹Fe-AWBRT-TIBC and UIBC, as well as between plasma iron, transferrin saturation and sideroblasts. The red cell indices showed no correlation with the other variables. Correlation coefficients $r > 0.4$ were sufficiently high to reject the null hypothesis at a level of $P < 0.01$. The confidence intervals (table II) show that the differences between most values are statistically significant. Factor analysis applied to the correlation matrices subdivided the variables into the following groups: (1) diffuse iron, haemosiderin, ⁵⁹Fe-AWBRT-TIBC and UIBC; (2) plasma iron, transferrin saturation and sideroblasts; (3) red cell indices (r between haematocrit, haemoglobin and erythrocytes + 0.86 to + 0.95).

The scatter diagram of figure 2 reveals the bivariate distribution of cytochemical iron and iron absorption. The arithmetic means of the




Fig. 2. Lateral iron absorption (0.56 mg F⁺⁺) as relation to RES-iron of bone marrow. Scatter diagram. Horizontal arrows: distribution of types of bone marrow reticuloendothelial iron and iron absorption (%). RES-iron = diffuse iron only; • diffuse iron with haemosiderin particles (the latter irrespective of their cytochemical grade).

⁵⁵Fe AWBRT increased significantly ($P < 0.01$) with the disappearance of the diffuse iron (fig 2, table III B). The same was true in homogenous clinical groups (table III A). Overlapping occurred in the transition zone between normosiderosis and hyposiderosis (fig 2). When diffuse iron was present together with polymorphous haemosiderin particles (fig 2, closed circles, table III B) no significant differences were observed in comparison with the diffuse iron $\geq 1+$ alone in normosiderosis (fig 2, open circles).

In different stages of iron deficiency increased iron absorption returned into normal range only after repletion of RE iron stores (table I B-D). In the subjects of table I B diffuse iron $1+$ or more was seen after a total dose of 6.0–12.0 g of divalent iron given for 60–120 days (50 mg fasting 1 hour before breakfast and 50 mg at least 2 h after dinner). Intravenous iron therapy (1.0–3.5 g saccharated iron oxide, Ferrophor®) (table I C and D) was characterized by the appearance of numerous uniform sized granules $2+$ and more, but

Table III. Iron absorption

Iron absorption	n	AM %	SD % \pm	Range %
A. Iron absorption in clinically homogeneous groups				
Iron deficiency	64	86.6	12.1	53.4-100.0
Latent iron deficiency	27	85.9	11.7	53.9-100.0
Prelatent iron deficiency	105	74.6	14.8	50.0-100.0
Normal females with normosideremia	38	29.6	11.5	4.0-50.4
Normal males with normosideremia	36	25.4	10.7	8.2-44.1

B. Iron absorption in groups with different grades of iron

1. Diffuse iron without haemosiderin particles

0	202	84.9	12.6	49.1-100.0
(+)	99	69.5	17.3	10.8-99.4
+	60	30.8	16.0	1.4-88.9
+/++	6	25.2	11.6	5.9-38.7
++	37	21.5	10.2	4.5-48.6
> ++	19	16.9	9.3	3.8-38.4

423

2. Diffuse iron with haemosiderin particles (the latter irrespective of their cytochemical grade)

0	3	56.0	43.8	12.5-100.0
(+)	10	49.0	26.9	8.2-80.6
+	37	31.3	17.4	0.6-87.4
+/++	13	19.6	9.5	4.1-40.5
++	61	20.3	11.4	3.2-45.5
> ++	99	16.8	9.8	1.4-49.6

223

number of subjects examined, AM arithmetic mean of iron absorption values, SD standard deviation.

transformation into the diffuse iron varied considerably from 0 to 3+. Relapse of iron deficiency occurred in patients with high ^{59}Fe whole body turnover rates despite of persisting residual bodies 1+ to 4+ and diffuse iron 0 (table IC, $n = 15$ in part other patients than $n = 16$).

In table IV the 780 subjects examined have been subdivided according to the clinical interpretation of iron absorption in relation to iron stores. Findings classified as abnormal have been confirmed as far as possible by repeated tests. Normal iron absorption in prelatent iron deficiency (table IV B1) increased in single cases with progression

Table IV Iron absorption

	Number of subjects	% of subjects
A. Iron absorption in relation to RES iron		
1. Increased absorption > 50% associated with hypsiderosis	304	33.0
2. Normal absorption < 50% associated with normosiderosis (or hypersiderosis)	422	54.0
	726	93.0
B. Iron absorption unrelated to RES iron		
Deviations of minor significance		
1. Normal absorption despite of prelatent iron deficiency $\left\{ \begin{array}{l} \text{No./total} \\ 9/114 \end{array} \right\}$	9	1.2
2. Normal absorption despite of neg. RES iron in advanced lymphocytic leukemia $\left\{ \begin{array}{l} 6/47 \\ 10/17 \end{array} \right\}$	16	2.1
3. Unexplained increase of absorption despite of normosiderosis	7	0.9
Deviations of major importance		
4. Normal absorption despite of iron deficiency anaemia (hereditary malabsorption functional disturbance?) $(2/66)$	2	0.2
5. Increased absorption despite of normosiderosis or hypersiderosis in sideroachroic anaemia $\left\{ \begin{array}{l} 7/14 \\ 3/10 \\ 2/11 \\ 1 \end{array} \right\}$	13	1.7
megaloblastic anaemia		
haemolytic anaemia		
renal anaemia $\left\{ \begin{array}{l} 4/7 \\ 3 \end{array} \right\}$	7	0.9
haemochromatosis		
chronic hepatitis		
	54	7.0
Sum A+B	780	100.0

of iron deficiency. Unexplained high iron retention despite of normosiderosis (table IV B3) returned spontaneously into normal range in 4 cases and persisted in 3 subjects. Far advanced chronic leukemia (table IV B2) was characterized by heavy bone marrow infiltration.

Normal iron absorption was associated with severe iron deficiency anaemia in two sisters showing poor response to oral iron, but ex-

cellent effect of parenteral iron (table IV B4) The ^{59}Fe whole body turnover rate was normal in 1 case.

In sideroachrestic anaemia increase of iron absorption into sideropenic range was found together with latent and manifest iron overload, in haemolytic and megaloblastic anaemia together with latent and prelatent iron overload (table IV B5) The group of haemochromatosis with increased ^{59}Fe retention consisted of 1 idiopathic case and 3 alcoholics.

Ten patients with osteomyelosclerosis without reliable estimation of bone marrow iron and without symptoms of iron deficiency showed normal absorption. Three individuals with splenectomy and hyposiderosis were included into group A 1 (table IV) 15 corresponding subjects with normosiderosis or hypersiderosis into group A 2.

Discussion

The data presented concern clinical problems studied already since many years [5] with a growing refinement of methods and an increasing number of individuals. Positive correlations between plasma iron, transferrin saturation and sideroblasts (table II) are in accordance with the work of others [32] In comparison of iron stores and intestinal iron absorption less variability [20] has been achieved after better recognition of the following facts probably not fully considered in the past

1 Special care must be given in every case to the instruction and co-operation of the subjects to be examined because iron absorption decreases by the factor 2-3 or more when the individuals are not completely fasting (table I A) during a critical period of about 10 h before and 2 h after the administration of the test dose. Dietary and secretory factors seem to render the divalent iron ascorbate less easily absorbable [8] Unregulated intraluminal inhibition of iron absorption is to be suspected when low or normal values are found in subjects with hyposiderosis, but corresponding observations can be made in every group. These irregular effects disappear usually in the course of repeated examinations after the confrontation of the subjects with the probable cause of abnormal results. Unexpected isolated malabsorption of iron as found in two sisters with long standing iron deficiency anaemia and poor response to oral iron for several years

(table IV) should be established by normal or low values in more than one test. In prelatent iron deficiency normal ^{59}Fe retention (table IV) can increase with progression of iron deficiency (functional disturbance?)

2. Heavy blood losses during the first 14 to 21 days after iron loading and ^{59}Fe whole body turnover rates of more than 1-2% daily can lead to erroneously too low results in measurement of iron absorption.

3. The diffuse cytoplasmatic Prussian blue reaction of bone marrow reticulo-endothelial cells is more closely correlated with the ^{59}Fe retention test than the polymorphous haemosiderin particles, mobilized slowly (table II, fig 2). These findings are of clinical significance because important work on the evaluation of iron stores has been done using unstained preparations which reveal the haemosiderin aggregates only [3, 28, 30]. Except by BRUTLER *et al.* [4] it has been not described [10, 23, 27, 29, 32] whether or to what extent the diffuse iron is included into cytochemical grading of iron.

4. To obtain groups with distinct diagnostic ranges of iron absorption it is necessary to classify exhausted iron stores with normal plasma iron and red cell indices as the first, 'prelatent' stage of iron deficiency which is a frequently observed symptomatic, co-morbid and co-normal phenomenon showing increased iron retention. Without this manipulation adequate organization of data is much more difficult.

For practical purposes cytochemical grading of non haeme iron in bone marrow reticuloendothelial cells as described can be regarded as the most appropriate single reference system for the clinical interpretation of iron absorption levels (table IV). The disappearance of a faint blue diffuse staining of bone marrow fragments and isolated macrophages in more than 25 to 50% of comparable microscopic fields coincided with an increase of iron absorption over 50% (table I, III, fig 2). This criterium seems to be a suitable dividing line between normosiderosis and hyposiderosis (fig 2). Consideration of the total or unsaturated iron binding capacity gives less clear cut results in the diagnosis of early iron deficiency.

In 93% of the subjects examined the findings indicate that iron absorption is regulated in relation to the reticuloendothelial iron deposits which are present in the bone marrow, liver, spleen and the lamina propria of the duodenal and jejunal mucosa. This rule concerns healthy subjects and the majority of diseases independent of age and sex. The iron storing capacity of the subepithelial macrophages in the

upper small intestine after oral or parenteral iron administration in animal experiments has been studied histochemically 100-40 years ago by numerous authors in relation to questions of iron absorption and iron excretion [2, 7, 18, 25]. Recently interest in these cells has been revived [1, 2, 7, 9, 25, 34]. The subepithelial macrophages are thought to act as transitory iron stores in iron absorption [2] or to contribute to iron excretion in iron overload when they transverse the columnar epithelium [1, 2, 9]. Intravenous application of 1.0-3.5 g saccharated iron oxide normalizes the increased iron absorption in all stages of iron deficiency (table I). Diffuse iron similar to that of the bone marrow has been seen in squash preparations and sections of biopsy material obtained during surgery from the jejunum only in the tips of the villi [unpublished]. Uniform sized iron granules smaller than the corresponding particles in the marrow were observed in the adjacent endothelial cells. Furthermore the subepithelial RES is suspected to phagocytize red cells.

The available data indicate that except in far advanced chronic leukemia (table IV) and severe osteomyelosclerosis the diffuse reticulo-endothelial iron of the marrow reflects rather reliably the intestinal subepithelial iron pool connected with mucosal inhibition of iron absorption when the macrophages are located in the tips of the villi, but probably less effective when these cells are dispersed irregularly within the lamina propria [1]. It is therefore not surprising that splenectomy removing a considerable part of the iron storing RES does not influence iron absorption. A proportionate negative feed back is suggested to occur in the tips of villi between the subendothelial RES cells iron laden from different sources (iron absorbed from the lumen, aged red cells and colloidal iron taken up from the blood vessels) and the absorbing epithelium iron laden in part in relation to the plasma iron [9]. This working hypothesis is flexible enough to explain the findings reported and to induce further studies.

A normal or elevated plasma iron up to 270 $\mu\text{g}\%$ does not substitute depleted iron stores in regulation of iron absorption as shown in prelatent iron deficiency (table III) (feed back deficiency). On the other hand in malignant diseases and infections normal or increased iron stores are sufficient to compensate extreme hypsideraemia which did not increase iron absorption in these cases [14] (feed back enhanced). In acute bleeding anaemia only or in pernicious anaemia after treatment with vitamin B_{12} during reticulocytosis low plasma

iron and anaemia seem to act additively to elevate iron absorption before the iron stores are exhausted [unpublished]. The increase of iron absorption into sideropenic range observed in a varying percentage of patients with sideroachrestic anaemia, pernicious anaemia, and haemolytic anaemia (table IV) despite of normosiderosis or different degrees of hyperosiderosis, but not in hypoplastic anaemia [13] can be attributed to the combined effect of severe anaemia, high plasma iron turnover and unequal distribution of iron within the RES (Inhibition of feed back?) In such cases it remains to be explored whether histochemistry and cytochemistry of non haeme iron in the intestinal mucosa can reveal morphological differences to haemochromatosis [17-34]. In the latter condition a hereditary or acquired feed back insufficiency with increased ^{59}Fe retention can perhaps be compensated by further increase of iron overload leading to normal absorption again [5]. Studies on the correlations between the diagnostic criteria of iron metabolism including the histochemistry and cytochemistry on iron in the columnar epithelium, the macrophages and the endothelial cells of the mucosa of the upper small intestine, will probably give more detailed insight in the regulation of iron absorption, but it should be considered that the Prussian blue reaction reveals only a part of the non haeme iron.

Summary

The diagnostic criteria of iron metabolism have been compared in 780 subjects (normal controls, patients with blood diseases, liver diseases, malignant diseases and infections). A high negative correlation has been computed between the diffuse Prussian blue reaction of bone marrow reticuloendothelial cells and the intestinal iron absorption. In 93% of the individuals examined the results indicate that iron absorption is regulated in relation to the reticuloendothelial iron stores in normal controls and the vast majority of diseases.

References

1. ASTALDI, G.; MEARIN, G. and LARRO, T. The iron content of jejunal mucosa obtained by Crosby biopsy in hemochromatosis and hemosiderosis. *Blood* 27: 70 (1966).
2. ASTALDI, G.; MEARIN, G.; T. VERHA, P. L. and ARZO, R. Eisenachrestie in der Dünndarmkrankheit. *Med. Klin.* 62: 1339 (1967).
3. BARTON, E. F. and FISCH, C. A. The diagnosis of iron deficiency anemia. *Amer. J. Med.* 37: 82 (1964).
4. BEUTLER, E.; ROSSON, J. M. and BUTTERWORTH, E. A comparison of plasma iron, iron-binding capacity, serum iron and other methods in the clinical evaluation of iron stores. *Ann. Intern. Med.* 48: 60 (1958).

5. BOTHEWELL, T. H. and FURCH, C. A. Iron Metabolism (Little, Brown, Boston 1963)
6. CARAWAY W. T. Macro and mikro methods for the determination of serum iron and iron-binding capacity. Clin. Chem. 9: 168 (1963)
7. CATTAN, D., DERRAY G., JOUR, J. P. et MARCIE, C.: Considérations sur le mécanisme régulateur de l'absorption intestinale de fer. Importance des macropinages du chorion villositaire. Une nouvelle théorie. Bull. Soc. méd. Hôp., Paris 116: 1635 (1963).
8. COOPER, M. E. and SCHADE, S. G. Ascorbic acid chelates in iron absorption. A role for hydrochloric acid and bile. Gastroenterology 33: 35 (1968).
9. CROFT, W. H. Mucosal block. An evaluation of concepts relating to control of iron absorption. Sem. Hematol. 4: 299 (1963).
10. HANSEN, H. A. and WEDFELD, A.: Hemosiderin estimations and sideroblast counts in the differential diagnosis of iron deficiency and other anemias. Acta med. scand. 163: 333 (1959).
11. HADMANN, K. Zytochemie des Nichtthromboglobulins und intestinale Eiseneresorption. Amsterdam, Symp. Ges. Histochemie, Hamburg 1968 (in press).
12. HADMANN, K. und KUHL, R. Eiseneresorption bei Blutkrankheiten. Klinische Interpretation der mit dem Gesamtkörper-Radioaktivitätsdetektor erhaltenen Ergebnisse. 12. Tagg. d. Ges. Haemat., Berlin 1966.
13. HADMANN, K.; KUHL, R., BARTELA, H. und HEIDRICH, H. C. Zytochemie des Nichtthromboglobulins, allgemeine klinische Faktoren und intestinale Eiseneresorption bei sideroachroischer Anämie. 13. Tagg. d. Ges. Haemat., Ulm 1968, p. 42 (Lehmann, München 1969).
14. HADMANN, K.; KUHL, R., BARTELA, H. und HEIDRICH, H. C.: Zytochemie des Nichtthromboglobulins, allgemeine klinische Faktoren und intestinale Eiseneresorption bei Lymphogranulomatose, Tumoren und Infekten. 13. Tagg. d. Ges. Haemat., Ulm 1968, p. 237 (Lehmann, München 1969).
15. HEIDRICH, H. C. und BARTELA, H. Bestimmung und Normalbereich der intestinalen Eiseneresorption beim Menschen bei Verwendung des ^{59}Fe -Resorptions-Gesamtkörperretentionsrates. 12. Tagg. d. Ges. Haemat., Berlin 1966.
16. HEIDRICH, H. C. und BARTELA, H. Bestimmungsmethoden und Normalbereiche der intestinalen Eiseneresorption beim Menschen. Eine kritische Übersicht. Klin. Wochschr. 45: 553 (1967).
17. HEIDRICH, H. C., GABER, E. E., MEINCK, B. und WELAND, D. H.: Die empfindliche und präzise Bestimmung der intestinalen Eiseneresorption bei Menschen durch ^{59}Fe -Gesamtkörperretensionsmessung in einem 4-Örörmigen-Radioaktivitäts-Detektor. Klin. Wochschr. 44: 627 (1966).
18. HODGKINS, R. und QUONCY, E. Über Eisen-Resorption und Ausscheidung im Darmkanal. Arch. exp. Path. Pharmacol. 37: 159 (1956).
19. HORST, P. Factor analysis of data matrices (New York 1963)
20. KIRBY, K., MOWAT, E. R., COOK, J. D. and FURCH, C. A. Iron absorption in man. J. Lab. clin. Med. 71: 713 (1968).
21. LUDWIG, H., HADMANN, K., FIEBELMANN, V., HEIDRICH, H. C. und BARTELA, H. Eiseneresorptionsstudien bei chronischen Lebererkrankungen. Verh. 24. Tagg. d. Ges. Verdau.-Stoffwechselerkrankh., p. 332 (Thieme, Stuttgart 1968)
22. LÜCK, H. Zum Eisenschwefel in Blut und Gewebsausstrichen. Schwed. med. Wochschr. 82: 1127 (1952).
23. LUNDQVIST, P., PERSSON, E. and WEDFELD, A. Comparison of hemosiderin estimation in bone marrow sections and bone marrow smears. Acta med. scand. 173: 383 (1964).
24. MANNHOFF, E. Eisenstoffwechsel und Leber. Verh. d. Ges. Verdau.-Stoffwechselerkrankh. 17: 3 (1954).
25. MOCCHIGLIANO, C. Villonite intestinale et métabolisme du fer. Rev. Hémat. 15: 472 (1960).

26. PETERS, T.; GIOVANELLO, T. J.; APT, L. and ROM, J. F.: A simple improved method for the determination of serum iron. *J. Lab. clin. Med.* 48: 280 (1956).
27. PRATT, P. T. and JOHNSON, M. E.: Marrow iron stores in anemia. *Arch. Intern. Med.* 93: 725 (1954).
28. RATE, C. E. and FOSCH, C. A.: Sternal marrow hemosiderin. A method for the determination of available iron stores in man. *J. Lab. clin. Med.* 32: 81 (1948).
29. SACHS, L.: *Statistische Auswertungsmethoden* (Springer Berlin/Heidelberg/New York 1968).
30. STEVENS, A. R.; COLEMAN, D. H. and FOSCH, C. A.: Iron metabolism. Clinical evaluation of iron stores. *Ann. Intern. Med.* 39: 199 (1953).
31. WALLERSTEIN, R. O. and POLLYDOVE, M.: Bone marrow hemosiderin and ferrokinetic patterns in anemia. *Arch. Intern. Med.* 101: 418 (1956).
32. WEDVOLD, A.: Storage iron in man. *Acta med. scand. Suppl.* 47: 1 (1964).
33. WEDVOLD, A. and HAMMAR, H. A.: Further studies on the interrelationship between hemosiderin and sideroblasts in bone marrow smears. *Acta med. scand.* 171: 23 (1962).
34. WÖHLER, R.; HEILMEYER, L.; EHRICH, D. and KAMM, S. H.: Zur Funktion des Ferritin bei der Eisenaufnahme. *Arch. exp. Path. Pharmacol.* 23: 107 (1957).

Authors' addresses: Dr. K. HAUBMANN and Dr. R. KUM, Hämatologische Abteilung, Allg. Krankenhaus St. Georg, 2 Hamburg 1; O. W. SCHUMACHER, Rechenzentrum der Universität, Dr. H. BARTHEL and Prof. H. C. HEIDRICH, Abteilung für Med. Biochemie, Physiol.-chem. Institut der Universitätsklinik Eppendorf, 2 Hamburg 20 (Germany).

Medizinische Universitätsklinik (Direktor Prof. H. E. Bock) Tübingen

Zytologische Untersuchungen zur Diagnostik und Ätiologie der Erythroleukämie

D MÜLLER¹

Über das Syndrom Erythroleukämie liegen zahlreiche Veröffentlichungen vor. Publierte Krankheitsabläufe und angewandte Nomenklatur weichen jedoch z.T. erheblich voneinander ab [1-6]. Nach HEILMEYER [3] handelt es sich bei Erythroleukämien um neoplastische Bluterkrankungen, bei denen die Erythropoese isoliert wie bei der akuten Erythrmie DI GUOLIELMO und der chronischen Erythroblastose HEILMEYER-SCHÖNER [4] oder zusammen mit anderen Zellsystemen befallen ist. DAMESHER und GUNZ [2] nehmen an, dass alle Formen nur verschiedene Stadien einer Erkrankung darstellen, wobei der Beginn als Erythrmie, spätere Phasen als finaler Myeloblastenschub [5] imponieren können. Sie wenden sich damit indirekt gegen die Existenz einer isolierten Erkrankung der Erythropoese und setzen eine gleichzeitige leukämische Umwandlung weisser und roter Blutzellen voraus.

Wann ist man aber berechtigt, bei vermehrtem Auftreten roter Vorstufen im Blut und Knochenmark im Ablauf einer akuten Leukämie das Vorliegen einer echten Erythroleukämie anzunehmen und eine Begleterythroblastose gleich welcher Genese auszuschliessen? In den letzten Jahren sind an leukämischen Zellen neue zytologische Befunde erhoben worden, die an den roten Vorstufen bei Kranken mit akuter Leukämie für die Diskussion um das Krankheitsbild Erythroleukämie zu überprüfen sind. 1. Gegenüber der normalen Granulopoese finden sich bei leukämischen Zellen eingreifende Veränderungen in der Art

und Weise der Zellvermehrung. Dies konnte durch zahlreiche Untersuchungen vorwiegend nach ^3H Thymidin-Inkubation gesichert werden [7-11]. 2. Bestehen in einer erheblichen Anzahl akuter Leukämien Chromosomenaberrationen, die die pathologische Entwicklung dieser Zellen unterstreicht. Bei chronisch myelosen Leukämien tritt fast regelmäßig das Philadelphia-Chromosom [12] auf, das deshalb als pathognomonisch für diese Erkrankung angesehen werden kann, wenngleich auch Ausnahmen beschrieben sind [13, 14]. 3. Schließlich gestatten moderne zytochemische Untersuchungen eine immer eingehendere und detailliertere Unterscheidung der Blutzellen, wobei allerdings Untersuchungen an verschiedenen Formen akuter Leukämien [15-17] gezeigt haben, dass die leukämisch entarteten Zellen in ihrer zytochemischen Beschaffenheit auffallende Ähnlichkeit mit dem Ausgangs- bzw. Muttergewebe aufweisen.

Methodik

1. Qualitative zytochemische Untersuchungen: alkalische Phosphatase, Asotkuppelungsreaktion nach KARLOW [18], Methode nach MARX und HEMMERL [19]; saure Phosphatase nach LÖNNER und BUCHHEIM [20]; alpha-Naphthylacetesterase, Methode nach LÖNNER [21]; PAS-Nachweis [22]; Sideroblasten-Nachweis [23] mit der Berliner-Blau-Reaktion.

2. Semiquantitativer Nachweis der Kern-DNS mit Hilfe der Feigen-Reaktion [24]: Formal-Fixation, 12 min (9-15 min) Hydrolyse in 1 M HCl bei exakt 60°C (Thermostat) 60 min Inkubation in Schiff'schem Reagens, Waschen in Kaliumacetatpuffer, aufsteigende Alkoholreihe, Eindecken in Caden (n/D 20° = 1,55) [25]. Erythrophotometrie mit dem Mikrospektrophotometer UVSF I von Zeiss [25, 26].

Krankengut

Von den in den letzten Jahren beobachteten Patienten mit akuter Leukämie wurden bei 56 nicht ausgewählten Fällen zytochemische Untersuchungen durchgeführt. Vergleichende Untersuchungen an Erythroblasten wurden bei 24 Patienten durchgeführt, bei denen der Anteil roter Vorstufen im Knochenmark im Krankheitsablauf z. T. über 10% lag. Bei 4 dieser Kranken wurden gleichzeitig quantitative DNS-Untersuchungen nach Feulgenphotometrie in der oben angegebenen Methodik angeführt. Zur Auswertung der Messergebnisse siehe bei [26]. Für Vergleichsuntersuchungen wurden Kranke mit normaler Erythro- und Granulopoese sowie mit sideroachretischen Anfällen [27] herangezogen.

Befunde

Die zytologische Differenzierung der akuten Leukämien erfolgte nach den früher angegebenen Kriterien [27]. Die Ergebnisse qualitativer zytochemischer Untersuchungen

Tabelle 1 Qualitative zytochemische Untersuchungsergebnisse an der Erythropoese bei akuten Leukämien

Leukämieform zytochemisch differenziert	Fallzahl	Reti /oo	Normoblasten in der Peri- pherie, %	Knochenmarkbefund			
				Anteil roter Vorstufen auf 100 weiße Zellen	Sideroblasten % (normal: 20-40)	PAS + rote Vorstufen % (normal < 2)	stark (++++) α-Naphthylace- tasetest-positiv rote Vorstufen (Fallzahl)
Undiff.	3	10,6	1,1	19,3	30,3	6,9	0
Myeloisch	11	18,8	1,8	10,5	34,1	10,6	2
Monocytoid	2	30,5	< 1	18,0	37,0	4,5	0
Lymphoid	8	13,8	< 1	5,7	37,0	5,7	0

methoden an der Erythropoese bei akuten Leukämien gehen aus Tabelle 1 hervor. Eine stark positive Esterasereaktion (++++) findet sich im Zytoplasma roter Vorstufen bei 2 Kranken mit myeloischen Paraneublastenleukämien. Ebenfalls findet sich der höchste Anteil PAS-positiver Erythroblasten bei myeloischen Paraneublastenleukämien. Der Anteil der Sideroblasten liegt im Durchschnitt aller Fälle im oberen Normbereich. Eine sichere Beziehung zwischen diesen zytochemischen Befunden und dem Anteil der roten Vorstufen im Knochenmark sowie dem Prozentsatz der in der Peripherie nachgewiesenen Normoblasten und Retikulozyten besteht nicht (Tab. 1).

Bei quantitativen Feulgen-photometrischen DNS-Bestimmungen in der Einzelzelle weist die Mehrzahl normaler Myelocyten, Promyelocyten und Myeloblasten bei der von uns angewandten Methodik der Zytophotometrie bei 29 Kontrollen einen Mittelwert von 33,0 Arbeitseinheiten (AE) auf ($33,0 \pm 2,8$ AE, Toleranzbereich 95% für 95% der Verteilung [27]). Der Rest der Zellen zeigt eine höhere Feulgensanfärbung. In nicht mehr teilungsfähigen segmentkernigen Granulocyten liegt die Feulgensanfärbung niedriger ($31,1 \pm 0,8$ AE im Durchschnitt von 10 Fällen [27]). Dasselbe gilt für nicht mehr teilungsfähige Normoblasten [27], weshalb die Mehrzahl aller kernhaltigen roten Vorstufen im Durchschnitt eine geringere Feulgensanfärbung ($32,0$ AE [27]) als Myelocyten, Promyelocyten und Myeloblasten aufweist. Das Maximum der Feulgensanfärbung wird in segmentkernigen Granulocyten, Granulocytenvorstufen und in roten Vorstufen nach einer 12minütigen Hydrolyse erreicht. Eine Hydrolysedauer von 9 wie von 15 min ergibt eine niedrigere Feulgensanfärbung.

Bei 4 Kranken mit akuter Leukämie ist die stärkste Anfärbung der Paraneublasten einmal über den Toleranzbereich normaler Granulocytenvorstufen erhöht, zweimal im oberen Normbereich und einmal im unteren Normbereich gelegen (Tab. II, Abb. 1). Die Feulgensanfärbung der Erythroblasten liegt in allen 4 Fällen gleichartige Verteilungen. Die stärkste Feulgensanfärbung ist in 2 Fällen erst nach 15 min Salzsäure-Hydrolyse erreicht. Leukämiezellen und Erythroblasten verhalten sich identisch, während die am gleichen Präparat untersuchten segmentkernigen Granulocyten wie bei den normalen Kontrollen ihre stärkste Feulgensanfärbung nach 12minütiger Hydrolysedauer aufweisen.

Der Zellanteil mit erhöhter Feulgensanfärbung als Zeichen der primären DNS-Synthese war in den selben Fällen (von denen 3 noch unbehandelt waren) bei den Paraneublasten und auch bei den roten Vorstufen gegenüber normalen Kontrollen verschleiert (Tab. II, Abb. 1).

Tabelle II. Qualitative und quantitative zytochemische Befunde bei 4 Kranken mit akuter Leukämie

	Myeloische Paraleuko- blastenleukämie Ra. ♂ 42J		Monos. Para- leukobl. L. Kr. ♀ 52J	Undiff. Pa- raleukobl. L. Ve. ♀ 37J
Peripheres Blut				
Rcti, %	6	20	5	14
Normoblasten, %	3	12	0	2,5
Knochenmark				
Anteil roter Vorstufen auf 100 weisse Zellen	7	45,0	7	31
Sideroblasten, %	50	8	12	46
PAS + rote Vorstufen, %	12	34	8	3
Stark (++++)				
α -Naphthylacetasesterase positive rote Vorstufen	0	+	0	0
Mittlerer DNS-Gehalt in Feulgen-AE in				
G ₁ -Paraleukoblasten	39,4	32,9	37,1	37,2
G ₂ -Erythroblasten	37,7	32,3	36,7	34,4
Zur stärksten Feulgenanfärbung erforderliche Hydrolysezeit, min				
Paraleukoblasten	12	9	15	15
Erythroblasten	12	12	15	12
Vorstufen mit erhöhter Feulgenan- färbung als Zeichen der DNS-Synthese, %				
Paraleukoblasten	< 1	3	1,5	< 1
Erythroblasten	7	14	2	17

Normale Myeloblasten, Promyelocyten, Myelocyten 35,0 \pm 2,0 AE [27]; rote Vorstufen 32,0 AE [27].

Normale Myeloblasten, Promyelocyten, Myelocyten 37,1% (Mittelwert von 12 Fällen [27]), normale rote Vorstufen 33,5% (Mittelwert von 7 Fällen [27]).

Diskussion

Bei Kranken mit akuter Leukämie wurden qualitativ und quantitativ zytochemische Untersuchungen unter der Fragestellung durchgeführt, ob mit den angewandten Methoden eine leukämische Umwandlung in der Erythropoese erkannt werden kann. Die Suche nach




Abb. 1 DNS-Gehalt in weissen und roten Vorstufen des Knochenmarks. Ordinate = Zellzahl, Abszisse = relativer DNS-Gehalt in Feulgen-AE. Oben: erhöhter DNS-Gehalt in weissen und roten Vorstufen bei myel. Paraleukoblastenleukämie. Sehr wenig Zellen mit höherem DNS-Gehalt als Zeichen der interphasischen DNS-Replikation. Unten: normale segmentkernige Granulozyten. Feulgenfärbung nach 12 min. Salzsäurehydrolyse.

objektiven Kriterien zur Beantwortung dieser Frage gründet sich darauf, dass rein morphologische Kriterien keine ausreichende Antwort bieten können. Die rein zahlenmäßige Vermehrung roter Vorstufen in der Blutperipherie mag in einzelnen Fällen beweisend für das Vorliegen einer Erythroleukämie sein. Wie verhält es sich aber wenn durch eine zytostatische Therapie sowohl der Anteil leukämischer weisser Blutzellen wie der Anteil roter Vorstufen in der Blutperipherie vermindert ist, oder wenn es sich, wie bei einem Teil der akuten Leukämien, von Beginn an um eine leukopenische Verlaufsform handelt? Wie reagieren in diesem Fall die roten Vorstufen? Auch die qualitativen Kriterien in der Morphologie der roten Vorstufen nach Pappenheimfärbung sind zum Teil subjektiv und kaum geeignet, als einziger Parameter für die Diagnostik einer Erythroleukämie zu dienen.

Nachdem verschiedene zytologische Untersuchungsmethoden in der Hämatologie Eingang fanden, wurden diese Techniken auch für die Differenzierung von Erythroleukämien herangezogen. HAYHOZ *et al.* [28] die 140 Kranke mit akuter Leukämie untersuchten, fanden in Fällen mit reichlich roten Vorstufen in der Blutperipherie gehäuft PAS-positive Substanzen im Zytoplasma der Erythroblasten. Dieser Befund wurde von VZALOOF [29] bestätigt und eine gleichzeitige Vermehrung der Sideroblastenzahl beschrieben. Schließlich fand LEXER [31] dass sich in den Erythroblasten bei Erythroleukämien eine besonders hohe Aktivität der alpha Naphthylacetatesterase im Zytoplasma nachweisen lässt.

Ähnliche Befunde wurden von uns an den Erythroblasten bei allen Kranken mit akuten Leukämien erhoben. Sie können deshalb nicht spezifisch für das Vorliegen «leukämischer» Erythroblasten sein. So fanden KLEIN *et al.* [30] fast stets PAS-positive Substanzen, also eine Anhäufung von Glykogen, Gluko- und Mukoproteinen in nekrobiotischen Erythroblasten. Da solche Zellen nicht mehr weiter ausreifen, ist dieser Befund ein Zeichen einer ineffektiven Erythropoese. Dem entspricht der Nachweis PAS-positiver Substanzen im Zytoplasma roter Vorstufen bei sideroachrestischen Anämien [29] bei denen das Vorliegen einer ineffektiven Erythropoese durch ferrokinetische Untersuchungen bekannt ist. Dieser Befund kann damit keineswegs spezifisch für eine Erythroleukämie sein.

Auch die Vermehrung der Sideroblasten weist lediglich auf eine Störung der Eisenutilisation bei der Hämoglobinsynthese hin. Bestehen bleibt die von LEXER [31] angegebene erhöhte alpha Naphthylacetat esteraseaktivität in «leukämischen» Erythroblasten, die in der Literatur bisher noch wenig diskutiert wurde.

Bei der Abgrenzung einer Erythroleukämie mit zytochemischen Methoden betonen deshalb auch HAYHOZ *et al.* [28] dass die Übergänge zwischen den Fällen mit einem hohen und einem niedrigen Anteil PAS-positiver Erythroblasten fließend sind. Es handelt sich um ein durch nichts begründetes Postulat, wenn die Autoren bei einem Anteil von 10 und mehr Prozent PAS-positiver Erythroblasten das Vorliegen einer Erythroleukämie annehmen. So nimmt es nicht wunder dass die eigenen qualitativen zytochemischen Untersuchungsergebnisse eine eindeutige Differenzierung einer Erythroleukämie nicht ermöglichen. Den höchsten Anteil PAS-positiver roter Vorstufen beobachteten wir unter den myeloiden Paraleukoblasten-

leukämien aber auch im Durchschnitt der anders differenzierten Leukämieformen fanden sich noch mehr als 5% PAS-positive rote Vorstufen. Die Sideroblasten waren zum Teil deutlich vermehrt, wiesen aber auch Beziehungen zur wechselnden Höhe des Eisenspiegels im Serum auf. Sehr stark Esterase positive rote Vorstufen fanden sich nur in zwei Fällen.

Eine schwere Störung in der Art der Zellneubildung wurde durch autoradiographische Untersuchungen mit ^3H Thymidin von zahlreichen Autoren [7-11] bei leukämischen Zellen nachgewiesen. Im Gegensatz zu den normalen Blutzellen stehen viel weniger leukämische Zellen in der Phase der prämitotischen DNS-Synthese. Dadurch ist zwar die Zellneubildung verlangsamt, durch eine gleichzeitige Störung der Zellausreifung bleiben jedoch mehr Zellen weiter teilungsfähig, weshalb es trotzdem zu einer schnellen Vermehrung der Gesamtzellzahl kommen kann. Ein herabgesetzter Anteil roter Vorstufen in DNS-Synthese wurde nach ^3H Thymidin Autoradiographie von GAVOSTO *et al.* [41] auch bei 2 Kranken mit einem DI GUILLAINO-Syndrom beobachtet. Unsere Untersuchungen an der Erythropoese bei 4 Kranken mit einer akuten Leukämie zeigten einen herabgesetzten Anteil roter Vorstufen wie Paraleukoblasten in DNS-Synthese (Tab. II). Nur einer dieser Fälle liess klinisch an das Vorliegen einer Erythroleukämie denken. Da drei der Kranken noch unbehandelt waren, kann der Befund nicht durch eine zytostatische Therapie verursacht sein. Die einzige Erklärung für diese Beobachtung scheint die Annahme einer gleichartig auftretenden Störung der Zellregeneration in verschiedenen Blutzellsystemen während der Leukämogenese zu sein.

Strukturelle und numerische Chromosomenaberrationen werden bei leukämischen Erkrankungen häufig beobachtet [32]. Sie treten auch bei Erythroleukämien auf. Da aber eine sichere Zelldifferenzierung an der gestreuten Metaphase in der Zellkultur wie am Knochenmark Direktpräparat nicht möglich ist, gelingt eine eindeutige Zuordnung einer ausgezählten Metaphase zur Granulo- oder Erythropoese im Einzelfall nicht. Deshalb kommt bei der engen Korrelation zwischen DNS-Gehalt und Chromosomenzahl [35] den eigenen getrennten quantitativen feulgenphotometrischen Kern-DNS-Messungen in den roten und weissen Vorstufen bei akuten Leukämien eine besondere Bedeutung zu. Bei allen 4 Kranken mit einer akuten Leukämie fanden wir enge Beziehungen zwischen dem DNS-Gehalt der leukämischen Blasten und dem der roten Vorstufen und zwar so-

wohl bei zwei myeloischen Paraleukoblastenleukämien als auch bei einer monozytoiden Paraleukoblastenleukämie und einer nicht näher differenzierbaren akuten Leukämie. Ausserdem zeigten sich an der Erythropoese gleichartige qualitative Veränderungen des Kernchromatins wie an den leukämischen Blasten. Bei zwei Kranken mit einer myeloischen Paraleukoblastenleukämie fand sich in leukämischen Blasten wie in der Erythropoese die stärkste Feulgenanfärbung nach 12 min Salzsäurehydrolyse. Bei einem Kranken mit einer monozytoiden Paraleukoblastenleukämie und einem anderen Kranken mit einer undifferenzierten Paraleukoblastenleukämie war die stärkste Feulgenanfärbung der leukämischen Blasten wie der roten Vorstufen erst nach 15 min erreicht. Dabei sprach gegen einen technischen Fehler das unveränderte Verhalten der verbliebenen normalen segmentkernigen Granukozyten (Anfärbung nach 12 min stärker als nach 15 min Hydrolyse). Ob die Empfindlichkeitsänderung der DNS gegenüber Salzsäurehydrolyse durch eine veränderte molekulare DNS-Histon-Bildung verursacht ist, lässt sich nicht sagen. Von Bedeutung ist jedoch das gleichartige Verhalten roter Vorstufen und pathologischer weisser Blutzellen.

Die quantitativen feulgenphotometrischen DNS-Befunde in der Erythropoese bei akuten Leukämien lassen uns den Schluss ziehen, dass im Einzelfall eine sichere Unterscheidung zwischen einer «leukämisch entarteten» Erythropoese und einer normalen Erythropoese bei Leukämie nicht möglich ist [a. a. 43-49]. Die roten Vorstufen zeigen viel mehr bei den von uns untersuchten Fällen Veränderungen, die den pathologischen Befunden an den leukämischen weissen Blutzellen ähneln. Wir sehen darin einen Hinweis dafür, dass die leukämische Zellumwandlung nicht ein Zellsystem sondern mehrere Blutzellsysteme gemeinsam erfasst und nur in einem Zellsystem stärker in Erscheinung tritt. Für diese Annahme sprechen die folgenden Überlegungen. Ein Philadelphia-Chromosom als scheinbar leukämiespezifische Chromosomenaberration wurde schon vor Jahren nicht nur in den weissen Blutzellen sondern auch in roten Vorstufen [34] ohne einen Anhalt für eine «leukämische» Erythropoese gefunden. Die hier beschriebenen qualitativen und quantitativen DNS-Befunde sind in Paraleukoblasten wie in roten Vorstufen bei myeloischer und monozytoider Paraleukoblastenleukämie gleichartig. Eine Störung der Zellneubildung findet sich in den weissen und roten Blutzellen. Ähnliche Veränderungen der Zellregeneration und des Kernchromatins mit Chromo-

somenabberationen [36-37] werden in der Erythro- und Granulopoese bei Panzytopenien beobachtet [27-42] die manche Autoren als präleukämische Stadien ansehen [37-40].

Zusammenfassung

Bei 24 Kranken mit akuter Leukämie wurden cytochemische Untersuchungen an der Erythropoese durchgeführt. Es fand sich eine Zunahme PAS-positiver Erythroblasten, Sideroblasten und stark Esterase-positiver Erythroblasten. Feulgen-photometrische DNA-Untersuchungen zeigten in der Erythropoese ähnliche Veränderungen des Kernchromatins wie in den leukämischen Blasten. Der Anteil roter Vorstufen in prämitotischer DNA-Synthese war ähnlich wie in den leukämischen Blasten herabgesetzt.

Die fließenden Übergänge zwischen normalen und pathologischen Befunden in der Erythropoese lassen eine Differenzierung zwischen Leukämie und Erythroleukämie mit den angewandten Methoden nicht zu. Die an roten Blutzellen wie an Paraleukoblasten beobachteten ähnlichen Veränderungen stützen die Vorstellung, dass es während der Leukämieentstehung zu einer gleichartigen Störung an granulopoetischen, monocytyären und erythropoetischen Zellen kommt.

Summary

Cytochemical studies of erythropoiesis were carried out on 24 patients with acute leukaemia. Increased numbers of PAS-positive erythroblasts, sideroblasts and strongly esterase-positive erythroblasts were seen. Determination of DNA by the Feulgen photometric method showed similar changes in erythropoiesis as in leukaemic blast cells. The proportion of red precursors in premitotic DNA synthesis was reduced as in leukaemic blast.

The continuous transition from normal to pathological findings in erythropoiesis make it impossible to distinguish between leukaemia and erythroleukaemia by the methods used. The similar changes observed in red cells and paraleukoblasts lend support to the view that there is simultaneous disturbance of monocytes, granulopoietic, and erythropoietic cells in the development of leukaemia.

Literatur

1. GUILLIEMO, de, G. *Le eritremie*. Haematologica 9, 301-308 (1928).
2. DANCIGER, W. and GUNZ, F. *Leukemia*. 2nd ed. (Grune & Stratton, New York 1964).
3. HEILMEYER, L. and BROHMANN, H. Blut und Blutkrankheiten. In *Hdb. exp. Med.*, 4. Aufl., vol. 2 (Springer Berlin/Heidelberg/Göttingen 1951).
4. HEILMEYER, L. and SCHÖNER, W. Die chronische reine Erythroblastose des Erwachsenen als leukämieparalleler Prozess des erythrocytären Systems. *Dtsch. Arch. klin. Med.* 187, 225-248 (1941).
5. WINTROW, M. M. *Clinical hematology*. 5th ed. (Lippincott Philadelphia 1961).
6. MÖNCHHELD, S. Erythroblastosen, Erythroleukämien und Erythroblastämien. *Folia haemat.*, Lpz. 64, 267-302 (1940).
7. GAVOTTO, F.; FILLER, A.; ALABANO, G. Incorporazione dei clonisti anarcati con

- trizio negli elementi del midollo osseo normale. *Leucemia. Indagini autoradiografiche. Haematologica* 44: 977-992 (1959).
8. GAVOTTO, F.; PILERI, A.; BACCI, G. and PROGIAMO, L.: Proliferation and maturation defect in acute leukaemic cells. *Nature, Lond.* 203: 92-94 (1964).
 9. KILLMAN, S. A.; CHOKKITE, E. B.; BOWN, V. P. and FLEISHER, T. M.: Proliferation of human leukaemic cells studied with tritiated thymidine *in vivo*. *Proc. VIIIth Congr. europ. Soc. Haemat., Vienna 1961* (Karger Basel/New York 1962).
 10. LAYTEA, L. G.: Kinetics of bone marrow stem cell population with reference to leukaemia. *Cancer* 15: 139-144 (1962).
 11. MACER, A. M., LAMPSON, B. C. and SAUNDERS, E. F.: Kinetics of leukaemic cells. *XIth Congr. int. Soc. Haemat., Sydney 1966, Plenary sessions*, pp. 42-47 (Bligh, Sidney 1966).
 12. NOWELL, P. C. and HENRICHSSEN, D. A.: A minor chromosome in human chronic granulocytic leukemia. *Science* 132: 1497 (1960).
 13. HEATH, C. W. J. and MOLONEY W. C.: The Philadelphia chromosome in an unusual case of myeloproliferative disease. *Blood* 25: 471-478 (1963).
 14. KEMP, N. H.; STAFFORD, J. L. and TAYLOR, R.: Chromosome studies during early and terminal chronic myeloid leukaemia. *Brit. med. J.* n. 1010-1014 (1964).
 15. LÖFFLER, H.: Zur Differenzierung unreiferer (akuter) Leukemien mit cytochemischen Methoden. Vortrag 8. Tag. deutsch. Ges. Hämatol., 1962. *Folia haemat., N.F.* 6: 112-117 (1963).
 16. MÜLLER, D.: Zur Morphologie und Differenzierung leukämischer Zellen. *Klin. Woch.* 45: 192-199 (1967).
 17. MÜLLER, D.: Die zytologische Differentialdiagnose leukämischer Erkrankungen. *Dtsch. med. Woch.* 93: 1769-1771 (1968).
 18. KARLOW, L. S.: A histochemical procedure for localizing and evaluating leucocyte alkaline phosphatase activity in smears of blood and marrow. *Blood* 10: 1023-1029 (1955).
 19. MEIERER, H. und HELLMEYER, L.: Das alkalische Phosphatase neutrophiler Leukozyten. *Dtsch. med. Woch.* 85: 233-238 (1960).
 20. LÖFFLER, H. und BERGHOFF, W.: Eine Methode zum Nachweis von saurer Phosphatase in Anstrichen. *Klin. Woch.* 40: 363-364 (1962).
 21. LÖFFLER, H.: Cytochemischer Nachweis von unspezifischer Esterase in Anstrichen. *Klin. Woch.* 39: 1220-1227 (1961).
 22. WACHSTEIN, M.: The distribution of histochemically demonstrable glycogen in human blood and bone marrow cells. *Blood* 4: 54-59 (1949).
 23. GARCERAN, H.: Siderocytes - new kind of erythrocytes. *Nature, Lond.* 148: 114-115 (1941).
 24. FREILICH, R. und ROSENBERG, H.: Mikroskopisch-chemischer Nachweis einer Nukleinsäure vom Typus der Thymonukleinsäure und die darauf beruhende direkte Färbung. *Z. physiol. Chem.* 221: 203-248 (1924).
 25. MÜLLER, D.: Erfahrungen mit der Feulgenfärbung für quantitative cytochemische DNS-Untersuchungen. *Histochemie* 7: 96-102 (1966).
 26. MÜLLER, D.: Studium der Proliferationsdynamik von Blutzellen mit Hilfe cytophotometrischer DNS-Bestimmungen in der Einzelzelle. *Klin. Woch.* 44: 174-180 (1966).
 27. MÜLLER, D.; HADJIMANN, W. und LOSBROCK, R.: Studium der Proliferationsdynamik von Blutzellen mit Hilfe zytophotometrischer DNS-Bestimmungen in der Einzelzelle. II. Untersuchungen der Erythropoese. *Klin. Woch.* 47: 49-57 (1969).
 - 27a. MÜLLER, D.: Zytologische Untersuchungen zur pathophysiologie leukämischer Zellen. *Anat. Forsch.* 2: 45-73 (1968).
 28. HAYMON, F. G. J., QUAGLIANO, D. and DOLL, R.: The cytology and cytochemistry of acute leukaemia. *Medical research council special reports series No. 304* (Her Majesty stationery office, London 1964).

29. VERLOOF M. C.: Zur Differentialdiagnose der essentiellen siderochromatischen Anämien; in Zyto- und Histochemie in der Hämatologie. 9. Freiburger Symp., 1962, pp. 555-573 (Springer Berlin/Göttingen/Heidelberg 1963)
30. KLEIN H. O.; DOBBERST M. und HELLER, A.: Experimenteller Beitrag zur Beziehung zwischen Niere und Erythropoiese. PAS-positive Erythroblasten im Knochenmark doppelseitig nephrektomierter Ratten. *Klin. Wochr.* 45. 644-648 (1967)
31. LEIDER, L. D.: Die ferroerythrochemische Erkennung normaler und neoplastischer Erythropoiesellen in Schnitz und Ausstrich. 11. Tg. dtsch. Ges. Haemat., Innsbruck 1965. *Blut* 15. 289-293 (1967).
32. SANDBERG, A. A.; ISHIMURA, T.; KROUCH, Y. and CROWWORTH, L. H.: Chromosomal differences among the cute leukemias. *Ann. N.Y. Acad. Sci.* 113. 663-716 (1964).
33. SANDERTEK, W. und BÖHM, N.: Atypische Hydrolysekurve bei der Feulgenreaktion von Mäuschensternzellen. *Naturwissenschaften* 51. 273 (1964)
34. TRUJILLO, J. M. and OROSO, E.: Chromosomal aberration of erythropoietic cells in chronic myeloid leukemia. *Acta haemat., Basel* 29. 311-316 (1965)
35. SANDERTEK, W. MÜLLER, D. und GROSSER, O.: Ultraviolett-mikrospektrophotometrische Messungen des Nukleinsäuregehaltes von Spermien und diploiden Zellen. *Acta histochem.* 16. 139-154 (1960)
36. SCHLÖTZER, T. M.; AUCHINCLOSS, F. und KNOFF, A.: Spontane Chromosomenaberrationen bei familiärer Panmyelopathie. *Humangenetik* 7. 194-196 (1964)
37. GERTLER, D.; WITKOWSKI, R.; SYLLM-RAPOPORT, I. und JACOBSON, G.: Chromosomenaberrationen und Stoffwechselstörungen der Blutzellen bei Fanconi-Anämie vor und nach Übergang in Leukose am Beispiel einer Patientin. *Dtsch. med. Wochr.* 92. 1701-1708 (1967).
38. BLOOM, M., JACOBSON, L. O. and BERNHARD, W. F.: Preleukemic acute human leukemia. *J. amer. med. Ass.* 152. 1018-1028 (1953)
39. GARBER, S. and CROSBY, W. H.: The incidence of leukemia in families of patients with hypoplasia of the marrow. *Blood* 14. 1008-1014 (1959)
40. VIGLIANI, E. C. and BATA, G.: Benzene and leukemia. *New Engl. J. Med.* 271: 872-876 (1964)
41. MAVORTO F., MARADEI, G. and PILERI, A.: Radioautographic investigations on DNA and protein-metabolism in two cases of DA Oculogland. disease. *Blood* 16. 1122-1132 (1960)
42. BECK, B.; SCHNEIDER, T., GRABER, U. und MORSCHLUS, S.: Experimentelle Untersuchungen über den Wirkungsmechanismus des Benzols auf das Knochenmark. *Schweiz. med. Wochr.* 96. 1274-1276 (1966).
43. DANKER, W.: Sideroblastic anaemia. Is this malignancy? *Brit. J. Haemat.* 11. 52-58 (1965)
44. DACEY, J. V., SARTIS, M. D., WHITE, J. C. and MOLLIN, D. L.: Refractory normoblastic anaemia. A clinical and haematological study of seven cases. *Brit. J. Haemat.* 5. 56-62 (1959).
45. FLICK, G.: Primäre Schädlen. *Ergebn. inn. Med. Kinderheilk.* 17. 263-381 (1962).

Institut de Biochimie, Université de Lausanne - Lausanne

Etude de la fixation non spécifique des immunoglobulines G sur les érythrocytes

II. Essais d'inhibition par des immunoglobulines G natives ou modifiées et par d'autres protéines

D. DES GOUTTES et H. ISLIER

Dans un premier travail [2] la fixation non spécifique des immunoglobulines G (IgG) sur les érythrocytes a été étudiée en fonction de la variation de différents paramètres: la quantité d'IgG, le nombre d'érythrocytes, le pH, la force ionique, la température, la durée d'incubation et le lavage des érythrocytes après l'incubation. Des conditions expérimentales permettant d'obtenir des résultats reproductibles ont été déterminées. La fixation des IgG sur le verre a également été considérée. Le présent travail étudie l'inhibition de la fixation de l'IgG marquée au ^{125}I par l'IgG native ou modifiée ou par d'autres protéines non marquées capables de prendre la place de l'IgG marquée au site de fixation cellulaire. Par analogie aux expériences d'inhibition de la fixation spécifique [5-9] cette étude a pour but de préciser s'il existe sur la molécule d'IgG une structure bien définie responsable de la fixation cellulaire non spécifique.

Matériel et méthodes

La préparation des érythrocytes, la purification et la iodation de l'IgG ont été décrites dans le précédent travail [2].

La digestion à la papaine de l'IgG a été faite selon la méthode de UTHMAN et KARIM [14] en incubant l'IgG avec la papaine (Worthington, Freehold, N.J. USA) pendant 20 h à 37°C dans un tampon acétate 0,1 M pH 4,5.

La préparation des fragments d'IgG a été faite selon la méthode de PORTER [10] en utilisant de la papaine deux fois cristallisée (Worthington, Freehold, N.J. USA) dans un tampon acétate 0,1 M, pH 7,0 en présence de cystéine 0,01 M et d'EDTA 0,002 M. Après séparation des produits de digestion sur CM-cellulose, le fragment Fab a été purifié sur Séphadex G-100 ou G-150 en utilisant comme éluant du bicarbonate d'ammonium 0,05 M. Le fragment Fc a été purifié selon la méthode de FRAEL [11]. Le coefficient de sédimentation des

fragments F b et Fc été estimé à 3,4 S. La pureté des différentes fractions utilisées été démontrée par la technique d'immuno-électrophorèse décrite par GRABAR [3] modifiée par SCHMIDHAUSEN [12] et la technique de double diffusion décrite par OUCHTERLOFF [8].

Les antisérum utilisés étaient les suivants : sérum de cheval anti-lapin, sérum de mouton anti-lapin², sérum de mouton anti-Fab de lapin², sérum de mouton anti-Fc de lapin². Le traitement de l'IgG à pH 2,9 a été fait par dialyse pendant 20 h contre un tampon acétate 0,3 M.

Les expériences d'inhibition de la fixation non spécifique de l'IgG-¹²⁵I sur les érythrocytes ont été faites en mélangeant à l'IgG marquée des protéines non marquées; ce mélange a été incubé avec des érythrocytes, et la radioactivité des culots d'érythrocytes été mesurée. Les données numériques sont exprimées en moyennes \pm l'erreur moyenne de la moyenne (\pm SE). La signification des différences entre les moyennes a été calculée en utilisant le test t selon les méthodes statistiques habituelles [15]. Des culots-contrôles incubés avec de l'IgG marquée seule représentent 100% de fixation. La différence, exprimée en pourcent, de la radioactivité entre les culots-contrôles et les culots-test indique l'inhibition de la fixation non spécifique de l'IgG-¹²⁵I. Afin de pouvoir affirmer que le système d'inhibition par les protéines non marquées est valable, il a été démontré que le processus de iodation ne modifie pas l'affinité de l'IgG pour les cellules. En effet, la fixation de l'IgG-¹²⁵I aux érythrocytes n'est pas influencée différemment par l'adjonction d'IgG non marquée ou d'IgG marquée à l'iode non radioactif. Vu l'absence d'une quantité définie d'IgG adsorbant la membrane érythrocytaire, les expériences d'inhibition ont été faites en ajoutant à une quantité constante d'IgG-¹²⁵I des quantités croissantes de protéines non marquées.

Résultats

Inhibition par l'IgG ou la sérumalbumine humaine (HSA) non marquées

La fixation de l'IgG-¹²⁵I de lapin aux érythrocytes est mesurée en fonction de l'adjonction de quantités croissantes d'IgG de lapin ou d'HSA non marquées. Les résultats représentés sur la figure 1 montrent que l'effet inhibiteur de ces protéines non marquées est faible, mais il est plus marqué pour l'HSA que pour l'IgG. Le pourcentage d'inhibition produit par l'HSA reste presque constant, malgré l'adjonction croissante d'HSA. Une expérience préalable montre par ailleurs que l'HSA-¹²⁵I ne se fixe pas plus que l'IgG-¹²⁵I sur les érythrocytes.

Inhibition par l'IgG traitée à pH 2,9 Le traitement de l'IgG à pH 2,9 produit des modifications de la structure de l'IgG. Dans ces expériences, la fixation de l'IgG-¹²⁵I sur le verre est incluse dans les valeurs obtenues pour le culot. On étudie l'effet inhibiteur de l'IgG traitée à pH 2,9 réajustée à pH 7,4 sur la fixation de l'IgG-¹²⁵I en quantité égale ou 5 fois plus grande. L'effet inhibiteur de l'IgG exposée à pH 7,4 et celui




Fig 1 Inhibition de la fixation de P^{125}I aux érythrocytes par l'adjonction de quantités croissantes d'IgG ou d'HSA non marquées. (a) Inhibition avec l'IgG non marquée. Des quantités croissantes d'IgG non marquées ont été ajoutées à 100 µg d'IgG- P^{125}I ; ce mélange est ensuite incubé avec $8,1 \cdot 10^8$ érythrocytes. La quantité d'IgG- P^{125}I fixée aux érythrocytes est exprimée en µg par culot pour différents rapports pondéraux de IgG/IgG- P^{125}I . (b) Inhibition avec l'HSA non marquée. Des quantités croissantes de HSA non marquée ont été ajoutées à 150 µg d'IgG- P^{125}I ; ce mélange est ensuite incubé avec $8,1 \cdot 10^8$ érythrocytes. La quantité d'IgG- P^{125}I fixée aux érythrocytes est exprimée en µg par culot pour différents rapports pondéraux de HSA/IgG- P^{125}I . Les échelles représentent la quantité d'IgG- P^{125}I fixée aux érythrocytes sans adjonction de protéines non marquées et permettent de calculer le pourcentage d'inhibition produit par l'adjonction d'IgG ou d'HSA non marquées.

de l'IgG non traitée sont également mesurés. Un témoin mesure la fixation cellulaire de l'IgG- P^{125}I sans adjonction d'IgG non marquée. Les résultats sont exprimés sur la figure 2. On voit que la fixation de P^{125}I aux érythrocytes n'est significativement diminuée que par l'adjonction d'IgG exposée à pH 2,9.

Inhibition par l'hydrolysat peptique de l'IgG Des quantités croissantes d'un hydrolysat peptique de l'IgG sont ajoutées à une quantité constante d'IgG- P^{125}I . La fixation de l'IgG- P^{125}I aux culots d'érythrocytes est comparée à celle d'un contrôle sans adjonction d'hydrolysat peptique de l'IgG. L'effet inhibiteur d'une même quantité d'IgG non digérée est aussi mesuré (tableau I). On constate que l'adjonction d'une quantité d'hydrolysat peptique de l'IgG égale, sur une base pondérale, à celle de l'IgG- P^{125}I , produit une diminution significative de la fixation de l'IgG- P^{125}I aux érythrocytes. Cette diminution n'est pas plus marquée en ajoutant 10 fois plus d'hydrolysat peptique de l'IgG.




Fig. 2. Inhibition de la fixation de $\text{FIgG-}^{125}\text{I}$ aux érythrocytes par FIgG traitée à pH 2,9 et réajustée à pH 7,4. Une quantité de 200 μg d' $\text{FIgG-}^{125}\text{I}$ est ajoutée à 200 μg ou 1000 μg d' FIgG non traitée, d' FIgG traitée à pH 7,4 ou d' FIgG traitée à pH 2,9. Ces différents mélanges sont incubés avec $32,4 \cdot 10^6$ érythrocytes. On compare la quantité d' $\text{FIgG-}^{125}\text{I}$ fixée en μg par celot dans les différentes séries. Les témoins représentent la quantité d' $\text{FIgG-}^{125}\text{I}$ fixée aux érythrocytes sans adjonction d' FIgG non marquée. Chaque point représente la moyenne de 5 valeurs \pm l'erreur moyenne de la moyenne ($\bar{x} \pm \text{SE}$). Différence statistiquement significative.

Tableau 1. Inhibition de la fixation de $\text{FIgG-}^{125}\text{I}$ aux érythrocytes par l'adjonction d'un hydrolysât peptique de FIgG

	μg d'inhibiteur	μg d' $\text{FIgG-}^{125}\text{I}$ fixé/celot
Contrôle	—	$1,35 \pm 0,16^1$
Hydrolysât peptique de FIgG	100	$0,78 \pm 0,05$ $p < 0,02^1$
	1 000	$0,71 \pm 0,07$ $p < 0,01$
IgG non digérée	1 000	$0,99 \pm 0,09$ NS ²

100 μg d' $\text{FIgG-}^{125}\text{I}$ ont été mélangés à 100 μg ou 1000 μg d'hydrolysât peptique de FIgG ou encore à 1000 μg d' FIgG non digérée. Ces différents mélanges ont été incubés avec $32,4 \cdot 10^6$ érythrocytes. La quantité d' $\text{FIgG-}^{125}\text{I}$ fixée aux différents celots est comparée à celle observée avec le contrôle sans adjonction d'inhibiteur. Valeurs \pm SE. La valeur de p indique une différence statistiquement significative.

Nombre d'essais $n = 3$.

Nombre d'essais $n = 4$.

Différence statistiquement non significative.

Inhibition par différents fragments de l'IgG Afin de rendre plus sensible le système d'inhibition, on utilise dans cette expérience une faible quantité d' $\text{IgG-}^{125}\text{I}$ à laquelle sont ajoutés les fragments Fc et Fab en quantité molaire 10 fois supérieure à celle de $\text{FIgG-}^{125}\text{I}$. On admet que

Tableau II Comparaison de différents inhibiteurs de la fixation de l'IgG-¹²⁵I aux érythrocytes

	µg d'inhibiteur	µg d'IgG- ¹²⁵ I fixés/µmol
Contrôle		1,03 ± 0,07
Fragment Fab	166	0,72 ± 0,04 p < 0,01
Fragment F	166	0,50 ± 0,06 p < 0,001
Fab + F	166	0,67 ± 0,08 p < 0,01
Hydrolysat peptique de l'IgG non dialysé	500	0,49 ± 0,04 p < 0,001
Hydrolysat peptique de l'IgG dialysé	500	0,42 ± 0,06 p < 0,001
IgG	500	0,65 ± 0,03 p < 0,01

50 µg d'IgG-¹²⁵I ont été incubés avec 32,4 · 10⁸ érythrocytes en présence ou non d'inhibiteur. Valeurs $\bar{x} \pm SE$, nombre d'essais = 3. La valeur de p indique une différence statistiquement significative par rapport au contrôle. La valeur de p indique une différence statistiquement significative entre deux inhibiteurs considérés. NS = différence statistiquement non significative.

le Fc et le Fab ont un poids moléculaire égal environ au $\frac{1}{2}$ de celui de l'IgG. L'effet inhibiteur de l'IgG native en quantité équimolaire aux fragments de l'IgG est également mesuré. De plus, on étudie le pouvoir inhibiteur de l'hydrolysat peptique de l'IgG avant et après dialyse (tableau II). Ces résultats montrent que tous les inhibiteurs ajoutés en quantité molaire 10 fois supérieure à l'IgG-¹²⁵I ont un effet inhibiteur statistiquement significatif par rapport au contrôle. En outre, l'effet inhibiteur du fragment Fc est significativement plus important que celui du fragment Fab. Par contre, il n'y a pas de différence significative entre l'effet inhibiteur de l'hydrolysat de l'IgG dialysé ou non dialysé. De ce fait, les peptides dialysables ne semblent pas jouer de rôle dans le pouvoir inhibiteur de l'hydrolysat peptique de l'IgG.

Inhibition par le sérum humain normal (SHN) et par le SHN absorbé sur des érythrocytes de lapin. L'effet inhibiteur du SHN a été étudié et comparé à celui du SHN absorbé 3 fois sur des érythrocytes de lapin (tableau III). Les résultats montrent que le facteur sérique inhibiteur de la fixation de l'IgG-¹²⁵I aux érythrocytes n'est pas épuisé par trois absorptions successives sur les érythrocytes de lapin.




Fig 3. Inhibition de la fixation de IgG^{125}I aux érythrocytes par le SHN, par l'IgG humaine, par l'HSA et par l'ovalbumine. Une quantité de 175 μg d'IgG- ^{125}I est mélangée à une quantité 10 fois plus grande de SHN, d'IgG humaine, d'HSA ou d'ovalbumine. Ces mélanges sont incubés avec $32,4 \times 10^6$ érythrocytes. L'effet inhibiteur de l'IgG ou de l'HSA à des concentrations sériques est aussi étudié. Le témoin représente la quantité d'IgG- ^{125}I fixée aux érythrocytes sans adjonction d'inhibiteur. On compare la quantité d'IgG- ^{125}I fixée aux érythrocytes des différentes séries à celle obtenue avec le contrôle. Chaque point représente la moyenne de 5 valeurs \pm l'erreur moyenne de la moyenne ($\bar{x} \pm \text{SE}$). Différence statistiquement significative ($p < 0,05$); NS = Différence statistiquement non significative.

Tableau III. Inhibition par le SHN et par le SHN absorbé sur des érythrocytes

μg de protéines sériques ajoutés	μg d'IgG- ^{125}I fixés/calot	μg d'IgG- ^{125}I fixés sur le verre
Contrôle	0,81 \pm 0,09	0,91 \pm 0,08
SHN absorbé 1750	0,51 \pm 0,03 $p < 0,02$	0,38 \pm 0,03 $p < 0,001$
	$p = \text{NS}$	$p = \text{NS}$
SHN non absorbé 1750	0,50 \pm 0,04 $p < 0,02$	0,38 \pm 0,02 $p < 0,001$

400 μg d'IgG- ^{125}I en présence de SHN absorbé ou non absorbé ont été incubés avec $32,4 \times 10^6$ érythrocytes. Valeurs $\bar{x} \pm \text{SE}$, nombre d'essais = 3. La valeur de p indique une différence statistiquement significative par rapport au contrôle. La valeur de p' indique une différence statistiquement non significative entre le SHN absorbé et non absorbé.

Enfin, on compare l'effet inhibiteur du SHN de l'IgG humaine, de l'HSA et de l'ovalbumine sur la fixation de l'IgG aux érythrocytes (fig 3). Les quantités d'inhibiteur utilisées sont égales à 10 fois celle de l'IgG ^{125}I . L'effet inhibiteur d'une quantité d'IgG (175 μg) ou d'HSA (875 μg) égale à celle contenue dans 1750 μg de protéines sériques est également étudié. On constate que l'IgG et l'ovalbumine

n ont d'effet inhibiteur qu'à une quantité 10 fois supérieure à celle de l'IgG-¹²⁵I. Le même effet inhibiteur est obtenu avec 1750 µg de SHN qu'avec la quantité d'HSA seule (875 µg) contenue dans 1750 µg de SHN. Par contre, la quantité d'IgG (175 µg) contenue dans 1750 µg de SHN n'a pas d'effet inhibiteur significatif.

Déplacement de l'IgG fixée aux érythrocytes par réincubation avec des protéines non marquées. L'expérience suivante démontre le déplacement de l'IgG-¹²⁵I fixée aux érythrocytes par l'adjonction d'IgG ou d'HSA lors d'une réincubation. Un contrôle est fait en remplaçant l'adjonction de protéines non marquées par du tampon. La quantité d'IgG-¹²⁵I fixée aux érythrocytes à la première incubation est comparée à celle mesurée après la deuxième incubation. Parallèlement, on mesure la quantité d'IgG-¹²⁵I présente dans le surnageant du dernier lavage, avant et après la réincubation. Dans ces expériences, la fixation de l'IgG-¹²⁵I sur le verre est incluse dans les valeurs obtenues pour le culot. Les résultats montrent que le déplacement de l'IgG-¹²⁵I fixée aux érythrocytes avec l'IgG ou l'HSA non marquées est négligeable et ne se distingue pas de façon significative de l'effet de dilution et d'éluion du tampon dans la série de contrôle (tableau IV).

Enfin, on étudie le déplacement de l'IgG-¹²⁵I fixée aux érythrocytes produit par la réincubation avec une quantité molaire d'IgG ou

Tableau IV Déplacement de l'IgG-¹²⁵I fixée aux érythrocytes au cours d'une réincubation d'IgG ou d'HSA non marquées

Première incubation avec IgG- ¹²⁵ I		Deuxième incubation (déplacement)	
µg d'IgG- ¹²⁵ I fixés/culot	µg d'IgG- ¹²⁵ I dans le surnageant	µg d'IgG- ¹²⁵ I fixés/culot	µg d'IgG- ¹²⁵ I dans le surnageant
I 2,56 ± 0,23 ¹	0,82 ± 0,07 ¹	I vec tampon (contrôle) 2,01 ± 0,13	1,89 ± 0,17
II 2,70 ± 0,16	0,98 ± 0,08	II avec IgG 1,93 ± 0,16 NS	1,74 ± 0,16 NS
III 2,73 ± 0,11	0,89 ± 0,08	III avec HSA 2,10 ± 0,13 NS	1,66 ± 0,15 NS

Pour les trois séries (I, II, III) la première incubation a été faite en présence de 200 µg d'IgG-¹²⁵I et 12,4 · 10⁸ érythrocytes. La deuxième incubation (déplacement) a été faite en ajoutant aux culots de la première incubation 200 µg d'IgG ou d'HSA, ou encore un volume égal de tampon ordinaire pour la série de contrôle. Les lavages ont été faits avec une solution isotonique de glucose, tamponnée avec le tampon ordinaire. Valeurs $\bar{x} \pm SE$, nombre d'essais $n = 5$.

Nombre d'essais $n = 6$. NS = différence statistiquement non significative.

Tableau V Déplacement de l'IgG-¹²⁵I fixée aux érythrocytes au cours d'une réincubation avec de l'IgG ou de l'HSA non marquées en grand excès

Première incubation avec IgG- ¹²⁵ I		Deuxième incubation (déplacement)	
μg d'IgG- ¹²⁵ I fixés/culot	μg d'IgG- ¹²⁵ I dans le surnageant	μg d'IgG- ¹²⁵ I fixés/culot	μg d'IgG- ¹²⁵ I dans le surnageant
I 6,16 \pm 0,30	1,55 \pm 0,03	I avec tampon 4 03 \pm 0,34 (contrôle)	2,61 \pm 0,17
II 6,39 \pm 0,09	1,39 \pm 0,12	II avec IgG 2,87 \pm 0,12 $p < 0,001$	4,57 \pm 0,13 $p < 0,001$
III 6,90 \pm 0,43	1,60 \pm 0,10	III avec HSA 4,20 \pm 0,20 NS	3,01 \pm 0,03 NS

Pour les 3 séries (I, II, III), la première incubation a été faite en présence de 400 μg d'IgG-¹²⁵I et 32,4 $\cdot 10^9$ érythrocytes. La deuxième incubation (déplacement) a été faite en ajoutant aux culots de la première incubation 4000 μg d'IgG ou d'HSA, ou encore un volume égal de tampon ordinaire pour la série contrôle. Les lavages ont été faits avec une solution de glucose isotonique tamponnée avec le tampon ordinaire. Valeurs $\bar{x} \pm 3E$; nombre d'essais $n = 5$. La valeur de p indique une différence statistiquement significative, par rapport au contrôle. NS = différences statistiques non significative.

d'HSA 10 fois supérieure à celle de l'IgG-¹²⁵I introduite lors de la première incubation (tableau V). Dans ces conditions, l'IgG non marquée déplace, significativement par rapport au contrôle, l'IgG-¹²⁵I fixée aux érythrocytes. Ceci est indiqué, lors de la réincubation, par une diminution de la radioactivité du culot et une augmentation de la radioactivité dans le surnageant. Ce déplacement n'a pas lieu de façon statistiquement significative avec une quantité molaire égale d'HSA non marquée.

Discussion

Nos résultats montrent que la fixation non spécifique de l'IgG aux érythrocytes ne peut être diminuée qu'en présence d'un grand excès d'inhibiteur. Il en est de même pour l'inhibition de la fixation spécifique par un inhibiteur non spécifique [5]. Le fait que la membrane érythrocytaire n'est pas saturée par une quantité bien définie d'IgG diminue la sensibilité du système d'inhibition. L'albumine est un meilleur inhibiteur que l'IgG ce qui pourrait s'expliquer par une différence d'hydratation moléculaire de ces deux protéines. L'albumine diminuerait les liaisons hydrophobes impliquées dans la fixation

non spécifique de l'IgG. L'effet inhibiteur du sérum humain normal serait dû à sa forte concentration en albumine, non épuisée par trois absorptions sur des érythrocytes. L'existence d'autres facteurs sériques inhibiteurs ne peut pourtant pas être exclue. Il faut noter que l'HSA ^{125}I ne se fixe pas plus que l'IgG- ^{125}I sur les érythrocytes. Ainsi l'efficacité de l'inhibiteur n'est pas nécessairement liée à la fixation cellulaire de l'inhibiteur comme le suggère BENAGHI [1]. De même, on observe que l'hydrolysat peptique de l'IgG est plus inhibiteur qu'une même quantité, sur une base pondérale, d'IgG native. Les travaux d'ISLER *et al.* [6] montrent que les γ G-globulines digérées par la pepsine, donc dépourvues du fragment Fc , ne se fixent plus non spécifiquement aux hépatocytes. Dans des conditions expérimentales favorisant l'inhibiteur nos résultats indiquent que le fragment Fc est plus inhibiteur que le fragment Fab . Les travaux de GROS *et al.* [4] montrent, par ailleurs, que la fixation cellulaire de ces deux fragments n'est pas différente.

Après la fixation aux érythrocytes, le déplacement des molécules d'IgG- ^{125}I est minime et nécessite une réincubation avec un grand excès d'IgG. L'ensemble de ces résultats ne permet pas de tirer des conclusions sur l'existence d'un site de fixation bien défini sur la molécule d'IgG d'une part ou sur la membrane érythrocytaire d'autre part. La présence d'un site de fixation non spécifique sur la membrane cellulaire impliquerait que la quantité d'IgG fixée soit directement proportionnelle au nombre d'érythrocytes ou à la surface cellulaire disponible, ce qui n'est pas observé dans nos expériences. De plus, il n'existe pas de parallélisme entre l'effet inhibiteur et la capacité de fixation cellulaire de l'inhibiteur suggérant que le processus d'inhibition n'est pas nécessairement situé au niveau d'un site de fixation.

On peut conclure que les molécules d'IgG se fixeraient à la surface de la membrane sans une orientation moléculaire définie. Ceci permettrait d'expliquer l'inhibition peu importante par les différentes protéines considérées. En effet, une orientation non définie de la molécule d'IgG fixée non spécifiquement et la grande capacité de fixation de la membrane érythrocytaire diminuent l'influence d'un inhibiteur. L'étude *in vitro* de l'inhibition de la fixation non spécifique de l'IgG aux érythrocytes nécessiterait d'établir dans quelle mesure ces observations reflètent les processus biologiques *in vivo*. Les conséquences et le mécanisme d'une inhibition *in vivo* telle qu'elle a été décrite chez un patient par JEANET *et coll.* [7] doivent encore être éclaircis.

Acknowledgments. Nos remerciements vont au Dr M. WALDENSTROM, pour sa collaboration et à Mlles HÉLÈNE WIL et BERNADETTE VILLOUX, dont l'assistance technique fut précieuse à l'élaboration de ce travail.

Ce travail fut rendu possible grâce à des subides du Fonds National Suisse de la Recherche Scientifique et à une contribution de la Maison F Hoffmann-La Roche.

Résumé

Différents inhibiteurs de la fixation non spécifique de l'IgG aux érythrocytes ont été étudiés. L'inhibition de la fixation non spécifique est peu importante et nécessite un grand excès d'inhibiteur. L'effet d'inhibition n'est pas nécessairement dû à la fixation de l'inhibiteur aux érythrocytes. Les inhibiteurs les plus efficaces sont l'albumine et le sérum humain. Dans des conditions favorisant l'inhibition, le fragment Fc est plus inhibiteur que le fragment Fab. Les molécules d'IgG pourraient se fixer non spécifiquement aux érythrocytes sans une orientation moléculaire bien définie.

Summary

Inhibition of the process of fixation is not readily accomplished and fixation of 125 I-IgG is significantly inhibited only with large excess of inhibitor. Inhibition is not necessarily due to fixation of the inhibitor to erythrocytes. The most potent inhibitors are human serum albumin and human serum. In conditions favorable to inhibition, F fragment is more active than F b fragment. The IgG molecules appear to be non specifically fixed to erythrocytes without any particular orientation.

Bibliographie

1. BORCHERS, A. A. Sensitization of guinea-pig ileum by rabbit γ G antibody and its interaction by non-specific γ -globulin; in *ALLENSTON and GRABAR Immunopathology Vth Int. Symp. on mechanism of inflammation induced by immune reactions*, Punta Ala 1967 p. 470 (Schwabe, Basel/Stuttgart 1967).
2. DES GOUTTES, C. D. et ILIKER, H. Etude de la fixation non spécifique des immunoglobulines III sur les érythrocytes. I. Influence de la variation de différents paramètres. *Acta haemat.* 42: 154-168 (1969).
3. GRABAR, P. et WILLIAMS, C. A. Méthodes permettant l'étude conjuguée des propriétés électrophorétiques et immunochimiques d'un mélange de protéines. *Biochim. biophys. Acta* 16: 193-194 (1955).
4. GEOR, P. J., FRANKEL, D., ILIKER, H. and MAROUDAKIS, S. P. Interaction of IgG and its fragments with red cells. *Immunology Lond.* 13: 489-499 (1967).
5. HALPERN, H. and FRICK, O. Protection against anaphylactic shock with γ -globulin in guinea pig and mice. *J. Immunol.* 88: 683-689 (1962).
6. ILIKER, H. Reversible inactivation of γ M-globulin. Anticomplementary activity and tissue affinity of human γ -globulin. *Proc. nat. Acad. Sci., Wash. Symposium on γ -globulin* - the National Research Council, p. 44 (1962).
7. JEANDET M.; BARANDON, S. et HILMO, A. Fixation de γ -macroglobulines sur les érythrocytes in vivo. *Vox Sang.* 9: 43-51 (1964).

8. OCHTERLOFF, O.: Antigen-antibody reactions in gels. IV. Types of reactions in coordinated systems of diffusion. *Acta path. microbiol. scand.* **37**, 231-240 (1953).
9. OVARY, Z. et BOER, C.: Action empêchant du sérum normal de lapin sur anaphylaxie cutanée passive du cobaye. *Ann. Inst. Pasteur* **81**, 443-445 (1953).
10. PORTER, R. R.: The hydrolysis of rabbit γ -globulin and antibodies with crystallin papain. *Biochem. J.* **73**, 119-126 (1959).
11. FRANK, J. W.: Enzymic degradation of the F fragment of rabbit immunoglobulin IgG. *Biochem. J.* **104**, 647-655 (1967).
12. SCHINDLER, J. J.: Une microméthode d'analyse immunoelectrophorétique. *Int. Arch. Allergy* **7**, 103-110 (1955).
13. SNEDECOR, G. W.: Statistical methods applied to experiment in agriculture and in biology (Iowa's State College Press, Ames 1950).
14. URRICH, R. and KARLST, F.: Peptic fragmentation of rabbit γ G immunoglobulin. *Biochemistry* **4**, 1766-1779 (1965).

Tabelle I. Anteil Immunglobulinhaltiger Zellen in Leukozytenkonzentraten aus dem peripheren Blut von Patienten mit verschiedenen Formen von Hepatitis

Fall Nr	Ig	kl. Ly in %	m. Ly in %	gr. Ly in %	Plz. in %	gestaut in /oo	davon Plz. in /oo	abs. MIN	Plz. in %
1	γ G γ A γ M	-	+	-	+	< 1 negativ	-	-	-
2	12. 11. 1968 γ G γ A γ M	25,2 24,0 -	49,4 79,2 +	5,7 9,6 -	18,2 8,4 -	14,6 3,5 < 1	2,7 0,14	2 775	19
	20. 11. 1968 γ G γ A γ M	4,6	64,8	14,0	16,7	18,5 nicht untersucht	3,1	2 448	2,1
3	γ G γ A γ M	57,0 + +	32,8 + +	6,6 - -	2,2 - -	8,7 < 1 < 1	0,13	2 250	4,3
4	γ G γ A γ M	81,4 + +	16,8 + +	- - -	3,1 - -	6,0 < 1 < 1	0,75	-	-
5	γ G γ A γ M	32,7 44,0 +	45,3 22,0 +	8,8 - -	14,4 33,0 +	6,8 3,0 1	1,0 1,0	-	-
6	γ G γ A γ M	20,0 + -	57,3 + +	10,5 - -	15,0 + -	5,0 < 1 < 1	0,75	6 040	-

kl. Ly = kleine Lymphozyten m. Ly = mittlere Lymphozyten gr Ly = grosse Lymphozyten, Plz. = Plasmazellen abs. MIN = nach dem Differentialblutbild errechnete Anzahl von mononukleären Zellen/mm³ + = immunzytologisch positive Zellen vorhanden.

Ergebnisse

Tabelle I zeigt den prozentuellen und absoluten Anteil Immunglobulinhaltiger Zellen in Leukozytenkonzentraten aus dem peripheren Blut einer Normalperson (Fall 1) und von Patienten mit verschiedenen Formen von Hepatitis. Fall 2-4 zeigen kurzlich das Bild einer unkomplizierten Hepatitis, die Leukozytenabnahme erfolgt innerhalb der ersten 10 Tage nach Auftreten eines Ikterus. Bei Fall

Tabelle II. Immunglobulinhaltige Zellen in Leukosytenkonzentraten von Patienten mit Agranulozytose und Mononucleosis infectiosa

Fall Nr	Ig	kl. Ly in %	m. Ly in %	gr. Ly in %	Plz. in %	gesamt in / ₁₀₀	davon Plz. in / ₁₀₀	abs. MN	Plz. in %
7	28.10.1968								
	γG	nicht differenziert				8,3	1	921	—
	γA	+	+	—	—	1			
	γM	+	+	—	—	0,9			
	4.11.1968								
	γG	16,8	73,2	7,2	2,4	8,4	0,2	3 025	1 7
8	γA	26,4	52,8	—	19,8	1,5	0,3		
	γM					negativ			
	γG	monocytoide Reizformen, keine Plz.				3,5		—	—
						nicht untersucht			
9	γG	+	+	—	+	< 1		2 520	—
	γA	+	—	—	—	1,0			
	γM					negativ			

kl. Ly = kleine Lymphozyten m. Ly = mittlere Lymphozyten; gr. Ly = grosse Lymphozyten;
Plz. = Plasmazellen; abs. MN = nach dem Differentialblutbild errechnete Anzahl von mononukleären
Zellen/mm³ + = immunologisch positiv. Zellen vorhanden.

5 wurde histologisch eine aktive, chronische Hepatitis, bei Fall II eine granulomatöse Hepatitis ungeklärter Ätiologie diagnostiziert. Auffällig und in seiner Bedeutung bisher ungeklärt ist der relativ hohe Anteil von γA haltigen Zellen bei Fall 2 und 5 — der prozentuelle Plasmazellanteil scheint parallel der absoluten Anzahl positiver mononukleärer Zellen anzusteigen. Ebenfalls nur beschrieben werden kann derzeit der stark wechselnde Anteil kleiner bzw. mittlerer Lymphozyten. Wurden bei der Auszählung von γA- oder γM-haltigen Zellen weniger als 1 /₁₀₀ positiver Zellen gefunden, so sind in der Tabelle lediglich der vorherrschende Zelltyp, meist kleine bis mittlere Lymphozyten, vermerkt.

In Tabelle II ist der Anteil Immunglobulinhaltiger Zellen in Leukosytenkonzentraten einer Patientin mit medikamentös bedingter Agranulozytose (Fall 7) sowie zweier Patienten mit Mononucleosis infectiosa (Fall 8 und 9) aufgeführt. Fall 8 befand sich im akuten Stadium, alle γG-positiven Zellen imponierten monocytoyd. Fall 9 kam III Monate nach einer Erkrankung an infektiöser Mononukleose

Tabelle III. Immunglobulinhaltige Zellen in Leukocytenkonzentraten von Patienten mit M. Hodgkin, chronischer Lymphadenose, γ G-Plasmocytom und M. Waldenström

Fall N	Ig	kl. Ly in %	m. Ly in %	gr Ly in %	Plz. in %	gesamt in / ₁₀₀	davon Plz. in / ₁₀₀	abs. MIN	Plz. in %
10	γ G γ A γ M	+	+	—	—	< 1 negativ	—	1 280	—
11	γ G γ A γ M					negativ		240 000	
12	19.4 1969 γ G γ A γ M κ		39,6 + 35,0	13,2 — 21,0	46,2 — 42,0	5,8 negativ < 1 7,0	2,7 — 2,9	1 310	2,8
	24.4 1969 γ G γ A γ M κ		87 + 84,0	6,0 — 8,0	6,0 — 6,6	11,1 1,5 negativ 12,5	0,8 — 0,8	4 940	—
13	19.4 1969 γ G γ A γ M κ	— — + analoge Zellpopulation positiv	+ + + analoge Zellpopulation positiv	— — + analoge Zellpopulation positiv	— — + analoge Zellpopulation positiv	< 1 < 1 etwa 1% etwa 1%	— — — etwa 1%	3 870	—
	24.4 1969	unverändertes Zellbild, analoge Anzahl positiver Zellen.							

kleine und mittlere Lymphocyten zusammen.

kl. Ly = kleine Lymphocyten m. Ly = mittlere Lymphocyten gr Ly = große Lymphocyten
Plz. = Plasmazellen abs. MIN = nach dem Differentialblutbild errechnete Anzahl an monoklonalen
Zellen/mm³ + = immunzytologisch positive Zellen vorhanden.

beschwerdefrei zu einer Kontrolluntersuchung die keinen krankhaften Befund erbrachte. Auch hier ist die Bedeutung der stark positiven γ A haltigen Lymphocyten ungeklärt. Neben den sorgfältigen Spezifikationskontrollen weisen immerhin auch diese unterschiedlich positiven Zellklassen auf die Spezifität des immunzytologischen Nachweises hin.

In Tabelle III wurden die Befunde von 4 Patienten mit malignen hämatologischen Erkrankungen zusammengefasst. Auffällig ist der spärliche bis negative Befund bei Fall 10, einem Patienten mit M. Hodgkin und Fall 11 einem mit chronischer Lymphadenose. Hier er




Abb. 1 Testknochenmarksausstrich eines Patienten mit γ A-Plasmosyom. Zahlreiche γ A-positive Plasmazellen (200)

Abb. 2 Zwei kleine periphere γ A-positive Lymphozyten. Fall 9 Status nach *Moronechoma infectiosa* (250)

Abb. 3 Mittelgroßer γ G-positiver Lymphozyt. Fall 3 akute Hepatitis (400)

Abb. 4 Periphere γ M-positive Plasmazelle. Fall 5 chronische Hepatitis (630)

Abb. 5 Zahlreiche κ -positive lymphoide Zellen in einem Leukosytenkonzentrat. Fall III ML Waldenström (200)

Abb. 6 γ M-positiver kleiner bis mittelgroßer Lymphozyt. Fall 13 ML Waldenström (630)



Abb. 7 Kleiner bis mittelgroßer κ -positiver Lymphozyt. Fall 13: M. Waldenström ($\times 630$).
 Abb. 8 Großer γ M-positiver Lymphozyt. Fall 13: M. Waldenström ($\times 630$).
 Abb. 9 κ -positiver grober Lymphozyt. Fall 17: γ G-Plasmozytom vom κ Typ ($\times 630$).
 Abb. 10 Großer γ G-positiver Lymphozyt. Fall 7: medikamentös bedingte Agranulokytose in Remission ($\times 630$).

geben sich Parallelen zu dem bei diesen Erkrankungen beschriebenen Antikörpermangelsyndrom. Fall 12 zeigt die Werte eines Patienten mit γ G-Plasmozytom vom κ Typ. Gegenüber allen anderen untersuchten Fällen fand sich hierbei im unbehandelten Zustand ein deutlich höherer Prozentsatz von Plasmazellen, der allerdings nach nur kurzer zytostatischer Therapie trotz Zunahme der Gesamtzahl von positiven Zellen zugunsten kleiner Lymphozyten auf 6% absank. Eine analoge Zellpopulation erwies sich als γ G- und κ -positiv, auffälligerweise auch alle Größenordnungen von Lymphozyten, so dass man sie wohl als ausgeschwemmte Tumorzellen zu betrachten hat. Bei Fall 13 handelt es sich um eine unbehandelte Patientin mit M. Waldenström, die ebenfalls einen relativ hohen Prozentsatz Paraproteinhaltiger mononukleärer Zellen in der Peripherie aufwies.

Diskussion

Die Frage, ob Plasmazellen aus Lymphozyten entstehen können, ist noch immer nicht endgültig geklärt. In Tierversuchen konnte gezeigt werden, dass nach Immunisierung ein kleiner Teil der peripheren Leukozyten Antikörper bilden kann [5, 7, 9, 12]. Die morphologische Einordnung dieser Population stößt allerdings auf Schwierigkeiten. Der elektronenmikroskopische Nachweis von endoplasmatischem Reticulum als Ausdruck einer Antikörperbildung konnte lange Zeit lediglich für Plasmazellen erbracht werden. Erst in letzter Zeit wurden Befunde erhoben, die für eine Entwicklung ruhender stoffwechsel-

inaktiver Lymphozyten über basophile «Blasten» mit spärlichen Proteinsyntheseorganellen in vollentwickelte Plasmazellen sprechen [3 4 7 8, 11]

Unsere Untersuchungen bestätigen, dass bereits bei Normalpersonen eine allerdings sehr kleine Zahl von peripheren, mittelgrossen Lymphozyten Immunglobuline enthalten [13]. Bei Erkrankungen mit peripheren «lymphatischen Reizformen» Virusinfekten und allergischen Reaktionen erhöht sich die Zahl dieser Zellen.

Ein gesetzmässiges Auftreten der einzelnen Zellklassen im Rahmen eines Krankheitsverlaufes ist bei den angeführten Fällen nicht zu sichern. Immerhin ist der Anteil grosser Lymphozyten gegenüber dem kleiner und mittlerer relativ konstant [3 4]. Es fiel weiterhin auf, dass die grossen Zellen mit häufigen Mitosen bei den Fällen mit Paraproteinämie etwas öfter « κ positiv» als γG - bzw. γM positiv waren. Dies ist möglicherweise der Ausdruck eines besonders aktiven intrazellulären «light-chain-pools» wie er bei Paraproteinämien mit Bence-Jones-Proteinurie beschrieben wurde [2].

Soweit diese Methode absolute Angaben zulässt, schwankte die Zahl der κ -positiven Zellen zwischen weniger als 1/100 und etwa 20/100. Bei einem Fall mit Morbus Waldenström waren 1% der mononukleären Zellen – alle Grössenordnungen von Lymphozyten, plasmoiden Zellen und Plasmazellen – peripher κ positiv.

Die drei Ig Klassen konnten im Zytoplasma aller lymphatischen Zellklassen gefunden werden, auch in eindeutig sehr kleinen Lymphozyten. VAN FURTH konnte in diesen Zellen nur γM nachweisen [13]. Die Erklärung dürfte in der Verwendung unterschiedlich starker Antiseren liegen.

Der Vergleich der κ positiven Plasmazellen mit dem nach morphologischen Kriterien errechneten Plasmazellanteil zeigte einen deutlich niedrigeren Wert. Diese schlechte Korrelation dürfte mit dem Verlust von Plasmazellen während der Präparation zusammenhängen. Es war schon bei früheren Untersuchungen aufgefallen, dass trotz eines 4–5%igen Anteiles von Plasmazellen im Differentialblutbild im Leukozytenkonzentrat manchmal nur mehr spärlich Plasmazellen zu finden waren. Die angegebenen Absolutzahlen der κ -positiven Plasmazellen liegen also sicher zu niedrig. Eine enge Beziehung zwischen Anzahl der «lymphatischen Reizformen» und κ positiven Lymphozyten ist nicht zu erwarten, da nur ein kleiner Teil der stoffwechselaktiven Zellen Ig synthetisieren [3 u.a.]

Versuche, die κ -positiven Zellen mit Ergebnissen der Methylgrünpyronin Färbung zu korrelieren zeigte eine ähnlich grosse Anzahl mittlerer und grosser Lymphozyten mit stark pyroninophilem Zytoplasma, obwohl diese Farbintensitätsunterschiede schwer zu objektivieren sind.

Aufschlussreich ist die Anzahl der positiven Zellen nach «Färbung» mit fluoreszierendem Anti κ -Serum bei den beiden Fällen mit γ G-Plasmazytom und M. Waldenström vom κ Typ. Es darf als gesichert gelten, dass eine Zelle jeweils nur einen Typ von Ig bildet, entweder Globuline mit leichten Ketten vom λ Typ oder λ Typ [14 u.a.] VAN FURTH [14] konnte in einer Untersuchung über den prozentuellen Anteil von κ und λ produzierenden Zellen im Knochenmark für Normalpersonen ein Verhältnis von 3:1 in der Peripherie von 3:5:1 ermitteln und diese Befunde mit der *in vitro* de novo-Synthese von κ und λ antigenen Globulinen korrelieren. In Knochenmarkspräparationen von Patienten mit Plasmazytom vom κ Typ waren 99% der Plasmazellen κ positiv. Bei benignen monoklonalen Paraproteinemien betrug das Verhältnis der κ : λ positiven Zellen im Knochenmark 11:2:1 während in der Peripherie keine wesentliche Veränderung gegenüber Normalpersonen beobachtet werden konnte (3,5:1) da in diesen Fällen offenbar das Hauptkontingent von Ig haltigen Zellen aus lymphatischen Organen stammt. Der Anteil κ positiver Zellen in der Peripherie von Patienten mit γ G Plasmazytom vom κ Typ wird nicht mitgeteilt. Die Auszählung der κ positiven peripheren Zellen bei unseren beiden Fällen zeigte, daß die überwiegende Zahl, aber nicht nur Plasmazellen sondern auch kleine und mittlere Lymphozyten das jeweilige Paraprotein im Zytoplasma enthielten und eine abzüglich der methodischen Fehlerbreite gleich grosse Anzahl und analoge Zellpopulation vom κ Typ waren. Es liegt nahe, alle Zellen die bei einem monoklonalen Plasmazytom an der Paraproteinbildung teilhaben als intermediäre Formen im Rahmen der Entwicklung von Plasmazellen zu werten.

Zusammenfassung

Es wurde bei 12 Patienten mit lymphatischen Reifformen im Differentialblutbild immunzytologisch Immunglobuline vom γ G-, γ A- und γ M-Typ im Zytoplasma kleiner mittlerer und grosser Lymphozyten und Plasmazellen nachgewiesen. Der prozentuelle Anteil der einzelnen positiven Zellklassen wies bei den kleinen und mittleren Lymphozyten sowie bei den Plasmazellen erhebliche Schwankungen auf, während der Anteil grosser

Lymphocyten relativ konstant um 10% lag. Die absolute Anzahl positiver Zellen schwankte zwischen weniger als 1/100 und 1/10 der mononukleären Zellen in den Leukocytenkonzentraten. Bei 2 unbehandelten Patienten mit κ -Typ-Paraproteinkämien (γ G-Plasmocytom, M. Waldenström) enthielten annähernd 100% der immunzytologisch positiven Zellen in der Peripherie das Paraprotein, welches noch zusätzlich durch seine κ -Eigenschaft charakterisiert wurde.

Summary

Immune globulins of the gamma-G, gamma-A and gamma-M types were found in the cytoplasm of small, medium and large lymphocytes and plasmacytes of 12 patients presenting signs of lymphatic irritation in the differential blood count. The percentage of positives varied widely in the small and medium lymphocytes and the plasma cells, but was relatively constant (about 10%) in the large lymphocytes. Absolute numbers of positive cells ranged from less than 0.1% up to 1% of the mononuclear cells in the leukocyte concentrates. In two untreated patients with kappa-type paraproteinaemia (gamma-G plasmacytoma, M. Waldenström) almost 100% of the immunologically positive cells in the peripheral blood contained the paraprotein, which was further characterized by its kappa property.

Literatur

1. ASANER, H., RUCANOV, G., HOLTHAUS, N. und GABL, F. Immunhistologische Befunde bei Schilddrüsenerkrankungen in einem endemischen Kropfgebiet. Arch. klin. Med. 215: 270 (1968).
2. ARKOVAT, B. A. and WILLIAMSON, A. R. Balanced heavy and light chain synthesis in immune tissue and disulphide bond formation in IgG assembly. In KILLANDER, ALMGREN and WENDEL. Gamma globulins. Nobel Symposium 3, Stockholm 1967 pp. 369-383.
3. BALFOUR, B. M., COOPER, E. H. and ALPER, E. L. Morphological and kinetic studies on antibody-producing cells in rat lymphnodes. Immunology Lond. 8: 230 (1963).
4. BERNECK, M. S. C. and HALL, J. G. Transformation in vivo of basophilic lymph cells into plasma cells. Nature, Lond. 216: 183 (1967).
5. GREENE, L. N.; GLADE, P. R., ASOFKEY, R.; BAKER, P. D., REINFELD, R. and TERRY, W. Studies on human peripheral blood lymphocytes in vitro. 3. Biosynthesis of immune-globulins. J. Immunol. 101: 456 (1968).
6. GLADE, P. R.; HIRSHAUT, Y., DOUGLAS, S. D. and HIRSCHOWITZ, K. Lymphoid suspension cultures from patients with viral hepatitis. Lancet 1273 (1968).
7. HOLM, M. The nature of the activated small lymphocytes; in JÖNSSON The lymphocyte in immunology and haematology, p. 46 (Arnold, London 1966).
8. HUNDELLER, K., HARRIS, T. N., TOMASCO, N.; HECHTEL, M. and FARR, M. R. Electron microscopic observations on antibody-producing cells in lymph and blood. J. exp. Med. 124: 255 (1966).
9. LARIVY, M., SANDERSON, R. P., BERNSTEIN, M. T. and JACKSON, A. L. Antibody production by leukocytes in peripheral blood. Nature, Lond. 204: 1320 (1964).
10. MACDONALD, A. A., J. Studies of plasma protein synthesis by peripheral cells from normal persons and patients with infectious mononucleosis. Blood 32: 217 (1968).
11. SELL, S. and ASOFKEY, R. Lymphocytes and immunoglobulins. Progr. Allergy vol. 12, p. 86 (Karger, Basel/New York 1968).

12. SORRELL, E. and LANDY M. Antibody production by blood leukocytes. *Experientia* 21: 677 (1965)
13. VAN FURTH, R., SORRELL H. R. E. and HJGMAA, W. The formation of immunoglobulins by human tissues *in situ*. 4. Circulating lymphocytes in normal and pathological conditions. *Immunology Lond.* 11: 29 (1966)
14. VAN FURTH, R.; SORRELL H. R. E. and HJGMAA, W. *In situ* synthesis and immunofluorescent studies of monoclonal IgG in non-myeloma bone marrow; in KILLANDER, ALMGREN and WIRELL. Gamma globulins, Nobel Symposium 3 Stockholm 1967 pp. 445-453

Department of Medicine, University of Aberdeen, Aberdeen

Exercise-Induced Thrombocytosis

A. V. DAWSON and D. OOSTON

Most investigators have reported that brisk exercise of short duration induces a transient rise in the platelet count [3, 10, 11] but there is not universal agreement on this [4]. The mechanism of the thrombocytosis in response to exercise is unknown. We report a study on the effect of exercise on the platelet count in healthy men and women and in asplenic subjects, and on a comparison of the platelet response to exercise before and after β -adrenergic blockade.

Methods and Subjects

Platelet counts were performed by the method of OVERTON and SPENCER [8] on citrous blood samples anticoagulated with disodium ethylenediamine-tetraacetate (EDTA). The normal range for healthy subjects in this laboratory is 150–270,000/mm³. It was calculated from the results of 30 duplicate blood samples with platelet counts ranging from 117,000 to 534,000/mm³ that the difference between duplicates, as a percentage of each mean platelet count, had a mean value of 10.8% ($SD \pm 6.8\%$).

Subjects. Twelve men and 6 women aged 18 to 36 years and in good health participated in the experiments. In addition, 4 men and 2 women aged 17 to 29 who had undergone splenectomy 11 months to 6 years previously were studied. Splenectomy had been performed as a result of trauma in 4 of these subjects, because of spontaneous rupture during infectious mononucleosis in one, and for the treatment of hemolytic anemia in the remaining subject. All were in good health at the time of the study.

Exercise was undertaken on an electrically braked bicycle ergometer (Lode, Instrametrica N.V., Groningen, Holland). Work loads are expressed in metre-kiloponds (mkp). The procedure took place at 9.30 a.m. or 2.15 p.m. After the subject rested for 15 min the initial blood sample was withdrawn. Further samples were obtained after 5 and 15 minutes' exercise and then after resting for 5 and 15 min.

Propranolol (Inderal®) was taken orally 60 mg in divided doses during the 24 h preceding the exercise, 20 mg being taken 1 h before the test.

Table 1 Effect of exercise on the platelet count of healthy men and women

Exercise load mlkp	Sex	No. in group	Platelet counts $\times 10^9/\text{mm}^3$ (mean \pm SD)				
			Before exercise	Minutes after start of exercise		Minutes after end of exercise	
				5	15	5	15
600	F	6	185 \pm 54	223 \pm 54	239 \pm 61	211 \pm 40	189 \pm 59
600	M	6	184 \pm 36	174 \pm 31	169 \pm 24	174 \pm 52	170 \pm 53
900	M	6	166 \pm 41	199 \pm 48	224 \pm 31	203 \pm 52	213 \pm 49

Results

Effect of exercise on the platelet count of healthy men and women. Six men and 6 women completed exercise at a work load of 600 mlp for a duration of 15 min and a further 6 men completed this period of exercise at a work load of 900 mlp. The mean platelet counts before, during and after exercise are presented in table I. At a work load of 600 mlp there was a significant rise in the platelet count in women after 15 minutes exercise ($p < 0.01$). In men there was no significant change in the platelet count ($p > 0.1$). The increase in the platelet count in men at a work load of 900 mlp was significant both at 5 min ($p = 0.05$) and at 15 min ($p < 0.01$). In contrast to the women, the platelet count of these men had not returned to the initial level after 15 minutes rest. The hematocrit changes during exercise were small or absent and could not account for the alterations in the platelet count.

Effect of propranolol on the rise in the platelet count induced by exercise. Three men and 4 women who had exercised at 900 mlp and 600 mlp respectively were retested at least 1 week later after receiving oral propranolol. The mean pulse-rate after exercise for 15 min fell from 137/min without propranolol to 102/min when propranolol was given before exercise: this suggests that propranolol had produced significant β -adrenergic blockage. The individual changes in the platelet count with and without prior propranolol are shown in figure 1. The mean rise in the platelet count with and without propranolol did not differ significantly ($p > 0.1$).

Effect of exercise on the platelet count in asplenic subjects. Four men and 2 women who had previously undergone splenectomy exercised at a




Fig. 1 Effect of propranolol on the rise in the platelet count induced by exercise. Platelet count before and after 15 minutes exercise shown. $\circ-\circ$ Men (900 mkp) $\bullet-\bullet$ women (600 mkp)

work load of 900 mkp and 600 mkp respectively for 15 min. The individual platelet counts are illustrated in figure 2 with the mean values obtained for 6 normal men and women undertaking the same exercise load. The changes in the platelet count induced by exercise in asplenic subjects were variable, but some showed a well-marked transient thrombocytosis. Two asplenic subjects with initially elevated platelet counts had a different pattern of response to exercise with a continued rise in the platelet count after completion of the period of exercise.

DISCUSSION

Studies on the response of the platelet count to exercise have produced differing conclusions. It seems likely that the discrepancies result partly from variations in the severity and duration of the exercise procedure. Most investigators have found that the platelet count at the completion of a prolonged period of physical activity is




Fig. 1. Changes in the platelet count induced by exercise in normal and asplenic subjects. (—) normal subjects (means \pm SE); (x) — asplenic subjects.

changed from the pre-exercise level [6, 9] although ISAACS and JORDON [5] judging only on the appearances of blood films, concluded that the platelet count at the end of a marathon race was considerably elevated. In contrast, most workers have found that short periods of brisk exercise induce a transient thrombocytosis [4, 10, 11]. Using a bicycle ergometer, a convenient means of regulating the amount of exercise performed, our results suggest that a critical amount of exercise is required to produce a detectable rise in the platelet count and that this differs between men and women.

The rapidity of the rise in the platelet count during brisk exercise indicates that the thrombocytosis must result from the release of formed platelets into the peripheral blood rather than from increased platelet production.

It is well-established that pharmacological doses of adrenaline cause a rapid rise in the level of the circulating platelets. This rise is prevented by prior administration of β -adrenergic blocking agents [7].

and it does not occur in asplenic persons [1]. The absence of a blocking effect of propranolol on the rise in platelets during exercise, and the rise in asplenic subjects, indicate that exercise-induced thrombocytosis is not mediated solely through stimulation of β -receptors by adrenaline and that the spleen is not the major source of the additional platelets appearing in the peripheral blood. BIERMAN *et al* [2] concluded from their study that the source of increased platelets after intravenous adrenaline was the pulmonary circulation: this is a possible source of the increased platelets during exercise.

Although the spleen does not appear to be the source of increased platelets during exercise, our results suggest that the spleen may have a modifying role in the response to exercise: in its absence 2 subjects had a continuing rise in the platelet count after completion of the exercise. It is notable that these were the 2 subjects with the highest initial platelet counts.

Acknowledgments We are grateful to the volunteers for their co-operation, to Miss MARY ALLARDYCE, ARLITT for technical assistance and to Dr GILLIAN FOWLER for statistical advice.

Summary

Short periods of brisk exercise induced a rise in the platelet count of normal men and women. This thrombocytosis was not prevented by the prior administration of the β -adrenergic blocking agent propranolol and occurred also in most asplenic subjects tested.

References

1. ASTER, R.H. Pooling of platelets in the spleen: role in the pathogenesis of 'hypersplenic' thrombocytopenia. *J. clin. Invest.* 45: 645 (1966)
2. BIERMAN, H.R., KELLY, K.H., CORDER, F.L., BYRON, R.L., J. POLSKATZ, J.A. and RAFFOORT, S. The release of leukocytes and platelets from the pulmonary circulation by epinephrine. *Blood* 7: 683 (1952)
3. BRON, R., MACFARLANE, R.G. and PHILLIPS, J. Observations on fibrinolysis. Experimental production by exercise and adrenaline. *Lancet* ii: 402 (1947)
4. GROSSER, E.B. and MILLER, R.T. The influence of brief periods of strenuous exercise on the blood platelet count. *Science* 89: 64 (1949)
5. LEACH, R. and GORDON, B. The effect of exercise on the distribution of corpuscles in the blood stream. *Amer. J. Physiol.* 77: 106 (1924)
6. KRSTICHOV, A. quoted by TOGIANIS, L.M. The mammalian blood platelet in health and disease. *Medicine* 17: 155 (1938)
7. McCLURE, P.D., INGRAM, G.I.C. and VAUGHAN JONES, R. Platelet changes after adrenaline infusions with and without adrenaline blockers. *Thromb. Diath. haemorrh.* 13: 196 (1965)

8. OETTEL, A. G. and SPANGLER, A. I. New optical and cytochemical techniques in haematology. In DYKE Recent advances in clinical pathology 2nd ed. (Churchill, London 1951).
9. PETERSON, G. D.; HARRISON, K. M.; SMITH, W. S., HAMILTON, A. and WOLFF, S. Effect of prolonged exercise on platelet adhesiveness. *Nature, Lond.* 197: 301 (1957).
10. SARAFAS, H. S. S.; KONTAKIS, A. and FRANK, M. H. Thrombocytosis evoked by exercise. *Nature, Lond.* 197: 721 (1961).
11. WACHSBERGER, K., PARCZWITZ, E.; ELLI, H. and KEMMLER, K. Der Einfluss körperlicher Arbeit auf die Zahl der Thrombocyten und auf deren Haftneigung. *Acta haemat., Basel* 18: 59 (1957).

Medical Service (Director: D.L. Deutner) USA General Hospital, Frankfurt/M

Severe Megaloblastic Anemia due to Nutritional Vitamin B₁₂ Deficiency

R. B. LEDBETTER, Jr and E. DEL POZO

In Western societies, the most common cause of vitamin B₁₂ deficiency is pernicious anemia. Various clinical conditions may predispose to this deficiency. It is stated that the occurrence of significant B₁₂ deficiency as a consequence solely of nutritional lack is rare [1, 2, 3]. This paper documents such a case and reviews the literature on the subject.

Case Report

E.S. (97th Gen H No. 233357) 19 years old white female, was admitted on March 28, 1967 with complaints of fever, nausea, excessive fatigue, and shortness of breathing. The fatigue and progressive dyspnea had begun approximately 2 months before admission. Fever began approximately 24 h prior to admission. Nausea had been noted for 3-4 weeks, with occasional vomiting. The patient denied menorrhagia, hematemesis, melena, diarrhea, or weight loss. She was employed as secretary and appeared to be fully carrying on her work until the day of admission. One of her associates had remarked to the patient just a few days before that she looked very pale. The patient had lived in the United States and Germany and had not travelled to tropical parts of the world. Her only significant past illness was bout of infectious hepatitis in May 1966 requiring 3-week hospitalization and with no apparent residual. Drug intake was limited to birth control pills which she had taken for several months prior to admission. Significantly the patient had been lacto-vegetarian for as long as she could remember.

Physical examination revealed: ery pale white female, alert and oriented and otherwise well nourished. No jaundice or cyanosis was visible. Temperature 38.6° C, pulse 126, blood pressure 110/70 mm Hg. There was no lymphadenopathy or petechia, but on funduscopy an area of hemorrhage was visualized on the temporal side of the left eye.

Laboratory studies. Initial hematocrit 10%, hemoglobin 4 g%, erythrocytes 1 million. Peripheral blood morphology: 2 nucleated red cells/100 white cells; marked anisocytosis and poikilocytosis, macrocytosis, polychromatophilia and basophilic stippling. Platelets definitely decreased on smear. Differential count of 500 leucocytes: segmented neutrophils 65.8%, bands 1.8%, metamyelocytes 1.2%, myelocytes 0.2%, promyelocytes 0.4%, lymphocytes 25.4%, eosinophils 0.4%, mononuclears 4.0%. Some of the mononuclears appeared to



Fig 1 Megaloblast in bone marrow smear ($\times 500$ photo $\times 4.25$).

have more lobate nucleus than usual. The segmented neutrophils occasionally showed hypersegmentation and slight toxic granulation.

Bone marrow on March, 29 marked megaloblastic erythropoiesis (fig. 1) giant myelocytes, metamyelocytes and bands. Megakaryocytes were decreased and somewhat hyperlobulated. Iron stain revealed adequate particulate iron. M.E. = 1.05. Hemoglobin electrophoresis A/A with 3.2% fetal. Coombs test negative. Serum Fe $61 \mu\text{g}^{100}$ total iron binding capacity $312 \mu\text{g}^{100}$ transferrin saturation 20%. Serum folic acid 10 ng/ml (Laribaich's test method normal 10–20 [4]).

Schilling test performed on the 5th hospital day normal with 21.5% of $0.47 \mu\text{C}$ $^{57}\text{CoB}_{12}$ excreted in urine in 24 h. D-xylose absorption test [5] normal with 12.4% excretion in urine in 5 h. Normal stomach acidity. Normal upper gastrointestinal and small bowel X-ray study. Serum carotene $70 \mu\text{g}^{100}$.

Urine analysis, blood urea, serum protein and electrophoresis, SGOT total bilirubin, all within normal limits. Blood and throat cultures, stool for ova, parasites and occult blood, all negative. Normal radiographs of chest, skull and femora.

Hospital course. Initially the patient was given 500 ml of packed red cells slowly and started on prednisone 40 mg daily because of her apparent critical condition. Prior to the bone marrow findings, other diagnoses were strongly entertained such as aleukemic leukemia, pancytopenia, myelofibrosis or myelophthisis of various types. After the bone marrow evaluation consistent with severe megaloblastic anemia, the patient was questioned more specifically regarding dietary history and found to have strong aversion of long standing to meat products. Prednisone was discontinued as soon as the basic problem was apparent. Parenteral B_{12} was administered $200 \mu\text{g}$ every 48 h followed by SCHILLING test (1,000 μg totaling to 2.2 mg B_{12} during the first 2 weeks. A definite hematologic response began about the 5th day and by day 10, the hematocrit, hemoglobin and red cell count had risen to 30%, 10 g% and 3 million respectively. No further B_{12} was given. The hematocrit, hemoglobin and red cell count continued to improve and by day 30 were 40%, 15g% and 5 million. The leukocytes remained low until second month and then returned to normal.

The patient continued to refuse meat products and could not be persuaded to change her abnormal eating habits. Over the next 2 months the patient was asymptomatic and the blood

counts remained stable. However the blood smear changed to macrocytic hypochromic pattern and serum iron confirmed the development of iron deficiency. Although iron stains of the initial bone marrow revealed adequate iron stores, the subsequent marked erythropoietic response to B₁₂ produced an iron deficiency. Apparently the iron reserves were borderline to start with, but appeared normal due to decreased F utilization before therapy.

Discussion

A careful review of the literature reveals that severe anemia due to isolated nutritional vitamin B₁₂ deficiency is very unusual.

A survey of 113 cases of nutritional megaloblastic anemia in India revealed that 54.9% had low serum folate, 5.3% had low serum folate and B₁₂, and 7% had deficiency of vitamin B₁₂ alone [6]. This study also attempted to correlate the serum folate and B₁₂ with the hematologic response to therapeutic trials of folic acid and B₁₂ parenterally. No correlation could be made. The conclusions which can be drawn from this study are that the major cause of megaloblastic anemia in India is folic acid deficiency and that nutritional B₁₂ deficiency is more common than in western societies. This is supported by other studies [7-8].

A survey of megaloblastic anemia in the South African Bantu revealed 34 cases associated with pregnancy, 111 cases in malnourished infants suffering from marasmus or Kwashiorkor, and one case in an adult male vegan [9]. The latter patient had free gastric acid after histamine and his hemoglobin rose slowly on normal diet. The other cases responded to therapeutic doses of either B₁₂ or folic acid given parenterally. In this study no absorption tests, X-rays, or stool examinations for ova and parasites were performed. Therefore, many factors which could have participated etiologically in the megaloblastic anemia were not excluded.

Moore *et al.* [10] studied a series of 23 patients with nutritional macrocytic anemia and evidence of multiple B vitamin deficiencies during 1940-1943 period. Most of these were older than 50 years, and males (widowers or bachelors) who cooked for themselves and therefore ate very poor diet particularly low in animal protein. All but 2 patients had experienced persistent diarrhea for months before admission. Many had evidence of cheilosis, peripheral neuritis, or pellagrous dermatitis. Stereal bone marrows were identical to those of pernicious anemia. Gastric analysis revealed normal acidity in 14, hypochlorhydria in 2, and achlorhydria in 9.

Since these cases occurred before vitamin B₁₂ or folic acid were isolated and purified, and there were chemical signs of multiple B complex deficiencies in many and evidence of malabsorption in those tested, it cannot be stated clearly whether or not any of these patients was suffering from isolated nutritional B₁₂ deficiency. Several other case reports in the older literature, prior to the discovery of B₁₂ and folic acid, may represent true nutritional B₁₂ deficiency but because of possible contributing factors, "shotgun therapy" and unavailability of specific B₁₂ absorption tests or serum levels, this cannot be established with accuracy [11-12, 13-14-15].

In a series of 333 cases of megaloblastic anemia studied with serum B₁₂ and folate levels by Varadi *et al.* [16] none was due solely to nutritional B₁₂ deficiency. Five cases were due to combined dietary deficiency of B₁₂ and folate. In addition, there were 161 cases of folate deficiency associated with pregnancy.

Worsh *et al.* [17] evaluated a group of 149 British vegans. The MCV of red cells was increased above normal, with the occasional finding of mild anemia. The average serum

B_{12} in British vegans was approximately 1/3 that of normal Briton. The hematologic changes were disproportionately slight.

SCHWARTZ [18] evaluated a group of 12 vegans ranging in age from 11 to 71 years and duration of veganism from 5-30 years. None had macrocytic anemia. Perhaps high intake of folic acid in these cases partially compensated for the hematologic deficiency of B_{12} . Interestingly two of these developed combined system disease.

SCHULMAN [19] reported a case of megaloblastic anemia in a young Hindu male vegan, student at the University of Minnesota. An initial SCHULMAN test, even with added intrinsic factor was abnormal. Vitamin A and glucose were malabsorbed also. The megaloblastic anemia responded to large doses of parenteral B_{12} and, 15 months later the SCHULMAN test had reverted to normal. However the vitamin A and glucose malabsorption did not improve. Tests for fat and folic acid absorption were normal, but were made more than a year after the anemia was corrected. Judging from the absorption studies, it is probable that this patient had tropical sprue, in addition to nutritional B_{12} deficiency and this combination led to his megaloblastic anemia.

HANAUER [20] presented a case of megaloblastic anemia in an elderly female who had been taking a diet of bread, margarine, tea and potatoes, plus 200 ml of milk daily for 11 years. In spite of a gastroenterostomy and achlorhydria, she had normal absorption of isotopic B_{12} . Interestingly the patient had consumed Glauber's salt daily for many years with a resultant 3-6 watery stools per day and this may have produced malabsorptive state. Presumably this cathartic was discontinued prior to the radioisotopic B_{12} absorption test. No folate studies were done, although almost certainly the above diet was deficient in folate as well. Treatment with parenteral B_{12} 200 μ g every 3 weeks resulted in hematologic improvement, however response to this dose of B_{12} is not of itself conclusive of pure B_{12} deficiency.

POLEKOVA [21] reported a case of "pernicious anemia" due to dietary B_{12} deficiency in a vegan of 8 years standing. Absorption of B_{12} was normal, however this was not tested until 3 weeks after therapy with parenteral B_{12} and folic acid was begun. In this regard, it is of interest that intestinal absorption of B_{12} has been shown to improve following treatment with B_{12} parenterally in various malabsorption states [22, 23]. Furthermore, although this patient undoubtedly had dietary B_{12} deficiency, consistent folate deficiency was not excluded.

BOCHER [24] reported a case of macrocytic anemia in a 40-year-old white female whose diet contained no meat or poultry however contained fish once weekly, an occasional egg or helping of cheese, and butter. Gastric analysis revealed free acid. The initial blood studies showed a red cell count of 3.8 million, Hb 11 g%, MCV 94 μ m³. Sternal marrow showed changes interpreted as typical of early megaloblastic anemia. A SCHULMAN test showed 7.8% excretion after treatment with oral intrinsic B_{12} had shown slow response. This case reacted suboptimally to super-physiologic doses of B_{12} given orally and even to large parenteral dose given with the SCHULMAN test. After repeated parenteral doses of B_{12} over several months, the red cell count and hemoglobin responded to near normal values. An isolated nutritional B_{12} deficiency in this case is questionable in view of the suboptimal response to B_{12} . A combination deficiency of folate and B_{12} would be suspected from the clinical course. A serum folate level might have resolved this question, but unfortunately was not obtained.

HINZ [25] reported a case of megaloblastic anemia in a male vegan of 13 years standing. A B_{12} absorption study was normal. Serum B_{12} was low and folate normal. The patient had been a habitual blood donor giving one pint of blood every 3 months for the preceding 3-4 years. Furthermore, he had hemorrhoids which had bled small amounts quite frequently. The important factor in this case was chronic blood loss, which produced an increased demand for B_{12} in a person with borderline reserves. This case offers an interesting similarity to ours, as the latter had been menstruating for 4-5 years.

CONNOR [26] described 75-year-old female vegan of 15 years duration, with megaloblastic anemia, histamine fast achlorhydria and biopsy proven atrophic gastritis. The patient was found to have CoB₁₂ normally and to have normal serum folate and low serum B₁₂. A good clinical response occurred after parenteral B₁₂ therapy. This case probably represents bona fide fratrilonal megaloblastic anemia due to B₁₂ deficiency however superimposed malabsorption of B₁₂ due to atrophic gastritis which later reversed on treatment, cannot be excluded.

A case of megaloblastic anemia in a vegan was reported by WILKINSON [7]. The patient was 64-year-old female vegan for 48 years, who was found to have low serum B₁₂, normal B₁₂ absorption, and had good clinical response to 1 mg of B₁₂ orally per day.

Lastly a special form of nutritional B₁₂ deficiency should be mentioned. This is known as megaloblastic anemia of infancy and usually occurs in breast fed infants during the first year post partum, and has been reported from Southern Europe particularly Italy [29-30] and from India [31]. In several cases reported from India, the mothers were found to have megaloblastic bone marrow, low B₁₂ in serum and breast milk, and normal SCHILLING tests [31]. Dietary history revealed that the mothers were vegans or lactovegetarians. LAMPERT [32] reported a case of this entity from Los Angeles in which mother was subsequently found to have pernicious anemia. The mother's breast milk was found to be very low in B₁₂ compared to milk from normal mothers. The old adage that 'mother milk is best' obviously is not true under these circumstances.

The patient described in our report had consumed no meat and only occasionally had taken milk or milk products for about 13 years, because of a personal distaste for animal flesh. She had remained well enough to carry on a sedentary job until a few days before admission, although she had felt progressively ill over a 2 month period. Her appearance on admission was that of an acutely ill, pale, toxic young female in good general nutrition. The initial impression was that she had either acute terminal leukemia or pancytopenia. Not until the bone marrow results were available did the examiner question her regarding dietary habits. This suspicion was aroused because of the rarity of pernicious anemia at this age, or folate deficiency in an otherwise well nourished young non-pregnant female. The dietary history coupled with normal gastric acidity and B₁₂ absorption (on the 5th hospital day), normal serum folate, and complete response to parenteral vitamin B₁₂, made the diagnosis of isolated nutritional B₁₂ deficiency almost certain. The borderline low D-xylose absorption and serum carotene were difficult to explain, especially in view of the normal upper gastrointestinal and small bowel series, and normal B₁₂ absorption. Perhaps there was some degree of malabsorption secondary to the effect of chronic B₁₂ deficiency on the epithelium of the small bowel [28] which did not affect B₁₂ or folate absorption.

The present case along with that of HIRSH [25], CONNOR [26] and

WEINAWER [27] represent those megaloblastic anemias in adults which most clearly are due to isolated nutritional deficiency of B_{12} .

Summary

A case is presented of severe megaloblastic anemia due to a nutritional deficiency of vitamin B_{12} in a young female lactovegetarian otherwise in good health and nutrition, and an attempt is made to review the literature pertaining to this subject.

References

1. SODERMAN and SODERMAN. Pathologic physiology; 4th ed., p. 806 (Saunders, Philadelphia/London 1967).
2. BISSON and McDONNELL. Textbook of medicine 15th ed., p. 1010 (Saunders, Philadelphia/London 1967).
3. WINTROBE. Clinical hematology; 6th ed., p. 544 (Lee & Febiger Philadelphia 1967).
4. BAKER, H.; HEUSERT V. FRANK, O.; PARKER, L. HUTNER, S. H. WASSERMAN, L. R. and SOMMER, H. A microbiologic method for detecting folic acid deficiency in man. *Clin. Chem.* 5: 275-280 (1959).
5. BISSON, J. A., J.; COLVER, P. J.; RAGLAND, S. JONES, C. M.; DUNN, G. D. and BOUTAS, E. The D-xylose absorption test in malabsorption syndromes. *New Engl. J. Med.* 235: 335-339 (1937).
6. BISSON, J. M. Some experiences with nutritional megaloblastic anemia. *J. postgrad. Med.* 11: 145-153 (1965).
7. DAS GUPTA, C. R. CHATTERJEA, J. B. and BASU, P. Vitamin B_{12} in nutritional macrocytic anemia. *Brit. med. J.* 5: 643-649 (1953).
8. TANNER, P. W. MOLLIS, D. L. and BERMAN, H. Vitamin B_{12} deficiency in the megaloblastic anemias of Malaya. *Brit. J. Haematol.* 4: 167-176 (1958).
9. METZ, J.; BLANCK, V. and STEVEN, A. Vitamin B_{12} and megaloblastic anemia in South African Bantu. *Brit. med. J.* 24-27 (1962).
10. MOORE, C. V. WILKINSON, R. MORGAN, V. and SPILL, T. D. Nutritional macrocytic anemia in patients with pellagra or deficiency of the vitamin B complex. *J. Lab. clin. Med.* 29: 1226-1255 (1944).
11. AYERLYD, W. R. Familial edema. *Brit. med. J.* 247-248 (1930).
12. O'HARA, D. and GREWAL, J. S. Unusual case of pernicious anemia. *Boston med. surg. J.* 197: 129-131 (1927).
13. KERN, R. A. Diet as a factor in the etiology of anemias. *Ann. Intern. Med.* 5: 729-730 (1931).
14. LOVOCOME, W. T. Importance of disturbances of nutrition in edematous states. *New Engl. J. Med.* 216: 1243-1250 (1931).
15. TOWNSEND, S. R. and BEAVER, F. B. Pernicious anemia due to deficiency of extrinsic factor. *Canad. med. Ass. J.* 47: 332-334 (1942).
16. VARADI, S. and EATON, A. Megaloblastic anemia due to dietary deficiency. *Lancet* 1162 (1964).
17. WOLFE, F. RADENOVICH, J. and STEINBERG, H. M. Human dietary deficiency of vitamin B_{12} . *Am. J. clin. Nutr.* 3: 373-382 (1953).

18. SMITH, A. D.: Vegetarian, clinical survey with observations on vitamin B₁₂ metabolism. *Brit. med. J.* **i**, 1635-1638 (1962)
19. SCHLESINGER, L. L. and SCHLESINGER, R. F.: Vitamin B₁₂ absorption studies in vegetarians with megaloblastic anemia. *Amer. J. clin. Nutr.* **12**, 70-74 (1963).
20. HARRISON, R. J., BOOTH, C. C. and MOLLER, D. L.: Vitamin B₁₂ deficiency due to defective diet. *Lancet* **i**, 727-728 (1956)
21. POLYCOVE, M., APT, L. and COLBER, M. J.: Pernicious anemia due to dietary deficiency of vitamin B₁₂. *New Engl. J. Med.* **253**, 164-169 (1956)
22. BRADY, E. A., ELLERY, S. and HARRIS, V.: Coexistent pernicious anemia and malabsorption in four patients. *Ann. Intern. Med.* **61**, 1246-1251 (1966)
23. HALTAVI, F. I., SODERQVIST, W. and GOLDSTEIN, F.: Intestinal malabsorption of vitamin B₁₂ in pernicious anemia. *Metabolism* **13**, 1312-1318 (1964).
24. BOWEN, M. S. and OLNEY, S.: Dietary deficiency of vitamin B₁₂. *Brit. med. J.* **ii**, 511-512 (1966)
25. HINES, J. D.: Megaloblastic anemia in an adult vegan. *Amer. J. clin. Nutr.* **19**: 260-268 (1966).
26. COVINO, P. M. and PIROLA, R. C.: Nutritional vitamin B₁₂ deficiency. *Med. J. Austr.* **451-453** (1963)
27. WINTER, S. J., STREET, R. R. and ZAMCHEK, N.: Gastric and hematologic abnormalities in vegans with nutritional vitamin B₁₂ deficiency. Effect of oral vitamin B₁₂. *Gastroenterology* **53**: 130-135 (1967)
28. BUDMAN, A.; ADOLAR, D. G. and ZAMCHEK, N.: D-xylose, potassium iodide absorption and serum carotene in pernicious anemia. *J. Lab. clin. Med.* **53**, 226-232 (1959)
29. PERRO, G. R., RUSSO, G. and LO JACONO, F.: Die hämatologische Reaktion auf kleine perorale Dosen von Vitamin B₁₂ bei der perniziösen Anämie des Säuglings. *Arch. Kinderheilk.* **152**: 109-121 (1956)
30. GERMAN, M.: Le anemia megaloblastica nell'infanzia. *Arch. ital. Pediat.* **20**, 395-402 (1960)
31. JADHAV, M., WEEB, J. K., VASHEVA, A. S. and BAKER, S. J.: Vitamin B₁₂ deficiency in Indian infants. A clinical syndrome. *Lancet* **ii**, 903-907 (1962)
32. LAMPERT, R. C., SWOPE, N. A. and CHADWICK, D.: Megaloblastic anemia of infancy secondary to maternal pernicious anemia. *New Engl. J. Med.* **274**, 1168-1171 (1966)

H. J. BENDISCH (editor) *Leukemia in Animals and Man*, 3rd International Symposium for Comparative Leukemia Research, Paris 1967. Bibliotheca Haematologica No. 50. Karger, Basel/New York 1968. XII+348 p., 89 fig., 1 cpl., 56 tab. Price sF 4.31 DM 79. / US \$ 18.95/1.8 s.

Since 1963 the "World Committee for Comparative Leukemia Research" promotes the co-operation of leukemia studies in man and animals by organizing symposia every second year. The proceedings of the 3rd symposium held in Paris 1967 are now being published. More than 80 contributions cover the large spectrum of basic research, pathogenesis, incidence and geographical distribution of leukemia in human and veterinary medicine. The reported main lectures are: Determinants of Viral Carcinogenesis (J. L. MELnick); Interactions of RNA Oncogenic Viruses and Cells (P. VANDER); Viral Research on Bovine Leukosis (R. M. DETROIT); The Epidemiology of Bovine Leukosis (R. R. MARSHALL and B. A. AIT); Advances in Feline Leukemia (O. JARRETT *et al.*) and Recent Studies on Leukemia and Solid Tumors in Mice and Man (L. DANCOWSKI). Unfortunately only short abstract is given of F. J. RAESCHER's main lecture "Progress in the Viral Research of Human Leukemia". In large number of additional communications variety of recent results in leukemia research are presented most of them dealing with viral etiology, immunology and electron microscopic observations. The book provides an excellent review of the actual basic knowledge in the field of leukemia and can be recommended to every hematologist. The subscribers to *Acta Haematologica* and *Vox Sanguinis* receive the volume at a reduced price.

H. R. MARTI, *Geneve*

R. GROSS *Medizinische Diagnostik. Grundlagen und Praxis*. Heidelberger Taschenbücher Band 48. Springer, Berlin 1969. 218 S., 12 Abb., 14 T. b. Preis DM 9.80 \$ 2.45.

Die vorliegende Monographie, die weit mehr als den Namen eines Taschenbuches verdient, habe ich, bevor das Besprechungs Exemplar eingetroffen war, in einem Zug und mit grossem Genuß und Gewinn durchgesehen. Die wohl abgewogenen 6 Kapitel mit reichlich Zitate und Literaturangaben zeigen dem Praktiker aber auch dem klinisch tätigen Arzt die verschiedenen Aspekte der Diagnostik, auch ihre Grenzen, Fehlerquellen und Abmessungen, die breite Fächerung und Bedeutung der Laboruntersuchungen und die mathematisch-mathematischen Methoden in ihrer zunehmenden Wichtigkeit. Beherrschende Ausführungen liegen über die Labor-Glaubwürdigkeit vor, wobei es der Praxis auffällt, wie kleine Abweichungen von der Norm oft überbewertet werden und nicht selten die Normalwerte schlechter bekannt sind als die gängigen Normkurven. Alles in allem eine ausgezeichnete Zusammenstellung über ein Gebiet, das nur ärztlichen Klinik gehört und im Zeitalter der aufkommenden Computer immer wieder zu überdenken ist. Gerade auch im Hinblick auf den ständigen Anspruch von M. McLennan: Ein Spezialist ist ein Mensch, der auch auf den kleinsten Fehler achtet, während er auf den grossen Trugschluss ruht.

F. WETTERBERG, *Hausbrühl*

H. L. ZOLLINGER *Pathologische Anatomie*. Thieme, Stuttgart 1968. Vol. 1 Allgemeine Pathologie. VII + 335 p., 136 meist zweifarbige Abbildungen in 197 Einzeldarstellungen. Flexibles Taschenbuch. Preis DM 9.80. Vol. 2 Spezielle Pathologie. XVI + 560 p., 575 meist zweifarbige Abbildungen in 335 Einzeldarstellungen. Flexibles Taschenbuch. Preis DM 14.80.

Es verdankenwerter Weise hat es der Verlag Thieme unternommen, seine bekannte und gut eingeführte Serie der Taschenbücher auf ein grosses Gebiet wie die pathologische Ana-

tonie auszuzeichnen. Dass dieser Versuch gelungen ist, ist in erster Linie darauf zurückzuführen, dass dafür ein im Unterricht so erfahrener Lehrer wie Prof. ZOLLNER als Autor gewonnen werden konnte. Wenn diese Bücher eine Bausteinsammlung bieten sollen, wie eindeutig gesagt wird, so handelt es sich um eine sehr oftbenutzte Sammlung, die in zwar knapper aber erschöpfender Weise die wesentlichen Daten vermittelt, die der Student benötigt. Aller überflüssige Ballast ist weggelassen, dafür werden die Grundlagen um so sauber und klarer herausgearbeitet. Es darf sogar erwartet werden, dass ein Student mit diesen Kompendien, ergänzt und vertieft durch eine umfassende Vorlesung auskommen mag. Eine klare und logische Gliederung des Stoffes und ein ausführliches Sachverzeichnis erleichtern das Studium und erlauben eine rasche Orientierung über jeden Fragenkomplex. Besonders hervorzuheben und in ihrer Art beispielhaft sind die zahlreichen skizzenhaften Abbildungen, die besser als jede Beschreibung die wesentlichen Befunde wiedergeben und über die reine Morphologie hinaus auch pathophysiologische Zusammenhänge zur Darstellung bringen.

Der erste Band vermittelt die Grundlagen der allgemeinen Pathologie (Mikrobildungen, regressive und progressive Veränderungen, Störungen von Atmung und Kreislauf, Entzündung, Tumoren, congenite Nosen). Im zweiten Band werden diese Grundlagen auf die einzelnen Organsysteme bezogen, wobei gerade hier die Ansätze auf Pathophysiologie und Klinik besonders wertvoll und anregend sind. Die hämatologischen Erkrankungen, sonst ein Stoffkind der pathologisch-anatomischen Lehrbücher, finden gebührende Würdigung, wobei sogar die hämorrhagischen Diathesen in ihrer Symptomatologie und Pathogenese dargestellt sind.

Autor und Verlag haben mit diesen beiden Bänden bewiesen, dass dem Studenten auch auf einem grossen Gebiet der Medizin mit dem Taschenbuch ein wertvolles Lehrmittel in die Hand gegeben werden kann. Darüber hinaus ist die Lektüre auch für den Anfänger und den praktisch tätigen Arzt, der über ein Gebot eine rasche Orientierung sucht, nicht nur mitbringend, sondern in mancher Hinsicht anregend.

H. LITKE, Basel

E. DUTCH, E. GILLICH and K. MOSE: *Metabolism and Membrane Permeability of Erythrocytes and Thrombocytes*. Thieme, Stuttgart 1969. XV + 480 p., 407 fig., 101 tab. Preis DM 110.

Biologische Membranen sind in den letzten Jahren dank der Entwicklung neuer physikochemischer Methoden auf immer grösseres Interesse gestossen. Fragen des allgemeinen Zellstoffwechsels sind aufs engste damit verknüpft. Die Zellen des Blutes eignen sich ganz besonders für solche Untersuchungen. Da das Schrifttum bald nicht mehr zu überblicken ist, war es ein glücklicher Gedanke, die verschiedenen am Membran- und Zellstoffwechsel interessierten Arbeitsgruppen zu einem gemeinsamen Gespräch in Wien zusammenzurufen. Gegen zweihundert Teilnehmer haben diesem Ruf Folge geleistet. Der vorliegende Band umfasst sämtliche (nahezu 100) vorgetragenen Referate, zum Teil in etwas gekürzter Form. Die ebenfalls wiedergegebenen Diskussionsvoten sind redaktionell geschickt bearbeitet worden.

Eine erste Gruppe von 11 Arbeiten befasst sich mit dem Stoffwechsel normaler Erythrozyten. Die folgenden 9 Artikel sind dem Stoffwechsel pathologischer Erythrozyten gewidmet, wobei auch die Bedeutung der Milz kurz gestreift wird. Eine weitere Gruppe beschäftigt sich mit den enzymatischen Analysemethoden. Ein besonders grosser Abschnitt ist dem Stoffwechsel und der Funktion der Thrombocyten gewidmet. Die drei letzten Kapitel befassen sich mit den Membranen von anderen Zellen (Thrombocytenmembran 11 Arbeiten, Erythrocytenmembran 11 Arbeiten, Permeabilität der Erythrocytenmembran 11 Arbeiten).

Die Zusammenfassung der Artikel zu den einzelnen Kapiteln scheint nicht immer zwingend, das übersichtliche Inhaltsverzeichnis und ein Sachregister erleichtern aber das Auffinden

Libri

H. J. BENDER (editor) *Leukemia in Animals and Man*. 3rd International Symposium for Comparative Leukemia Research, Paris 1967. Bibliotheca Haematologica Vol. 30.arger Basel/New York 1968. XII + 348 p., 89 fig. 1 cpl., 56 tab. Price: sF 40 DM 79 -/ US \$ 18.95/158 s.

Since 1963 the World Committee for Comparative Leukemia Research promotes the co-operation of leukemia studies in man and animals by organizing symposia every second year. The proceedings of the 3rd symposium held in Paris 1967 are now being published. More than 80 contributions cover the large spectrum of basic research, pathogenesis, incidence and geographical distribution of leukemia in human and veterinary medicine. The reported main lectures are: Determinants of Viral Carcinogenesis (J. L. MILLICK), Interactions of RNA Oncogenic Viruses and Cells (P. VIGOU), Viral Research on Bovine Leukosis (R. M. DETCHER), The Epidemiology of Bovine Leukosis (R. R. MARHAM and D. A. ARR), Advances in Feline Leukemia (O. JARRETT *et al.*) and Recent Studies on Leukemia and Solid Tumors in Mice and Man (L. DMOCHOWSKI). Unfortunately only short abstract is given of F. J. RAJCHOWSKI's main lecture 'Progress in the Viral Research of Human Leukemia'. A large number of additional communications, variety of recent results in leukemia research are presented, most of them dealing with viral etiology, immunology and electron microscopic observations. The book provides an excellent review of the actual basic knowledge in the field of leukemia and can be recommended to every hematologist. The subscribers to *Acta Haematologica* and *Vox Sanguinis* recieve the volume at reduced price.

H. R. MAST, *Amst*

R. GROSS *Medizinische Diagnostik. Grundlagen und Praxis*. Heidelberger Taschenbücher Band 48. Springer Berlin 1969. 218 S., III Abb., 14 T. b. Preis DM 9.80 \$ 2.43.

Die vorliegende Monographie, die weit mehr als den Namen eines Taschenbuches verdient, habe ich, bevor das Besprechungs-exemplar eingetroffen war, in einem Zug und mit grossem Genuß und Gewinn durchgesehen. Die wohl abgegrenzten 6 Kapitel mit reichlich Zitate und Literaturangaben zeigen dem Praktiker, aber auch dem Klinisch tätigen Arzt die erschöpfenden Aspekte der Diagnostik, auch ihre Grenzen, Fehlerquellen und Abstraktionen, die breite Fächerung und Bedeutung der Laboruntersuchungen und die mathematisch-maschinellen Methoden in ihrer zunehmenden Wichtigkeit. Beherzungs-werte Ausführungen liegen über die Labor-Glaubwürdigkeit vor, wobei an der Praxis auffällt, wie kleine Abweichungen von der Norm oft überbewertet werden und nicht selten die Normwerte schlechter bekannt sind als die gängigen Börsenkurse. Alles in allem: eine ausgezeichnete Zusammenfassung über ein Gebiet, das zur ärztlichen Klausur gehört und im Zeitalter der aufkommenden Computer immer wieder zu überdenken ist. Gerade auch im Hinblick auf den zu erwartenden Ausdruck von M. McLEMAN: Ein Spezialist ist ein Mensch, der auch nicht den kleinsten Fehler macht, während er auf den grossen Troschuh zutrifft.

F. WERNER, *Hinterlar*

H. U. ZOLLINGER *Pathologische Anatomie*. Thieme, Stuttgart 1968. Vol. 1 Allgemeine Pathologie. XII + 335 p., 136 meist zweifarbige Abbildungen in 192 Einzelanstellungen. Flexibles Taschenbuch. Preis DM 9.80. Vol. 2 Spezielle Pathologie. XVI + 360 p., 375 meist zweifarbige Abbildungen in 553 Einzelanstellungen. Flexibles Taschenbuch. Preis DM 14.80.

In erdankenswerter Weise hat es der Verlag Thieme unternommen, seine bekannte und gut eingeführte Serie der Taschenbücher auf ein grosses Gebiet wie die pathologische Ana-



Ludwig Hellmeyer

Prof LUDWIG HELLMAYER who died unexpectedly on September 6 at the age of 70 was particularly interested in haematology. Already many years ago when he was Associate Professor of Medicine at the Medizinische Universitätsklinik in Jena he published his studies on Iron therapy, Serum iron and Iron Deficiency.

Later when he held the chair of Internal Medicine at the University of Freiburg i. Br. he was the author of the outstanding Atlas der klinischen Hämatologie (with BROEMAN) and edited the comprehensive Handbuch der gesamten Hämatologie. Since ACTA HAEMATOLOGICA were founded (1948) HELLMAYER was very active as one of our Contributing Editors. A number of his important papers appeared in our journal.

The International Society of Haematology had elected HELLMAYER President for the meeting which will take place in München 1970.

His untimely death is deeply felt.

The Editors-in-Chief and the Publisher

Department of Anatomy State University of New York at Buffalo, Buffalo, N.Y.

Electron Microscopic Study of the Granules in Guinea Pig Bone Marrow Basophils¹

BEATRICE S. T. CHAN²

It is generally agreed that the three principal types of granulocytes develop by a common pattern of maturation through the stages of myeloblast, progranulocyte, myelocyte, metamyelocyte, band cell and mature cell. During development the three cell lines - neutrophil or heterophil, eosinophil and basophil - can be identified as early as in the progranulocyte stage by the appearance of their specific granules. It would be, therefore, interesting to know how these specific granules develop from a common ancestral myeloblast. The development and maturation of the granulocytes and their granules had been studied previously by PEARSE [8, 9] WINQVIST [17] BAETON and FARQUHAR [1] TAKEOKA *et al.* [11] and WETZEL *et al.* [14] and of the mast cells and their granules by HUBB *et al.* [6] THIERY [12] COMBS *et al.* [4] and COVBS [3]. The exact mode of formation of basophil granules, however, has not been elucidated. This paper is to report electron microscopic observations on the granules of developing basophils in the guinea pig bone marrow.

Material and Methods

Thirteen male guinea pigs of Dunkin-Hartley strain, weighing 400-600 g., were used. Previous investigations [2, 15] showed that the production of basophils in the bone marrow was increased after administration of horse serum. In order to have a greater number of basophils for the study a single i.p. injection of 0.5 ml. of horse serum was given to each

Supported by Public Health Service research grant CA3158 from the National Cancer Institute and in part by grant P 394 from the American Cancer Society.

On leave from the University of Hong Kong, under Dr. Henry C. and Bertha H. Burwell Fellowship grant of the State University of New York at Buffalo.




Fig 1 Golgi complex of basophil myelocyte. Budding off of granule precursors (arrows) from the ends, and *tu* from the convex side of Golgi cisternae. Some (G) are scattering in the vicinity of Golgi complex ($\times 10,600$); *b* A finely granular vacuole is pinching off from the convex side of Golgi cisterna (arrow). Small, young granules (G) are seen close to the Golgi complex ($\times 10,600$).

animal 7 days before it was killed. Perfusion-fixation with warm 0.1 M phosphate-buffer solution, pH 7.4 followed by cold 4% glutaraldehyde in the same buffer was performed through the abdominal aorta of the animal under chloral hydrate anaesthesia (1 ml of 3.5 aqueous chloral hydrate per 100 g body weight). Both femora were removed immediately after perfusion and the pencils of bone marrow were immersed quickly into fresh cold 4% glutaraldehyde. The bone marrow was then cut into small pieces (0.1–0.2 mm thick) with sharp razor blade, and the chosen pieces were reimmersed in fresh 4% glutaraldehyde for 1–1 h. They were then postfixed in phosphate-buffered 1% osmium tetroxide for 1 h at 4°C [7]. The tissue specimens were dehydrated with graded ethanol, and embedded in Maraglas mixture [10].

Ultrathin sections were cut on Sorvall Porter Blum MT 2 ultramicrotome with glass knives. They were stained with lead citrate [13] prior to examination with JEM-6C electron microscope.

Results

The majority of basophils observed in the bone marrow sections were myelocytes and metamyelocytes, which were characterized by their relatively large and oval-shaped granules and their eccentric nucleus. The basophils could usually be distinguished from the eosinophils because the latter had smaller granules which were often elliptical in shape with one (occasionally two) rectangular profiled crystalline structure.

The Golgi complex was very prominent in the basophil myelocytes and metamyelocytes. Profiles of centriole were occasionally observed in close relationship to the Golgi complex. The cytoplasm of myelocytes and metamyelocytes contained granules of different stages, numerous ribosomes and abundant rough-surfaced endoplasmic reticulum which appeared slightly dilated with a finely particulate material of medium opacity in the cisternae. Mitochondria were large and moderately dense.

Formation of basophil granules During electron microscopic examination of the bone marrow sections the Golgi complex was prominently in view in the developing basophils. Its flattened cisternae became dilated and sacculated with a lower electron-opaque material than the surrounding cytoplasmic matrix. As the saccules of the cisternae were well formed, they seemed to have pinched off one after another from the ends of the cisternae (fig. 1a) and from both sides of the sacculations along the cisternae to form vacuole-like granules (fig. 1b). Some of them were still connected to the cisternae and had not yet completely separated from them. These vacuole-like granules of various sizes were seen scattering in the vicinity of the Golgi complex between the



Fig. 2. Golgi complex of basophil myelocyte showing the distribution of the granules (G) between cisternae on both the convex and concave surfaces, and around the Golgi complex. Er = endoplasmic reticulum ($\times 10,500$).



Fig. 1. Two basophil granules showing their close relationship with the rough-surfaced endoplasmic reticulum. Gr. The continuity between the limiting membrane of granule and the cistern of endoplasmic reticulum is shown by arrow. 10,000

cisternae on the convex and concave faces and around the sides of the Golgi complex (fig 2) The definite granules of early forms were membrane bound and had a finely granular structure of medium density They looked quite similar to the cross-sectioned cisternae of the endoplasmic reticulum They were identifiable by their smooth outline, and denser and more osmiophilic content while the endoplasmic reticulum usually had a rough outline studded with ribosomes, and was relatively lighter in density and less osmiophilic.

Aggregation of small granules to form larger granules might be present in basophils in the process of development but it did not seem to be so evident as in the developing eosinophils The content of some basophil granules appeared coarser than that of the others. As the granules moved away from the Golgi region, they were often seen to have close relationship with the rough-surfaced endoplasmic reticulum the latter either surrounded the granules or contacted their limiting membrane. In some instances, a continuity could be observed between the limiting membrane of the granules and the cisternae of the endoplasmic reticulum (fig 3 arrow) The electron density of the granules seemed to increase with the maturity of the granules. There might be reorganization and condensation of the granule content for the mature granules appeared to be smaller denser and more homogeneous.

All the basophil granules had a well-defined limiting membrane beneath which a low electron-dense area of varying width might be present and appeared like a halo (fig 3)

Internal ultrastructure of basophil granules The majority of basophil granules in myelocytes and metamyelocytes showed a lamellated structure (fig 4a) The lamellation consisted of two-dimensional sets, each having a series of parallel electron-opaque lamellae of about equal thickness. These lamellae were spaced regularly apart and the spacings were about the same in thickness as the lamellae The lamellation therefore, appeared as a series of alternate dense and light lines (fig. 4a) One lamella and its adjacent spacing together measured 10 nm thick. The lamellae of both sets ran obliquely to the long axis of the granule but in different directions and at an angle of 112.5 degrees between them they interdigitated to produce a regular network (fig 5) In the sections, therefore four possible types of lamellation could be seen The granules might be cut along the plane of either set of the lamellation (fig 4a A) or obliquely to the lamellae (fig 4a, B) the sections might be exactly at the intersections of the two




Fig. 4a. Basophil granules. *A* Lamellation cut along the plane of the lamella showing series of alternate dense and light lines of equal thickness. *B* Lamellation cut obliquely to the lamella. *C* Higher magnification of basophil granule showing honeycomb lamellations.



Fig. 5. Basophil granules showing interdigitations of the lamellae with each other (squares) and the dotted appearance of the granule (D) when cut between lamellae of one set and across those of the other ($\times 25,000$).

sets of lamellae (honeycomb pattern in fig. 4b, C) or right across the spacing of one set and the lamellae of the other (fig 5 D)

Discussion

The formation of granules in the basophils of guinea-pig bone marrow observed in this investigation is essentially similar to that in neutrophil and eosinophil series described by BASTON and FARQUHAR [1] and WETZEL *et al* [14] namely that the granule precursors are produced from Golgi complex. These authors reported that the granule precursors are formed by budding off from the ends of Golgi cisternae. My observations show however that the formation can take place at the ends as well as along the sides of the cisternae. The granules seen in the vicinity of Golgi complex are of various sizes and of slightly different density. This may indicate different stages of the granule development. The granules are closely related to the endoplasmic reticulum through which new material may be continuously added to the granules. Further maturation of the granules may probably take place by reorganization and condensation, because the mature granules are often smaller and denser than the immature ones.

It was noted in the bone marrow sections that the basophil granules are limited by a membrane and that some granules are surrounded by a halo of electron density beneath the limiting membrane. These features may be due possibly to partial separation of the granule from its membrane as a result of fixation and dehydration.

Two sets of lamellation are present in the basophil granules. The third-dimensional lamellation which, if present [5] would run longitudinally along the long axis of the granule has not been observed. In any longitudinal sections of the granules, the lamellae are never running straight on the sections from one end to the other. Further more if the lamellations were three-dimensional at least one set of the lamellae in any possible sections would appear either straight or oblique and the whole granule would never be honeycomb in appearance as seen in figure 4b.

During my examination of basophil granules, the formation of eosinophil granules was also observed. Though the eosinophil granule precursors are produced in the same manner as the basophil precursors from the Golgi complex, the content of the former is different from

that of the latter. In the eosinophils some highly electron-dense material appears first inside the cisternae of Golgi complex. This dense material then accumulates to form the core of the granule precursors. The aggregation of immature granules from the small to the big ones is more evident in eosinophils than in basophils. Intimate relationship of the immature granules with the endoplasmic reticulum has also been seen in the eosinophils. Synthesis, reorganization and condensation of the granule constituents may also be suggested for further maturation of eosinophil granules.

Acknowledgment. I wish to express my sincere gratitude to Dr OLIVER P JONES and Dr JOSEPH C. LEE for reading my manuscript, for their comment, and for the laboratory facilities available to me during the course of this investigation. I also wish to thank V. JONES WORTH and Miss A. S. SCOTCHDOPOLE for their technical assistance.

SUMMARY

The development and maturation of basophil granules were studied electron-microscopically in guinea-pig bone marrow. The granules of basophils appeared to be produced by budding off from the Golgi complex. There might be aggregation of small granules to form larger ones during the process of development and the granules might also increase their constituents and size by continuous contribution of new material from the adjacent rough-surfaced endoplasmic reticulum. The basophil granules are characterized by lamellar ultrastructure which is composed of two-dimensional sets, running obliquely to the long axis of the granule and interdigitating with each other at an angle of 112.5 degrees. Each lamella and its adjacent spacing (one dense and one light line together) measured about 10 nm in thickness.

References

1. BARTON, D. F. and FARBER, M. G. Origin of granules in polymorphonuclear leukocytes. *J. Cell Biol.* **20**, 277-301 (1966).
2. CHAN, B. S. T. and LOVLEY, J. M. The basophil cells of guinea-pig bone marrow and their response to bone serum. *Immunology, Lond.* **3**, 237-243 (1960).
3. CONN, J. W. Maturation of rat mast cells. An electron microscope study. *J. Cell Biol.* **31**, 563-575 (1966).
4. CONN, J. W.; LACHOWITZ, D. and BENNETT, E. P. Differentiation and proliferation of embryonic mast cells of the rat. *J. Cell Biol.* **25**, 577-592 (1965).
5. FIDORCO, M. E. and HIRSCH, J. G. Crystalline structure in granules of guinea-pig basophils and human mast cells. *J. Cell Biol.* **26**, 973-976 (1965).
6. HONE, R. O., BURCH, G. E. and PHILLIPS, J. H. Electron-microscopic observations on the human mast cell. *Amer. Heart J.* **60**, 121-127 (1960).
7. MILLENO, G. Further observations on phosphate buffer for osmium solution. *Proc. 5th Int. Congr. Elect. Micro., Philadelphia*, vol. 2, p. P-8 (Academic Press, New York/London 1962).

8. FLAIZ, D. C. Marrow cells seen with the electron microscope after ultrathin sectioning. *Rev. Haemat.* 19: 300-313 (1955).
9. FLAIZ, D. C. An electron microscopic study of red bone marrow. *J. Haemat.* 11: 201-226 (1956).
10. SMITH, R. O., KATTAK, V. C. and FREEMAN, J. V. Technical modifications in Maraglas embedding. *J. Cell Biol.* 17: 203-207 (1963).
11. TAKIURA, O., MATSU, S. and ASHIMURA, T. Electron microscopic observations on the finer structure of basophilic granulocytes of newt. *Acta haemat., Basel* 35: 344-349 (1966).
12. TREURY, J. P. Etude au microscope électronique de la maturation et de l'excrétion des granules des mastocytes. *J. Microscopie* 2: 49-56 (1963).
13. VENABLE, J. H. and COOPERHILL, R. A simplified lead citrate stain for use in electron microscopy. *J. Cell Biol.* 25: 407-408 (1963).
14. WATZEL, B. A., HOWE, R. G. and SPICER, S. S. Fine structural studies on the development of heterophil, eosinophil, and basophil granulocytes in rabbits. *Lab. Invest.* 16: 419-523 (1966).
15. WINGWIT, G. Experimental production of basophil granulocytes in the guinea pig. *Exp. Cell Res.* 15: 7-12 (1960).
16. WINGWIT, G. The ultrastructure of the granules of the basophil granulocyte. *Z. Zellforsch. Mikroskop. Anat.* 52: 475-481 (1960).
17. WINGWIT, G. Electron microscopy of basophilic granulocytes. *Ann. N.Y. Acad. Sci.* 101: 35-53 (1963).

Department of Medicine, University of Cambridge, Cambridge

Periodic Acid-Schiff Reaction in Human Basophilic Leucocytes

D. T. KAUF

Relatively few studies have been made on the PAS reaction and glycogen content of the basophilic leucocytes because of their scarcity in the peripheral blood. Basophils are generally considered to be PAS positive. However opinions differ regarding the substance responsible for the PAS positivity. SMITH [1] and WILLOCK *et al* [2] showed that the PAS positive material represented glycogen and was completely removed by salivary diastase. ASTALDI [3] found the granules to be only partially diastase labile. ACKERMAN [4] found both diastase labile and resistant granules, the latter probably containing heparin monosulfuric ester. There was also disagreement regarding the identity of the basophilic and the PAS positive granules. SMITH [1] found the basophilic granules to be PAS negative. ACKERMAN [4] stated that the diastase resistant PAS positive granules represented the basophilic granules. DUNN and SPICER [5] also suggested that the basophilic granules were PAS positive. In view of these controversies, this study was undertaken to determine the PAS reactivity of the basophilic granules and the diastase lability of the PAS positive granules.

Methods

Air dried peripheral blood smears or buffy coat smears were stained with the Leshman technique. The basophils were identified and photomicrographs were taken. The slides were then stained with the PAS technique according to the method of HAYDON *et al* [6]. The same cells were again identified and photographed. Salivary amylase digestion was done before the periodic acid treatment. Specimens for electron microscopy were prepared according to the methods of ANDERSON [7] and WATANABE [8]. One μ m thick Araldite




Fig. 1 Basophils, consecutive Leishman (left) and PAS stains (right) *a, b, c, d* from patient with chronic myelocytic leukaemia, *f* from normal man, *g, h* from another patient with chronic myelocytic leukaemia.

sections directly adjacent to the ultra-thin sections were mounted on microscopic slides and stained with the PAS technique. Salivary amylase digestion was done prior to fixation with glutaraldehyde.

Results

Consecutive Leishman and PAS stains Photomicrographs of 36 basophils from 3 normal men and 2 patients with chronic myelocytic leukaemia and elevated basophilic counts were compared. The discrete basophilic granules were PAS negative. The discrete PAS positive granules corresponded with clear spaces in the Leishman stained specimens (fig. 1). Some basophils showed no discernible PAS positive granules (fig. 2). In a few areas where there were dense aggregates of basophilic granules, faint PAS positivities could be seen which did not correspond in sizes or shapes to the basophilic granules. There was no apparent difference between the normal and leukaemic basophils except that some basophils of one of the leukaemic patients showed unusually large blocks of PAS positive material.

Salivary amylase digestion. Buffy coat smears from 4 normal men were stained with the PAS technique with and without salivary amylase digestion. In the untreated smears PAS positive basophils were readily identified. No PAS positive cells could be seen in the smears previously treated with salivary amylase. Similarly smears from 3 patients with chronic myelocytic leukaemia and white cell counts of 15 600 (18 basophils), 9 800 (6.6 % basophils) and 11 700 (3.6 basophils) showed no PAS positive basophils after salivary amylase digestion.

Electron microscopy Seven basophils in ultra thin and thick section pairs from one patient with chronic myelocytic leukaemia and elevated basophilic count were compared. Three basophils in ultra thin sections showed conspicuous localized aggregates of glycogen in addition to scattered particles in the cytoplasm. These areas corresponded well with the PAS positivities in the adjacent thick sections of the same cell. On the other hand areas which contained aggregates of basophilic granules in the ultra-thin sections showed no PAS positivity in the corresponding areas of the thick sections (fig. 3). The glycogen particles in the ultra thin sections were completely removed by salivary amylase digestion.

It would appear from these studies that basophilic granules are not identical with the PAS positive granules. Since the PAS positivity




Fig 2 Basophils, consecutively Leshman (left) and PAS stains (right) a, b from patient with chronic myelocytic leukaemia, c, d from normal man.

is completely removed by salivary amylase, it must represent glycogen in the cytoplasm of the cell. The diastase labile particles in the ultrathin sections stained with lead were also identified as glycogen [8-9]. The close proximity of these glycogen particles to the basophilic granules as shown previously by several workers [6-7, 10] and also in this study may well explain the occasional overlapping of PAS positive material and basophilic granules.

Acknowledgments. The author is indebted to Professor F. G. J. HAYMON for his helpful suggestions and to Messrs. R. J. FLEMING and M. A. PEACOCK for the microscopic and electron microscopic reproductions.

Summary

By the use of consecutively Romanowsky and PAS stains and the correlation of ultrathin and thick sections, basophilic granules in human leucocytes were found to be PAS negative. The PAS positive material in the cytoplasm corresponded to the extra-granular glycogen which was removed by salivary amylase.



Fig. 2. Adjacent thick and ultra-thin sections of basophil. Ultra-thin section stained with lead citrate ($\times 12,800$) thick section stained with PAS.

References

1. SMITH, C. Glycogen in basophilic leucocytes in human blood serum. *Proc. Soc. exp. Biol.*, NY 77: 209-210 (1949).
2. WILLOCK, G. B., RHEDGOLD, J. J. and DEMPSEY, E. W. The occurrence of the Periodic acid-Schiff reaction in various normal cells of blood and connective tissue. *Blood* 4: 562-568 (1949).
3. AITALA, G., RONDANELLI, E. G. et BERNARDINI, E. Recherches cytochimiques sur la moelle osseuse et le sang d'une leucémie à basophiles. *Rev. Hémat.* 2: 105-118 (1953).
4. ACKERMAN, G. A. Cytochemical properties of the blood basophilic granulocytes. *Ann. NY Acad. Sci.* 103: 376-393 (1963).
5. DEVER, W. B. and SPENCER, S. B. Sulfated mucosubstances and basic proteins in human granulocytes. *Fed. Proc.* 27: 671 (1968).
6. HAYMER, F. G. J., QUAGLIARO, D. and FLEHMAN, R. J. Consecutive use of Romanowsky and periodic-acid Schiff techniques in the study of blood and bone marrow cells. *Brit. J. Haemat.* 6: 23-25 (1960).
7. ANDERSON, D. R. Ultrastructure of normal and leukemic leukocytes in human peripheral blood. *J. Ultrastruct. Res. Suppl.* 8: 1-42 (1966).
8. WATANABE, I., DORANTE, S. and HODGATT, N. Method for electron microscopic studies of circulating human leukocytes and observations on their fine structure. *J. Ultrastruct. Res.* 20: 366-382 (1967).

9. BIA, A. C. Identification and structural forms of human particulate glycogen. *Lab. Invest.* 12: 1179-1197 (1963)
10. REVEL, J. P. Electron microscopy of glycogen. *J. Histochem. Cytochem.* 12: 104-114 (1964)
11. ZUCKER FRANKLIN, D. Electron microscopic study of human basophils. *Blood* 28: 878-890 (1967)

Department of Internal Medicine, Research Institute for Nuclear Medicine and Biology
Hiroshima University (Director: Prof. H. Uchiryo) Hiroshima

Ultrastructural Localization of Alkaline Phosphatase in Human Neutrophils

T. NAKATSU

Since the histochemical demonstration of alkaline phosphatase in leukocytes was established by WACISTERY [1] in 1946 several methods have developed and its clinical significance has been clearly ascertained in some disorders. The ultrastructural localization of alkaline phosphatase was also found in such tissues as kidney intestine and cerebrum [2]. Recently fine structural localization of this enzyme in rabbit heterophil leukocytes was described [3-4] but not that in human neutrophil leukocytes.

In the present study the ultrastructural demonstration of alkaline phosphatase in human neutrophil leukocytes was undertaken according to MAYAHARA's alkaline phosphatase procedures [2] which have recently been developed for tissue section staining.

Materials and Methods

Heparinized venous blood obtained from a woman was centrifuged for 5 min at 500 rpm and the supernatant was centrifuged again for 5 min 2,000 rpm in cold room. The leukocyte sediment was suspended in saline solution and rinsed three times, and the sediment was added to MAYAHARA's alkaline phosphatase incubating medium which was prepared just before incubation. Immediately after adding the medium, the specimens were frozen in dry ice and alcohol mixture at -80°C , then thawed at room temperature and allowed to stand for 3 h at room temperature without exchange of the medium. The incubating medium consists of 1.4 ml of 0.5 M Tris-HCl buffer pH 8.5 (28 mM in the final concentration), 2.0 ml of 0.1 M sodium β -glycerophosphate (20 mM), 2.6 ml of 15 mM magnesium sulfate (3.9 mM) and 4.0 ml of 0.5% alkaline lead citrate solution, pH c. 10.0 (2.0 mM). Sucrose may be added in final concentration of 8%. Final pH is adjusted to pH 9.2-9.4 with 0.1 N HCl. After 3 h incubation, the specimens are centrifuged, rinsed with cacodylate buffer fixed



Fig 1 Mature neutrophil leukocyte from venous blood of female. Some types of granules contain dense reaction product indicative of alkaline phosphatase activity showing reaction in (1) medium-sized granules, (2) large vacuoles or autophagic vacuoles, and (3) small round or oval granules ($\times 10,000$)

in cacodylate buffered 3% glutaraldehyde and 1% osmium tetroxide for 1 h at 4°C, dehydrated by routine procedures and embedded in Epon. Thin sections stained with lead acetate were examined in Hitachi HS 7 type electron microscope. As the control, the incubating medium without substrate was used for the specimens in the same procedure.

Results

Reaction product was found in the cytoplasm of mature neutrophil leukocytes as follows: (1) medium-sized round granules, some of which contained dense materials (fig 3); (2) membrane of large vacuoles or autophagic vacuoles, some of which fused with reaction positive



Fig. 2. Mature neutrophil leukocyte showing reaction product granules ($\times 8,000$).

granules (fig. 1) and (3) small round or oval granules and sometimes a long tubular duct in the peripheral region of the cytoplasm. These are scanty in the central region of the cells (fig. 1, 2). In the absence of substrate, no reaction products were observed.

Discussion

Technical considerations. Since the activity of human neutrophil alkaline phosphatase is low, it is difficult to demonstrate this enzyme ultrastructurally in good preservation of fine structures. It usually needs 15 h incubation in Gowori's lead salt method to stain alkaline



Fig. 2. Medium-sized granules which contain reaction product around the dense materials ($\times 10,000$).

phosphatase in human leukocyte smears histochemically whereas in other tissues, such as kidney intestine or cerebrum, it needs only 1 and $1\frac{1}{2}$ h incubation.

It was found in the preliminary trials that glutaraldehyde and para formaldehyde fixation inactivated the activity of this enzyme. In the present study no fixatives were used before incubation. Due to the phagocytic function of the neutrophilic leukocytes there is a possibility that the neutrophils take in some reaction precipitates which react with serum alkaline phosphatase for this reason the leukocyte suspension in the incubating medium was allowed to undergo immediate freezing and thawing in order to prevent phagocytosis.

Among several methods for ultrastructural demonstration of this enzyme no precipitates were formed in MAYAHARA's new lead-citrate method in high alkaline pH without chelating agent which is known to have an inhibitory effect on this enzyme.

Localization of alkaline phosphatase in human neutrophil leukocytes. It was reported that fine structural studies of heterophil leukocytes in rabbit had revealed heterogeneity among their cytoplasmic granules and at least three types of heterophil granules had been distinguished namely (1) large dense primary or azurophil granules, (2) the smaller less dense secondary granules, and (3) tentatively defined tertiary granules (small pleomorphic dense granules).

WETZEL [3] demonstrated for the first time alkaline phosphatase in secondary granules of rabbit heterophil myelocytes by electron microscopy which appeared in intermediate heterophils and later predominated in mature cells, and also demonstrated that this

enzyme in Golgi complex coincided with secondary granulocytogenesis. BARTON [4] also showed this enzyme in Golgi cisternae and immature specific granules of rabbit heterophil myelocytes. HORN [6] described alkaline phosphatase in phagocytic vacuoles surrounding an ingested bacterium in rabbit exudate heterophil leukocytes during phagocytosis. Using the differential centrifugation method, it is reported that neutrophilic granule fraction isolated from horse [7] and rabbit [8] blood leukocyte homogenate contained alkaline phosphatase.

As the ultrastructural localization of alkaline phosphatase in human neutrophil leukocytes has not yet been observed the correlation between the enzyme and human neutrophil granules is quite unknown although it is known that this enzyme appears in human neutrophil myelocytes and increases in number in mature neutrophils. Human neutrophil leukocytes have two types of granules [5]. The first (type A) (from 0.4–0.6 μm in length and 0.2 μm in width) are often elongated like rice grains and after staining with uranium acetate, are relatively clear. The second (type B) are smaller 0.6–0.2 μm in diameter. After staining, they are very dense. Their population varies from one cell to another but it seems that in man in the normal state there are about 70% of type A and 25% of the granules of type B.

In the present study it was found that the reaction positive granules were most likely to be specific granules. Furthermore, the localization of these granules appears to be somewhat different from acid phosphatase positive granules which are thought to belong to primary azurophil granules.

Acknowledgments. The author wishes gratefully acknowledge the kind guidance and valuable suggestions of Prof. K. OHTA and Dr H. MAHARA and to thank Prof. H. FUJII for his helpful advice in preparing the manuscript.

Summary

Ultrastructural cytochemical demonstration of alkaline phosphatase in human neutrophil leukocytes was carried out using MAHARA lead-citrate method. The reaction products are found to be clearly localized in some types of granules. The technical considerations and the localization of this enzyme were discussed.

References

1. WACHTELIN, M. Alkaline phosphatase activity in normal and abnormal human blood and bone marrow cells. *J. Lab. clin. Med.* 31: 1 (1946).

2. MAYAHARA, H., HIRANO, H., SAITO, T. and OHAWA, K. The new lead citrate method for the ultracytochemical demonstration of activity of non-specific alkaline phosphatase. *Histochemie* 11: 88 (1967).
3. WETZEL, R. K., SPICER, S. S. and HOAR, R. G. Fine structural localization of acid and alkaline phosphatase in cells of rabbit blood and bone marrow. *J. Histochem. Cytochem.* 15: 311 (1967).
4. RADTKE, D. F. and FARGNAR, M. G. Differences in enzyme content of azurophil and specific granules of polymorphonuclear leukocytes. II. Cytochemistry and electron microscopy of bone marrow cells. *J. Cell Biol.* 30: 299 (1968).
5. BEISS, M. Ultrastructure of normal and leukemic granulocytes. *Proc. Int. Conf. Leukemia-Lymphoma*, pp. 281 (Leak & Febiger Philadelphia 1968).
6. HOAR, R. G., SPICER, S. S. and WETZEL, R. K. Phagocytosis of bacteria by heterophil leukocytes. Acid and alkaline phosphatase cytochemistry. *Amer. J. Path.* 45: 327 (1964).
7. OHTA, H. A biochemical study on the neutrophilic granules isolated in pure state from leukocyte homogenate. *Acta haemat. jap.* 27: 555 (1964).
8. BACCOLINI, M., HIRATA, J. G. and DE DUVE, C. Resolution of granules from rabbit heterophil leukocytes into distinct populations by zonal sedimentation. *J. Cell Biol.* 46: 529 (1969).

Institut für Balneologie und Klimaphysiologie (Direktor Prof. G. GÖFFERT) Medizinische
Klinik (Komm. Direktor Prof. J. SCHUMMERT) und Institut für medizinische Statistik und
Dokumentation (Direktor Prof. E. WALT) der Universität, Freiburg/B.

Über die Wirkung des Mittelgebirgsklimas und des Wetters auf das Blutbild¹

H. SCHULTE WISSERMANN, H. HILLE, H. J. JESDINSKY
H. GÖFFERT und K. G. v. BOROVICZÉNY

Es ist bekannt, dass bei einem Höhenaufenthalt oberhalb 2000 m der Erythrozyten- und Hämoglobingehalt des Blutes deutlich ansteigt [20-27]. Über den Einfluss des Mittelgebirgsklimas auf das Blutbild findet man in der Literatur dagegen recht unterschiedliche Ansichten. Der Arbeitskreis um VERZAR spricht dem Mittelgebirgsklima jegliche Wirkung auf das Blutbild ab [11-27, 28]. Dies sei nach Ansicht jener Autoren auch nicht anders zu erwarten, da aufgrund der Barroftischen O_2 -Dissoziationskurven in diesen Höhen die Sauerstoff sättigung im Blut nur verhältnismäßig wenig absinkt.

In neuerer Zeit wird jedoch von verschiedener Seite die von VIZACHER [21] schon vor 70 Jahren veröffentlichte Theorie wieder aufgegriffen, dass zwischen dem roten Blutbild und der Höhenexposition eine kontinuierlich progrediente Beziehung ohne irgendeinen markanten Schwellwert besteht. Diese Anschauung wird von LOZKY [20] mit Nachdruck vertreten. GARTMANN [13] wies nach, dass bei einem Aufenthalt in 1500 m die Erythropoese deutlich verstärkt wird, und v. MURALT [22] beobachtete, dass bei einigen seiner gesunden Versuchspersonen ein Höhenwechsel von 500 m leichte, aber doch deutliche Blutbildveränderungen auslöste.

Die Blutbildveränderungen treffen jedoch nicht nur die roten Zellen, auch die Leukopoese wird durch eine Höhenexposition beein-

¹Mit Unterstützung der Bundesversicherungsanstalt für Angestellte der Landesversicherungsanstalt Baden und des Wirtschaftsministeriums Baden-Württemberg.

flusst BÜRGER *et al* [9] fanden bei ihren Untersuchungen auf der Schatzalp in 1850 m Höhe, dass die Gesamtzahl der Leukozyten etwas abnimmt. KOLLER *et al* [18] teilten dagegen mit, dass in 3500 m Höhe die Leukozytenzahl ansteigt. Das gleiche fand GÜNTHER [14] bei einem Aufenthalt in 1000 m. KNOLL [17] untersuchte die Leukozytenwerte in der Höhe bei Arbeit. Er konnte zeigen, dass – im Gegensatz zum Verhalten bei Körperruhe – unter Arbeit die Zahl der neutrophilen Zellen wesentlich ansteigt, während die der Lymphozyten abfällt. AMELUNG [1] beobachtete bei Kuren in ca. 400 m Höhe zwischen der 2.–4. Woche eine Lymphozytose.

Auf Grund der verhältnismäßig wenigen und sich zum Teil auch noch widersprechenden Literaturangaben schien es angebracht, sich erneut mit dem Problem der hämatologischen Wirkung des Mittelgebirgsklimas zu befassen. Bei der Durchführung derartiger Untersuchungen stößt man auf einige grundsätzliche Schwierigkeiten, die vor allem dadurch ausgelöst werden, dass jede Höhenexposition mit Veränderungen zahlreicher verschiedener Klima- und Wetterfaktoren einhergeht.

Material und Methodik

Um nach Möglichkeit vergleichbare und übersichtliche Bedingungen zu erhalten, gingen wir bei unserem Experiment folgendermaßen vor. Während des Semesters wurden in Freiburg 30 gesunde Studenten genau voruntersucht und damit ein Kollektiv geschaffen, dessen biologische Daten bekannt waren. Aus diesem Kollektiv bildeten wir dann nach zufälliger Verteilung zwei Gruppen, von denen gleichzeitig die eine nach Bad Krozingen, 250 m ü. N.N., die andere nach Hocherschwand, ca. 1000 m ü. N.N. (s. 6 V.) oben zu einem stationärverordneten Aufenthalt geschickt wurden.

In Bad Krozingen – nur 15 km von Freiburg entfernt – herrscht praktisch das gleiche Klima wie in Freiburg. Die hier untergebrachte Gruppe war im wesentlichen als Kontrollgruppe anzusehen, denn die in Krozingen eventuell zu beobachtenden biologischen Veränderungen bei unseren Versuchspersonen können – ur Folge des gegenüber Freiburg veränderten Mikroklimas oder des Wettereinflusses der Grosswetterlage sein.

Hocherschwand liegt nur 40 km ostwärts von Krozingen auf dem sanft nach Osten abfallenden Schwarzwaldplateau. Beide Orte werden gleichzeitig von Änderungen der Grosswetterlage getroffen. Auch hinsichtlich der Geopsychie [HELLPACH] waren beide Orte gewisse Ähnlichkeiten auf. Wir konnten also ziemlich sicher sein, dass eine Differenz in dem Befinden beider Gruppen als Folge des Höhenklimas gedeutet werden kann.

Die Versuche wurden von Mitte Februar bis Ende Mai 1963 durchgeführt. Zeitlich gliederte sich die Untersuchung in drei Phasen. Dem 6 Wochen dauernden Hauptversuch in den Kurorten ging eine dreiwöchige Voruntersuchung im Freiburger Institut voraus. Den Abschluss bildete eine sechswöchige Nachuntersuchung, bei der in der 1. und 2. sowie in der 5. und 6. Woche nach dem Ende des Hauptversuches gemessen wurde.

Der Gemeinde von Bad Krozingen und der Familie Porten in Hocherschwand gebührt unser Dank für die großzügige Unterstützung des Untersuchungsprogramms.

Am Ende des Versuches konnten die klimatologischen Daten von 27 Personen verglichen werden. Die Probanden waren während der Hauptversuchszeit gemeinsam in einem hierfür bereitgestellten Haus untergebracht. Die Verpflegung war an beiden Orten landwirtschaftlich Fett- und Eiweißreichtum einhaltend, der Tagelauf streng geregelt.

Alle Blutentnahmen erfolgten ausschließlich am Finger. Während der Zweiwöchigen Voruntersuchungen wurde einmal pro Woche morgens nüchtern, während der 11 wöchentlichen nachher 3mal wöchentlich und in der Nachuntersuchungsperiode wiederum einmal wöchentlich Blut entnommen. Bei allen Untersuchungen wurden Doppelbestimmungen an zwei gesondert abgenommenen Blutproben vorgenommen. Während der gesamten Untersuchung nahmen bei den einzelnen Versuchspersonen jeweils die gleichen Hämokritik das Blut ab. Im einzelnen bestimmten wir folgende Werte:

1. Die Gesamtzahl der Leukozyten und Erythrozyten wurde mit Hilfe eines elektronischen Zählautomaten (Coulter Counter D) nach der von BOROVICZKY, GERVILL und BAUMGARTEN beschriebenen Methode bestimmt.

2. Den absoluten Hämoglobingehalt ermittelten wir nach der internationalen Standardmethode (ICSH DIN 58931). Als Photometer diente ein Gerät der Fa. Eppendorf.

Die Bestimmungen von 1 und 2 führten wir zentral in Freiburg durch. Das Blut wurde für diesen Zweck unmittelbar nach der Entnahme mit einem PHW nach Freiburg transportiert.

3. Für die Hämatokritbestimmungen dienten hochtourige Zentrifugen (12000 U/min). Das Blut wurde in heparinisierten Glaskapillaren, deren exakte zylindrische Form vorher geprüft worden war, 10 min zentrifugiert.

4. Den mittleren Erythrozyten-Durchmesser ermittelten wir kalometrisch nach der Methode von BOROVICZKY und SAPPAS im monochromatischen Licht von 550 nm am Elektroskop.

5. Die Retikulozyten wurden nach der Methode von HENRIKSEN gefärbt und an jedem Ausstrich 3000 Erythrozyten ausgerechnet.

6. Für die Differenzialblutbilder wurden frische Ausstriche gefärbt und von jedem Ausstrich 200 Zellen ausgerechnet. Die statistische Auswertung der Messergebnisse führte das Institut für medizinische Statistik und Dokumentation der Universität Freiburg durch. Dabei wurde für die varianzanalytische Behandlung der hier einfließenden von der Methode der Orthogonalergänzte Gebrauch gemacht, und zwar gewöhnlich vom Orthogonalpolynom sowie z.T. auch für Merkmale, an denen keine physischen Schwankungen erwartet werden, von Orthogonalpolynomen zur Erfassung des Eodes eines besetzten Trends. Die Abhängigkeit einiger Merkmale des weissen Blutbildes von Wettereinflüssen wurde mittels der multiplen Regressionsrechnung untersucht.

Außer den Blutuntersuchungen wurden am gleichen Versuch noch Tests am Kreislauf, Atmung, Stoffwechsel, Wärmeabfuhr und im ZNS durchgeführt. An beiden Versuchsorten registrierten wir fernerhin noch die üblichen meteorologischen Daten, wie Temperatur, Feuchte, Luftdruck, Strahlung, Wind, Niederschlag und Abkühlungsgrößen.

Resultate

Rotes Blutbild. Vergleicht man die Zahl der Erythrozyten beider Kollektive (Abb. 1) dann fällt auf, dass beide Gruppen im zeitlichen Verlauf der Untersuchung teilweise gemeinsamen phasischen Schwankungen unterliegen. Die Zahl der roten Blutkörperchen weist drei Gipfel auf. Der erste Gipfel liegt zwischen der ersten und der zweiten Woche des Hauptversuches, der zweite in der vierten Woche und der

dritte in der sechsten Woche. Dieser Verlauf – mathematisch mit einem Polynom fünften Grades zu beschreiben – ist statistisch mit $p < 0.01$ gesichert. Diesem Trend folgen in der Höchenschwander Gruppe auch die Werte des Hämatokrites. Gemeinsam ist beiden Kollektiven auch eine deutliche Zunahme der Erythrozytenzahl im Verlauf der Hauptuntersuchung und der Abfall in der sich anschließenden Nachuntersuchung.

Neben dem gemeinsamen Verlauf beobachteten wir jedoch auch Unterschiede zwischen beiden Gruppen. Es ist dies einmal ein gegenläufiges Verhalten zwischen der Tal- und der Höhengruppe in der ersten Untersuchungswoche, wo in der Höhe die Zahl der Erythrozyten stark ansteigt, während sie im Tal etwas abfällt. Zum anderen wächst die Zahl der roten Blutkörperchen im Gesamtverlauf der Hauptuntersuchungsperiode in Höchenschwand deutlich stärker an als in Kreuzingen. Der Unterschied ist mit $p < 0.001$ statistisch signifikant. In der Nachuntersuchung fällt die Zahl der Erythrozyten dann in beiden Kollektiven auf Werte ab, die unter dem Ausgangsniveau der Voruntersuchung liegen.

Recht eindrucksvoll ist das gegenläufige Verhalten der Retikulozyten während der Hauptuntersuchung (Abb. 1). Bei der Höhengruppe beobachtet man in der ersten Woche eine deutliche Retikulozytenausschwemmung. Mit 47200 Zellen/mm³ ist die Zahl der Retikulozyten am Ende der ersten Woche doppelt so hoch wie bei der Voruntersuchung. Die statistische Sicherung für den unterschiedlichen Verlauf an beiden Orten beträgt $p < 0.001$. Nach diesem primären Anstieg pendeln sich die Werte nach Art einer gedämpften Schwingung auf einen niedrigeren Pegel ein, der jedoch am Ende der Hauptuntersuchung noch immer über den Ausgangswerten liegt. Bei der Talgruppe beobachtet man demgegenüber, dass die Zahl der Retikulozyten nach einem primären Abfall ziemlich stetig bis zum Versuchsende ansteigt. Auch dieser Trend ist mit $p < 0.001$ signifikant.

Die mittleren Erythrozyten Durchmesser verändern sich während der Hauptuntersuchung in beiden Orten annähernd gleichartig (Abb. 1). Sie weisen einen mit $p < 0.01$ gesicherten positiv quadrati-

Abb. 1 Mittelwertkurven der Erythrozyten, der Retikulozyten und der mittleren Erythrozytendurchmesser. I der Abszisse entspricht während der Vor- und Nachuntersuchung jeder Wert einem Wochenmittel, bei der Hauptuntersuchung dagegen jeweils einer Doppelbestimmung. Die Zahlen auf der Abszisse betreffen die Untersuchungswochen.



Abb. 1

schen Trend auf. Vier Wochen nach Ende des Hauptversuches werden die Erythrozyten beider Versuchsgruppen deutlich grösser. Ihr Durchmesser liegt bei der Krozinger Gruppe $0.16 \mu\text{m}$ bei der Höchenschwander um $0.27 \mu\text{m}$ über den Werten der Voruntersuchung. Das entspricht einer Sicherung von $p < 0.001$.

Ebenso wie bei den roten Blutkörperchen ist auch bei den Hämoglobinwerten ein Höhen Einfluss zu bemerken, obgleich die Befunde hier weniger eindrucksvoll sind. Nachdem in der Voruntersuchungsperiode bei beiden Gruppen praktisch gleich grosse Hämoglobinwerte gefunden wurden, liegen die Werte der Höhen Gruppe vom Ende der zweiten Hauptuntersuchungswoche – ausser bei einer Messung – immer über denen der Talgruppe. Der über dem gesamten Hauptversuch gemittelte Hämoglobingehalt liegt in Höchenschwand deshalb mit $15.8 \text{ g}/100 \text{ ml}$ um $0.19 \text{ g}/100 \text{ ml}$ über den Krozinger Werten. Dieser Unterschied ist aber statistisch nicht zu sichern.

Vom Hämatokrit wurde bereits erwähnt, dass er bei der Höchenschwander Gruppe den physischen Veränderungen der Erythrozytenzahlen zeitlich folgt. Bei der Krozinger Gruppe ist diese Koppelung nur am Versuchsbeginn nachweisbar. Es ist darüber hinaus bemerkenswert, dass die Prozentzahlen in Höchenschwand während der Höhenexposition um 3.1% anstiegen (statistische Sicherung des unterschiedlichen Trendes $p < 0.01$) während die Werte der Krozinger Gruppe eher etwas absinken.

Neues Blutbild. Bei der Gesamtleukozytenzahl ist das Absinken zu Beginn der Hauptuntersuchung und der anschliessende starke, ziemlich stetige Anstieg beider Gruppen auffallend (Abb. 2). Im Detail unterscheidet sich allerdings der Anstieg der Zellzahl in beiden Gruppen. Die Krozinger Gruppe zeigt eine fast gradlinige Tendenz, während die Höhen Gruppe in der 5. und 6. Woche auf einem Plateau verharrt. Die Unterschiede sind mit $p < 0.001$ statistisch gesichert. Bei dem Gang der Gesamtleukozytenzahl konnten wir den Einfluss des Wetters nachweisen. Das Auf und Ab der einzelnen Werte ist – vor allem bei der Höhen Gruppe – den Luftdruckschwankungen entgegengesetzt. Die negative Korrelation ist statistisch mit $p < 0.01$ gesichert. Der Abfall des Luftdruckes um 1 mm Hg lost im Durchschnitt einen Leukozytenanstieg um $75 \text{ Zellen}/\mu\text{l}$ aus.

Im Differentialblutbild, das während der Voruntersuchung und am Ende der Nachuntersuchung recht einheitliche Werte aufweist, sieht man während des Hauptversuches bei verschiedenen Zellarten sowohl




Abb. 2. Mittelwertskurven der Leukozyten und der Tagesmittel des Luftdruckes. Abmessung wie bei Abbildung 1. Da zwischen Leukozyten und Luftdruck eine umgekehrte Proportionalität besteht, ist die Ordinatenrichtung für den Druck (rechts) von oben nach unten beschriftet. Hg. = Höchenschwander Gruppe, Kr = Kroninger Gruppe

recht deutliche Unterschiede zwischen der Hohen und der Talgruppe als auch im zeitlichen Verlauf der Messgrößen während der Kur. Sämtliche Werte für die segmentkernigen Granulozyten liegen in Höchenschwand deutlich über den entsprechenden Zahlen im Tal (Abb. 3). Die stabkernigen Granulozyten zeigen ein ähnliches Verhalten wie die bereits beschriebenen Retikulozyten. Sie wurden in der Höhe zu Versuchsbeginn stärker ausgeschüttet als in Kroningen (Abb. 4). Später im zweiten Drittel des Hauptversuches jedoch ändert sich die Situation, da liegen die Werte der Talgruppe über denen von Höchenschwand. Dieser unterschiedliche Trend zwischen der Hohen Schwander und der Kroninger Gruppe ist mit $p < 0.01$ statistisch gesichert. Im übrigen spiegelt sich auch bei den Stabkernigen die Abhängigkeit der Absolutwerte von den wetterbedingten Luftdruckschwankungen mit einer Signifikanz von $p < 0.01$ wider. Des weiteren konnte eine direkte Korrelation zur Temperatur mit $p < 0.01$ gesichert werden. Hierbei ist allerdings zu bedenken, dass die markantesten Luftdruckschwankungen in unserem Experiment unglücklicherweise mit den Zeitpunkten zusammenfielen, an denen man nach HILDEBRANDT [15, 16] mit phasenhaft ablaufenden regulativen Reak-




Abb. 3. Prozentwert des Differentialblutbildes in Prozenten. Abweichung wie bei Abbildung 1

tionen als Antwort des Organismus auf den Klimareiz rechnen muss. Es wäre also auch möglich, dass die Zellzahländerungen auf die sogenannte Kurreaktion zurückzuführen sind.

Die Absolutwerte der Eosinophilen (Abb. 4) zeigen bei der Talgruppe im Gesamtverlauf des Hauptversuches eine ansteigende Tendenz, die man bei der Hochschwanger Gruppe nur in der ersten Hälfte des Hauptversuches beobachtet. Der Anstieg ist mit $p < 0.001$




Abb. 4 Miktwert des Differentialblutbildes in absoluten Werten pro μ l. Abszissensteilung wie bei Abbildung 1.

gesichert. Über diesen Trend hinaus spiegelt sich auch bei den Eosinophilenzahlen der Einfluss des Wetters wider. Hier korrelieren auch die Werte der Kreuzinger Gruppe negativ mit dem Luftdruck. Entsprechend der niedrigeren Gesamtgranulosytenzahl in Kreuzingen ist der prozentuale Eosinophilengehalt des Blutes im Tal während des Hauptversuches grösser als in der Höhe. Die statistische Sicherung dieses Unterschiedes beträgt $p < 0,05$.

Die Lymphocyten verhalten sich während des Hauptversuches ähnlich wie die Segmentkernigen. Bei beiden Gruppen steigt die Zellzahl im Verlauf der Hauptuntersuchung etwas an, wobei die Höhen-Gruppe der Talgruppe wieder etwas vorausschlägt. In der Nachuntersuchungsperiode sinken die Werte wieder auf das Ausgangsniveau ab. Bei der Höhengschwander Gruppe kann man darüber hinaus eine Wetterabhängigkeit wie bei den Segmentkernigen erkennen, deren Sicherung $p < 0.01$ ist.

Diskussion

Die Ergebnisse unserer Verlaufsuntersuchung zeigen, dass sowohl das Höhenklima als auch die akute Wettersituation einen Einfluss auf das Blut ausüben. Darüber hinaus löste aber bei unseren Studenten auch der Milieuwechsel vom angespannten Semesterbetrieb in die Geborgenheit eines Sanatoriumsaufenthaltes Veränderungen am Blutbild aus. Wie anders sollte man sich sonst die systematische Befundsänderung bei der Krazinger Gruppe während des Hauptversuches erklären, wo sich die Messwerte gegenüber der Vor- und Nachuntersuchung deutlich abheben.

Versuchen wir nun die Effekte dieser drei Wirkungskomponenten voneinander zu trennen. Der Anstieg der Erythrocyten zu Beginn des Höhengaufenthaltes im Mittelgebirge ist gesichert, wie dies vom Hochgebirge bereits bekannt ist. Die gleichzeitig einsetzende Retikulozytose beweist, dass es sich hierbei um einen echten hämatopoietischen Reiz handelt und nicht nur um die Ausschüttung von Erythrocyten aus Blutspeichern, wie dies von SCHÖNHOLZER und LÖTHI [24] angenommen wird.

Die Ähnlichkeit der Reaktion mit den vom Hochgebirge her bekannten Vorgängen legt es nahe, in beiden Fällen als Ursache die Verminderung des Sauerstoffpartialdruckes anzunehmen. Dabei kann vorerst nicht entschieden werden, ob die Druckminderung direkt als auslösendes Agens fungiert oder ob sekundär der durch jene ausgelöste, geringfügige Abfall der Sauerstoff sättigung des Blutes verantwortlich gemacht werden muss. Beide Wege scheinen uns möglich. Dagegen halten wir es nicht für angezeigt, bei der Stimulation der Erythropoese im Mittelgebirge nach einem anderen auslösenden Agens als im Hochgebirge zu suchen.

Neben diesen Reizen auf die Erythropoese laufen bei einem Höhenaufenthalt in den ersten Tagen, wie BECK *et al* [4] nachweisen konnten destruktive Prozesse unbekannter Genese am Erythrozyten ab die sich in einer Realtenzminderung der roten Blutkörperchen in einer Bilirubinämie [12] und Urobilinogenurie [27] äußern. Es ist möglich, dass die etwas niederen Erythrozytenwerte bei der ersten Blutentnahme unserer Höhengruppe auf derartige Prozesse zurückgeführt werden können. Ähnliche Befunde teilten DIRKAGE *et al* [10] von einer Untersuchung in Oberstdorf (850 m ü N N) mit.

Interessant ist der Verlauf der Retikulozytenzahl in Höchenschwand während des Hauptversuches, denn hier sieht man, wie sich ein aus dem steady state gebrachtes Regelsystem in Form einer gedämpften Schwingung auf ein neues Niveau einstellt. Die Schwingungsdauer beträgt hierbei von Maximum zu Maximum etwa 10–12 Tage. Auf derartige Einschwingungsvorgänge, die man lange Zeit übersehen hat, machte vor allem HELDEBRANDT [16] aufmerksam.

Wesentlich schwieriger sind die phasischen Verläufe der Erythrozytenzahlen zu deuten, die im Prinzip in beiden Gruppen gleichartig ablaufen, bei denen jedoch – wenn man von der ersten Woche absieht – ganz deutlich eine Phasenverschiebung zwischen Höchenschwand und Kroxingen festzustellen ist, dergestalt, dass die Werte in Kroxingen immer etwas vor denen von Höchenschwand abfallen. Die synchron mit den Erythrozytenzahlen veränderten Hämatokritwerte von Höchenschwand lassen an Hydratationsvorgänge als auslösende Ursache für diese Phasen denken. Dem stehen jedoch die Befunde von Kroxingen entgegen wo kein Zusammenhang zwischen diesen beiden Messgrößen besteht. Es liess sich auch keine Korrelation dieser Phasen mit irgendeinem meteorologischen Befund nachweisen. Dagegen fiel auf, dass die Ausscheidung der 17 Hydroxy Verbindungen im Harn bei unseren Probanden in Höchenschwand und Kroxingen ähnlich synchronen Schwankungen unterworfen war [23]. Wir müssen diese phasischen Gänge der Erythrozytenwerte in jene eigenartigen Schwingungsvorgänge einreihen die in der physikalischen Therapie bei den verschiedensten Kuren bereits von zahlreichen anderen biologischen Funktionen her bekannt sind [16]. Eine stichhaltige Erklärung für solche Phänomene konnte hierfür bisher noch nicht gegeben werden.

Einer kurzen Erwähnung bedarf noch die in der zweiten Hälfte des Hauptversuches verbesserte Erythropoese der Talgruppe. Hier kommen wohl vor allem zwei Komponenten zum Zug. Einmal wirkt – das

konnte durch gleichzeitig mit den hämatologischen Studien durchgeführte Untersuchungen am Kreislauf, Stoffwechsel und ZNS nachgewiesen werden – der einfache Milieuwechsel auch im gleichen Klima wie ein Stress. Diesem Stress schloss sich dann eine Phase echter Erholung im Sanatorium an. Schließlich war die Ernährung unserer Probanden während des Hauptversuches hochwertiger als während der Semesterzeit, so dass auch über den Umweg eines verbesserten Eisens und Eiweißangebotes ein günstiger Effekt auf die Bluthildung ausgeübt werden konnte.

Im roten Blutbild konnten wir nur Veränderungen beobachten, die durch den Einfluss des Klimas und des Milieus hervorgerufen wurden. Im weissen Blutbild dagegen zeigte es sich, dass auch akute Wetterveränderungen das morphologische Substrat beeinflussen können. Die bisher in der Literatur beschriebenen Befunde hinsichtlich des Verhaltens der Gesamtleukozytenzahl bei Klimakuren widersprechen sich teilweise. So fand GÜNTHER [14] bei Untersuchungen an Arthritikern in Bad Gastein (1000 m) einen signifikanten Anstieg der Zellzahlen während eines vierwöchentlichen Aufenthaltes. Ähnliches teilen KOLLER *et al.* [18] aus 1600 m Höhe mit. Diese Autoren fanden, dass mit der Leukozytose eine vermehrte Ketosteroid- und Corticoidausschüttung einhergeht. BÜRGER *et al.* [9] teilen dagegen von einer vierzehntägigen Beobachtung in 1850 m das Gegenteil mit. Wir können uns mit unseren Befunden hinsichtlich der Gesamtleukozytenzahl grundsätzlich den Beobachtungen von GÜNTHER und KOLLER *et al.* anschließen, denn wir fanden, dass nach einem primären Abfall der Leukozytenzahl beide Kollektive einen signifikanten Anstieg der Gesamtleukozytenzahl aufwiesen. In der Art, wie dieser Anstieg verläuft, unterscheiden sich jedoch die Gruppen voneinander. Während bei der Talgruppe die Zellzahl von der zweiten Woche an stetig und kontinuierlich zunimmt, und diesem – auch bei der Höhengruppe vorhandenen Anstieg – bei den Höchenschwander Probanden deutlich wetterabhängige Schwankungen überlagert.

Dieser Einfluss des Wetters wird vor allem bei einer eingehenden Analyse des Differentialblutbildes deutlich. Zur Analyse dieses Einflusses wurden die Merkmale des weissen Blutbildes beider Orte mit der multiplen Regressionsanalyse getrennt untersucht. Ausser den meteorologischen Daten von Temperatur, Luftdruck, Niederschlag und Strahlung berücksichtigten wir noch den Zeitfaktor durch Hinzunahme der Nummern des Messtages und deren Quadraten, um so

einen allgemeinen Trend während der Hauptversuchszeit von wetterbedingten Effekten abtrennen zu können. Die negative Korrelation zwischen dem Luftdruck und den Gesamtleukozyten wurde bereits erwähnt. Darüber hinaus zeigte sich aber in Höchenschwand bei den stabkernigen Granulozyten ein mit $p < 0.05$ signifikant senkender Einfluss der Temperatur auf die Zellzahl. In Krozningen hinwieder sank die Zahl der Monozyten mit steigender Temperatur ab (Signifikanz $p < 0.05$). Die eosinophilen Granulozyten zeigten eine positive Partialkorrelation ($p < 0.05$) zur Strahlungsintensität, wenn man die gemittelten Partialkorrelationen für beide Orte zusammenfassend betrachtet.

Die aufgezählten Daten zeigen, dass das Wetter einen Einfluss auf die Zusammensetzung des weissen Blutbildes ausüben kann, der in der Höhe stärker ist als im Tal. Das mag daran liegen, dass die Höhengruppe während der Hauptversuchszeit einem höheren Reizpegel ausgesetzt war und dadurch eine Sensibilisierung erfolgte, auf meteorologische Reize stärker zu reagieren.

Bei den Lymphozyten konnte keine Beeinflussung durch das Wetter festgestellt werden. Hier steigt die Zellzahl im Verlauf der Hauptuntersuchung bei beiden Gruppen an. Wir sehen hierin eine Bestätigung der von AMELUNG [1] beschriebenen Akklimatisationslymphozytose.

Schliesslich scheint es uns noch erwähnenswert, dass der Verlauf der Retikulozyten und der Stabkernigenzahlen der Höhengruppe im Hauptversuch gewisse Ähnlichkeiten zeigt.

Man muss sich vor einer zu speziellen Interpretation unserer Ergebnisse hinsichtlich des Wettereinflusses auf das Blutbild hüten. Wenn gesagt wurde, dass einem bestimmten Luftdruckanstieg eine definierte Zellzahlveränderung entspricht, dann soll dies nicht heissen, dass mit der Drucksenkung allein diese Veränderung reproduzierbar sein müsste. Derartige Kausalzusammenhänge mit einzelnen Wetterfaktoren sind bis jetzt experimentell nur selten nachgewiesen worden. Die Biometeorologie konnte nur in Ausnahmefällen zeigen, welche meteorologischen Einzelfaktoren einen spezifischen Einfluss auf biologische Funktionen ausüben. Es kommt im Wettergeschehen nie vor, dass sich nur eine meteorologische Komponente allein verändert. Es sind immer sehr komplexe Vorgänge, bei denen zahlreiche Einzelfaktoren in systematischer Weise miteinander verknüpft sind. Wir möchten deshalb unsere Befunde dahingehend deuten, dass die signifikanten Be-

ziehungen zwischen den Blutwerten und den einzelnen Wetterfaktoren als Zeichen dafür anzusehen sind, dass ein meteorologischer Komplex – sei es Schönwetter, Regen oder Frontendurchgang – eine Rückwirkung auf das biologische Geschehen ausübt, ohne dass wir im einzelnen wissen, welche Detailfaktoren hierbei die entscheidende Rolle spielen.

Zusammenfassung

An 2 Kollektiven mit 13 bzw. 14 Versuchspersonen, wurde der Einfluss des Klimas auf das Blutbild untersucht. Schon in 1000 m Höhe nach einem Höhenanstieg von ca. 750 m erfolgte eine deutliche Stimulierung der Erythropoiese. Als auslösende Ursache wird der Einfluss des erniedrigten O_2 -Partielldruckes in der Höhe angenommen. Die Erythrocytenwerte wiesen darüber hinaus im Verlauf der Kur planische Schwankungen in einem Rhythmus von 9-10 Tagen auf, während die Zahl der Reticulocyten in der Höhe nach überschüssiger Reaktion auf einen höheren Wert eingestellt wurde. Sowohl im Tal als auch in der Höhe konnte eine verstärkte Leukopoiese nachgewiesen werden. Vor allem wurde der Einfluss des Wetters deutlich. Die Gesamtzahl der Leukocyten sank bei steigendem Luftdruck. Noch deutlicher reagierten die zahlreicheren Granulocyten und die Monozyten auf wetterbedingte Temperaturschwankungen. Ausserdem bestand eine positive Korrelation zwischen der Zahl der eosinophilen Granulocyten und der Strahlungsintensität.

Summary

The influence of climate on the blood count was studied in two groups of 13 and 14 subjects respectively. Erythropoiesis is strongly stimulated at a height of 1,000 m after an ascent about 750 m. The causative mechanism is considered to be the reduced partial pressure of oxygen in the atmosphere at this altitude. Furthermore, the erythrocyte values fluctuate in cycles of nine to ten days during the course of the treatment, while the number of reticulocytes, after an initial exaggerated response to the high altitude, settled down at raised level. Increased leukopoiesis was found in both the mountain and the valley group. In particular the influence of the weather was obvious. As the pressure rose, the total number of leukocytes fell. Staff cells and monocytes were even more sensitive to temperature changes resulting from the weather. The number of eosinophilic granulocytes was also correlated positively with the intensity of radiation.

Literatur

1. ASCHLING, W. *Klimatische Behandlung innerer Krankheiten* (Berlin 1941).
2. ASCHLING, W., LOTZ, W. und SCHMIDT, L. Experimentelle Untersuchungen und kritische Beobachtungen zur Frage der vegetativen Labilität. *Arch. phys. Ther.* 19: 7-221-224 (1935).
3. BLACKBURN, J. *Respiratory function of the blood*, p. 64 (Cambridge 1914).
4. BUCK, J., SAN-KORTJAAK, A. und VERRA, F. *Höhenklimaforschungen*. 1, p. 75-82 (Schwabe, Basel 1945) S. 75-82.

5. BOROVICKÝ K. G. Erfahrungen mit Blutkörperchen-Zählapparaten. *Ärzt. Lab.* 8: 161-178 (1962).
6. BOROVICKÝ K. G. v.: Über die Hämoglobincyanidmethode. *Schweiz. med. Wochschr.* 94: 1397-1401 (1964)
7. BOROVICKÝ K. G. GIESE, R. und RAUSGARTEN, E. Erythrocytenzählung mit einem elektronischen Apparat. *Wien. Z. inn. Med.* 4., 267-278 (1961)
8. BOROVICKÝ K. G. v. und SAFFAR, H. Halometrische Erythrocyten-Durchmesserbestimmung. *Schweiz. med. Wochschr.* 92: 1327-1329 (1962)
9. SCHERER, W.; COLLATZ, B.; MEHLBERGER, M. H. und SCHWOLZ, G. Die physiologischen Wirkungen des Höhenklimas. *Nova Acta Leopold.* 13: 91 (1915).
10. DEMAGEL, H., DREXEL, H. und GERNARDT, W.: Experimentelle Untersuchungen über die Wirkung eines Ortswechsels München-Oberstdorf. *Arch. phys. Ther. Lpz.* 4: 195-198 (1962).
11. DOSTIG, R., VERZÁR, F. und VÖTTL, W. Höhenklimaforschungen. I., p. 69-76 (Schwabe, Basel 1945)
12. FITZGERALD, O.; MASOV, M. und VERZÁR, F. Höhenklimaforschungen. I. pp. 61-68 (Schwabe, Basel 1945)
13. GASTMANN, J. C. Das Höhenklima und seine therapeutische Bedeutung. *Schweiz. med. Wochschr.* 89: 908 (1959)
14. GÖTTKE, R. Beeinflussung des Blutbildes Rheumakranker durch die Gesteiner Radon-Thermal-Anwendungen. *Z. angew. Bäder-Klimak.* 8: 282-301 (1961)
15. HILDEBRANDT, G. Reaktionsprognostik in der Balneotherapie. *Arch. phys. Ther. Lpz.* 4: 39-51 (1962)
16. HILDEBRANDT, G. Störungen der rhythmischen Koordination und ihre balneotherapeutische Beeinflussung. *Z. angew. Bäder-Klimak.* 10: 403-420 (1963)
17. KNOLL, W. Die sportärztlichen Ergebnisse der 2. Olymp. Winterspiele in St. Moritz 1928. Bern 1928.
18. KOLLER, F.; SCHWAB, E. und MARTI, M. Über die Reaktion der Nebennierenrinde beim Aufstieg ins Hochgebirge. *Acta endocrin., Kbh.* 16: 118-140 (1954)
19. LEGOWSKI, S. und BOROVICKÝ K. G. v. Exakte Hämoglobinbestimmung in der täglichen Praxis. *Dtsch. med. Wochschr.* 87: 1955-1960 (1962)
20. LOEWY, A. Physiologie des Höhenklimas, p. 72 (Springer Berlin 1932)
21. MIESCHKE, F. Gesamtheitliche Arbeiten (1895)
22. MICHAEL, A. v. Klimaphysiologische Untersuchungen in der Schweiz. *Helv. physiol. pharmacol. Acta* 2, Suppl. III (1944)
23. RATTNER, R. *Issag. Dem. Freiburg/Bz.* (1966)
24. SCHÖNWEILER, G. und LUTER, K. Das Erythrocytenvolumen im Hochgebirge. *Helv. physiol. pharmacol. Acta* 2, Suppl. III p. 81 (1944).
25. VERZÁR, F. Höhenklimaforschungen I, pp. 41-50 (Schwabe, Basel 1945)
26. VERZÁR, F. Fünfzehn Jahre Höhenklimaforschung der Klimaphysiologischen Station St. Moritz-Bad. *Schweiz. med. Wochschr.* 93: 231 (1963)
27. VERZÁR, F. und VÖTTL, W. Höhenklimaforschungen. I, pp. 13-40 (Schwabe, Basel 1945).
28. VERZÁR, F. und VÖTTL, W. Höhenklimaforschungen. II, pp. 65-74 (Schwabe, Basel 1948)

Adresse der Autoren: Dr. H. SCHULTE-WINTERMANN, Dok. Dr. H. HILL, Prof. Dr. H. GÖTTKE, Institut f. Klimaphysiol. d. Univ. H. Harder-Strasse 7 D-78 Freiburg; Dr. H. J. JORDANY, Institut f. med. Statist. d. Univ. St. Moritz-Strasse 26, D-78 Freiburg, Dr. K. G. BOROVICKÝ, Med. Univ. Klinik, Hugstetter Strasse 55, D-78 Freiburg (Deutschland)

I Medizinische Klinik und Poliklinik der Johannes-Gutenberg-Universität
(Direktor: Prof. H. P. Weiss) Mainz

Der Einfluß dysproteinhämischer Seren auf die Resistenz normaler Erythrozyten

F. GRAMLICH und F. KIRSCHHOFF

Die Ursachen extrakorpuskulär bedingter hämolytischer Anämien sind vielfältig. Während hämolytische Syndrome relativ häufig beobachtet werden, etwa in Form der sogenannten symptomatischen hämolytischen Anämien bei Infektionskrankheiten, malignen Tumoren, bei Leberzirrhosen und rheumatischen Erkrankungen, gelingt der Nachweis immunogener Autohämagglutinine nur relativ selten [5]. Als weiterer extrakorpuskulär wirksamer Hämolysefaktor konnte zwar die erythroklastische Sequestration des retikuloendothelialen Systems in Milz und Leber gesichert werden, doch wurde gleichzeitig als allgemein gültiges pathogenetisches Prinzip hämolytischer Erkrankungen erkannt, dass eine Primärschädigung des Erythrozyten der Blutmauserung durch das retikuloendotheliale System vorausgehen muss [1, 2]. Als schädigende Agentien, die über das Blutplasma an die roten Blutzellen herantreten, fanden sich neben den Autohämagglutininen und einigen anderen Immunkörpern bisher lediglich Stoffe mikrobieller Herkunft [6]. Einen weiteren Hinweis auf die Pathogenese extrakorpuskulärer hämolytischer Anämien lieferten die Mitteilungen von FURCHHOFF und PONDOR [3, 4] über die Existenz eines albuminähnlichen «antiphosphingous factor», der die Oberfläche der roten Blutkörperchen filmartig überzieht und die Membraneigenschaften bzw. die Stabilität der typischen Erythrozytenform mitbestimmen soll. Tatsächlich konnte durch wiederholte Erythrozytenwaschungen mit isotoner Glukoselösung gezeigt werden, dass vom physiologischen Plasmaeiwassmilieu formerhaltende Wirkungen auf

die roten Blutkörperchen ausgehen [15]. Dass eine Dysproteinämie die Membraneigenschaften der roten Blutkörperchen im Sinne einer Forminstabilität und Oberflächenschädigung mit konsekutiver Sequestration zu beeinflussen vermag, konnte bisher allerdings nicht bewiesen werden [7].

Auf Grund eigener Untersuchungen über den Plasmaproteinfilm der Erythrozyten [11] haben wir den Einfluss dysproteinämischer Seren auf die Resistenz roter Blutkörperchen erneut geprüft.

Methode

Erythrozyten. Aus Blut gesunder Spender der Blutgruppe O Rh+ wurden unter Blutbankbedingungen Blutkonserven hergestellt. Die Verwendung normaler Spendererythrozyten sollte Einflüsse korpunkulärer Mindererkrankungen, die Wahl der Blutgruppe Isoagglutinations-Reaktionen ausschließen. Die Weiterverarbeitung erfolgte am Entnahmetag durch 5maliges Waschen in der Zentrifuge mit dem 6fachen Volumen kalter physiologischer Kochsalzlösung. Die Leukocyteschicht wurde abgesaugt. Für die Inkubationsanalysen wurde das Erythrozytensediment nach der letzten Waschung ($\text{MRZ} = 1250 \times \text{g}$, 5 min) unverzüglich benutzt.

Seren. Zur Untersuchung gelangten Nüchternseren von 35 jugendlichen Personen (Kontrollgruppe) und Proben von 67 Patienten bestimmter Krankheitsgruppen (Tab. I). Die Seren wurden durch Zentrifugation vom Blutkuchen getrennt, vor der Inkubation mit dem Testerythrozyten 30 min bei 56°C im Wasserbad inkubiert, um hämolysierende Komplementwirkungen auszuschalten, und elektrophoretisch analysiert. Die Phärogrammwerte der Kontrollgruppen lagen im Normbereich. 41 Proben der pathologischen Seren wiesen über 20 re% α_2 und α_2 -Globuline auf, und 26 pathologische Seren enthielten über 30 re% γ -Globuline (T. b. I).

Verfahreneinsatz. In Wassermantel-Röhrchen wurden Erythrozyten und Seren unter sterilen Bedingungen im Volumenverhältnis 2:1 vermischt und erschlossen 20 h lang im Wasserbad bei 57°C inkubiert. Damit wurde beobachtet, den sogenannten Endoparasiteneffekt, unter dem die Blutmauerung in der roten Pulpa der Milz stattfindet, auf den in vitro-Ansatz zu übertragen. Blutproben für die Resistenzprüfung wurden nach 1 und 20 h entnommen.

Resistenzprüfungen. a) Mechanische Resistenz nach SCROVORUS [14]; b) osmotische Resistenz gegen 0,10–0,85 g% Kochsalzlösungen, gemessen 30 min nach Inkubation bei Zimmertemperatur; c) Spontanhämolysen im Serum der Proben (Extraktionsmessung bei $I = 346 \text{ nm}$, $D = 10 \text{ mm}$, gegen mitinkubiertes Leerserum).

Auswertung. Die mechanische Hämolysen wurde in % der Totalhämolysen errechnet. Die osmotische Hämolysen wurde für die einzelnen Kochsalzkonzentrationen in % der Totalhämolysen bei 0,1% Kochsalz ermittelt. Für die Auswertung wurden der Hämolysengrad bei 0,5% Kochsalz und die Kochsalzkonzentration der 50% Hämolysen benutzt. Bei der Spontanhämolysen wurden die Logarithmen der Extinktionswerte miteinander verglichen.

Die statistische Bewertung der Ergebnisse erfolgte zunächst mittels BASSETT Test [12] und der einfachen Varianzanalyse [13], wobei 3 Gruppen (Normaheren, Seren mit α_2 - und Seren mit γ -Globulinvermehrung) miteinander verglichen wurden. Da die Varianzanalyse nur Gruppenunterschiede feststellt, wurde zur Klärung der Frage, welche Gruppen sich voneinander abheben, der DUNCAN-Test [16] für Stichproben herangezogen.

Tabelle 1 Relative Prozentwerte der α - und γ -Globuline bei den 6 untersuchten Krankheitsgruppen

Patienten		1	2	3	4	5	6	7	8	9	10	11	12	13	14
1. Metastasierende Karzinome 14	α	28	-	26	-	34	23	23	31	24	21	28	21	22	
	γ	-	31	-	36	-	32	-	30	-	-	30	-	-	31
2. Hämoblastosen (Lympho- granulomatose, Leukosen, Myelome, Retikulosen) 16	α	27	31	28	-	24	23	-	32	23	21	-	27		
	γ	-	-	-	32	-	-	36	-	-	-	31	-	33	31
3. Akute Infekte (Pneumonie, Pleuritis, Cholezystitis) 9	α	30	28	36	-	28	26	23	23	24					
	γ	-	-	40	30	-	-	-	-	-					
4. Leberzirrhosen und chro- nische Hepatiden 9	α	-	-	-	-	-	-	-	-	-					
	γ	43	31	38	40	31	32	25	32	32					
5. Akute rheumatische Erkrankungen (akute Polyarthritis, PCF) 7	α	23	22	22	23	23	21	24							
	γ	-	-	-	-	-	-	-							
6. Kompensierte Nieren- erkrankungen (chronische Glomerulo- und Pyelone- phritis, Nephrosen, Zysten- nieren) 12	α	23	22	23	26	27	22	30	30		27	-			
	γ	-	-	-	-	-	-	-	-	33	-	42	31		

α -Globuline < 18, γ -Globuline < 24 rel%

Ergebnisse

1. *Erythrozytenresistenz und Dysproteinämie.* In Tabelle II sind die statistisch ausgewerteten Ergebnisse der mechanischen und osmotischen Hämolyseprüfung sowie der Spontanhämolyse der Testerythrozyten unter dem Einfluss von Normalseren und Dysproteinämien wiedergegeben. Die *mechanische Resistenz* wird durch dysproteinämische Seren mit α oder γ -Globulinvermehrungen nicht signifikant verändert ($p > 0.05$). Dagegen nimmt die *osmotische Resistenz* unter dem Einfluss dysproteinämischer Seren ab. Die Steigerung der osmotischen Hämolyse bei einer Kochsalz Konzentration von 0,5% wird gleichermaßen von den α und γ -Globulin-reichen Seren bereits nach 1stündiger deutlicher aber nach 20stündiger Inkubation hervorgerufen. Die

Tabelle II Varianzanalyse Irrtumswahrscheinlichkeit (p) mit der sich die hämolysierende Potenz dysproteinämischer Seren von Normalseren unterscheidet

		1 h	20 h
Mechanische Resistenz	α -Glob. > 20 rel%	> 0,05	> 0,05
	γ -Glob. > 30 rel%	> 0,05	> 0,05
0,5% NaCl Osmotische Resistenz	α -Glob. > 20 rel%	< 0,01	0,001
	γ -Glob. > 30 rel%	< 0,01	0,001
50% Hämolysen	α -Glob. > 20 rel%	> 0,05	0,001
	γ -Glob. > 30 rel%	> 0,05	0,001
Spontanhämolysen	α -Glob. > 20 rel%	< 0,01	> 0,05
	γ -Glob. > 30 rel%	< 0,01	> 0,05

50%ige Hämolysen wird nach 20stündiger Inkubation mit den dysproteinämischen Seren schon bei signifikant höheren Kochsalzkonzentrationen erreicht als bei Normalseren.

Während bei der 50% Hämolysen nur der 20-Stunden Wert einen signifikanten Unterschied zwischen dysproteinämischen und normalen Seren erkennen läßt, war bei der Spontanhämolysen lediglich nach 1stündiger nicht aber nach 20stündiger Inkubation ein vermehrter lytischer Einfluß der dysproteinämischen Seren nachweisbar.

Besonders bemerkenswert ist, daß die Steigerung der Hämolysen durch Seren mit α -Globulinvermehrung als auch durch Seren mit γ -Globulinvermehrung in gleichem Maße erzielt wurde.

2. *Auswertung nach Krankheitsgruppen* Für die Untersuchungen wurden den Krankheitsgruppen (Tab. I) ausgewählt, bei denen einerseits extrakorpusskuläre Hämolyseneinflüsse häufig beobachtet werden und die andererseits mit stärkergradigen Dysproteinämien einhergehen. Es konnte varianzanalytisch festgestellt werden, daß zwischen den Hämolysengraden der untersuchten Krankheitsgruppen keine Unterschiede bestehen.

Diskussion

Der Versuchsansatz mit hoher Erythrozytenkonzentration und Inkubation bei 37°C bis zu 20 h beobachtete, die physiologischen Verhältnisse der Blutmauserung in der Milz im Experiment nachzuahmen. Die Erythrozyten waren während der *in vitro*-Inkubation auch ähnlichen Stoffwechselbelastungen ausgesetzt wie in der Milz

[17] Die Überprüfung der Wasserstoffionen Bikarbonat und Glukosekonzentration sowie der Viskosität (Ostwaldt Kapillarviskosimeter $\eta = 0.05$ cm) und der Filtrierbarkeit (Sartorius-Membranfilter Göttingen Porendurchmesser $5 \mu\text{m}$) des Versuchsansatzes während der 20stündigen Inkubation ergab charakteristische Veränderungen, die unterschiedslos in den Kontroll- und dysproteinämischen Proben angetroffen wurden. Mit Utilisation der Glukose durch die erythrozytäre Glykolyse wurde zunehmend Laktat gebildet, wodurch Bikarbonat verbraucht und das pH im Ansatz absank. Die Säuerung des Blutes bewirkte ihrerseits einen sphärischen Gestaltwandel der Erythrozyten, erkenntlich am Ansteigen des Hämatokrits. Gleichzeitig nahm die relative Viskosität des Blutes zu und die starren Sphärozyten passierten die Poren des Filters nicht mehr.

Wie die Versuchsergebnisse in Tabelle I zeigen, wirken sich die Stoffwechselbelastungen auf Erythrozyten im dysproteinämischen Milieu, gemessen an der osmotischen Belastbarkeit und der Spontanhämolyse neigung signifikant stärker aus als in den euproteinämischen Kontrollansätzen. Bemerkenswert ist dabei, dass die vermehrte Hämolyse von Seren mit α - und γ -Globulinvermehrung ohne Unterschied herbeigeführt wird. Die mechanische Resistenz der Erythrozyten dagegen wies bei grosser Streubreite der Messwerte in allen Gruppen keine Unterschiede auf. Auch von Hämolyseuntersuchungen bei immunnhämolytischen und korpuskular bedingten, hämolytischen Anämien ist bekannt, dass die Empfindlichkeit geschädigter Erythrozyten gegen mechanische Einflüsse weniger gut darstellbar ist als gegen osmotische Einwirkungen [1].

Im Hinblick auf die Hämolyseursache bleibt nach Ausschluss korpuskular oder durch «Komplement» bedingter Hämolyseinflüsse durch den Versuchsansatz die Frage, ob das dysproteinämische Serummilieu die Membranstabilität der Erythrozyten beeinflussen kann. Da die hämolytische Wirksamkeit von Gewebshämolytinen oder mikromolekularen Serumbestandteilen wenig wahrscheinlich ist [1], ist zu diskutieren, ob bei Dysproteinämien Normabweichungen in der Zusammensetzung des Plasmaproteinfilms an der Oberfläche der Erythrozyten deren Membraneigenschaften verändern.

Durch Anwendung radioaktiv markierter reiner Plasmaproteine war es uns [6] und anderen Autoren [8, 9] möglich, die Existenz eines Plasmaproteinfilms an der Erythrozytenoberfläche zu beweisen und darüberhinaus auch die Zusammensetzung des Proteinfilms abschätzen sowie die Bedingungen zu studieren, mit denen sich die Serumproteine an die Erythrozytenmembran binden. Auf Grund wesentlichlich hoher Bindungsaffinität

der einzelnen Plasmaproteine zur Erythrozytenoberfläche unterscheidet sich die prozentuale Zusammensetzung der Proteine im Serum grundsätzlich von der Zusammensetzung am Erythrozyten. So sind beispielsweise γ G-Globulin, Fibrinogen, α -Lipoprotein, α_2 -Makroglobulin und Präalbumin auf Kosten insbesondere des Albumins und des Transferrins auf der Erythrozytenoberfläche um das 1,2-3-fache angereichert [10]. Die Zusammensetzung des Plasmaproteinfilmes ist unter dysproteinämischen Bedingungen gegenüber der Norm verändert [11] wobei Auswirkungen auf die Membraneigenschaften der Erythrozyten postulierte werden können [6].

Die Veränderungen der Serumweißzusammensetzung betraf in den vorgelegten Versuchen die α oder die γ -Globuline. Unter ihnen ist eine besonders hohe Erythrozytenbindungseigenschaft der Lipoproteine und Makroglobuline des α Bereiches bzw. der γ G-Globuline nachgewiesen worden [6]. Dass der Plasmaproteinfilm die Membraneigenschaften der Erythrozyten mitbestimmt, lässt sich aus experimentellen Befunden ableiten wonach die Plasmaproteine mit prinzipiell gleichen, wenn auch geringeren physikalischen Kräften als immunogene Hämaggregation mit der Erythrozytenoberfläche in Kontakt treten [6]. Im Gegensatz zu der Membranschädigung der spezifischen Hämagglutinine [1] wirkt sich die Bindung der Plasmaproteine an der Erythrozytenoberfläche unter normalen Bedingungen stabilisierend auf die roten Blutkörperchen aus [7]. Unter dysproteinämischen Bedingungen kann vermutlich durch Änderung der normalen Zusammensetzung des Plasmaproteinfilmes an der Erythrozytenoberfläche eine Störung der Membranstabilität eintreten, die die Lebenszeit der Erythrozyten verkürzt. Gerade der zunächst überraschende Befund, dass die Hämolyseempfindlichkeit der Erythrozyten unabhängig von den Krankheitsgruppen sowohl durch Vermehrung der α als auch der γ -Globuline gleichgerichtet zunimmt stützt die Hypothese, dass die Membranschädigung der Erythrozyten unspezifisch erfolgt und über die Änderung der Zusammensetzung des regulären Plasmaproteinfilmes bei stärkergradigen Dysproteinämien und bei Paraproteinämien zustandekommt.

Zusammenfassung

Die Inkubation normaler Erythrozyten mit dysproteinämischen Seren führt zu einer Steigerung der Spontanhämolyse und zu einer Herabsetzung der osmotischen Resistenz. Die mechanische Resistenz wird dabei nicht verändert. Der Einfluss dysproteinämischer Seren wird auf eine Störung der normalen Zusammensetzung des Plasmaproteinfilmes an der Oberfläche der roten Blutkörperchen und damit auf eine Beeinträchtigung der Membraneigenschaften zurückgeführt.

Quick [37], partielle Thromboplastinzeit nach LAUGHELL [25] mit Kaolinextrakt (Reagenzien der Behringwerke) Heparintoleranztest nach MAURER und WORTHEIMER [29] mit 0,5 und 0,2 IE Heparin pro ml Ansatz, Prothrombinverbrauchstest nach SOULIER [40], Thrombolysezeit (mit 5 E Thrombin/ml) Thrombelastogramm nach HARTERT [18] Fibrinogen nach CLAUSS [10], Faktor VIII nach BARROW *et al.* [1].

2. *Testung der Thrombocytenfunktion.* Thrombocytenfaktor 3 nach DEUTSCH, Thrombocytenfaktor 4 nach DEUTSCH [12] Retraktion nach BARROER [8] und BENTHAUS [3], Thrombocytenumbrichtung nach BARROER und BACH [8], Thrombocytenadhäsivität nach BARROER [7]. Die Thrombocytenaggregation wurde photometrisch nach BOWEN [5] bestimmt. 1,0 ml plättchenreiches Plasma, das durch Zugabe von plättchenarmem Plasma auf eine konstante Thrombocytenzahl von 80.000 eingestellt wurde, wurde zunächst 2 min auf 37°C vorgewärmt und dann in eine thermostatisierte Küvette eines EEL-Photometers (Evans-Electroscopium-Ltd., Halstead, Essex) gegeben. Die Lichtdurchlässigkeit wurde mittels eines Beckman-Schneiders kontinuierlich registriert. Die aggregierenden Substanzen (ADP Adenosin und Kollagen) wurden mittels Mikropipetten zugegeben (Volumen 10–100 µl). Als Maß der Aggregation wurde die Initialgeschwindigkeit (V) der Extinktionsänderung angegeben [2], wobei $V = \text{mm/min}$.

Die Anfnahme von markiertem Serotonin wurde in folgender Weise gemessen. 9,0 ml plättchenreiches Plasma wurden mit 1,0 ml ¹⁴C markiertem Serotonin (Auerbach, 5 µg/ml) in alkalisierten Glasröhrchen unter Schütteln bei 37°C inkubiert. In Abständen von 15 min wurden 1,5 ml Inkubationsmischung entnommen, 5 min bei 2500 rpm zentrifugiert, das Plättchen sediment in 1,0 ml EDTA-NaCl resuspendiert und neuerlich bei 2500 rpm 5 min zentrifugiert. Das Sediment wurde mit 0,8 ml NCS verdaut und als Zentrifugationsflüssigkeit Toluol zugegeben. Die Bestimmung der Radioaktivität erfolgte mit einem Liquidszintillationszähler (Packard).

3. *Die Bestimmung der Enzymaktivitäten und der Substratkonzentrationen in den Thrombocyten* erfolgte mit den früher beschriebenen Methoden [32].

4. *Ultrastrukturelle Untersuchungen der Thrombocyten.* Zur elektronenmikroskopischen Darstellung der Thrombocyten wurden zwei Methoden angewandt: Bei Methode A wurden 8 ml Venenblut des Patienten mit 1 ml EDTA, 0,5 ml Glutaraldehydalkohol (5% Glutaraldehyd in 0,1 mol. Kalkdijalyspuffer pH 7,3) und 0,5 ml 5%ige Dextrose in einem alkalisierten Zentrifugentröhrchen gemischt und bei 3000 Umdrehungen 10 min bei Zimmertemperatur zentrifugiert. Das überstehende plättchenarme Plasma wurde möglichst vollständig abgeseugt und dann vorsichtig Glutaraldehyd-Colliden (Glutaraldehyd 16%, in Collidpuffer 0,066 mol, pH 7,3) überschichtet. Nach 10-min Inkubation bei 4°C ist das Thrombocyten-Leukocyten-Häntchen hart und kann mittels einer Öse leicht entfernt werden. Die weitere Behandlung erfolgt wie früher angegeben [26]. Die Kontrastierung erfolgt mit Uranylacetat-Bleibstrat. Bei dieser Methode werden die Thrombocyten sofort nach der Blutentnahme fixiert, es bleibt daher ihre *in situ*-Form (= Scheibchenform) erhalten. Verschiedene Strukturen in Mikrocytall lassen sich mit dieser Methode besonders gut darstellen [41].

Bei der Methode B enthält das Gemisch, in das das Blut aufgenommen wurde, keinen Glutaraldehyd, sondern nur 1 ml EDTA-Lösung und 0,5 ml 5% Dextrose. Die weitere Verarbeitung erfolgt wie bei Methode A. Bei Anwendung dieser Methode werden die Thrombocyten nicht sofort fixiert, sondern erst nach Aufbringen des konzentrierten Glutaraldehyds auf das Thrombocyten-Leukocyten-Häntchen. Thrombocyten, die nach dieser Methode präpariert werden, haben annähernd Kugelform, zeigen leichte Fortsatzbildung, und es kommt zu einer Separierung von Hyalomere und Granulomere. Die Mikrocytall sind kaum erkennbar. Hingegen ist das System der T-bull und Blächen sehr gut beeinflusst. Bei Anwendung dieser Methode lassen sich in den Präparaten auch reichlich Leukocyten auffinden.

5. *Ordnungsbestimmung der Thrombocyten.* Zur Ordnungsbestimmung der Thrombocyten wurden mehrere Verfahren angewendet.




Abb. 1. Stammbaum der Familie S.

a) Die Thrombocyten wurden im mit May-Grunwald-Giemsa gefärbten Ausstrichpräparat mittels eines Mikrometers ausgemessen.

b) Die Thrombocyten wurden entweder mit Methode A oder B präpariert, (Ziff. 4) und in der üblichen Weise eingebettet. Die Größe der Thrombocyten wurde in Photographien (Vergrößerung: 2000) von Semidünnschnitten 0,5–1 µm ausgemessen (für Details

41). Bei vorfixierten Thrombocyten, die Plättchenform haben, wurden bei jedem Thrombocyten der Längs- und der Querdurchmesser ausgemessen, bei nicht orfixierten, die annähernd Kugelform haben, nur ein Durchmesser. Aus den gemessenen Werten wurde die wahre Größenermittlung der Thrombocyten mit der Methodik von HIRVON (21) ermittelt. Für die kugelförmigen Thrombocyten wurde das Volumen mit der Formel $4/3 \pi r^3$ und die Oberfläche mit der Formel $4 \pi r^2$ berechnet.

c) Zur Berechnung der mittleren Anschnittfläche in den elektronenmikroskopischen Bildern wurde ein Punktzählverfahren (39) angewendet. Nach der elektronenmikroskopischen Vergrößerung wurde ein Punkteraster mit einem Punkteabstand von 5 oder 10 µm angelegt und die Zahl, der auf einen Thrombocyten fallenden Punkte, abgelesen.

6. Chromosomenausstrichung aus dem Nasenblut (31)

Familie (Abb. 1)

S.E., männlich, geb. 1916, Vater der Familie, stammt aus der Schweiz. In der Ascendenz sind keine Fälle von Blutungsneigung bekannt. Der Vater des Patienten war Asthmatiker und erkrankte an einem Herzleiden. Die Mutter soll an einer Krebserkrankung im hohen Alter verstorben sein. Der Patient hat eine gesunde Schwester. Er hatte 16 Kinder blutige Nasenbluten, später nahmen sowohl Frequenz als auch Intensität des Nasenblutens ab, und in den letzten Jahren hatte der Patient fast nur mehr Nasenbluten. Nach stärkeren Traumen kommt es gelegentlich zu Hämorrhoiden. Im übrigen hat der Patient nie eine stärkere Blutungsneigung bemerkt. So erlitt er im Krieg eine Splitterverletzung an der linken Hand komplikationslos. 1956 wurde eine Appendektomie ohne Blutungskomplikationen durchgeführt. Postoperativ soll es allerdings zu einer Wundheilung gekommen sein. 1966 wurde eine Hämorrhoidenoperation, ebenfalls ohne jede Blutungskomplikationen, durchgeführt. 1968 hatte der Patient eine Hepatitis durchgemacht.

S.C., weiblich, geb. 1933, gab an, dass sie als Kind häufiger Nasenbluten gehabt habe. Außerdem soll eine Hämatomenneigung bestehen. Nach 2 Geburten kam es zu postpartalen Blutungen, wobei die Patientin einmal sogar Bluttransfusionen erhalten musste. In der Familie sind keine weiteren Fälle von Blutungsneigung bekannt. Beide Eltern der Patientin sind gesund. Von den 5 Geschwistern ist ein Bruder im 35 Lebensjahr an Magenkrebs gestorben, 4 Geschwister sind gesund.

S.E., männlich, geb. 1933 (Abb. 1) Anamnestisch keine Blutungsneigung

S.M. weiblich, geb. 1956 (Abb. 1) leidet an häufigem Nasenbluten und Neigung zu Hämatomen.

S.A., weiblich, geb. 1960 (Abb. 1) Keine Blutungsneigung

S.R., männlich, geb. 1963 (Abb. 1) Das Kind hatte im 2. Lebensjahr erstmals Nasenbluten, anfangs nur wenig und selten, später immer häufiger schließlich täglich. Der Blutverlust war gewöhnlich gering, gelegentlich musste das Kind aber doch tamponiert werden. 1966 kam es zu einer ungewöhnlich starken Epistaxis, so dass das Kind in ein Krankenhaus eingeliefert werden musste und Bluttransfusionen erhielt. Wegen starken Nasenblutens musste es seit damals noch insgesamt 5× in ein Spital aufgenommen werden. Außerdem besteht eine Hämatomenneigung nach kleinen Traumen. Blutungen anderer Art wie Hämaturie, Meläna sind nie aufgetreten. Operationen wurden bisher nicht durchgeführt.

Bei den übrigen Kindern, S.H., männlich, geb. 1965 (Abb. 1) und den im Jahre 1967 geborenen Zwillingen S.M. und S.C. (Abb. 1) ist bisher keine Blutungsneigung aufgetreten.

Die Untersuchungen der Thrombozytenfunktion und -morphologie wurden bei der Mutter (S.C.) dem Vater (S.E.) und einem Sohn (S.R.) durchgeführt.

Befunde

1 Vorkommen von Dohle'schen Körperchen und Riesensplättchen

Es wurden 9 Mitglieder der Familie untersucht, und zwar die Eltern und alle Kinder (Abb. 1). Beim Vater und bei 5 der 7 Kinder konnten im peripheren Blutstrich bei der May-Grünw.-Id-Giemsa-Färbung Dohle'sche Körperchen in Leukocyten und Riesensplättchen nachgewiesen werden. Die Dohle'schen Körperchen zeigten die von den früheren Untersuchern angegebenen Charakteristika. Sie fanden sich vor allem in den neutrophilen Granulocyten und waren aber auch in den Eosinophilen und Monocyten vorhanden. Meistens waren sie als Halbmonde im Rand der Zelle lokalisiert, gelegentlich wurden sie als kugelige Gebilde auch im Inneren der Zelle, in der Gegend des Zellkerns gefunden. Bei der lichtmikroskopischen Betrachtung der Plättchen fielen neben ihrer Größe noch das Vorkommen von sogenannten blauen Plättchen auf, wie sie in charakteristischer Weise für diese Krankheit beschrieben werden. Im übrigen zeigte das Blutbild keine Besonderheiten.

2 Routinegerinnungsuntersuchungen

Die Ergebnisse der Routinegerinnungsuntersuchungen beim Vater (S.E.) bei der Mutter (S.C.) bei einem Sohn (S.R.) und bei einer Tochter (S.A.) sind in Tabelle 1 dargestellt. Bei allen drei Patienten mit der Anomalie fanden sich eine multiplen Thrombocytopenie und dementsprechend ein erlangerter Heparintoleranztest, ein erweiterter Prothrombinverbrauch und eine verminderte Retraktion. Eine plasmatische Gerinnungsstörung war nicht nachweisbar.




Abb. 2. Größenerteilung der Thrombocyten bei Normalen (●—●) und S.E. (○—○).

3. Untersuchungen an den Thrombocyten

a) *Gelös.* Im Blutausstrich ergab sich für die Thrombocyten des Vaters ein mittlerer Durchmesser von $4,02 \mu\text{m}$, für die des Sohnes (S.R.) von $3,26 \mu\text{m}$, für Normalthrombocyten von $2,7 \mu\text{m}$.

Am Schältrpräparat nicht vorfixierter Thrombocyten (Methodik 5b) ergab sich nach Korrektur der Werte nach der Methode von Havva das in Abbildung 2 dargestellte Größenerteilung der Thrombocyten. Aus diesen Werten wurden der mittlere Durchmesser, das mittlere Volumen und die mittlere Oberfläche der normalen und der Patiententhrombocyten ermittelt (Tab. II).

Beim Vergleich von Längs- und Querdurchmesser offizierter Thrombocyten ergab sich, dass der Quotient von Längs-Querdurchmesser bei den Patiententhrombocyten wesentlich geringer ist als bei Normalthrombocyten, was für eine plumpere Form spricht.

b) *Thrombocytenaktivität 3 und 4* (Tab. III). Die Aktivität gewaschener Patiententhrombocyten im Thromboplastinbildungsstest war bezogen auf die Thrombocytenzahl normal, sowohl bei Testung intakter als auch bei durch Frieren und Tauen aufgeschlossener Thrombocyten.

Bei der Bestimmung des Thrombocytenfaktors 4 ergab sich schon, wenn die Ergebnisse auf die Thrombocytenzahl bezogen wurden, eine erniedrigte Freisetzung von Thrombocytenfaktor 4 wie auch eine absolute Verminderung in den aufgeschlossenen Thrombocyten. Diese Verminderung wird natürlich stärker, wenn man sie auf das Thrombocytenvolumen bezieht. Die Thrombocyten von S.R. und S.E. haben somit eine deutlich erniedrigte Ausbreitungsaktivität.

c) *TA* \ \ Im Ausbreitungsbild der Patiententhrombocyten fand sich eine ausgeprägte Linkverschiebung mit Vermehrung großer Ausbreitungsformen und Riesformen. Im Hysalomer der Riesensplättchen fallen vereinzelt Vakuumbildungen auf.

Tabelle I. Gerinnungsbefunde

	S.E.	S.R.	S.C.	S.A.	Normal
Rinnungszeit, sec	100-135	185	60-195	210	<180
Thrombocytenzahl	45 000-67 000	59 000-98 000	177 000-184 000	74 000	150 000-350 000
Retraktion (8), %	54	70	92	64	>90
Retraktion (31), %	—	44/50	57/89	—	>60/>70
Gerinnungszeit, min	6	5 ^m	8	—	5-9
Prothrombinzeit, %	85	85	95	100	70-110
Partielle Thromboplastinzeit, sec	43	50	49	—	40-55
Hepartintoleranz test (0,5 E) min	5 ^m	5	5	—	3-5
(0,2 E) min	3	3 ^m	2 ^m	3 ^m	1 ^m 3
Serumprothrombin nach 1 h, %	15,5	5	22	—	<10
Thrombinzeit, sec	12,4	13,9	12,3	—	9-15
Thrombelastogram R	13,15	14 15	16,45	12,15	10,30-15
Thrombelastogram mE	96	122	108	89	90-150
Fibrinogen, mg%	370	295	462	—	200-500
Faktor VIII, %	75	130	100	—	70-180

Tabelle II. Größenbestimmung der Thrombocyten

	Normal (n=4)	S.E.	S.R.	S.Ch.
Mittlerer Durchmesser μm	$2,52 \pm 0,2$	4,5	4 1	2,52
Mittleres Volumen, μm^3	$8,55 \pm 0,47$	48	36,5	8,55
Mittlere Oberfläche, μm^2	$20,1 \pm 0,8$	68	53	20
Mittlerer Längsdurchmesser μm	$3,75 \pm 0,47$	4 7	5,3	4 1
Mittlerer Querdurchmesser μm	$0,96 \pm 0,09$	2,0	1,8	1,23
Verh. Längs-/Querdurchmesser	3,9	2,35	3,0	3,54

d) Die Adhäsivität der Thrombocyten an silikonisiertes Glas, gemessen mit der Methode von BALDOON, war im Vergleich zu Normalthrombocyten deutlich gesteigert (Tab. III).

e) Thrombocytenaggregation. Es wurde die Aggregierbarkeit der Plättchen durch ADP, Adrenalin und Kollagen in jeweils zwei Konzentrationen geprüft. In Tabelle III ist der graphisch ermittelte Initialgeschwindigkeit der Aggregation im photometrischen Teil angegeben, wobei ein höherer Wert einer stärkeren Aggregation entspricht. Gegenüber einer zur gleichen Zeit getesteten Normalperson, deren plättchenreiches Plasma auf die gleiche

Tabelle III Thrombocytenfunktionsprüfungen

		S.E.	S.R.	S.C.	Normal
Ausbreitung [8]	Rieschenformen u. große Ausbreitungsformen	32,4	39,2	—	-7,6
	kleine Ausbreitungsformen	17,6	8,0	—	32,5-78
	Übergangsformen	13,8	10,2	—	4,5-33,5
	Splachn	36,2	42,6		-40,6
Adhäsion an Glas [8], %		2,9	3,41		0,8-2,0
Aggregation [5] mm/min	ADP 50 μ mol	0,9	6,2	4,2	2,6
	ADP 2 μ mol	1,2	6,4	3,9	1,8
	Adrenalin 100 μ mol	1,7	6,3	5,7	2,6
	Adrenalin 10 μ mol	0,9	6,3	3,4	2,3
	Kollagen 1 10	0,4	4,2	2,0	1,1
Thrombocytenzahl 80 000	Kollagen 1 20	0,2	2,7	1,0	0,5
Scrotoninaufnahme, mg/10 ⁶ Thrombocyten		350	400		100-200
Thrombocytenfaktor 3 (12) sec	200 000 intakt	12,4	11,6		<12
	200 000 aufgeschl.	8,8	8,2		<10
	60 000 intakt	17,8	16,6		<16
	60 000 aufgeschl.	10,6	10,4		<13
Thrombocytenfaktor 4 (12), E	10 ⁶ intakt	0,0085	0,009		0,02-0,04
	10 ⁶ aufgeschl.	0,0225	0,0215		0,06

Thrombocytenzahl eingestellt wurde, hatte der Sohn eine stärkere der Vater eine leicht errierte Initialgeschwindigkeit der Aggregation.

f) Die *Scrotoninaufnahme* der Thrombocyten war erhöht. Bezieht man die Scrotoninaufnahme jedoch auf die Oberfläche der Thrombocyten, ergibt sich ein normaler Wert.

4. Enzymaktivitäten und Substratkonzentrationen in den Thrombocyten

In Tabelle IV sind die Aktivitäten der Enzyme und die Konzentrationen der Substrate in den Patiententhrombocyten angegeben. Werden die Werte wie gewöhnlich für 10⁶ Thrombocyten angegeben, so sind alle Enzymaktivitäten und Substratkonzentrationen erhöht, wobei allerdings das Ausmaß der Erhöhung sehr unterschiedlich ist. Bezieht man die Werte jedoch auf das Thrombocytenvolumen, indem man die Werte der Patiententhrombocyten durch jenen Faktor um den das Volumen der Patiententhrombocyten größer ist als das von Normalthrombocyten, dividiert, so zeigt sich, dass eine Reihe von Enzymen und Substraten im Normalbereich sind, dass einige Enzyme wie die Hexokinase und die Aldolase sogar noch eindeutig erhöht sind. Andere Enzyme wie die Phosphoglycerokinase, die Phosphofruktokinase, die Glutathionreduktase, sowie das ATP sind dagegen deutlich vermindert.

5. Ultrastruktur der Thrombocyten

Bei der ultrastrukturellen Untersuchung der Thrombocyten ist in erster Linie die Größen- und Formveränderung der Thrombocyten auffallend. Man sieht in den Schnitt-

Tabelle IV Enzymaktivitäten und Substratkonzentrationen in den Thrombocyten

	S.E.	b	S.R.	Li	Normal
Hexokinase	39	6,8	33,8	7,9	3,95 ± 0,3
P-Hexokinomerase	210	36,6	203	47	81,3 ± 10,3
Fruktose-6-P. Kinase	6,8	1,2	21	4,9	9,2 ± 1,6
Aldolase	33,8	5,9	30	7,0	4,1 ± 1,2
Phosphoglyceratkinase	97,5	17,0	90	21	63 ± 11,8
Glycerinaldehyd-P. Dehyd.	475	82,5	490	114	120 ± 29,5
Phosphoglyceratkinase	545	93	467	109	115 ± 12,2
Epoase	125	21,8	126	29	23,5 ± 6,8
Pyruvatkinase	300	52,2	394	91,3	83,2 ± 25,1
Laktaldehydogenase	630	110	713	163	148,5 ± 24,5
Glukose-6-P-Dehydrogenase	52	9,1	57,0	8,6	10,1 ± 3,8
Glukonat-6-P. Dehydrogenase	12,5	2,2	17,3	4,0	2,4 ± 0,3
Glutathionreduktase	13,9	2,4	16,3	3,8	8,5 ± 1,6
Myokinase	30	5,2	33	8,1	11,3
ATP	34,3	6,0	32,4	7,6	16,3
ADP	9,7	1,7	12,2	2,8	3,8
ADP	11,3	2,0	10,8	2,5	8,1

) Enzymaktivitäten in 10^{10} Thrombocyten und Substratkonzentrationen in $\mu\text{mol}/10^{11}$ Thrombocyten.

b) Enzymaktivitäten und Substratkonzentrationen in $174 \cdot 10^6$ Plättchen (bei Pat. S.E.) bzw. $2,32 \cdot 10^8$ Plättchen (bei Pat. S.R.) Das Volumen dieser Plättchenzahlen entspricht jeweils dem von 10^{11} Normalplättchen, da die Plättchen von S.E. das 3,75fache und von S.R. das 4,3fache Volumen von Normalplättchen haben.

präparaten nur selten die typischen Spindelformen, sondern meistens runde bis ovale Formen, was dafür spricht, dass die Thrombocyten weniger die Form einer Scheibe, sondern mehr eines Ellipsoids haben (Abb. 3).

Bei der quantitativen Auswertung der Zellorganellen (T b. V) wird ersichtlich, dass die Zahl der dichten Granula und der Mitochondrien pro Thrombocyt vermehrt ist. Bezieht man diese Zahl jedoch auf die Anschnittfläche [39] die bei diesen Thrombocyten viel grösser ist, sind diese Werte annähernd normal. Auffallend war das ungewöhnlich häufige Vorkommen von schmalen, schlängelartigen dichten Granula, die entweder als Auswulspung der normalen dichten Granula zu sehen waren oder auch keine Beziehung zu den runden dichten Granula aufwiesen (Abb. 4). Derartige Stäbchen und schlängelartige Bildungen lassen sich in grosser Zahl auch in normalen Megakaryocyten finden, und es liegt daher die Vermutung nahe, dass es sich um Vorstufen der dichten Granula handelt. Diese Bildungen sind daher möglicherweise als Zeichen der Unreife der Thrombocyten zu deuten. Auch andere Zeichen der Unreife wie Oberflächengranula, Golgi-Felder und in einzelnen Thrombocyten sogar ruhendes endoplasmatisches Retikulum lassen sich nachweisen. Das System der Tubuli und Bläschen war sehr ausgeprägt, wobei sich häufig längere zusammenhängende Schläuche nachweisen liessen. Die Anordnung dieser Schläuche erinnert an man-



444 2. Vergleich von normalen und Patiententhrombozyten 2. Präp. nach Methode A
(10.000)





Tabelle I* Ultrastruktur der Thrombocyten

	S. E.		S. R.		Normal = 10
Dichte Granula	21.14	9.9 ²	21.02 ¹	12.6 ³	9.4 ± 1.67
Mitochondrien	2.52	1.18 ²	2.83	1.73 ¹	1.2 ± 0.28^3
Tubuli und Bläschen	2.12		2.78		1.3 ± 0.23
Glykogen ⁴	1.1		0.9		
Schmale Stäbchengranula	48 ₂		56	33.5	4.5 ± 3.6
Dicke Stäbchengranula	0			1 ₂	
Ochsenzungengranula	16		18 ²	10.8	0.5
Riesengranula	0		0	0	<1 ₂
Golgefächer ¹	2		2	1.2	<1
Vakuolen	52 ²		36 ₂	21.5	13 ± 4.6

Organellen pro Plättchen

Gehalt an Organellen bezogen auf die GröÙe der Schnittfläche (Normal = 100%)

S.E. = 13 %, S.R. = 167%)

geschätzt mit subjektiver Skala 1-4

2 der Thrombocytenanschnitte die solche Organellen enthalten

den Thrombocyten an die plättchenmarkierenden Zonen in den Megakaryocyten. In einzelnen Thrombocyten arbeiten diese Tubuli den Thrombocyten direkt in einige Abschnitte zu teilen.

6. Ultrastruktur der Leukocyten

Die Dohleschen Körperchen lassen sich auch ultrastrukturell darstellen. Sie erscheinen elektronenmikroskopisch als uncharakteristisch begrenzte Areale an oberflächlichem Zytoplasma. Im Inneren weisen sie eine große Zahl an annähernd parallel verlaufenden Fibrillen auf und sind von zahlreichen Körnern durchsetzt, die nach ihrer Färbbarkeit mit Uranylacetat und ihrer Größe (Abb. 5) wahrscheinlich Ribosomen entsprechen dürften. Auffallend ist die nahe topographische Beziehung der Dohleschen Körperchen zu Schläuchen des rauen endoplasmatischen Retikulums. Man trifft fast bei jedem Dohleschen Körperchen am Rand einen mehr oder weniger langen, an Ribosomen besetzten Schlauch des endoplasmatischen Retikulums an, der zuweisen das Körperchen fast umschlossen scheint (Abb. 6).

7. Die Chromosomenuntersuchung am Venenblut ergab einen normalen Befund.

Abb. 4 (S.E.) Riesenthrombocyt mit unregelmäßig angeordneten Mikrotubuli, Stäbchengranula (St) und Golgistrukturen (G). O = Ochsenzungengranula ($\times 20000$) (Methode A)

Abb. 5 (S.R.) Ausschnitt aus neutrophilem Granulozyten mit Dohleschen Körperchen. Innerhalb des Körperchens sind fibrilläre Strukturen und dunkle granuläre Einlagerungen in einer homogenen Matrix erkennbar. Die Granula liegen in der Größenordnung an Ribosomen ($\times 22800$) (Methode B)



Abb. 6. (S.R.) Neutrophiler Granulozyt mit Einschlusskörper. Die kleinen Mitochondrien meist gequollen. Am Rande des dichten Einschlusskörpers liegen Ribosomen-besetzte Membranen des endoplasmatischen Retikulums (\rightarrow) ($\times 12.500$) (Methode B)

Diskussion

Die May Hegglin'sche Anomalie ist eine seltene Erkrankung. Insgesamt sind bisher 44 Fälle beschrieben worden, die 14 verschiedenen Familien angehören [9, 11, 16, 19, 20, 22, 23, 28, 33, 35, 36, 38, 42]. Die hier beschriebene Familie entspricht in ihrer Symptomatologie und hinsichtlich der hämatologischen Befunde der klassischen Beschreibung von HEGGLIN [19].

Auch der Vererbungsmodus in unserer Familie steht mit der bisherigen Annahme [9 20 '98, 33 35 '49] in Einklang dass die Krankheit autosomal dominant vererbt wird. Die Chromosomenkultur aus dem peripheren Blut ergab einen normalen Befund. LUXNER *et al* [28] fanden ebenfalls ein normales Chromosomenmuster während BUCHANAN *et al* [9] geringe chromosomale Abnormitäten fanden. Es ist allerdings zu bedenken dass eine Chromosomenuntersuchung aus dem peripheren Blut hauptsächlich Chromosomen aus den Lymphozyten erfasst und nicht aus den Granulozyten in denen sich ja die Abnormität findet.

Unsere Untersuchungen beschäftigen sich vor allem mit der Thrombozytenfunktion und morphologie bei dieser Erkrankung wobei uns vor allem interessierte ob die morphologisch abnormen Thrombozyten auch funktionell verändert sind. Die zu diesem Zweck durchgeführten Thrombozytenfunktionsteste ergaben unterschiedliche Ergebnisse. Bei den Thrombozytengerinnungsfaktoren wurde bezogen auf Thrombozytenzahl eine normale thromboplastische Aktivität gefunden sowohl bei Testung intakter als auch aufgeschlossener Thrombozyten. Sogar wenn man das grosse Volumen dieser Thrombozyten berücksichtigt, ist die Thrombozytenfaktor 3-Aktivität noch nahezu normal. Dementsprechend war auch der Prothrombinverbrauch normal, bzw. nur leicht pathologisch. Damit unterscheidet sich die May Hegglin'sche Anomalie wesentlich von einer anderen Riesen-thrombozytopenie der *Dystrophie thrombocytaire hémorragique BERNARD-SOULIER* [4] bei der ein schwerer Thrombozytenfaktor 3-Mangel besteht, der einen schlechten Prothrombinverbrauch zur Folge hat [4 24 34]. Allerdings fanden PETZ *et al* [36] und LUXNER *et al* [28] auch bei der May Hegglin-Anomalie eine leichte Verminderung der thromboplastischen Aktivität der Plättchen. Die Thrombozyten-4-Aktivität war in den Patientenplättchen, schon wenn man nur auf die Thrombozytenzahl bezieht, deutlich erniedrigt. Die Retraktion war bei allen untersuchten Patienten leicht vermindert, allerdings nicht stärker als sie der Verminderung der Thrombozyten entspricht. Wir glauben daher dass in unseren Fällen keine Störung der Retraktionsaktivität der Thrombozyten vorliegt, während HEGGLIN *et al* [20] eine solche postulieren. Die Adhäsivität der Plättchen war deutlich gesteigert, wahrscheinlich infolge der grossen Oberfläche der Plättchen. Auch die Aufnahme von markiertem Serotonin war entsprechend der Vergrösserung der

Plättchenoberfläche gesteigert. Hinsichtlich der Plättchenaggregation lässt sich nur mit Sicherheit sagen, dass sie weder bei Zusatz von ADP, Adrenalin oder Kollagen grob gestört ist. Die bekannte Schwierigkeit der Standardisierung von Thrombozytenaggregationstests erlaubt jedoch nicht eine Aussage über geringere Unterschiede der Aggregierbarkeit dieser Plättchen. Auch NAJEAU *et al* [33] sowie LACHNER [28] fanden normale Aggregation der Patientenplättchen mit ADP und Kollagen. Im Gegensatz dazu ist die Aggregation der Plättchen bei der Bernard-Soulierschen Erkrankung eher vermindert [34]. Wenn man die Ergebnisse dieser Tests zusammenfasst, so lässt sich sagen, dass abgesehen von einer Ausnahme (Thrombozytenfaktor 4) die Funktion dieser Riesenplättchen normal (Retraktion, Aggregation) oder sogar gesteigert ist (Adhäsivität: Ausbreitung, Serotoninaufnahme). Die vom klinischen Bild sich aufdrängende Vermutung, dass diese Thrombozyten aktiver sind als normale Thrombozyten, findet daher in den *in vitro*-Tests eine gewisse Bestätigung.

Die biochemische Untersuchung der Patiententhrombozyten lieferte uneinheitliche Ergebnisse. Wenn wie üblich die Enzymaktivität auf die Thrombozytenzahl bezogen wurde, fand sich durchwegs eine Erhöhung der Enzymaktivitäten und der Substratkonzentrationen im Vergleich zu Normalthrombozyten. Diese Erhöhung verlief allerdings graduell sehr verschieden. Wenn man jedoch berücksichtigt, dass die Patiententhrombozyten das 4–6fache Volumen von Normalthrombozyten haben (Tab. II) und man die Enzymwerte und die Substratkonzentrationen der Substrate auf das Volumen der Thrombozyten bezieht, ergibt sich ein anderes Bild. Einige Enzyme (Hexokinase, Aldolase) zeigen auch dann noch eine erhöhte Aktivität, andere Enzyme wie vor allem die Phosphoglyceromutase und Glutathionreduktase hingegen eine deutliche relative Verminderung ebenso das ATP. Diese Veränderungen waren bei beiden untersuchten Patienten in sehr ähnlicher Weise ausgeprägt. Enzymuntersuchungen an Thrombozyten mit May Hegglin'scher Anomalie wurden bisher nur von GROSS *et al* [20] durchgeführt. Unsere Ergebnisse stimmen in drei wesentlichen Punkten mit denen von GROSS *et al* überein. Erstens finden sie ebenfalls eine generelle Zunahme der Enzymaktivitäten und Substratkonzentrationen, wenn sie auf die Thrombozytenzahl bezogen, zweitens war auch bei ihnen die Aktivitätszunahme der verschiedenen Enzyme sehr unterschiedlich und drittens konnte auch bei ihren Patienten ein deutlicher relativer Mangel an ATP

gefunden werden. Aus diesen Untersuchungen lässt sich nur mit Sicherheit sagen dass kein isolierter schwerer Enzymdefekt vorliegt. Wieso es zu der eigentümlichen Verteilung der Enzymaktivitäten in diesen Thrombozyten kommt, ist unklar. Es läge die Vermutung nahe dass es sich um unreife Thrombozyten handelt, die ein anderes Enzymmuster haben. Der Beweis dafür kann im Moment allerdings nicht erbracht werden da eine isolierte Untersuchung jugendlicher Thrombozyten bisher nicht möglich war.

Bei der Morphologie der Thrombozyten ist in erster Linie die Grösse auffallend. Die Grössenverteilungskurve ergab dass ein kleinerer Teil der Patiententhrombozyten offenbar normal gross ist während der grössere Teil Makrothrombozyten sind, mit einem Häufigkeitsmaximum zwischen 4 und 4,5 μm Durchmesser. Eine ähnliche doppelgipfelige Verteilungskurve fand auch HEGOLIN [20]. Aus dem Vergleich von Längs- und Querdurchmesser im elektronenmikroskopischen Schnitt konnte auch wahrscheinlich gemacht werden, dass die Thrombozyten dieser Patienten nicht nur grösser sondern auch dicker und plumper als normale sind.

Die ultrastrukturelle Untersuchung ergab einen erhöhten Gehalt der normalen Zellorganellen wie der α Granula und der Mitochondrien pro Thrombozyt. Bezogen auf die Anschaltfläche ist die Zahl der Organellen jedoch normal. Auffallend ist das häufige Vorkommen von ungewöhnlichen Formen wie Stäbchengranula oder schlauchartigen Granula sowie Ochsenaugengranula und Stücken des rauhen endoplasmatischen Retikulums. Diese Veränderungen sind aber keineswegs spezifisch [26] sondern lassen nur auf eine Unreife dieser Thrombozyten schliessen. Auch HEGOLIN *et al.* [20] fanden in ihrem Fall eine hohe Zahl von Stäbchengranula. LUTTER [28] fand hin gegen eine normale Struktur der Thrombozyten. Im Hinblick auf die Pathogenese bedeutsam konnte der Nachweis schlauchartiger Bildungen, ähnlich der plättchendemarkierenden Zonen der Megakaryozyten, in den Makrothrombozyten sein. Auch NAJEAN *et al.* [33] beschreiben derartige Bildungen. Dies konnte die Folge der von HEGOLIN [19, 20] an den Megakaryozyten beschriebenen Demarkierungsstörung der Plättchen sein.

Die Dohleschen Körperchen entsprechen in ihrer Ultrastruktur den Beschreibungen früherer Untersucher [23, 28, 33]. Wir mochten jedoch noch hinzufügen dass uns die nahe topographische Beziehung von Schlauchen des rauhen endoplasmatischen Retikulums zu den

- Thrombocyten von Patienten mit Thrombopathien. *Thromb. Diath. haemorrh. Suppl.* 24 (Thrombocytae Gerinnungsstörungen) p. 175.
- 27 LEE, R. I. and WHITE, P. D. A clinical study of the coagulation time of blood. *Amer J med. Sci.* 143: 495 (1913)
- 28 LUDER, J. M., SCHUMMER, J., MATSUMI, I. and E. AM, R. K. The May Hegglin anomaly Platelet function, ultrastructure and chromosome studies. *Blood* 32: 950 (1968)
- 29 MARKET, R. und WINTERSTEIN, A.: Der Heparintoleranztest. *Ann. Forsch.* 1: 460 (1955)
- 30 MAY, R. Leukozytenoschläume. *Dtsch. Arch. klin. Med.* 96: 1 (1909)
- 31 MOONSHAN, P. S.; NOWICK, P. C.; HELLM, W. J.; BATIFFA, D. M. and HOGGELARON, D. A. *Exp. Cell Res.* 20: 613 (1960)
- 32 MOSER, H., LECHNER, K. and VIKARELL, H. A hitherto not described enzyme defect in thrombocytopenia-glycylglycine reductase deficiency *Thromb. Di. (h. haemorrh.* 19: 47 (1968)
- 33 V. JEAN, Y., SCHABON, G., BEYER, J. L., DRECH, C. et BERNARD, J. Le syndrome de May Hegglin. *Presse méd.* 74: 1649 (1966)
- 34 NYHARONEN, S., POPLANSKI, A., PROKOPOWICZ, J., LECHNER, K. and STOCKVOER, L. Abnormalities of platelet function and ultrastructure in macrothrombocytic thrombopathia. *Scand. J. Haemat.* (in press)
- 35 OZZI, F. A., NADE, V. J. L., ALLEN, D. M. and DIAMOND, L. K. Leucocyte inclusions Double bodies associated with platelet abnormality (the May-Hegglin anomaly) *Blood* 20: 637 (1962)
- 36 PRITZ, A., STETZ, L. and NELSON, W. The May Hegglin anomaly. A study of three cases. *Abstr. Clin. Res.* 2: 215 (1960)
- 37 QUICK, A. J. Hemorrhagic diseases (Thomas, Springfield)
- 38 SCHOLZ, V. H., DAWID, H. und SCHWAB, M. Beobachtungen einem weiteren Teil der May Hegglin'schen Anomalie der Leukocyten und Blutplättchen. *Schweiz. med. Wochschr.* 90: 1269 (1960)
- 39 SETTE, H. Morphometrische Untersuchungen an Zellen. In WENZEL und ELLIS Quantitative Methoden in der Morphologie (Springer Berlin/Heidelberg/New York 1967)
- 40 VON NER, J. P. Nouvelle de diagnostic de l'hémophilie utilisant les sangs veineux et capillaires coagulés. *Sang.* 19: 78 (1948)
- 41 STOCKVOER, L., WENZEL, M. and LECHNER, K. Thrombocytenpräparation und -untersuchung. *Mikroskopie* (in Druck)
- 42 WINTERSTEIN, D. R., HAMILTON, H. E. and SHERRY, R. F. May Hegglin anomaly. *J. Amer. med. Ass.* 183: 737 (1963)

Adresse der Autoren: Drs. K. LECHNER, K. MOSER, I. Medizinische Klinik der Universität, Spitalgasse 23, 4-1090 Wien Prof. Dr. L. STOCKVOER, Hist. embryolog. Inst. d. Universität Wien (Wien Österreich) PD Dr. K. BARDEN, Dr. E. WENZEL, I. Med. Klinik der Universität Frankfurt Frankfurt a. Main (Deutschland)

Department of Clinical Therapeutics, Athens University Medical School (Director: Prof. B. MALAMOS) Radiolotope Department (Director: Dr E. GYTTAKI) Alexandra Hospital and Blood Research Laboratory of the Hellenic Red Cross (Director: Dr M. CONSTANTOULAKIS) Athens

Urinary and Faecal Iron Excretion in Thalassemia Syndromes

B. MALAMOS, M. CONSTANTOULAKIS, E. GYTTAKI, M. KENZ ELIAS and
O. AUGUSTAKI

Although it is accepted that normally only low amounts of iron escape from the body with urine and faeces, there are several clinical conditions where the excretion may be elevated. Radioiron has been used by several investigators for this study in animals and in man. In animals the iron excretion was studied by HAJEN *et al* [6] AUSTON and GREENBERG [1] and by COPP and GREENBERG [2]. In man, studies of short and long term excretion of radioiron were also carried out. Thus DUBACH *et al.* [4] explored the problem of iron excretion in faeces and sweat in different haematological conditions. They found two patients with congenital haemolytic anaemias who were losing higher amounts of iron than normal persons. GREEN *et al* [5] have attempted to document obligatory iron losses in adult normal males and iron loaded subjects using a variety of isotopic and chemical methods. The total loss of iron in iron loaded subjects was higher than in normals. The excretion of iron in thalassemia has not been studied, with the exception of one case [13] although haemolysis takes place and there is a significant accumulation and disturbance of iron metabolism.

In the present work the loss of I.V. administered iron was studied in urine and faeces of patients with heterozygous and homozygous thalassemia, sickle cell thalassemia and in normal subjects.

Material and Methods

After i.v. administration of ^{59}Fe the excretion of the radioisotope was studied in the urine and the faeces in 17 patients with various types of thalassaemia and in 4 non-anaemic patients.

A sample of the patients own plasma was incubated *in vitro* for 1 h with about 10 μCi of ^{59}Fe in adults and 4 μCi in children below the 14th year of age; the mixture was injected i.v. The administered ^{59}Fe is considered as completely bound to transferrin since its specific activity was high (1 $\mu\text{Ci}/0.15 \mu\text{g}$) and the volume of the available plasma always large.

The collection of the urine and the faeces started after the injection of ^{59}Fe . Twenty four-hour urine specimens were collected for at least 5 days and in some patients for 10 days. In 6 patients urine was collected separately at 3 h intervals for the first 24 h.

Iron concentration was determined in each sample chemically with a modification of the method for blood of Kow and Wala [9]. Radioactivity of the samples was measured in a well type scintillation counter (Nuclear Chicago No. 132).

Since the volume, which can be measured in the well counter is limited and because the radioactivity in the samples was low 100 ml of urine were placed in dialysis bags and left in front of an air stream to be evaporated and be reduced to final volume of 4 ml.

Faeces were collected separately every 24 h for 5 days and in some patients for 10 days. The faeces of each day were diluted with HCl and homogenised. Then they were dehydrated by heat. The dry remaining was weighed and a sample of known weight was assayed for radioactivity. The results of radioassay are expressed as the percentage of administered radioactivity which was excreted in the whole amount of urine or faeces per day.

Detection of transferrin in the concentrated urine of 5 patients was carried out using immunodiffusion with specific anti-transferrin serum (obtained from Hyland Laboratories, Los Angeles, CA). Transferrin in concentrated urine was quantitated by the radial diffusion technique (Immunoplates obtained from Hyland Laboratories).

Results

The haematologic data of the patients studied are shown in table I.

Urine The results of ^{59}Fe urine excretion after i.v. administration are expressed as first day excretion and as total amount from day 2-5 and from day 2-10 separately for each patient. The mean values for each group are also calculated (table II and fig. 1). The ^{59}Fe excretion during the first 24 h is quite high in all the groups studied with a wide range which in general corresponds to the levels of excretion of the subsequent days.

In order to find when the maximum ^{59}Fe excretion occurred during the first 24 h, radioactivity was counted in urine collected at 3 hourly intervals (table III and fig. 2). In all the patients irrespective of disease, the maximum of the excreted radioactivity occurs during the first 3 h after the i.v. administration of transferrin bound ^{59}Fe .

During the subsequent days the control patients excreted per day




Fig. 1 Urinary ^{59}Fe loss (mean value per day % of the administered dose) ○ Thalassemia ● thalassemia trait; ▲ S/Th △ controls.

Fig. 2 Urinary ^{59}Fe loss 3 h intervals during the first day (% of the administered dose). The numbers of the curves correspond to the case numbers of the tables I, II.

very low amounts of ^{59}Fe , which ranged from 0.002 to 0.013 % of the injected dose (fig. 1). Similar results were obtained in heterozygous thalassemia. In microdrepanocytic anaemia (thalassaemia-haemoglobin S disease) the excretion is somewhat higher than in the above groups. The excretion in homozygous thalassemia is significantly higher and more or less stable during all the days of observation ranging from 0.022 to 0.042 % per day (fig. 1).

In 5 patients the concentrated urine used for counting the radioactivity was tested for the presence of transferrin, using the immunodiffusion technique with a specific antitransferrin serum. All samples tested gave a well defined precipitation line, indicating the presence of transferrin.

The quantitative estimation of transferrin was carried out in the urine of 4 patients. One to three samples of urine of different days from each patient were used. In case No. 8 the amount of transferrin

Table I. Haematological data

Case No.	Age years	Sex	Hb g%	HCT %	Hb electroph.	Serum iron $\mu\text{g}/\%$	Iron excretion in urine mg/24 h	Spleen ect.	Transf.
Thalassemia									
1	12	M	8.3	31	F(30%)	222	1.38	yes	frequent
2	28	M	6.1	21	A ₂ A ₀ F(40%)	131	0	no	rare
3	21	F	7.8	29	A ₂ A ₀ F(20%)	76	0	no	frequent
4	7	F	5.7	19	A ₂ A ₀ F(30%)	225	0.67	no	frequent
5	14	M	7.7	28	F(30%)	280	0.98	yes	frequent
6	32	F	7.2	23.5	A ₂ F(80%)	120	-	no	no
7	27	M	8.6	30	A ₂ A ₀ F(60%)	160	0	yes	rare
8	20	F	10.5	34	A ₂ A ₀ F(60%)	115	0	no	frequent
9	9	M	6.3	24	F(35%)	160	0	no	frequent
10	8	F	8.7	29	A ₂ A ₀ F	218	0	no	rare
11	12	M	8.9	28	F(75%)	240	0.40	yes	frequent
Thalassemia trait									
12	24	F	11.7	36	A ₂ A ₀ F(2%)	127	0	no	no
13	34	F	11.4	39	A ₂ A ₀ F(2%)	127	0	no	no
14	39	F	12.5	40.5	A ₂ A ₀ F(4.7%)	-	0	no	no
15	50	F	12.5	43	A ₂ A ₀ F(traces)	124	traces	no	no
S/Th.									
16	25	F	7.7	25	A ₂ F,S	210	-	no	no
17	21	F	7.2	28	A ₂ F,S(F=5%)	102	traces	no	no
Controls									
18	48	M	-	-	normal	103	0	no	no
19	42	M	13.2	35	normal	79	traces	no	no
20	53	M	16.4	49	normal	158	0	no	no
21	22	F	13.4	43	normal	-	0	no	no

was approximately 0.25 mg/100 ml urine and in cases No. 9 and 10 0.1 mg/100 ml of urine. Because the amount of transferrin in the urine was very small and the method used is accurate only (for much higher concentrations 10 mg %) the results cannot be considered dependable except in the sense that they demonstrate the presence of transferrin.

Faeces The excretion of ^{59}Fe in the faeces during the first 5 days varies among the different groups studied but to a lesser extent as compared with urine (table II). It is interesting that the faecal excretion is inverted as compared with urine, except in the group of micro-

Table II ⁵⁴F loss (percentage of the administered dose)

Case No.	Urine		Faeces		
	1st day	Total amount from day 2-5	Total amount from day 2-10	Total amount for the first 5 days	Total amount from day 6-10
Thalassemia					
1	1.644	0.294	0.527	0.077 ^a	0.148
2	0.450	0.021	0.051	0.065	0.220
3	0.127	0.027	0.040	0.035	0.040
4	0.292	0.103	0.201	0.111	0.100
5	2.697	0.363	0.819	0.377	0.260
6	0.077	0.062	~	0.054	-
7	0.033	0.0.9	~	0.066	-
8	0.087	0.090	~	0.060	-
9	0.639	0.043	~	0.074	-
10	0.855	-	~	0.057	-
11	0.091	-	~	0.124	-
	0.637 ^a	0.114	0.523	0.008 ^a	0.154
Thalassemia trait					
12	0.064	0.018	~	0.009	0.097
13	0.009	0.027	~	~	-
14	0.015	0.023	~	0.103	-
15	0.108	0.048	~	0.291	-
	0.072 ^a	0.030	~	0.162 ^a	-
S/T_h					
16	0.088	0.072	0.105	0.045	0.070
17	0.032	-	~	0.155	-
	0.060 ^a	~	~	0.100 ^a	-
Normal					
18	0.025	0.024	~	0.125	0.048 ^a
19	0.016	0.064	~	0.083	0.151
20	0.036	0.013	~	0.121	-
21	0.103	0.056	~	0.192	-
	0.045 ^a	0.040	~	0.130	0.100

Mean value.

Faecal collection up to 8th day

drepanocytic anaemia in which the iron found was low. So in homozygous thalassemia the mean faecal excretion per 5 days is 0.098% and in controls 0.130%.

Table III. Urinary ^{59}Fe loss in 3 h intervals during the first day (percentage of administered dose)

Case No.	Hours after ^{59}Fe administration							
	3	6	9	12	15	18	21	24
4 ¹	0.361	0.069	0.021	0.003	0.001	0.002	0.001	0.001
15 ²	0.051	0.018	0.014	0.009	0.003	0.002	0.005	0.004

Homozygous thalassemia.

Heterozygous thalassemia.

The faecal excretion during the first day was very low and there after became much higher with wide daily variations during the 5- to 10-day period of collection. The wide daily variation may be accounted for by the different volumes of faeces passed by the patients. However there was no significant change of the ^{59}Fe excreted between the first and second 5-day period in the patients tested (table II)

Discussion

All our cases showed maximum urinary excretion of radioiron during the first 24 h and when collection in 6 patients was performed at 3 h intervals (fig. 2) the maximum excretion occurred during the first 3 h. The early urinary iron excretion, could be in part related to the presence of a considerable amount of diffusible iron in the plasma for a short interval [6]. However in the present work, the administered ^{59}Fe was of high specific activity and was incubated with large amounts of plasma, thus bound to transferrin. In addition in case 11 ^{59}Fe was incubated *in vitro* with the plasma of the patient's mother. Further similar increased ^{59}Fe excretion was noted in normal controls who have a high percentage of unbound transferrin in their plasma. Therefore the early ^{59}Fe loss can be attributed to a normal mechanism of transferrin-Fe excretion occurring when iron circulates bound with transferrin before it leaves the plasma going to the bone marrow and the iron stores. In all urine samples tested, transferrin was detected and further it was too early to find radioactive haemoglobin iron from haemolyzed red cells. In favour of this assumption are the results of

DAGO *et al* [3] and TRAEGER *et al* [15] who found increased sideruria in patients with proteinuria and siderophiluria. Contrary to the first hours most of the urinary ^{59}Fe in the subsequent days is probably due to exfoliated epithelial cells and erythrocytes as suggested by others [3-5].

The highest ^{59}Fe excretion, both of the first 24 h and of the subsequent days, was observed in thalassaemic patients. This can be explained in addition to the above factors by the recirculation of ^{59}Fe [11-12] and by the severe degree of haemosiderosis and increased saturation of transferrin which causes non-specific unloading of iron to various tissues [8]. In support of this possibility are our findings that thalassaemic patients with high serum iron levels, excrete more iron than patients with low levels (with one exception No. 4). The same applies to patients with clinical haemosiderosis and numerous transfusions, in whom the excretion is much higher [14]. SEARS *et al* [13] also state that in haemolytic anaemias the significantly increased urinary iron excretion is due to haemosiderinuria and exfoliation of iron loaded epithelial urinary tract cells. They found in addition, in the one thalassaemic patient studied, that the daily ^{59}Fe urinary excretion was 3 times higher than normal. In our study this difference, as a mean is more pronounced, being about 10 times above normal.

Among the groups studied the urinary excretion, both during the first 24 h and the 5- to 10-day period, varies between the lowest in control patients and the highest in thalassaemics. The heterozygote thalassaemics excreted similar amounts as the controls, while the double heterozygotes for thalassaemia haemoglobin S disease showed slightly higher amounts in the urine. In the above groups no significant increase in serum iron levels was found, which could partially account for the higher and continued excretion. It is possible that in all groups, including thalassaemia, intra-vascular haemolysis may have been also responsible. This view is reinforced by the higher excretion of iron found in hapto-globin depleted patients [13].

The amount of excreted radioiron in faeces was low and comparable to the previously reported values [7-4]. If one accepts that the faecal iron comes from the sloughing of epithelial cells and intestinal blood loss, then the very low radioactivity of the first day is not unexplained. The faecal radioactivity of the first 5-day period did not vary significantly among the groups studied, although there is a tendency to be reverse in comparison with the urinary excretion. This could be due

to either less ^{59}Fe uptake by the already loaded epithelial cells in thalassaemics, in contrast to the normals and heterozygotes, or to the excretion by the urine of the available for diffusion quantity.

It is interesting that increased levels of radioactivity were obtained during the second 5-day period in thalassaemia but not in controls. GREEN *et al* [5] reported that in normal subjects the faecal ^{59}Fe activity in the stools drops after day 5-8. This finding may suggest that two mechanisms are responsible for the late increase of faecal radioactivity in our thalassaemic patients: (a) sloughing of the initially labelled epithelial cells whose turnover rate according to LARSEN *et al* [10] was calculated to be between one and 4 days and (b) biliary ^{59}Fe especially for the sustained radioactivity considering that most of the patients investigated had variable degrees of dyshaemopoiesis (ineffective erythropoiesis, low red cell iron uptake).

That the faecal radioactivity was lower in thalassaemics initially does not oppose the assumption that the total iron excretion in the stool is significantly higher in haemoderotic patients than in normal controls.

Summary

Determination of the percentage of radioiron excretion in faeces and urine has been made, after ^{59}Fe administration, in thalassaemic patients, carriers of thalassaemia trait, patients with sickle cell thalassaemia and normal subjects. All the cases studied showed maximum urinary excretion of radioiron during the first 24 h. The highest excretion both of the first 24 h and of the subsequent days was observed in thalassaemia patients. The excretion of ^{59}Fe in the faeces during the first 5 days varies among the different groups studied and it is inverted as compared with urine being higher in thalassaemia trait and in normal subjects. The interpretation of the results is discussed.

References

1. AUSTON, N. E. and GREENBERG, D. M.: Studies in iron metabolism with the aid of an artificial radioactive isotope. *J. biol. Chem.* 134: 27 (1940).
2. COFF, D. H. and GREENBERG, D. M.: A tracer study of iron metabolism with radioactive iron. I. Methods—absorption and excretion of iron. *J. biol. Chem.* 164: 377 (1946).
3. DAHO, J. H., SCOTT, J. A. and GOLDBERG, A.: Urinary excretion of iron. *Clin. Sci.* 32: 493 (1966).
4. DURACK, R., MOORE, C. V. and CALLENDER, S.: Studies in iron transportation and metabolism. IX. The excretion of iron as measured by the isotope technique. *J. lab. Med.* 43: 599 (1965).
5. GREEN, R., CHARLTON, R., SEFTHEL, H., BOTTWELL, T., MAYR, F., ABRAHAM, B., FICK, C. and LAYMAN, M.: Body iron excretion in man. *Amer. J. Med.* 45: 536 (1968).

6. HANE, P. F., BALE, W. F.; HETTING, R. A., KAMEN, M. H. and WIPPLER, G. H. Radio-arthron and its excretion in urine, bile and feces. *J. exp. Med.* 78: 413 (1939).
7. HOMAR, F.; MARIAGLIA, G. and FRUCH, C. A. Blood ferrokinetics in normal man. *J. clin. Invest.* 46: 1 (1957).
8. JONES, J. H., INGLE, J. A., SHERWOOD, R. L. and ALEX, D. W. Transfer of iron from serum iron-binding protein to human reticulocytes. *J. clin. Invest.* 33: 161 (1959).
9. KOS, D. A. and WILD, F. Serum iron determination. *J. clin. Path.* 13: 241 (1960).
10. LEVINE, M.; SHERLOCK, P. and BELL, B. Cell proliferation kinetics in the gastrointestinal tract of man. II. Cell renewal in stomach, ileum, colon and rectum. *Gastroenterology* 45: 721 (1963).
11. MALAMOS, B., BELCHER, E. H., GYFTAKI, E. and BRONFELDER, D. Simultaneous radio-arthron tracer studies of erythropoiesis and red-cell destruction in thalassemia. *Brit. J. Haematol.* 7: 411 (1961).
12. POLLYCOVE, M. and MORTIMER, R. The quantitative determination of iron kinetics and hemoglobin synthesis in human subjects. *J. clin. Invest.* 40: 753 (1961).
13. SEARS, D. A., ADESON, P. R., FOR, A. L., WILLIAMS, H. L. and GROSS, W. H. Urinary iron excretion and renal metabolism of hemoglobin in hemolytic diseases. *Blood* 28: 708 (1966).
14. SMITH, R. S. Iron deficiency and iron overload. *Arch. Dis. Child.* 42: 313 (1965).
15. TRAGER, J., ZECH, P., REVILLARD, J. P. et MAUCEL, V. Excrétion rénale du fer protéinurique. *Nouv. Rev. franç. Hématol.* 7: 293 (1967).

Authors' addresses: Prof. Dr B. MALAMOS, Dr E. GYFTAKI and Dr N. KENNEDY, Departments of Clinical Therapeutics, University of Athens, Alexandra Hospital, Athens; Dr M. CONSTANTOPOULOS, and Dr O. ALDOUSTAKIS, Blood Research Laboratory Hellenic Red Cross, Athens (Greece).

Department of Medicine, St. Elizabeth Hospital, Boston, and Tufts University School of Medicine

Megakaryocytes and Platelets in Central Venous and Arterial Blood¹

ALICE KALLINIKOS-MANIATIS

The observation that megakaryocytes inhabit the capillaries of the lung dates back to 1893 [1] and since then the question of their origin has been a matter of controversy [2-3]. The presence of megakaryocytes in the blood was originally thought to be associated only with pathologic conditions in which the bone marrow was under strain (i.e. myeloid metaplasia, chronic myelogenous leukemia *sensu* [4]) as well as with malignancies [5]. More recently megakaryocytes have been recognized as normal inhabitants of the blood since they are always found although in small numbers in the blood of normal individuals [6-7-8].

It is the opinion of most investigators at the present that circulating megakaryocytes are produced in the bone marrow and are trapped in the capillaries of the lungs where they release platelets [3-7-8]. If this is true a significantly larger number of megakaryocytes should be present in the venous as compared to the arterial blood.

The following study was undertaken to determine the difference in numbers of megakaryocytes as well as platelets between the central venous and central arterial blood in subjects undergoing cardiac catheterization who were normal from the hematologic standpoint. Previous studies have been done on patients undergoing thoracotomy for pulmonary diseases [8, 9].

Materials and Methods


Ten human subjects, 7 females and 3 males ranging in age from 15 to 62 years were included in this study. The above subjects were undergoing diagnostic cardiac catheterization; 7 of them were found to have cardiac abnormalities, 2 were considered normal and 1 was thought to have a cardiac tumor but this was not proven on exploration. Patients were sedated with Valium 100 mg i.m., prior to the catheterization. A total of 20 ml of blood was obtained from each patient, prior to injection of any radio-opaque media, 10 ml from the pulmonary artery (or the high right atrium, if left to right shunt was present) and 10 ml from the aorta. The blood was collected in plastic syringes, through Courmand polyethylene catheter for the venous blood and Seldinger or TSP catheter for the arterial. The catheters were flushed with heparinized 5% dextrose in water solution (20 mg of heparin in 1,000 ml 5% D/W) prior to sampling. The blood was immediately placed in buffered formalin-polyvinylpyrrolidone (PVP) fixative and the saponin-hemolytic leukoconcentration technique of HIRSHYAL [10] as modified by RACHIA [7] was followed. By this technique all the nucleated blood cells are concentrated on millipore filters and the megakaryocytes either with or without cytoplasm can be easily recognized and counted by scanning of the filters under low power of the light microscope. Megakaryocytes with cytoplasm appear elongated presumably because of their passage through narrow catheters (fig. 1). Only cells with intact nuclei were included in the counts.

Platelet counts were performed according to the direct method of BARCKEN and CAPOVILLA [11]. Eight simultaneous counts were done on each sample; this has been shown to reduce the error of the mean to $\pm 4\%$ [12].

Results

In all 10 patients studied megakaryocytes were present in both the central venous and central arterial blood (table I). The numbers in the central venous blood varied from 3-32 cells per 10 ml of blood, whereas only 1-4 cells/10 ml were found in central arterial blood. Cells with cytoplasm varying in numbers from 2-19/10 ml with an average of 10.3 were present in the central venous blood of all 10 patients, while in the central arterial blood of only 3 patients were cells with cytoplasm found (1 or 2/10 ml).

Platelet numbers were determined in 8 patients, 5 of whom showed larger numbers in the central arterial blood with a difference between arterial and venous blood ranging from 30,000-80,000/mm³ with a mean of 43,500; this difference is statistically significant ($p=0.001$). Only one patient (M.P.) showed approximately equal numbers in both samples. The morphological appearance of the megakaryocytes was similar to that described by KAUFMAN *et al* [7] with a predominance of elongated or paddle-shaped cells (fig. 1).



Megakaryocyte with elongated cytoplasm in the central venous blood ($\times 1,000$)

Discussion

1. Ongoing experimental data confirm the observation that
 2. megakaryocytes are found in the circulating blood of normal subjects.
 3. The data obtained in this study are slightly different from those re-
 4. ported by KAUFMAN *et al* [7]. The average number of megakaryo-
 5. cytes in antecubital venous blood was 1.78/ml (range 0.3–3.7) as compared
 6. with 1.1 cells/ml found by KAUFMAN. This difference can be ex-
 7. plained by the fact that the above authors included in their counts
 8. all megakaryocytes while only intact nuclei were counted in the pres-
 9. ent study. MELAMED *et al* [8] reported much larger numbers of mega-
 10. karyocytes in antecubital venous blood (range 1–100/ml). This in-
 11. crease may be due to the use of a technique which is less traumatic to
 12. the megakaryocytes.

13. If the venous blood was found to contain 6 times as many mega-
 14. karyocytes as the arterial blood and approximately 25 times more
 15. megakaryocytes with cytoplasm, KAUFMAN *et al* [7] in their study
 16. found similar differences but their data are inadequate since arterial
 17. samples were obtained from two subjects. The authors do not specify

Table 2. Numbers of megakaryocytes and platelets in the central arterial and venous blood of 10 subjects

Patient	Diagnosis	Megakaryocytes 10 ml		Platelets $\times 10^9$		Difference	
		Venous blood Total No.	With cytoplasm	Arterial blood Total No.	With cytoplasm	Arterial blood	Venous blood
C.C.	Mitral stenosis	22	10	2	0	—	—
J.B.	Normal	8	4	3	0	45,000	42,400
A.B.	Atrial septal defect	32	17	4	0	407,500	177,500
B.L.	Aortic stenosis and insufficiency	20	7	5	0	231,000	217,000
R.J.		19	9	4	1	232,000	162,500
A.K.	Aortic stenosis	13	10	4	2	203,000	125,000
D.C.	Coronary artery disease	16	11	2	0	152,000	120,000
M.P.	Normal	15	9	4	1	240,000	235,000
R.V.	Mitral stenosis	3	2	1	0	227,000	162,000
O.R.	Mitral stenosis	30	15	3	0	262,000	232,000
—	Average	17.8	10.3	3	0.4	—	43,500

whether these were central or peripheral blood samples. In the latter case the difference could be attributed to destruction of megakaryocytes in the circulation and not to trapping in the lungs. In the study by SCHREINER and KOIVUJÄRVI [9] it is stated that megakaryocytes were definitely more frequent in pulmonary arterial blood than in pulmonary venous blood, but the actual numbers of megakaryocytes are expressed per sample of blood, the volume of which is not specified. Furthermore, the subjects used were patients with pulmonary diseases (mostly malignancies) undergoing thoracotomy. Both the disease [5] as well as the operation could have influenced the results [13].

As to the question of platelet release in the lungs the data indicate a definite enrichment of platelets in the blood leaving the lungs. Simultaneously obtained red cell counts indicated that this was not due to

hemoconcentration TOCANTINS [14] using his method for counting platelets reported similar differences between arterial and venous blood. This platelet gradient across the pulmonary vascular bed however cannot be accounted for by platelet production from the circulating megakaryocytes alone. It has been estimated that the number of platelets produced by one megakaryocyte is $\approx 4,000$. The megakaryocytes therefore that arrive to the lungs could only account for a small fraction of the observed platelet number difference between arterial and venous blood. One could assume that the lungs act as a pool of platelets and that the experimental conditions (i.e. cardiac catheterization) disturb the existing steady state causing a release of platelets into the arterial blood. ASTER however in his study was unable to demonstrate any significant pool of platelets in the lung [15].

It is finally possible that the adhesiveness of platelets in the venous blood is greater than it is in the oxygenated arterial blood and this may lead to clumping of platelets and a falsely low value. Although clumps were not observed in the counting chamber this possibility is under further investigation at the present time.

Acknowledgments. I am grateful to Dr T. J. RYAN for providing the blood samples and to Dr B. EASE, Dr F. STOLLMAN, J. and Dr W. H. CROSBY for their advice.

Summary

Megakaryocyte and platelet numbers were determined in blood samples obtained during cardiac catheterization from the pulmonary artery and the aorta of 10 hematology normal subjects. Significantly larger numbers of megakaryocytes were found in the pulmonary artery as compared to the aorta. Platelet numbers on the opposite were higher in the arterial than in the venous blood. It is concluded that passage of the megakaryocytes through the lung capillaries results in fragmentation of their cytoplasm and release of platelets, while the nuclei are mostly retained in the capillaries.

References

1. AMOFF L. Über capilläre Embolien an Riesenkern-haltigen Zellen. Verh. anat. Arch. path. Anat. 139: 11-25 (1893).
2. HOWELL, W. H. and DONATKE, D. D. Production of blood platelets in the lung. J. exp. Med. 65: 177-204 (1937).
3. SHARNOFF J. G. and KRAE, E. S. Evaluation of pulmonary megakaryocytes. Arch. Path. & 176-182 (1958).

4. MINOT □ R. Megakaryocytes in the peripheral circulation. *J exp Med.* 37: 1-7 (1922).
5. HUNT, R. WEST L. T. MALINSOFF, R. A. and H. E. A. Quantitative observations of circulating megakaryocytes in the blood of patients with cancer. *New Engl. J. Med.* 279: 111-117 (1968).
6. KATZMAN, R. M.; AISO, R. POLLACK, S.; CR. W. H. and DOMANICK, R. Origin of pulmonary megakaryocytes. *Blood* 25: 67-77 (1965).
7. KATZMAN, R. M.; AISO, R. POLLACK, S. and CROWT W. H. Circulating megakaryocytes and platelet release in the lung. *Blood* 26: 31 (1965).
8. MALAMED, M. R. CLIFFTON E. E. MERCIER, C. and KOW, L. G. The megakaryocyte blood count. *Amer J med. Sci.* 252: 301-308 (1966).
9. SCHWARTZ, T. M. and KORNVEIT, A. P. Megakaryocytes in the pulmonary circulation. *Blood* 22: 82-87 (1963).
10. HERREVAL, R. Recherche des cellules cancéreuses dans le sang et les liquides d'exsudats, par la leucoconcentration. *Presse méd.* 69: 149 (1961).
11. BAUCHE, G. and CROVETZ E. P. Morphology and enumeration of human blood platelets. *J appl. Physiol.* 9: 365-377 (1950).
12. BAUCHE, G.; SCHWEDERSKY, M. and CROVETZ, E. P. The reproducibility and constancy of the platelet count. *Amer J. clin. Path.* 27: 15-26 (1955).
13. BARKLOW A.; KATZMAN, R. M. and L. W. A. R. The effect of surgery on the concentration of circulating megakaryocytes and platelets. *Blood* 27: 393-401 (1966).
14. TOCANTON, L. M. The mammalian blood platelet in health and disease. *Medicine, Balt.* 17: 155-258 (1938).
15. ASTER, R. H. Pooling of platelets in the spleen. Role in the pathogenesis of "hyper splenic thrombocytopenia. *J. clin. Invest.* 45: 645-657 (1966).

Medizinische Universitätsklinik, Section für Hämatologie und Klinische Immunologie,
Göttingen

Panmyelophthie und Virushepatitis

Experimentelle Untersuchungen mit dem Mäusehepatitis-Virus MHV

W. HUCHT, E. PERROS, B. EGGELS und N. UHL

Im Gefolge der Virushepatitis des Menschen können sich in sehr seltenen Fällen Panmyelophthien entwickeln. Solche Komplikationen bei einer Infektion mit hepatotropen Viren erwecken doppeltes Interesse: einmal werden sie als Seltenheit registriert und zumest publiziert, zum anderen steht eine Erklärung für das Phänomen der Koexistenz dieser verschiedenartigen Erkrankungen aus.

In der Absicht, einen Beitrag zur Klärung dieser Frage zu liefern, unternahmen wir tierexperimentelle Untersuchungen mit dem Mäusehepatitis-Virus MHV₁ [10].

Material und Methode

Als Versuchstiere dienten 98 infantile männliche und weibliche Mäuse vom Stamm CF mit einem Gewicht von 10-12 g. Dieser Stamm ist im Gegensatz zu anderen Mäusen immun nicht gegen das MHV₁-Virus resistent. Das Virus-Lyophilisat MHV₁ bezogen wir von der Tissue Culture Collection, Washington, D.C.

Da es sich bei unseren Experimenten um orientierende Untersuchungen handelte, richteten wir auf die bei Virusexperimenten üblichen Tierbestimmungen in der oben angegebenen Injektionsdosis. Wir gingen von einer Viruskonzentration von 10^6 i.u./ml aus. Eine Stammlösung von 1 ml wurde geteilt dem Ergebnis eigener Versuche, mit 0,5% NaCl-Lösung zu 1:10, 1:20, 1:50, 1:100 und 1:200 verdünnt. Intraperitoneal injiziert wurden 0,1 ml der jeweiligen Verdünnung pro g Körpergewicht bei 5 Gruppen von je 10 Mäusen. Tiere dienten als Kontrollgruppe. 72 Stunden nach Infektion dekapierten wir aus den Gruppen A und B 6 Mäuse, und zwar diejenigen, die sich am schlechtesten Allgemeinzustand befanden. Die rapide Verschlechterung des Zustandes der Mäuse in Gruppe A und B ließ uns erwarten, dass zur Tötung aller Tiere dieser Gruppe nach weiteren 6 Stunden. Die Tiere der Gruppen C, D und E töteten wir wie vorgesehen nach 81, 132 bzw. 187 h. Tötung des Kontrollkollektivs nach 3 Tagen.

Sternum und Oberschenkel sowie Leber, Lunge und Eierstock und in üblicher Weise histologisch in Metacryl eingebettet.

Niere und Milz wurden in Form eines Teils des Gewebes wurde

Ergebnisse

1. Verhalten der Tiere

Zwischen dem 2 und 3 Tag nach Virusbeginn traten allgemeine Krankheitszeichen auf wie Fress- und Bewegungslustlosigkeit, stumpfes Fell und *ante finem* hastige Atmung und zusammengelümmelte Haltung. Diese Symptome beobachteten wir in allen Versuchsgruppen häufiger nach Gabe der höheren Viruskonzentrationen. Ebenso befanden sich in allen Gruppen Tiere, die ausserlich keine Anzeichen einer Erkrankung hatten, besonders in den Gruppen mit 1:100 und 1:200 der Stammlösung.

2. Histologische Knochenmarkbefunde

Gruppe A (1:10 MHV_{10} , 72 bzw. 78 h post mortem getötet). Bei allen Tieren fanden sich ausgedehnte Nekrosen (Abb. 1), zum Teil Kolliquationsnekrosen. Zwar war in der Regel das Mark in ganzer Ausdehnung befallen, doch liessen sich herdförmige Bezirke mit besonders ausgeprägter Zellerstörung und Ansammlung von Ödemflüssigkeit nachweisen. Solche Areale erinnerten an metastatisch septische «Mikroabszesse». Reparative Vorgänge waren nur bei wenigen Tieren nachweisbar.

Gruppe B (1:20 MHV_{10} , Tötung nach 72 bzw. 78 h). Auch in dieser Gruppe zeigten – bis auf eine Ausnahme – alle Tiere Nekrosen im Sternum und Femur. Bei einem Tier bestand im Femur eine ausgedehnte Markaplasie. Gleichzeitig waren grossflächige Nekrosen im Sternum entwickelt. Bei 9 weiteren Tieren fanden sich grosse aplastische Bezirke neben kleineren Nekrosearealen. Bei einem Teil der Tiere war es bereits zu lebhaften reparativen Vorgängen mit Phagozytose und retikulärer Reaktion gekommen. Auch bestand eine Zunahme von Proerythroblasten und Promyelocyten unmittelbar neben noch nekrotischen Arealen.

Gruppe C₁–C₆ (1:50 MHV_{10} , Tötung nach 84 h). 2 Tiere zeigten

Tabelle 1 Histologische Befunde in Beziehung zu Versuchsdauer und Virusverdünnung
(13 orzontig gestorbene Tiere blieben unberücksichtigt)

Virus- verdünnung	Zeit in Stunden		84	132	180
	72	78			
1:200			x o x x o	o o o o o	o o o o
1:100			x o o x o o	o o o o o o	o o o o o o
1:50			x o x o o	o o o o o	o o o o o
1:20	x o x o	o x o o x o o			
1:10	x x	o o o o x o o			

x Ausgedehnte Nekrosen, o diskrete Nekrosen, o ohne Befund

massive Nekrosen bei 2 Tieren war das Mark normal. Bei einem Tier fanden sich nur diskrete Einzelzellnekrosen

In Gruppe C₁-C₁₁ (Tötung nach 132 h) wiesen 3 Tiere Einzelzellnekrosen auf. Häufiger fanden sich mit Kernresten überladene Phagen (Abb. 2). Noch immer bestand eine Zunahme der Mitoserate, doch war die «Linksverschiebung» nicht mehr so auffällig. 2 Tiere blieben ohne Befund.

Tiere der Gruppe C₁-C₁₈ (Tötung nach 180 h) zeigten keine Veränderungen mehr.

In der Gruppe D-D₆ (1:100 MHV₂, Tötung nach 84 h) zeigten 2 Tiere frische ausgesprochen kleinherdige Nekrosen (Abb. 3). Die nach 132 bzw. 180 h getöteten Tiere dieser Gruppe (D₇-D₁₁) boten einen praktisch normalen Markbefund. Vereinzelt waren Schaumzellen und phagozytierende Retikulumzellen als Residuen eines vorangegangenen Markschadens auffindbar.

Die Kontrolltiere zeigten einen normalen Markbefund.

Ähnliches gilt für die Gruppe E. Auf der Tabelle 1 sind die histologischen Befunde in Korrelation zu Versuchsdauer und zur injizierten Virusverdünnung aufgetragen. Die Tabelle zeigt, dass mit Zunahme




Abb. 1 Ausgedehnte, diffuse, herdartig betonte Knochenmarknekrosen mit zahlreichen kugeligen pyknotischen Kernresten. Kleine Ödembezirke. Einzelne Schaumzellen. Oberchenkel (Mason-Goldner 420)

Abb. 2 Abstrumzelle mit zahllosen Kernresten im Zytoplasma. Der Zellkern tritt als Aussparung hervor. Angrenzend große promyelocytäre Elemente. Außerdem noch nicht phagozytiertes Kernmaterial überall im Bild. Unten links kleinere phagozytierende Zelle. Sternchen (Mason-Goldner 670)

[11 16] Temporäre Verminderungen eines oder mehrerer hämopoetischer Zellsysteme sind bei verschiedenen Viren bekannt, z.B. beim Mumps Virus [9] dem Röteln Virus [27] und beim Denguefieber [5] FIKRIG und BERKOVICH [9a] haben kürzlich nach Infektion mit Cox sackie B₁ Virus bei Mäusen temporäre Aplasien der Erythropoese erzeugt

Unsere Befunde zeigen nun erstmals, dass für die hämatologischen Veränderungen nach MHV₁ Virus massive Knochenmarknekrosen verantwortlich sind. Wir fanden in allen Tiergruppen Nekrosen unterschiedlichen Alters. Sie reichen vom Bild der frischen Entparenchymisierung mit Ödemseen (Abb 1) bis zu kleinen herdförmigen Gruppennekrosen hämopoetischer Zellen (Abb 3) Stets waren die Veränderungen an verschiedenen Stellen der untersuchten Markabschnitte anzutreffen Die nekrotischen Zellreste wurden im Ablauf einer Reparationsphase von retikulären Abraumzellen aufgenommen und eliminiert. Häufig ließen sich in späten Stadien mit zahllosen Kernresten angefüllte Speicherzellen nachweisen (Abb 2) Die angrenzenden, intakt gebliebenen Gewebsabschnitte zeigten Regenerationsansätze mit Vermehrung myelopoetischer Vorstufen und gehäuft Kernteilungsfiguren.

Nur in einem Fall war es nicht zur reparativen Wiederbesiedlung des zerstörten Knochenmarks gekommen. Es hatte sich vielmehr eine Hypoplasie des blutbildenden Gewebes entwickelt. Bei diesem Tier fand sich ein Bild, wie es bei der Markaplasie nach Virushepatitis des Menschen beschrieben worden ist Zwei weitere Tiere zeigten ein hypoplastisches Mark, aber keine vollständige Phthase

Die im Knochenmark nachgewiesenen Nekrosen sind das Analogon zu Veränderungen die in Milz und anderen lymphatischen Geweben schon durch HIRANO und RUERNER [12, 13] festgestellt worden waren Die Knochenmarkbefunde blieben bisher unerkannt was sich daraus erklärt, dass die Voruntersucher vom Knochenmark keine histologischen Schnitte sondern zytologische Ausstrichpräparate analysiert hatten Bei der Ausstrichtechnik lassen sich umschriebene Markprozesse aber nicht erfassen. So haben PIAZZA *et al* [25] die sich speziell mit den hämatologischen Veränderungen inokulierter Mäuse befassten nur zytologische Veränderungen der Hämpoese gesehen Sie fanden eine relative Verminderung der linksverschobenen Erythropoese und eine starke Zunahme der unreifen granulopoetischen Vorstufen. Letzteres deuteten PIAZZA *et al* als Reifungsstörung Nach unseren Ergeb-

nissen ist die Linksverschiebung jedoch ein Ausdruck der Wiederbesiedlung nekrotischer Markbezirke

Am nahezu regelmäßigen Befall des Knochenmarkes bei der experimentellen Hepatitis der Maus kann kein Zweifel herrschen. Durch *PIAZZA et al* [25] waren bereits hohe Viruskonzentrationen in den hämopoetischen Organen wie Milz, lymphatisches System und Knochenmark nachgewiesen worden. Wir fanden bei vielen Tieren ausserdem im Knochenmark synzytiale Riesenzellen als Ausdruck des zytopathogenen Effektes des MHV Virus (Abb 4). Diese Riesenzellen, von *MALUCCI* [22] in Peritonealdeckzellkulturen als typisch beschrieben, kommen auch in den Lebern inkubierter Tiere vor.

Unsere experimentellen Befunde legen eine Analogie zur menschlichen Hepatitis nahe. Sie lässt sich herleiten aus der beim Menschen – nach *PIRCHE* und *SPENCE* [26] häufiger – vorkommenden Veränderungen des peripheren Blutbildes mit Leuko- und/oder Thrombopenie sowie diskreten Anämie mit verkürzter Erythrozytenlebenszeit und Anstieg der Retikulozyten [6]. Die Analogie ist auch nahelegend wegen der gelegentlich auftretenden Kombination von Panmyelophthase und Hepatitis. Diese Kombination trat bei unseren Versuchen nur einmal auf. Daher ist anzunehmen, dass es sich im Stadium der Virämie zwar um häufig auftretende, aber reversible Veränderungen handelt, entsprechend der starken Regenerationspotenz des Knochenmarkes.

Genetische Schädigung der Hämpoese Wie schon im vorangegangenen Absatz diskutiert, sind Schädigungen der Hämpoese bei verschiedenen Viruserkrankungen bekannt. Der Erreger des Denguefiebers und das Masernvirus können schwere Chromosomenschädigungen hervorrufen. Beim Masernvirus sind sogar völlige Zertrümmerungen der Chromosomen (Pulvernation) beschrieben worden [24]. Eine Regenerationsstörung würde bei so schweren Zellschädigungen nicht überraschen. Wenn auch derartig schwere Schäden an Chromosomen des Menschen bei akuter Hepatitis nicht bekannt sind, so liegen doch Berichte über Chromosomenanomalien bei dieser Erkrankung vor [1]. Ausserdem haben *MELLA* und *LANG* [23] gezeigt, dass eine Mitosehemmung in Leukozytenkulturen eintrat, sobald man mit Serum von Hepatitiskranken inkubiert.

3. Eine *toxische Markschädigung* für den Menschen von verschiedenen Autoren diskutiert, lässt sich beim Fehlen jeglicher Korrelation zwischen Schwere der Leberfunktionsstörung und Häufigkeit der Kno-

chenmarkschädigung kaum vorstellen. Bei unserem Versuchsmodell sind toxische Schädigungen ursächlich nicht in Erwägung zu ziehen. Wie PIAZZA *et al.* [25] gezeigt haben, ist die Viruskonzentration im Knochenmark hoch. Dieser Befund passt zu den von uns nachgewiesenen Nekrosen, welche Folge eines Virusbefalles des Knochenmarkes sind. Die Annahme einer «toxischen» Markschädigung ist zumindest für das Modell der Mäusehepatitis überflüssig.

4 *Antikörper gegen Blutzellen Immunerkrankung* Die Frage, warum die Phthuse als Folge des Knochenmarkbefalles auch tierexperimentell so selten ist, bleibt offen. Belege für einen ursächlich denkbaren Immunprozess fehlen uns. Für den Menschen hat BEICKERT [3] darauf hingewiesen, dass die Veränderungen «an die Verhältnisse bei immunologischen Zweitkrankheiten oder autoimmunologischen Störungen erinnern». Im Rahmen dieser Arbeit kann wegen des Fehlens entsprechender Befunde hierzu nicht Stellung genommen werden.

Zusammenfassung

Neunzig infantile CF-Mäuse wurden mit Mäusehepatitis-Virus (MHV) intraperitoneal infiziert, um mögliche Knochenmarkveränderungen zu analysieren. 15 der infizierten Mäuse starben inner 72 h. Die überlebenden 75 Tiere wurden bis zu 180 h später getötet. Im Knochenmark von Sternum und Femur fanden sich histologisch unterschiedlich ausgeprägte Nekrosen. Mit Fortschritt der Versuche und in grober Korrelation zu erschwerenden Verdunstungen nahmen die Nekrosen ab und die reparativen Vorgänge zu. Nach 180 h fanden sich praktisch normale Befunde. Bei einem Tier hatte sich eine unvollständige Phthuse entwickelt, zwei zeigten Markhypoplasien. Die bisherige Annahme, die Schädigung blutbildender Zellen bei der experimentellen Hepatitis sei eine Regulationsstörung, kann sich aufrecht erhalten werden.

Summary

90 infantile CF-mice had been inoculated intraperitoneally with mouse hepatitis virus, MHV, in order to study reactions of the bone marrow. 15 of the infected animals died within 72 h, and the surviving 75 were sacrificed at intervals up to 180 h. Histological examination of the marrow of sternum and femur showed necrosis of varying extension. With progressing time and in loose correlation to the different virus dilutions the necrosis disappeared and reparative changes took place. Histological findings were usually normal after 180 h. One animal developed an incomplete myelophthisis, two others a hypoplastic marrow. The so far prevailing interpretation regarding the disturbance of blood-forming cells during experimental hepatitis as signs of maturation delay cannot be maintained.

Literatur

1. EL-ALFI, O. S., SMITH, P. M. and BRESLE, J. H.: Chromosomal breaks in human leucocyte cultures induced by an agent in the plasma of infectious hepatitis patients. *Hereditas, Lond.* 52: 283-294 (1965).
2. ALT, H. L. and SWANK, R. L.: Thrombocytopenic purpura associated with catarrhal jaundice. Report of case. *Ann. intern. Med.* 10: 1049-1053 (1937).
3. BECKERT, A.: Panmyelopathien nach akuter Hepatitis. *Dtsch. med. Wochr.* 19: 1461-1462 (1966).
4. BECKERT, A. und SCHÜDLO, H.: Immunpancytopenie mit Auftreten heterophiler Antikörper bei akuter Hepatitis epidemica, kompliziert durch eine schwere Myokarditis. *Acta haemat., Basel* 19: 51-61 (1958).
5. BERMAN, H. R. and NELSON, E. R.: Hematodepressive virus diseases of Thailand. *Ann. intern. Med.* 117: 170-172 (1966).
6. COVELL, M. E., SCHWARTZ, F. D. and YODanis, A. A.: Infectious hepatitis - generalized disease. A study of renal, gastrointestinal and hematologic abnormalities. *Amer. J. Med.* 37: 789-801 (1964).
7. DILLER, J. J., CHICKEN, W. J. and MARCARELLI, J.: Fatal pancytopenia associated with infective hepatitis. *New Engl. J. Med.* 225: 297-299 (1962).
8. DICKE, F. E. and GOLDSO, J. R.: Agranulocytosis associated with infective hepatitis. *Brit. med. J.* 48: 738-740 (1957).
9. FANDIA, P. G., P. TUN, W. B. and BOSTOCK, M. L.: Thrombocytopenic purpura complicating icterus. *Brit. med. J.* 4: 1244-1249 (1964).
10. FERRIS, S. J. L. and BERLOVICH, S.: Virus induced plastic crisis in mice. *Blood* 33: 582-583 (1969).
11. GLEDHILL, A. W., DICK, G. W. A. and NIVEN, S. F.: Mouse hepatitis virus and its pathogenic action. *J. Path. Bact.* 63: 299-309 (1955).
12. HANSON, W. P. and MARSH, R. E.: The leucocyte response of patients with experimentally induced infectious hepatitis. *Amer. J. med. Sci.* 212: 129-138 (1964).
13. HIRANO, T. and RICEVOCH, B. H.: The effect of murine hepatitis virus infection on lymphatic organs. *Lab. Invest.* 14: 488-500 (1965).
14. HIRANO, T. and RICEVOCH, B. H.: Studies on the mechanism of destruction of lymphoid tissue in murine hepatitis virus (MHV₁) infection. Selective prevention of lymphoid necrosis by cortisone and penicillin. *Lab. Invest.* 15: 270-282 (1966).
15. JEDERWICK, L. and RADIKOWSKA-ORLOVSKA, H. I.: Aplazja szpica kostnego po wirusowym zapaleniu wątroby prześl. *Epidem. Z.* 383-386 (1967); *Zh. n. Esmerpja Medica* Section Hematology 2, Nr. 2361 (1968).
16. KETTER, W.: Hepatitis epidemica und Panmyelophthase. *Dtsch. med. Wochr.* 91: 1923-1924 (1968).
17. KIVEL, R. M.: Hematologic aspects of acute viral hepatitis. *Amer. J. digest. Dis.* 6: 1017-1031 (1961).
18. KOLAN, N.: Pancytopenie als Komplikation einer Hepatitis und Ursache einer Leber dystrophie. *Dtsch. med. Wochr.* 10: 794-796 (1956).
19. KRAMER, A.: Panmyelophthase und Virushepatitis. *Acta hepato-splenol.* 10: 228-233 (1963).
20. LEIDWIKER, R., MUELLER-ECKHARDT, Ch., NOHKE, K., WALT, D. und LÖFFLER, H.: Hepatitis und Panmyelophthase. *Dtsch. med. Wochr.* 92: 841-842 (1967).
21. LEVY, R. N., SAWTNEY, A., FLOMAN, A. L. and ROWE, E.: Fetal splenic anemia after hepatitis. Report of 5 cases. *New Engl. J. Med.* 273: 1118-1123 (1965).
22. LORENZ, E. und QUAMER, K.: Pancytopenie nach Hepatitis epidemica. *Wien. med. Wochr.* 105: 19-22 (1953).

22. MALLORY, L.: Observations on the growth of mouse hepatitis (MHV₁) in mouse macrophages. *Virology* 25: 30-37 (1965)
23. MELLA, B. and LAMB, E. J.: Leucocyte mitosis. Suppression *in vivo* associated with acute infectious hepatitis. *Science* 155: 80-81 (1967)
24. NICHOLS, W. W.; LEVAY, A.; ADLA, P. and NORDBY, E.: Extreme chromosome breakage induced by measles virus in different *in vitro* systems. *Hereditas, Lund* 57: 380-382 (1964).
25. PIAZZA, M. L., PROCCO, F. and MATANO, S.: Hematological changes in viral (MHV₁) murine hepatitis. *Nature, Lond.* 205: 1034-1035 (1965)
26. PRITCHARD, C. S. and SPENCER, E. M.: Fatal marrow aplasia complicating infectious hepatitis. *Brit. med. J.* 1: 171-172 (1963)
27. RAUBER, A. R., RUCHTER, P., TALLAL, L. and COOPER, L. Z.: Hematologic effects of intruterine rubella. *J. amer. med. Ass.* 192: 111-117 (1967)
28. ROWE, L. and GOTTLIEB, A. A.: Virushepatitis og pancytopeni. T. norske Lægeforen. 87: 1906-1908 (1967). *Zk. n. Excerpta Medica Section Hematology* 2, Nr. 2362 (1968).
29. RUSBY, E.; GOTTLIEB, Ch. and VOGL, P.: Syndrome of hepatitis and aplastic anemia. *Amer. J. Med.* 45: 88-97 (1968).
30. SCHWARTZ, E.; BAIRDORF, R. L. and DIAMOND, L. K.: Aplastic anemia following hepatitis. *Pediatrics* 37: 681-683 (1966)
31. SHIMSON, K.: Infective hepatitis and marrow aplasia. *Brit. med. J.* 4: 473 (1963)
32. SPATZ, R., BORGHESE, H. G. and ZOLL, H.: Knochenmarkschädigung bei Virushepatitis. *Med. Klin.* 63: 1761-1765 (1968).
33. VAKSZA, J. und SCHAMLOWA, L.: Pancytopenie nach akuter Hepatitis. *Med. Klin.* 63: 757-759 (1968).
34. SOLIS, J., DE SOLMENTAL, J. et LAPERRONNE, Ch.: Hépatite virale et anémie aplasique. *Schweiz. med. Wochs.* 98: 1105-1109 (1968)
35. SEIZERTHO, H.: Pancytopenie nach Virushepatitis. *Med. Klin.* 64: 1073-1075 (1969)

Laboratoire d'Anatomie Pathologique, Université de Liège, and Institute of Developmental Biology Academy of Sciences of USSR, Moscow

Quantitative Study of the Hemopoietic Recovery after a Sublethal X Irradiation in the Mouse

J. HAOT and N. F. BARAKINA

During the last decade, many researchs have been devoted to the problem of the small cell population of the marrow ('bone-marrow lymphocytes') and it has been suggested that this population contains the marrow stem cells [1-2]. Particular attention has been drawn on the accumulation of small mononucleated cells in the bone-marrow of animals recovering from an irradiation [3-4]. These cells, morphologically similar to the lymphocyte from which they can nevertheless be distinguished by some cytological characters, have received the name of 'transitional cells' [5-6].

In a preceding work, we have studied the variations of this cell population in the mouse. Using for these investigations an electronic particle counter equipped with a plotter we have shown that it was possible to differentiate in the femoral marrow between two populations of cells. The first is composed of small lymphoid cells in the volume range of 100-150 μm^3 . The second one forms a peak at 220 μm^3 and contains cells of the granulocytic series [7-8]. We have followed these two populations after an X-ray irradiation. The small cells rebound at the 11th day to a value higher than the normal while the population of larger cells recovers according to a biphasic pattern with a plateau at the 11th post-irradiation day. Combining the electronic counter method with a classical cytological study and the electron microscopy we have shown [9] that between the 10th and the 13th post irradiation day the group of small cells and medium sized 'lymphoid cells' was very heterogenous and was composed of at least 3 cell

types firstly the lymphocytes secondly some young granulocytic cells and thirdly a peculiar type of lymphoid-like cells, we called λ -cells. In the animals selected by means of the electronic counter for this experiment, the percentage of λ -cells could be as high as 62% while the small lymphocytes seemed to represent no more than 14% of the total nucleated cells.

The purpose of the present work was to give some more precision on the variations of the marrow lymphoid cells during the recovery period. We decided to compare the cell populations that we could observe by means of the electronic counter and the populations calculated from the myelogram. With the first method, we expect to obtain information about the population of small lymphoid cells (small lymphocytes.) The second method should allow the study of the total lymphoid like population including the λ -cells. On the other hand, it appeared interesting to follow in the same animals the modifications of the other lymphoid organs: thymus, lymph nodes and spleen.

Material and Method

R3 female mice 10 to 12 weeks old were X-irradiated with dose of 300 r (Scablivolt Siemens apparatus, 190 kV 18 mA, 0.5 mm Cu filter 35 cmFD, output 210 r/min). Eight to 15 mice were killed by section of the cervical blood vessels each other day from the 2nd to the 20th post-irradiation day. Eight to 10 additional animals were sacrificed on the 24th, 28th and 32nd post-irradiation days.

The blood was collected into glass tubes containing EDTA. 0.1 ml were hemolyzed in a cetrimide solution. 0.1 ml blood are dispersed in 23.7 ml balanced salt solution. After careful agitation, 1.2 ml benzolytic agent are added. This agent is prepared from stock solution of cetrimide at 20% acidified by acetic acid: 4 parts plus 1 part acetic acid. The leukocyte counts were made with an electronic particle counter. Hematocrit were measured. Smears were also prepared and stained with the MAY-GRAWWALD-GIESMA method. The number of granulocytes, lymphocytes and monocytes expressed in 10 per μ l were calculated from the total number of leukocytes and their percentages on the smears.

The bone-marrow was extracted from the two femurs with 1 ml balanced salt solution (Hanks solution) and dispersed through a 24G needle. The suspension was kept in the refrigerator for 4 h. 0.1 ml were diluted in 25 ml cetrimide solution for the counting of the nucleated cells with the electronic counter. 0.25 ml dispersed in 50 ml balanced salt solution served for the preparation of size distribution curves.

A B model Coulter Counter equipped with particle size distribution plotter was used. The aperture was 100 μ m. The technical data were fixed in order to cover the volume range 0-300 μ m³. Two populations of cells were calculated in the range 100-150 μ m³ (small lymphocytes population) and 200-300 μ m³ (large cell population composed of myeloid cells). The absolute number of cells in these populations was obtained from their percentages on the graphs and from the total number of marrow nucleated cells.

The remainder of the marrow suspension was centrifuged and 2 drops fetal calf serum were added to the cell sediment. Smears were prepared and stained by the May

GRÜNWALD-GIESMA method. The cells were grouped in 5 major populations, i.e. young and intermediate granulocytic cells, mature granulocytic cells, erythroid cells, lymphoid cells, reticulo-endothelial cells. These populations were expressed in absolute number (percentages in the myelogram multiplied by the total number of marrow nucleated cells determined with the electronic counter).

Thymuses carefully dissected, blotted on filter paper were weighed. They were then delicately cut into pieces with pincers and scissors. After dispersion in 10 ml RSS, the suspension was passed through needles. The nucleated cells were counted after dilution in citrinide solution. part of the suspension was used for size distribution curves.

The spleen and lymph nodes were fixed in Bouin solution and embedded in paraffin slides were stained with hematoxylin-eosin for further histological study.

Results

Figure 1 gives the results of the peripheral hematological values. The hematocrit is only slightly reduced between the 4th and the 12th day and is subnormal after this delay. The blood leukocytes drop sharply at the second day. they thereafter increase slowly till the 12th day. The recovery is accelerated after the 14th day and a normal level is reached at the 24th day.

The discrimination between the major cell types in the peripheral blood shows that the absolute number of granulocytes falls to a lower




Fig. 1 Effect of 500 rad irradiation on the hematocrit, the leukocyte counts and the absolute numbers of blood granulocytes and lymphocytes.




Fig 4 Comparison of lymphoid (a) and myeloid (b) populations studied by the electronic counter (—) and from the myelograms (---). Absolute number of cells from two femurs after a 500 irradiation.

it must be reminded that the cell number measured between 200 and 300 μm^3 (large cell population) represents only a fraction of the total myeloid population. After irradiation the curve relative to the large cell population detected with the Coulter (granulocytic cells) is in parallelism with the curve of the total granulocytic population determined by means of the myelograms. In both cases, the curves follow a biphasic pattern with a first recovery phase coming to a plateau around the 10th day and a second recovery phase starting after the 14th day.

The lymphoid population calculated from the smears that we shall call total population and the small lymphocyte population (from 100 to 150 μm^3) detected with the electronic counter show an overshoot about the 12th day. However the methods give results that are quantitatively very different. The overshoot is much more important when the population is calculated from counts on smears than when it is estimated from the volume distribution curves obtained with the counter.

In the thymus the total number of cells (fig. 5) drops sharply and remains very low till the 4th post irradiation day. The regeneration begins at the 6th day, is accelerated after the 8th day and normal levels are reached between the 12th and 14th days. After this delay we observed, as did many authors, a secondary atrophy. The vari-




Fig. 5. Variations of the weight and total cell number of the thymus after 500 irradiation.

ations of the thymus weight are very similar to those of the total cell number.

The spleens are reduced in size and weight during the first post irradiation days. The recovery occurs at different rates for the hemopoietic (myelopoietic and erythropoietic) tissues and for the lymphoid tissue. At the 4th day blast cells and small clumps of erythrocytic cells are scattered through the organ. The myeloid clumps are rare. All the hemopoietic foci are differentiated at the 8th day. After this delay they grow bigger and are confluent. From the 10th to the 20th post irradiation day the spleen, the weight of which is far above the normal, is mostly an hemopoietic organ. After the 20th day there is a decrease of the erythropoietic and myelopoietic tissues with a slow return to normal level. During the whole observation period, the megacaryocytic elements show only small variations.

The number and size of the lymphoid follicles are reduced during the first few days. The recovery seems to start between the 8th and the 10th day. After the 12th day the regeneration is very fast and a return to a normal picture is seen between the 16th and the 20th day.

In the lymph nodes, the destruction seems more severe than in the spleen and the recovery begins later on, around the 12th day, is slower and is only completed after the 20th day. As already described by many authors, the plasma cells are very numerous from the 6th to the 24th day. Rare myeloid colonies are detected between day 12 and 20.

DISCUSSION

In the mouse exposed to a sublethal irradiation the two cell populations measured with an electronic counter regenerate according to very different patterns. The recovery of the large cell population appears to be biphasic with a plateau between day 12 and day 16. As we could expect the variations of this population which constitutes a representative sample of the total myeloid series are parallel to the results obtained with the myelogram. The plateau around the 12th day corresponds to a lack of mature granulocytic cells (metamyelocytes and polymorphonuclear cells) the percentage of which sharply drops on the smears, while the young and intermediate cells are still increasing. This is probably related to the delay required for the maturation of the dividing granulocytic compartment of the marrow the value of which was still very low a few days before.

The small cell population (small marrow lymphocytes) 100–150 μm^3 detected with the electronic counter recovers earlier with a small rebound at the 12th post irradiation day. A more impressive overshoot is observed at the same delay for the total lymphoid population calculated from the myelograms. This difference is mostly due to the appearance in the marrow of lymphoid-like cells very similar to the marrow lymphocytes, with which they can easily be confused. Previous ultrastructural investigations have shown that these cells we called λ -cells are however different from the small marrow lymphocytes [9].

The size of these cells is a little bigger than that of the lymphocytes: on the volume distribution curves they are located between the small lymphocytes and the myeloid series. Therefore, they are situated in an overlap between the two populations detected in the marrow by the electronic counter. For this reason it is impossible to measure accurately this cell group by this mean.

We have tried to estimate indirectly the λ -cells group by comparing the myelogram values and the volume distribution curves. From the electronic counter data, we have calculated the small lymphocyte population while on the smears we have determined the total lymphoid population which includes the λ -cells besides the small lymphocytes and an insignificant proportion of small sized myeloid cells. The difference between the total lymphoid population and the small lymphoid population calculated with the electronic counter can then give a good measure of the λ -cells group.

Under our experimental conditions, it appears that the number of λ -cells is very low at day 10 rises to a value of more than 6 millions at day 12 and recedes rapidly at day 14. What is the significance of this rapidly changing λ -cells population? It is likely that these cells are the same as the lymphoid cells called transitional cells by other authors which assume a relation between the transitional cells and other marrow elements [3 4 5 6 10]. The present results are in contradiction with this assumption. It appears from the comparison of the curve of the total number of nucleated cells in the marrow and of the variations of the λ -cells population that the occurrence of the latter in the marrow coincides with a sharp increase of the total cell number and that their disappearance is parallel to a decrease of this number. If the λ -cells were to transform into other cell lines, one would not expect such a decrease after the λ -cell peak. On the other hand a rapid increase of some other cell lines would be observed. No such variations happen and it seems necessary to find another explanation for the behaviour of the λ -cells. In the absence of any sign of cell destruction in the marrow one must consider the possibility of an λ -cell migration to other organs, for example the thymus, or the peripheral lymphoid organs. The evidence of a cellular exchange between the marrow and the thymus [11 12] supports this hypothesis. There is indeed some parallelism between the development of the λ -cells population in the marrow and the thymus regeneration. However this could be purely coincidental. At the present, there is no direct proof for such an exchange as far as λ -cells are concerned.

Summary

In the mouse exposed to sublethal λ -ray irradiation, the various cell populations of the bone marrow regenerate according to very different patterns. The erythroid series and the proliferative compartment of the myeloid series recover early between the 10th and 12th day while the maturation compartment is restored later on between the 14th and 24th day. The lymphoid population behaves quite differently and overshoots within 11 days. This rebound must be related to the appearance in the marrow of a peculiar population of lymphoid-like cells (λ -cells or transitional cells). The relation between these lymphoid cells and other marrow elements is discussed.

References

- 1 CUBIKOWICZ, G., USTOV, A. C., SMITH, L. H., GOWLER, D. G. and HUGHES, W. L. An approach to the characterization of stem cells in mouse bone marrow. *Ann. N. Y. Acad. Sci.* 114: 571 (1964).

3. CUDKOWICZ, G.; BENNET N. and SHARON, G. N. Pluripotent stem cell function of the mouse marrow lymphocyte. *Science* **188** 866 (1964)
4. HARRIS, P. F.; HARRIS, G. and KUTLER, J. H. Observations on the accumulation of mononuclear cells and the activities of reticular cells in bone marrow of guinea pig recovering from whole-body γ -irradiation. *Acta haemat., Basel* **22**: 166 (1963)
5. HARRIS, P. F. Quantitative studies of bone-marrow cells in the early stages of final haemopoietic recovery in irradiated guinea pigs. *Brit. J. Haemat.* **6**: 107 (1960)
6. LOFFRY J. M. The lympho-myeloid complex. *Ciba Found. Symp. Haemopoiesis: Cell Prod. Regulation*, p. 1 (1960)
7. LOFFRY J. M. Quantitative cellular haematology (Thomas, Springfield 1960)
8. HAOT J., HADCHTORY, G. and REVESZ, L. Changes in the cellular composition of bone-marrow in mice irradiated with different X-ray doses. *Europ. J. Cancer* **3**: 67 (1967)
9. HAOT J., REVESZ, L. et HADCHTORY, G. Une nouvelle méthode d'étude de la moelle hématopoïétique basée sur la détermination des volumes cellulaires. *Bull. Cancer* **54**: 159 (1967)
10. SOKAL, L. J.; HAOT J. et BETZ, E. H. Etude ultrastructurale de la moelle hématopoïétique à cours de la régénération après irradiation. *Europ. J. Cancer* **4**: 329 (1968)
11. BAUGHMAN, G., EXENCOTT, R. M., GIER, H. and BLAUWIESE, H. P. Effects of X-ray on lymphoid and hemopoietic tissues of albino mice. *Blood* **2**: 1259 (1948)
12. LOFFRY J. M. The fourth circulation. In LOFFRY The lymphocyte in immunology and haemopoiesis, pp. 1-10 (1967)
13. SCHÖLLER, J. C. and SHAROVITZ, M. M. The thymus and the recirculating lymphocyte pool. In LOFFRY The lymphocyte in immunology and haemopoiesis, pp. 1-10 (1967)

Abteilung für Hämatologie Zentrum der Inneren Medizin, Johann-Wolfgang-Goethe-Universität, Frankfurt M. (Direktor: Prof. H. Marten)

Presence of Two Ph1 Chromosomes in Cells with 49 Clones from Patient in Blast Crisis of Granulocytic Leukemia

M. H. KUJAN and H. MARTEN

Typical cases of chronic myeloid leukaemia (CML) are characterized by the presence of one Ph1 chromosome with altogether diploid number. Two Ph1 chromosomes like the aneuploidy have been reported in various cell lines of CML patients during the terminal phase of the disease. We report here a case of CML in blast crisis showing two Ph1 chromosomes in a cell-line with 49 chromosomes.

Case Report

A 57-year-old female was diagnosed as having CML in 1963. She was effectively treated with Busulfan till 17th of Feb. 67 when blast crisis occurred. The spleen was 12 cm and the liver 10 cm under the costal margin, Hb 11.2 g%, red cells 3.8 mill./mm³, platelets 122,000/mm³, white cells 129,000 with 64% myeloblasts. Bone marrow puncture at the time of admission revealed features of blastic transformation. Cytogenetic material was prepared directly from the same bone marrow specimen. On admission she was treated with 6-mercaptopurine (150 mg/daily) and prednisone (200 mg/daily). She died on the 27th Feb. 1968.

Results are shown in table I. A karyotype of bone marrow shown in figure 1.

Discussion

New cell lines which may arise through mitotic non-disjunction from the 46 Ph1 positive CML cells by gradual neoplastic evolution are chronologically coincident in the great majority of the cases with the deterioration of clinical as well as haematological picture. In the

Table 1 47 available mitoses revealed Ph1 disomy 27 mitoses were analysed

Cell No.	Chromosome No.	Extra chromosome	Mitotic chromosome
4	47	Ph1 Ph1	C
1	48	Ph1 Ph1 C, F	C D
1	48	Ph1 Ph1 C, F	C, E
21	49	Ph1 Ph1 C, F	G

case reported 49 cell line appears to be selected because of some particular advantage. 49 cell line in the terminal phase of the disease may be of interest in view of the other reported cases in which such a cell line with one Ph1 chromosome [3-7] and two Ph1 chromosomes [1, 2, 4] have dominated. The clonal evolution seems to have evolved by a duplication of the Ph1 chromosome and acquisition of a C and a F extra chromosomes. Similar karyotypic pattern have been reported in two CML patients studied in blast crisis [1, 6]. It is generally agreed that additional chromosomal changes in the Ph1 positive CML cells would foreshadow an acute exacerbation. Ph1 disomy in diploid, hypodiploid and hyperdiploid cells may be exhibiting different trends of clonal evolution but as yet clinico-haematological differentiation cannot be revealed.

Ph1 anomaly is supposed to be present in the stem cells of erythroid megakaryocytic and granulocytic precursors. The high frequency of Ph1 positive cells in the bone marrow of CML patient suggest that these cells with Ph1 anomaly are capable to become end cells. The chromosomal defect seems to be more deleterious to the granulocytic end cells. It could be speculated that cells with two Ph1 chromosomes as well as the aneuploid cells may not be capable to become end cells. Even if they do become end cells then it is quite reasonable to assume that such cells are functionally less capable than the CML cells having one Ph1 chromosome. In culture it has been demonstrated that the cells of CML have shorter life span than the corresponding normal cells [5]. The chromosomal defect appears to be responsible for the disturbed homeostasis of the hematopoietic tissue. The exaggerated activity of cambium layer producing increased number of precursor cells and the congregation of the precursor cells due to delayed differentiation and maturation will affect the environment incessantly resulting




Fig.1 Karyotype of cell from bone marrow with 47 chromosomes.

in a vicious circle which will in turn enhance new mutations. The dominance of the established new clone or clones (e.g. Ph1 disomic cells) may implicate that the disease has irrevocably merged into its acute stage. It is rather early to comment on the differentiation and maturation capability of the aneuploid cell lines. Better understanding of the process of differentiation in the light of the present cytogenetic may be of some help in the circumvention of the neoplastic evolution.

We wish to acknowledge the expert technical assistance of Miss CURTIS, Medical Techn.

Summary

A hyperdiploid cell line with 49 chromosomes was dominant in the terminal phase of chronic myeloid leukaemia. Ph1 density and acquisition of C and F extra chromosomes as well as loss of G member as consistent finding.

References

1. Goss, K. Cytogenetic studies in blastic crisis of chronic myelocytic leukaemia. Arch. Intern. Med. 120: 315-320 (1967).
2. Kline, N. H., S. ARONSON, J. L. and TAYLOR, R. Chromosome studies during early and terminal chronic myeloid leukaemia. Brit. med. J. 1: 1010-1014 (1964).

3. HANON, Y. et KOCZANEK, L. Etude clinique et cytogénétique de 1 patient atteint de leucémie myéloïde chronique. *Europ. J. Cancer* 3: 83-93 (1967).
4. KROEMER, E., LEWIS, J. P. and DORVILLE, W. J. Chromosome aberrations in two patients with chronic granulocytic leukaemia undergoing acute transformation. *Amer. J. Clin. Path.* 49: 161-170 (1968).
5. O'GOOD, E. L. and KATZPARINE, M. L. Comparison of the life span of leukemic and non-leukemic neutrophils. *Acta haemat., Basel* 13: 153-160 (1955).
6. FIGORARO, L., PILERI, A., ROVERA, G., GAYOTTO, F.: Trisomia del cromosoma Filadelfia (Ph1) nella crasi mieloica di un caso di leucemia mieloide cronica. *Tumori* 53: 315-321 (1967).
7. TOCCH, L. M., COTTEY BROWN, W. M., BAKER, A. G., BECKETT, K. E., HANCOCK, D. G., JACOB, W. A., JUNG, M. J. and McLENNAN, J. A. Cytogenetic studies in chronic myeloid leukaemia and acute leukaemia associated with monophasia. *Lancet* i: 411-417 (1961).

H. STORAX und R. STREGLITZ: Autoimmunerkrankungen in der Hämatologie. Hämatologie und Bluttransfusionswesen, Vol. 3. Medizin. Verlag Berlin 1969. 163 p. Preis DM 36.

In diesem Bändchen sind ausgewählte Beiträge und Diskussionen der IV. Hämatologentagung der DDR 1967 in Berlin zusammengestellt. Das Thema "Autoimmunerkrankungen in der Hämatologie" wird in erster Linie von der klinischen Seite her angegangen, wobei anhand von Patienten neben der klinisch Labordiagnostik auch pathogenetische und ätiologische Gesichtspunkte besprochen werden. Auch die Therapie mit immunsuppressiven Medikamenten wird behandelt. Verschiedene Autoren betonen die noch ungewisse Indikationsstellung und die beim Menschen noch unbekannten Nebenwirkungen bei Langzeitbehandlung. Die 14 Aufsätze geben einen guten Überblick über den heutigen Stand des Wissens, speziell nützlich für den praktizierenden Internisten und Hämatologen. Für diese kann das Bändchen wärmstens empfohlen werden.

T. L. VICTORIA, Basel

R. BUTLER: Isospecificity of Human Plasma Proteins, Blut und co. Haematologica No. 31. Karger Basel New York 1963. + 107 p. 2 fig. 14 tab. Preis sF DM 33 -/L 5 \$ 7.90 66s.

With an already large and expanding volume of literature in this relatively new yet important field, this review about isospecificity of human plasma proteins must be welcomed. After giving the necessary definitions, the isospecific structures mainly those on immunoglobulins and low-density lipoproteins are reviewed. The corresponding antibodies, their possible mechanisms of formation in humans and their importance in clinical medicine are dealt with competently in the last chapter. The bibliography abundant and up-to-date (December 1963). This book has been translated from the German language. Phrasing corrections possible in German are often awkward to read in the translated English. However, this is minor disadvantage considering the amount and quality of information presented.

T. L. VICTORIA, Basel

R. D. EATMAN: Klinische Hämatologie. Springer Berlin Heidelberg New York 1968. VII + 215 p. Preis DM 8.80 \$ 2.20.

Das kleine, handliche und erfreulichere sehr billige Buch beschreibt nicht die ausgeübten Wege der systematischen Lehrbücher sondern versucht auf ganz andere Art dem Arzt oder Studenten eine Fülle von Information zu vermitteln. Dabei ist der Titel

Klinische Hämatologie für deutschsprachige Leser sehr irreführend. Das Buch beschäftigt sich nämlich in erster Linie mit den verschiedenen, in der Hämatologie gebräuchlichen Laboratoriumsmethoden, was im deutschen Sprachgebrauch unter Klinik verstanden wird, in demgegenüber berücksichtigt. Im Laufe der letzten Jahre haben die Laboratoriumsuntersuchungen im Rahmen der klinischen Medizin aber immer mehr an Bedeutung gewonnen. Damit der Arzt dieses wertvolle Hilfsmittel voll ausnützen und aus den Ergebnissen die entsprechenden Schlüsse ziehen kann, muss er die Methoden richtig einsetzen und die gegebenen Resultate zu interpretieren wissen. Das Taschenbuch ist ganz darauf ausgerichtet, schnell und zuverlässig über die verschiedenen Labormethoden und ihre klinische Bedeutung zu informieren. Damit schließt es zweifellos eine empfindliche Lücke im deutschen Schrifttum.

Neben Definitionen und kurzen Beschreibungen der Prinzipien der Methoden wird das Hauptgewicht auf die Interpretation der Resultate gelegt. Wie sind die Normalwerte, was bedeuten pathologische Werte für die Klinik. Immer wieder und auch pathophysiologische Grundlagen eingestreut. Der Hauptakzent liegt auf der morphologischen Hämatologie. Im ersten Kapitel werden Hämoglobin und erkrankte Pigmente besprochen. Es folgen zwei

Abschnitt über Leukämien und Anämien, sodann zwei Kapitel über periphere weisse Blutzellen und Knochenmark. Mehr als ein Drittel des Buches wird vom Kapitel "Blutungen, Bluttransfusion und Transfusion" eingenommen. Der mehr hämatologisch interessierte Leser wird allerdings nur wenige - nicht immer ganz präzise - Hinweise finden, während die perinatal-hämatologischen Methoden sehr eingehend behandelt sind.

Die Themenliste Gliederung und vorwiegend tabellarische Präsentation des Textes erlaubt eine rasche Orientierung und ist vor allem didaktisch von grossem Wert. Die kleinen Literaturhinweise beschränken sich meist auf einschlägige, wenn auch ältere zugängliche Arbeiten. Die Übersetzung kann im ganzen als sorgfältig bezeichnet werden. Der Bearbeiter hat einige nicht unwesentliche Ergänzungen und Korrekturen eingebracht. Das Buch wird besonders dem jungen Arzt, aber auch dem hämatologisch interessierten Studenten ein grosser Helfer sein. Zweifellos wird auch das technische Hilfspersonal viel Nutzen daraus ziehen. Wir wünschen dem für die praktische Tätigkeit sehr nützlichen Buch jedenfalls eine weite Verbreitung.

L. BOSTER, Oslo

E. PRINGSCH: Chromosome Evolution in Chronic Myelogenous Leukemia. Monograph, Copenhagen, 1972. Relation of Chromosomes to Progression and Treatment of the Disease. XI - 151 p., Price: Dkr. 50.00.

This monograph reports a detailed and convincing study of the frequency and character of aneuploidy in the leukemic cells of 30 patients with chronic myeloid leukemia in relation to the clinical and haematological progression of the disease. After a preliminary survey of the cytogenetic background leading to the discovery of the Ph¹ chromosome and a description of the methods used in the study of chromosomes from haematopoietic cells, the author presents evidence confirming the hypothesis that not only granulocytic precursors but also erythroblasts and probably megakaryocytes in chronic myeloid leukemia are Ph¹ positive. He then shows that patients in a late stage of the disease and those currently or recently receiving treatment have higher prevalences of Ph¹ positive hyperdiploid cells than patients in early stages of the illness. Hyperdiploidy also correlated with higher prevalences of myeloblasts and promyelocytes in peripheral blood, whereas when myeloblasts were numerous hyperdiploidy was infrequent.

A detailed analysis of the karyotype abnormalities at different stages of the disease suggests that the Ph¹ positive cell population progresses gradually to more and more abnormal karyotypes as the disease evolves. There is some evidence that cytotoxic treatment may accelerate this progression. Such progression occurs in Ph¹ positive cells from the same patients, e.g. in phorbol acetate-stimulated blood cultures, where at least some of culture derived leucocytes produce Ph¹ negative and Ph¹ positive cells with karyotype profile including extra chrom. and missing and absence of members of group C, T7-10 and a single marker in chromosome numbers of karyocentromere dist.

The mechanisms of this elegant work in the wide field of chromosome and all concerned with chromosome studies in malign. resident in F

not con-
from

L. E. GARLEY: Genetic Markers in Human Blood. Blackwell, O. C. 1971. Pp. 172.

This excellent book covers a wide field of laboratory and genetics. The author LLOYD E. GARLEY is Research Professor of Washington State School of Medicine and Head of Immunologic Central Blood Bank, Seattle, Wa. In the first part of the volume

described which exhibit genetic polymorphism: the immunoglobulins and their allotypes Gm and Inv, haptoglobin, transferrin, the Gc system, the β -lipoprotein allotypes with the Ag and Lp systems, pseudocholinesterase, plasma alkaline phosphatase, albumin variants, the protease inhibitor Pi system, ceruloplasmin, the α_2 -macroglobulin Xn system and the α_2 -acid glycoprotein types. In the second part of the book genetic markers of blood cells are reviewed: the red cell blood group antigens, the normal and abnormal hemoglobins and the enzyme variants of which the red cell acid phosphatase, glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, phosphoglucomutase and adenylate kinase are most completely described. Smaller chapters deal with other enzyme markers such as lactate dehydrogenase, malate dehydrogenase, phosphohexose isomerase, carbonic anhydrase, red cell esterases, peptidases, glutathione reductase, methemoglobin reductase, catalase, galactose-1-phosphate uridylyl transferase and isodopamine oxidase. In the third and last part the basic principles of genetics and the contributions of blood genetic markers to studies of human biology are summarized.

The book provides a review of the basic advances as well as instructions for the applications of these advances to the understanding of disease in this rapidly growing field of modern hematology. It can be recommended to laboratory investigators, clinical hematologists and blood bank serologists.

H. R. MARTI, *Geneva*

CH. A. OWEN, J. E. W. BOWEN, P. DODGSON and J. H. THOMSON: *The Diagnosis of Bleeding Disorders*. Little, Brown, Boston 1969. 300 p. Price: US \$ 15.00.

This book in the series of laboratory medicine is a concise presentation mainly written from the viewpoint of clinical pathologists. Consequently the methods for diagnosis of these disorders are well described. The introductory chapter covering the history of coagulation and hemostasis is a welcome evaluation of the physiologists and clinicians who built the foundations of this topic. Their photographs with short biographic notes are given (among those MORAVITZ, BEZZUOLO, FORD, HANMARSTEN, ALEX. SCHMIDT, HOWELL, TOGATINI, WILLENBRAND). A number of typical illustrative cases for the various haemorrhagic diseases are given. (The reading of the book would have been facilitated if these case histories had been printed in smaller type.) Each chapter has a fairly comprehensive list of references.

The book will be of value as an introduction into the concept and methods of examination of blood coagulation and hemostasis which, as the authors rightly mention, are 'in state of flux'.

G. ROSENOW, *New York, N.Y.*

Progress in Hematology, Vol. 6. Editors: E. B. BAUGH and C. V. MOORE. Grune & Stratton, New York 1968. 382 p. Price: US \$ 11.75.

The new volume of this series contains critical reviews among others immunosuppression (PAROLE and V. VRA), auto-immune hemolytic anemias (J. V. DACE and SM. WOLLEDGE), prevention of Rh hemolytic disease (W. POLLAK, J. GORNA and V. FREDA), plasma fractions in the treatment of hemophilia and von Willebrand's disease (C. R. RIZZA and R. BOON), control of human hemoglobin synthesis and function in health and disease (D. WHITTINGERALL and J. B. CLEGG).

G. ROSENOW, *New York, N.Y.*

Varia

18th Colloquium on Proteins of the Biological Fluids

April 29-30, May 1-3, 1970, Bruges

General topics (1) Proteins during development in health and disease, (2) Protein-protein interaction, (3) Techniques.

International Atomic Energy Agency (IAEA)

IAEA Symposium on Dynamic Studies with Radioisotopes in Clinical Medicine and Research

August 31 - September 4 1970 Rotterdam

Organizers: International Atomic Energy Agency Kärntnering 11 13, 1040 Vienna, Austria. *Secretaries:* Dr. T. Nagai and Dr. E. H. Beuzman, Medical Application Section.

The Symposium will be concerned with all applications of radioisotopes in clinical medicine and research which involve measurements of the temporal patterns of uptake, metabolism, clearance or excretion of administered radioactive materials. Topics to be covered include cardiac, gastrointestinal, hepatic, pulmonary renal and thyroid function studies, regional blood flow studies, calcium, copper, iron, protein and vitamin B₁₂ turnover studies and studies of red cell destruction. The Symposium will give emphasis to new instruments, techniques and methods of data analysis. Studies based on scintigraphic techniques will be excluded except in so far as they are concerned with dynamic situations.

Further information and forms to accompany abstracts of papers intended for presentation at the Symposium may be obtained from national authorities for atomic energy matters. Abstracts must be submitted through these authorities so as to reach the International Atomic Energy Agency before April 20, 1970.

Index rerum ad Vol 42

Confect G. BOKER Basel

(B) = Book reviews - Buchbesprechungen - Livres sous presse

- Absorption and excretion of cyanocobalamin after oral administration of large dose in various conditions, 1
- Absorption, Intestinal absorption
- Actualité hématologique (2^e série) 190 (B)
- Adenylate kinase in red blood cells, hereditary deficiency 111
- Advances, Progress (B)
- Age, Alkaline phosphatase, Transketolase activity
- Ahaptoglobinaemia, Haptoglobin
- AHG A (= Antihaemophilic globulin A) Factor VIII
- Albumin, human serum albumin, Immunoglobulines III
- Alkaline phosphatase of leukocytes (The effect of age and sex) 18
- Alkaline phosphatase, ultrastructural localization in human neutrophils, 273
- Alter Alkaline phosphatase, Transketolase activity
- Altitude, Mittelgebirgsklima
- Amino acids distribution of amino acids in urine, plasma, leukocytes and erythrocytes of leukaemic and normal subjects, 85
- Anaemia, mediterranea, Thalassemia, Thalassemia syndromes
- Anaemia megaloblastic, severe, due to nutritional vitamin B₁₂ deficiency 247
- Anaemia, pernicious evaluation of dual radioisotope urinary excretion test in diagnosis of pernicious anaemia, 183
- Vitamin B₁₂ absorption
- Anknen, hämolytische und Hamolyse, 128 (B)
- Anaemias, pathologische (Vol. 1 Allgemeiner Pathologie, Vol. 2 Spezielle Pathologie) 254 (B)
- Animal malaria blood proleukocytes in human and animal malaria, 129
- Animals leukaemia in animals and man (3rd international symposium for comparative leukaemia research, Paris 1967) 254 (B)
- Antigen immunogenicity of human plasma proteins (Bibliotheca haematologica, V 31) 361 (B)
- Antihaemophilic globulin A (= AHG A) Factor VIII
- Anti-nutritive factor Anemia, pernicious (see family (in Leaf Adenylate kinase (deficiency))
- Arterial blood, central megakaryocytes and platelets in central venous and arterial blood, 330
- Asia bodies case of acute leukaemia with pseudo-Pelger cells containing Asia bodies, 50
- Automatensystemen in der Hämatologie (Hämatologie und Bluttransfusionswesen, Vol. 5 361 (B)
- Autoradiography (microautoradiography) Lymphocyte cultures, Proleukocytes
- Basophilic leukocytes, human periodic acid-Schiff reaction in human basophilic leukocytes, 269
- Basophils of bone marrow electron microscopic study of the granules in guinea-pig bone marrow basophils, 258
- Biological fluids, proteins, 18th colloquium (April 29 - May 3 1970, Bruges) 365

- Blast crisis in granulocytic leukaemia, Ph 1 chromosomes
- Blasted transformation, v Lymphocyte transformation
- Bleeding disorders, diagnosis, 363 (B)
- Blood, central megakaryocytes and platelets in central venous and arterial blood, 330
- Blood coagulation, Bleeding disorders (B) Cryofibrinogenæmia, Factor VIII
- Blood disorders of the blood (Diagnosis, pathology treatment, technique) (10th ed.), 256 (B)
- Blood, human, genetic markers, 362 (B)
- Blood, peripheral, v Cyclophosphamide
- Blood proliferocytes in humans and animal malaria, 129
- Blood transfusion, v Transfusion sanguine (B)
- Blutbild Wirkung des Mittelgebirgsklimas und des Wetters auf das Blutbild, 261
- Blutplättchen, Platelets, Thrombocytes, Thrombocytes (B) Thrombocytosis
- Blutbildung, stark beschleunigte, v Cryofibrinogenæmia
- Bone marrow basophils electron microscopic study of the granules in guinea-pig bone marrow basophils, 258
- Bone marrow reticulo-endothelial cells, v Iron stores
- Bone marrow Cyclophosphamide, Hepatitis-Virus M(HV), Reticulosis, V-irradiation
- Book reviews, 127 128 (B), 188-192 (B) 254-256 (B), 361 363 (B)
- Bovine erythrocyte Erythrocyte, bovine Bray's clinical laboratory methods (7th ed.), 128 (B)
- Bocherbeurteilungen, 127 128 (B), 188-192 (B) 254-256 (B) 361 364 (B)
- Cancer proceedings of the International symposium on carcinopathies, infections, cancer and immunity (Paris, 1967), 127 (B)
- Carcinoma, Cancer (B)
- Cardiac catheterization, Arterial blood, central
- Catheterization, cardiac, Arterial blood, central
- Cercaria parvella, Guinea-pig
- Cell cultures, Lymphocyte cultures, Lymphocyte transformation, Lymphopoeia
- Cell-degeneration pattern in bone marrow and blood of guinea pigs following administration of cyclophosphamide, 42
- Cell kinetics in human leukaemia, 188 (B)
- Central venous and arterial blood, megakaryocytes and platelets, 330
- CF₂-Mäuse, v Hepatitis-Virus M(HV)
- Children, v Phosphatidylchocol (B) Transketolase activity
- Chromosomes presence of two Ph 1 chromosomes in cells with 49 clone from patient in blast crisis of granulocytic leukaemia, 357
- ; lo studio dei cromosomi umani, 188 (B)
- Chronology of the mitotic cycle of acute leukaemia cells, 76
- Cine-micrography (phase-contrast) Leukaemia, acute chronology
- Clima des montagnes secondaires, v Mittelgebirgsklima
- Climate of the upland region, Mittelgebirgsklima
- Clinical laboratory methods (Br. v' / 7th ed.) 126 (B)
- Clinical medicine, International Atomic Energy Agency
- Coagulation of blood, Bleeding disorders (B) Cryofibrinogenæmia, Factor CIII Co⁵⁷B₁₂/Co⁵⁷B₁₂ Cyanocobalamin
- Cobalt, radioactive, Anaemia, pernicious Cobalt, Guinea-pig
- Cold-precipitable proteins, Cryofibrinogenæmia
- Colloquium, 18th, on proteins of the biological fluids (April 20 May 2, 1970 Bruges) 363
- Comparative leukaemia research, Leukaemia in animals (B)
- Conference, Lymphoma (B)
- Congress, Haematology Transfusion sanguine (B) Transplantation
- Cromosoms umani: lo studio dei cromosomi umani, 188 (B)
- Cryofibrinogenæmia, studies, B
- Culture des cellules, Lymphocyte cultures, Lymphocyte transformation, Lymphopoeia
- Cultures des tumeurs, Cultures des cellules
- Cyanocobalamin absorption and correction of cyanocobalamin after oral administration of large dose in various conditions, 1

- evaluation of dual radioisotope urinary excretion test in the diagnosis of pernicious anaemia, 123
- severe megaloblastic anaemias due to nutritional vitamin B₁₂ deficiency 1
- Cylophosphamide: cell-degeneration pattern in bone marrow and blood of guinea pigs following administration of cyclophosphamide 42
- Cytochemistry Basophilic leukocytes, Erythroleukämie Lymphocyte cultures, Neutrophils, Phosphatase
- Cytogenetic evolution in chronic myelogenous leukaemia, 362 (B)
- Cytology diagnostic and its histopathologic basis (2nd ed.) 194 (B)
- Cyto Zyto
- Degenerating cells, Cyto-phosphamide
- Deoxyribonucleic acid (= DNA) synthesis, Lymphocyte cultures, Proliferocytes
- Diagnostic cytology and its histopathologic basis (2nd ed.) 192 (B)
- Diagnosis of bleeding disorders, 363 (B)
- Diagnosis, Anaemia, pernicious Erythroleukämie
- Diagnostik Medizinische Diagnostik, Grundlagen und Praxis, 251 (B)
- Dosage Path chromosomes
- Disorders of the blood (Diagnosis, pathology treatment, techniques) (10th ed.) 256 (B)
- Diversification, haematologic, Leukaemia leuka, myeloid (Gellay)
- DNA (= Deoxyribonucleic acid) synthesis, Lymphocyte cultures, Proliferocytes
- Douglas's Körperchen, MA Hämatologische Anomalie
- Dysprotektinämische Serien, Einfluss auf die Reaktion normaler Erythrozyten, 296
- Osmotic fragility
- Eaten, Iron excretion, Iron stores
- Electron microscope electron microscopic study of the granules in guinea-pig bone marrow basophils, 256
- Basophilic leukocytes, Cylophosphamide, MA Hämatologische Anomalie
- Neutrophils, Reticulocytes
- Electrophoresis starch gel quantitation of electrophoresis of haemoglobin variants in the thalassaemia syndromes, 1
- Adenylate kinase (deficiency), Glycerolnephrocinemia, Haemoglobin H per globin, Intransfusionsphänotypus f. d. B
- Enzyme Phosphate function 27 → ketolase activity
- Enzymatic and hemical haem synthesis, Erythrocyte cultures, 133
- Enzymes, Ferments
- Erythrocyte bone marrow for effect of hydrocortisone, 109
- Erythrocytes, Reticulocytes Enzymatische Funktion der Erythrozyten normaler Erythrozyten, 99
- Erythrocyte bone
- Erythrocytes distribution of serum acids in urine plasma, leukocytes and erythrocytes of leukaemic and normal in vivo, 86
- Étude de la fraction non spécifique des leucocytes globulaires G par les érythrocytes
- I. Influence de la variation de la teneur parasitaire, 154
- II. Essai d'inhibition par des leucocytes globulaires G autres ou modifiés par d'autres protéines, 219
- Hereditary deficiency of adenylate kinase in red blood cells, 111
- Membrane permeability and metabolism of erythrocytes and thrombocytes, 213 (B)
- Ketolase activity of red blood cells from infancy to old age, 148
- Hämatologie (B)
- Erythroleukämie; cytologische Untersuchungen zur Diagnostik und Ätiologie der Erythroleukämie 208
- Erythrophagocytosis, Reticulocytes
- Erythropoiesis; Wirkung des Nierengrößens und des Weiteins auf das Blutbild, 281
- Erythroleukämie
- Excretion and absorption of cyanocobalamin after oral administration of large dose various conditions, 1
- Excretion of iron; urinary and faecal iron excretion in thalassaemia syndromes, 221
- Extracellular thrombocytopenia, 211
- Factor I Cryoglobulinemia
- Factor VIII (= Antihemophilic globulin A = A11G A); In vitro des inhibiteurs faibles du facteur VIII 27
- Factor I and urinary iron excretion in thalassaemia syndromes, 221
- Only Adenylate kinase (deficiency) MA Hämatologische Anomalie

- Fe²⁺ v Iron excretion, Iron stores
 Feinstruktur Basophilic leukocytes,
 Basophils of bone marrow Cyclophosphamide, MAY-HEDGELT'sche Anomalie,
 Neutrophils, Reticulosis
- Fe³⁺ v Iron excretion, Iron stores
- Ferments; enzymatic and chemical changes
 in human lymphocyte cultures, 138
 Adenylate kinase (deficiency) Phosphatase, Transketolase activity
- Fibrinogen studies in cryofibrinogenemia,
 8
- Fine structure, Basophilic leukocytes,
 Basophils of bone marrow Cyclophosphamide, MAY-HEDGELT'sche Anomalie,
 Neutrophils, Reticulosis
- Fingerprint (peptide chromatogram)
 Haemoglobin L
- Fixation non spécifique des immunoglobulines G sur les érythrocytes, étude. I
 Influence de la variation de différents paramètres, 154
 II. Essai d'inhibition par des immunoglobulines G natives ou modifiées par d'autres protéines, 219
- Fluorescent antibody technique, Immunoglobulin
- Foie, Hepatitis-Virus MHV
- Fragility osmotic, Osmotic fragility
 - Rostens
- Gammopathies proceedings of the international symposium on gammopathies, infections, cancer and immunity (Bari, 1967) 127 (B)
- Gastric juice, human, Anaemia, pernicious
- Genetic markers in human blood, 362 (B)
- Genetics progress in medical genetics (Vol. VII) 363 (B)
- Genetics, Adenylate kinase (deficiency) MAY-HEDGELT'sche Anomalie
- Giant platelets, MAY-HEDGELT'sche Anomalie
- Globulins, Immunoglobulines G
- Globuline (Dysproteinämie) Erythrocytes, Rostens
- Glucose-6-phosphate dehydrogenase (= G6PD) Adenylate kinase (deficiency)
- Graffi-virus studies on the pathogenesis and mechanism of haematologic diversification by re-isolation of the myeloid leukaemia virus (GRAFFI) 63
- Granules in guinea-pig bone marrow basophils, electron microscopic study 256
- Granulocytic leukaemia, blast crisis, Leukaemia, myeloid, chronic
- Guinea-pig cell-degeneration pattern in bone marrow and blood of guinea-pigs following administration of cyclophosphamide, 42
 electron microscopic study of the granules in guinea-pig bone marrow basophils, 256
- Hämatologie* Autoimmunreaktionen in der Hämatologie (Hämologie und Bluttransfusionswesen, Vol. 3) 361 (B)
- Hämologie, Klinische, 361 (B)
- Hæmatology actualités hématoologiques (T^{re} série) 190 (B)
 - XIIIth international congress of haematology (Münich, 2-8 August 1970) 64
 - progress (Vol. 6) 363 (B)
- Hæmoglobin L Pernian Gelf a57 (E6) glycine + arginine, 169
- Hæmoglobins starch gel quantitative electrophoresis of hæmoglobin as screening in the thalassaemia syndromes, 98
- Hämolyse und hämolytische Anämien, 128 (B)
- Hämolyse, Spontanhämolyse, v Erythrocytes, Rostens
- Hämolytische Anämien und Hämolyse, 128 (B)
- Hæmophilie, Factor VIII
- Hæmophilie, Cyclophosphamide, Hepatitis-Virus MHV
- Hæmopoietic recovery after sublethal X-irradiation in the mouse, quantitative study 347
- Hæmostase, F actor VIII
- Haptoglobin in thalassaemia, 176
- Hb L, Hæmoglobin L
- HEDGELT; MAY HEDGELT'sche Anomalie (Beschreibung einer neuen Parallele und Untersuchung zur Funktion, Biochemie und Ultrastruktur der Thrombozyten), 303
- HILMEYER, LUDWIG † 257
- Hématologie actualités hématoologiques (T^{re} série) 190 (B)
- Hematology progress (Vol. 6), 363 (B)
- Hepar Hepatitis-Virus MHV
- Hepatitis-Virus MHV Panmyelophthysis und Virushepatitis (Experimentelle Le-

- verwachungen mit dem Mänschepatitis-Virus MHN₁) 346
- Hereditary deficiency of adeny late kinase in red blood cells, 111
- Hereditary, v Genetic markers .. (B)
- Ma-Hämatologische Anomalie
- Herztheterismus, Blood, central
- Histiocytic medullary reticulos (Case report with electron microscopic study), 50
- Histochemistry v Basophilic leukocytes, Erythroleukämie, Neutrophils, Lymphocytes cultures, Phosphatase
- Histopathology: diagnostic cytology and in histopathologic bases (7ed ed.) 192 (B)
- Hobnagel Mangelkrankheiten
- Hosue, Man
- H₂-thymidine, v Lymphocytes cultures, Proferocytes
- Human basophilic leukocytes, periodic acid-Scharr reaction, 269
- Human blood, genetic markers, 362 (B)
- Human chromosomes, Chromosomal unusual (B)
- Human gastric juice, v Anaemia, pernicious
- Human leukaemia, Man (B)
- Human leukaemia, cell kinetics, 188 (B)
- Human lymphocyte cultures, cryoprotection and chemical changes, 138
- Human lymphocyte transformation, suppression by RNA, 94
- Human malaria blood proferocytes in human and animal malaria, 129
- Human neutrophils, ultrastructural localization of alkaline phosphatase, 275
- Human plasma proteins, leucotogenicity 361 (B)
- Human serum albumin, Immunglobulins G
- I₁₈ (I₁₈) Immunglobulins G
- IAEA (International Atomic Energy Agency) symposium on dynamic studies with radiolabels in clinical medicine and research (August 31 - September 4 1970 Rotterdam), 364
- IgG, Immunglobulins G
- Immunoelectrophoresis, Cryofibrinogenemia
- Immunoelectrophoresis-Fibel. Grundlagen und Anleitung zum Verständnis typischer Bilder 128 (B)
- Immunglobulin; der zytologische Immunglobulinnachweis in lymphatischen Reiszellen, 230
- Immunity proceedings of the International symposium on gammaopathies, infections, cancer and immunity (Burl, 1967) 127 (B)
- Immunoglobulins G, fraction non spécifique sur les érythrocytes, étude. I. Influence de la variation de différents paramètres, 154
- II Essai d'inhibition par des immunoglobulins G natives ou modifiées et par d'autres protéines, 219
- Immunology: Autoimmunerkrankungen in der Hämatologie (Hämatologie und Bluttransfusionswesen, Vol. 5) 361 (B)
- Inderal® (= propranolol = β -adrenergic blocking agent) Thrombocytosis
- Infancy Phosphatidstoffwechsel (B) Transketolase activity
- Infections, International symposium (B)
- Inhibiteurs faibles du facteur VIII, leur rôle, 27
- International Atomic Energy Agency (= IAEA) symposium on dynamic studies with radiolabels in clinical medicine and research (August 31 - September 4, 1970, Rotterdam), 365
- International conference on leukaemia lymphomas, proceedings (Ann Arbor 1967) 191 (B)
- International, XIIIth, congress of haematology (Münich, 2-8 August 1970) 64
- International Society of Haematology International, XIIIth
- International, 3rd, symposium for comparative leukaemia research, Paris, 1967 Leukaemia in animals and man, 254 (B)
- International symposium; proceedings of the International symposium on gammaopathies, infections, cancer and immunity (Burl, 1967) 127 (B)
- International, 3rd, transplantation congress (The Hague, 7-11 September 1970) 64
- Intestinal absorption inter-relations between iron stores, general factors and intestinal iron absorption, 193
- Intrinsic factor deficiency Anaemia, pernicious
- Iodine, radioactive, Immunglobulins G
- Iron in women, Haemoglobin L

- Iron, radioactive, v Iron excretion, Iron stores
- Iron excretion urinary and faecal Iron excretion in thalassaemia syndromes, 321
- Iron stores; inter-relationships between iron stores, general factors and intestinal iron absorption, 193
- Irradiation, X-irradiation quantitative study of the haemopoietic recovery after a sublethal X-irradiation in the mouse, 347
- Isotogenicity of human plasma proteins (Bibliotheca haematologica, Nr 31) 361 (B)
- Isootope, radioaktive, v Antemia, pernicious Immunoglobulinen G International Atomic Energy Agency Iron excretion Iron stores; Lymphocyte cultures; Proliferocytes
- Kälteblutung, v Cryofibrinogenasaemia
- Karyogramme, v Chromosome studies (B) Cytogenetic evolution (B) Ph 1 chromosomes
- Katheter Herzkatheterismus, Blood, central
- Kerne (Zellkerne) Chromosome studies... (B) Cytogenetic evolution (B) Ph 1 chromosomes
- Kindesalter Phosphorstoffwechsel (B) Transketolase activity
- Klima Wirkung des Mittelgebirgsklimas und des Wetters auf das Blutbild, 281
- Klinische Hämatologie, 361 (B)
- Knochenmark, Bone marrow Bone marrow basophils, Cytidiphosphamide, Hepatus-Virus MHV₁₀, Reticulosis, X irradiation
- Körperliche Arbeit, Thrombocytosis
- Kongress, Congress
- Laboratory methods, clinical (BRAT') (7th ed.) 128 (B)
- Leber Hepatus-Virus MHV
- Leucithin, Lysocithin
- Leukaemia, acute case of acute leukaemia with pseudo-Piccola cells containing Azur bodies, 58
— chronology of the mitotic cycle of acute leukaemia cells, 76
- Leukaemia in animals and man (3rd international symposium for comparative leukaemia research, Paris 1967) 254 (B)
- Leukaemia, granulocytic, blast crisis, Leukaemia, myeloid, chronic
- Leukaemia, human, cell kinetics, 188 (B)
- Leukaemia, lymphatic, chronic, v Lymphopoietin
- Leukaemia, myelogenous, chronic, cytogenetic evolution, 362 (B)
- Leukaemia, myeloid, chronic presence of two Ph 1 chromosomes in cells with 49 clone from patient in blast crisis of granulocytic leukaemia, 337
- Leukaemia; proceedings of the international conference on leukaemia lymphoma (Ann Arbor 1967), 191 (B)
- Leukaemia virus, myeloid (Gaarn); studies on the pathogenesis and mechanisms of haematologic diversification by re-isolation of the myeloid leukaemia virus (Gaarn), 65
- Leukaemic subjects distribution of amino acids in urine, plasma, leucocytes and erythrocytes of leukaemic and normal subjects, 86
- Leukocyte alkaline phosphatase (The effect of age and sex), 18
- Leukocyten mit Dörmerschen Körperchen, v May-Haenrichsche Anomalie
- Leukocytes; distribution of amino acids in urine, plasma, leucocytes and erythrocytes of leukaemic and normal subjects, 86
—; basophilic, human periodic acid-Scharr reaction in human basophilic leucocytes, 269
—; neutrophil, human; ultrastructural localization of alkaline phosphatase in human neutrophils, 775
—; v Proliferocytes
- Leukopoiesis, Mittelgebirgsklima
- Libri, 127-128 (B), 188-192 (B), 254-256 (B) 361-364 (B)
- Lichtmikroskopie; Einführung in die neuere Methoden der Lichtmikroskopie, 189 (B)
- Liver v Hepatus-Virus MHV
- Livres nouveaux, 127-128 (B), 188-192 (B) 254-256 (B) 361-363 (B)
- Lymphatic leukaemia, chronic, Lymphopoietin
- Lymphatische Reizellen; der zytologische Immunoglobulinnachweis in lymphatischen Reizellen, 230
- Lymphocyte cultures enzymatic and chemical changes in human lymphocyte cultures, 158

- Lymphocyte transformation suppression by RNA of human lymphocyte transformation, 91
- Lymphoma; proceedings of the international conference on leukaemia lymphoma (Ann Arbor 1967), 191 (B)
- Lymphopoietin, 23
- Lysocleidin, effect on bovine erythrocytes osmotic fragility 106
- Mäusehepatitis-Virus MHV; Panmyelophthie und Virushepatitis (Experimentelle Untersuchungen mit dem Mäusehepatitis-Virus MHV), 316
- ; Maus
- Malaria; blood proleurocytes in human and animal malaria, 129
- Maus; leukaemia in animals and man (3rd international symposium for comparative leukaemia research, Paris 1967) 234 (B)
- ; Immun
- Maus, v Leukemia virus, myeloid (Gaarn); Mäusehepatitis-Virus MHV; Mouse
- MAY HEDGECOCK'S Anomalie (Beschreibung einer neuen Familie und Untersuchung zur Funktion, Biochemie und Ultrastruktur der Thrombocyten) 309
- Mechanische Resistenz, v Erythrocytes, Resistent
- Medicine, chemical, International Atomic Energy Agency
- Medizinische Diagnostik. Grundlagen und Praxis, 234 (B)
- Mediterranean anaemia, Thalassemia, Thalassemia syndromes
- Medulla osseae, Bone marrow Bone marrow basophils, Cyclophosphamide, Hepatitis-Virus MHV, Reticulosis, X irradiation
- Medullary histiocytic reticulosis (Case report with electron microscope study) 50
- Mensch, Mensch, pfg
- Megakaryocytes and platelets in central venous and arterial blood, 130
- Megaloblastic anaemia, severe, due to nutritional vitamin B₁₂ deficiency 247
- Membrane permeability and metabolism of erythrocytes and thrombocytes, 233 (B)
- Mensch, Man
- Metabolism and membrane permeability of erythrocytes and thrombocytes, 233 (B)
- Metabolism of iron, Iron stores
- Methode, Immunhistochemie-Fibel
- (B) Klinische Hämatologie (B) Laboratory methods (B) Lichtmikroskopie (B)
- Mice, Leukemia virus, myeloid (Gaarn); Mäusehepatitis-Virus MHV Mouse
- Microautoradiography Lymphocyte cultures, Proleurocytes
- Microscope à contrast de phase v Leukemia, acute chronology
- Microscope électronique, v Basophilic leucocytes, Basophils of bone marrow Cyclophosphamide, MA-Histocytische Anomalie, Neutrophils, Reticulosis
- Mikroskopie; Einführung in die neuen Methoden der Lichtmikroskopie, 189 (B)
- Myeloid cycle of acute leukemia cells, chronology 76
- Mitochondrien; Wirkung des Mitochondrieninhalts und des Wirters auf das Blutbild, 281
- Moelle osseae, Bone marrow Bone marrow basophils, Cyclophosphamide, Mäusehepatitis-Virus MHV, Reticulosis, X-irradiation
- Mononuclear blood cells capable of proliferation, Proleurocytes
- Mouse- quantitative study of the haemopoietic recovery after sublethal X-irradiation in the mouse, 317
- ; Leukemia virus, myeloid (Gaarn); Mäusehepatitis-Virus MHV
- After osseae, Leukemia virus, myeloid (Gaarn) Mäusehepatitis-Virus MHV; Mouse
- Myelogenous leukemia, chronic, cytogenetic evolution, 302 (B)
- Myeloid leukemia, chronic; presence of two Ph 1 chromosomes in cells with 49 clone from patient in blast crisis of granulocytic leukemia, 357
- Myeloid leukemia virus (Gaarn) studies on the pathogenesis and mechanism of haematologic diversification by re-isolation of the myeloid leukemia virus (Gaarn) 63
- Necrology, 257
- Neutrophils, human, ultrastructural localization of alkaline phosphatase, 275
- Noyau, Ph 1 chromosomes
- Nuclei, Ph 1 chromosomes
- Nutritional vitamin B₁₂ deficiency severe megaloblastic anaemia, 247

- Old age, v Transketolase activity
 O₂-Partialdruck, v Mittelgebirgsklima
 Osmotic fragility; effect of lysoclitin on bovine erythrocyte osmotic fragility 106
 - Resistenz von Erythrozyten
 Oxygen, partial pressure, v Mittelgebirgsklima
 Panmyelophthase und Virushepatitis (Experimentelle Untersuchungen mit dem Mäushepatitis-Virus MHV₁) 346
 Parahaemocyto-blastic acute leukaemia, v Leukemia, acute chronology ..
 PAS, v Periodic acid-Schiff
 Pathologie des Phosphatstoffwechsels, v Phosphatstoffwechsel (B)
 Pathologische Anatomie (Vol. 1: Allgemeine Pathologie. Vol. 2: Spezielle Pathologie) 254 (B)
 Pelzer-cells; a case of acute leukaemia with pseudo-Pelzer cells containing Azur bodies, 58
 Peptide chromatogram, (fingerprint) v Haemoglobin L
 Periodic acid-Schiff (=PAS) reaction in human basophilic leukocytes, 269
 Permeability v Membrane permeability (B)
 Pernicious anaemia evaluation of dual radiotracer urinary excretion test in the diagnosis of pernicious anaemia, 183
 - Megaloblastic anaemia
 Perle Gell, v Haemoglobin L
 PHA, v Phytohaemagglutinin
 Phase-contrast microscope, Leukemia, acute chronology Lichtmikroskopie (B)
 Ph 1 chromosomes (=Philadelphia chromosomes) presence of two Ph 1 chromosomes in cells with 49 clone from patient in blast crisis of granulocytic leukaemia, 357
 Philadelphia chromosomes, v Ph 1 chromosomes
 Phosphatase, alkaline, in human neutrophils, ultrastructural localization, 275
 - of leukocytes (The effect of age and sex) 18
 Phosphatstoffwechsel zur Physiologie und Pathologie des Phosphatstoffwechsels unter besonderer Berücksichtigung der Phosphatverbindungen des kindlichen Erbes, 191 (B)
 Physiologie des Phosphatstoffwechsels, v Phosphatstoffwechsel (B)
 Phytohaemagglutinin (=PHA) v Lymphocyte cultures, Lymphocyte transformation, Lymphopoietin
 Plaquettes sanguines, v Platelets, Thrombocytes, Thrombocytes (B), Thrombocyto-sis
 Plasma distribution of amino acids in urine, plasma, leukocytes and erythrocytes of leukaemic and normal subjects, 86
 Plasma proteins, human, leucogenicity (Bibliotheca haematologica, Nr. 31) 361 (B)
 Platelets and megakaryocytes in central venous and arterial blood, 330
 Platelets, v Thrombocytes, Thrombocytes (B), Thrombocyto-sis
 Précipitation par froid, v Cryofibrinogenae-mia
 Proceedings of the international conference on leukaemia lymphoma (Ann Arbor 1967) 191 (B)
 Proceedings of the international symposium on gammagopathies, infections, cancer and immunity (Bari, 1967) 127 (B)
 Progress in hematology (Vol. 6), 363 (B)
 Proliferative activity v Leukemia, acute chronology
 Proliferocytes blood proliferocytes in human and animal malaria, 129
 Propranolol (β -adrenoreceptor blocking agent), v Thrombocyto-sis
 Proctine (Dyproctinase), Erythrocytes, Resistenz
 Proteins leucogenicity of human plasma proteins (Bibliotheca haematologica Nr. 31) 361 (B)
 Protein, v Immunoglobulins G
 Protides of the biological fluids, 18th colloquium (April 29 - May 3, 1970, Bruges) 364
 Pseudo-Pelzer cells; case of acute leukaemia with pseudo-Pelzer cells containing Azur bodies, 58
 Radiation, v X-irradiation
 Radio-cobalt, v Vitamin B₁₂
 Radio-iodine, v Immunoglobulins G
 Radio-iron, v Iron excretion, Iron stores
 Radiotracer test evaluation of dual radiotracer urinary excretion test in the diagnosis of pernicious anaemia, 183

- Vitamin B₁₂
 Radioisotopes, v International Atomic Energy Agency
 Rays, X, X-irradiation
 Red blood cells transketolase activity of red blood cells from infancy to old age 148
 hereditary deficiency of adenylate kinase in red blood cells, 111
 Erythro
 Re-isolation of the myeloid leukaemia virus (Gaarn) Leukaemia virus, myeloid (Gaarn)
 Resistenz von Erythrocyten Einfluss dysproteinämischer Seren auf die Resistenz normaler Erythrocyten, 298
 -; v Osmotic fragility
 Resorption, Absorption
 Reticulo-endothelial cells (bone marrow) Iron stores
 Reticulosis, histiocytic, medullary (Case report with electron microscopic study), 30
 Ribonucleic acid (=RNA) suppression by RNA of human lymphocyte transformation, 94
 Ribonucleic acid (=RNA) synthesis, Lymphocyte cultures
 Riesenthrombocyten, MAY-HISGOLD'sche Anomalie
 RNA, Ribonucleic acid
 Röntgenbestrahlung, X-irradiation
 Saugstoff, Partialdruck, Mittelgebirgsklima
 Sedimentation rate, highly increased, v Cryofibrinogenemia
 Serum albumin, human, Immunglobulines G
 Sex, Phosphatase
 Society Haematology Transfusion sanguine (B) Transplantation
 Sowa's, Leukaemia virus, myeloid (Gaarn); Minkhepatitis-Virus MHV Mouse
 Spontanhämolyse, Resistenz von Erythrocyten
 Starch gel quantitative electrophoresis of haemoglobin as screening in the thalassaemia syndromes, 99
 Statistische Auswertung, Cyanocobalamin Cyclophosphamide; Erythrocyten, Resistenz Immunglobulines G; Iron stores Lymphocyte transformation Minkhepatitisvirus; Osmotic fragility
 Phosphatase Thrombocyten Transketolase activity
 Strahleneinwirkung, v X-irradiation
 Submicroscopical structure, Basophilic leukocytes, Basophile of bone marrow Cyclophosphamide, MAY-HISGOLD'sche Anomalie, Neutrophils, Reticulosis
 Symposium, Immunity (B), International Atomic Energy Agency Leukaemia in animals (B)
 Temps, Wetter
 Thalassemia haaptoglobin in thalassemia, 176
 Thalassemia syndromes; screening the starch gel quantitative electrophoresis of haemoglobin as screening in the thalassemia syndromes, 99
 — urinary and fecal iron excretion in thalassemia syndromes, 321
 Thrombocytes MAY-HISGOLD'sche Anomalie (Beschreibung einer neuen Familie und Untersuchung zur Funktion, Biochemie und Ultrastruktur der Thrombocyten) 303
 Thrombocytes membrane permeability and metabolism of erythrocytes and thrombocytes, 153 (B)
 ; Plasmas
 Thrombocytopoiesis exercise-induced thrombocytopoiesis, 241
 Thymidine (H³-thymidine) Lymphocyte cultures, Prothrombocytes
 Tissue cultures, Cell cultures
 Transferrin, Iron excretion
 Transfusion sanguine actes du VI congrès national de transfusion sanguine (Tours, 22-26 June 1966) (tomes I/II), 127 (B)
 Transketolase activity of red blood cells from infancy to old age, 148
 Transplantation congress, 3rd, international (Transplantation Society) (The Hague, 7-11 September 1970) 64
 Travail manuel, Thrombocytopoiesis
 Tumors, Cancer (B)
 Ultrastructural localization of alkaline phosphatase in human neutrophils, 275
 Ultrastructure, Basophilic leukocytes, Basophile of bone marrow Cyclophosphamide, MAY-HISGOLD'sche Anomalie, Reticulosis
 Upland region, climate, Mittelgebirgsklima

- Urinary excretion test: evaluation of dual radioisotope urinary excretion test in the diagnosis of pernicious anaemia, 183
- Urinary and faecal iron excretion in thalassaemia syndromes, 321
- Urine; distribution of amino acids in urine, plasma, leukocytes and erythrocytes of leukaemic and normal subjects, 86
- Varia, 64 365
- Venous blood, central; megakaryocytes and platelets in central venous and arterial blood, 330
- Virus, Gaarn-virus; studies on the pathogenesis and mechanism of haematologic diversification by re-isolation of the myeloid leukaemia virus (Gaarn) 63
- Virushepatitis und Pannmyelophthie (Experimentelle Untersuchungen mit dem Mäusehepatitis-Virus MHV₂) 348
- Vitamin B₁₂; absorption and excretion of cyanocobalamin after oral administration of a large dose in various conditions, 1 -; evaluation of dual radioisotope urinary excretion test in the diagnosis of pernicious anaemia, 183
- Vitamin B₁₂ deficiency; severe megaloblastic anaemia due to nutritional vitamin B₁₂ deficiency 247
- Wetter: Wirkung des Mittelgebirgsklimas und des Wetters auf das Blutbild, 281
- Wheater v Wetter
- X-irradiation, sublethal quantitative study of the haemopoietic recovery after sublethal X-irradiation in the mouse, 347
- Zellkerne, Kerne
- Zellstrukturen, v Lymphocyte cultures, Lymphocyte transformation, Lymphopoiesis
- Zell -, v Cell
- Zentral v Central
- Zytologische Untersuchungen zur Diagnostik und Ätiologie der Erythroblastik, 208
- Zytologischer Immunoglobulinschweis in lymphatischen Reizreizen, 230
- Zyto -, v Cyto

Index autorum ad Vol. 42

(B) = Book reviews - Buchbesprechungen - Livres nouveaux

- Ackermann, P. G., v Baner J. D.
- Ausser H., und Braunsteiner H., 230
- Azaldi, G. 188 (B)
- Angoustaki, O. Mahmos, B.
- Barakata, N. F., Haot, J.
- Barigazzi, G. M., Rondanelli, E. G.
- Bartels, H., Hausmann, K.
- Baner J. D. Ackermann, P. G., and Toru, G. (Editores) 128 (B)
- Beck, E. A., 256 (B)
- Bell, T. K., and Lee, D. 183
- Bendheim, H. J. (Editor) 254 (B)
- Ben-Zur Jodith, Saenberg, A.
- Bernard, J. (Editor) 190 (B)
- Berstein, E. P. v Gerlin, S. R.
- Bianco, G., v Ricci, G.
- Bolger C. Denise, v Lee, Maureen B.
- Bonomo, L., v Ghini, V.
- Borovicksky K. G. v Schrike-Wismann, H.
- Bowie, E. W. Owen, Ch. A. Jr
- Braunsteiner H., v Ausser H.
- (Bray W. E., 178 (B))
- Bredkin, K., v Lechner K.
- Bridges, J. M., Lee, Maureen B.
- Britton, C. J. C., 256 (B)

- Brown, E. B., and Moore, C. V. (Editors) 363 (B)
- Bucher U. 233 (B) 361 (B)
- Bürker R., 127 (B) 361 (B)
- Chaa, Beatrice S. T. 256
- Charlton, E. (Editor), 127 (B)
- Chiel, V. Bonomo, L., and Sirtori, C. (Editors) 127 (B)
- Constantoulakis, M., Malamou, B.
- Dahl, M., Markkanen, T.
- Dawson, A. A., and Ogston, D., 241
- del Pozo, E., Ledbetter R. B. Jr. 361 (B)
- Des Gouttes, D., et Ishler H., 154 219
- Deutsch, E., Gerlach, E., and Moser K. (Editors), 255 (B)
- Didakchis, P. Owen, Ch. A. Jr.
- Eastham, R. D. 361 (B)
- Eggeling, E., v. Hunstein, W.
- Falchi, F. Rondanelli, E. G.
- Fey F. 63
- Fischer Dina, Rosenzajn, L. A.
- Fisher E. R., Zawadzki, Z. A.
- Franoon, M., 189 (B)
- French, A., Racconig, G.
- Gallimberti, A., Riggio, G. 186 (B)
- Gallo, E., Ricco, G.
- Garbo, S. R., Shea, M. A., and Bernstein, E. F. 106
- Gavendo, Elva, Szernberg, A.
- Gehrman, G., 128 (B)
- Gerlach, E., Deutsch, E.
- Giblett, E. R., 362 (B)
- Göpfert, H., Schulze-Wiermann, H.
- Gouttes, D. des, Des Gouttes, D.
- Grainlich, F. und Kirchhoff, F. 296
- Gross, R., 254 (B)
- Grundmann, E., 192 (B)
- Gyfiaki, E., Malamou, B.
- Hägg, A., 127 (B)
- Haci, J. and Barakine, N. F. 347
- Hausmann, K., Kuse, R., Sonnenberg, O. W. Bertels, H., and Heinrich, H. G., 193
- Haybos, F. G. J. 362 (B)
- Heinrich, R., Markkanen, T.
- Heinrich, H. G., Hausmann, K.
- Hille, H., Schulze-Wiermann, H.
- Hudson, G., Kaul, M.
- Huonstein, W. Perings, E., Eggeling, E., und Uhl, N., 338
- Ishler H., Des Gouttes, D.
- Jenny L., 189 (B)
- Jednaký H. J. Schulze-Wiermann, H.
- Johnson, D. M., v. Rigby P. G.
- Kahana, D. Seinfeld, A.
- Kallinikos-Manolatis, Alice, 350
- Kaul, M., and Hudson, G., 42
- Kamig, D. T. 269
- Keme-Elias, M., Malamou, B.
- Khan, M. H., and Martin, H., 357
- Kinderkerer Judith, L., Rahbar S.
- Kirchhoff F. Grainlich F.
- Kos, L. G., 192 (B)
- Kuhn, R. A., 128 (B)
- Kuse, R., Hausmann, K.
- Lechner K., Breddin, K., Moser K., Stockinger L., und Wenzel, L., 303
- Ledbetter R. B. Jr. and del Pozo, E., 247
- Leder L.-D. 58
- Lac, D. v. Bell, T. H.
- Lee, Mervyn B. Bolger C. Denis, and Bridges, J. M., 86
- Lehmann, H., Rahbar S.
- Luchinger U. 186 (B)
- Lidin, H., 190 (B) 254 (B)
- Magbala, E., Rondanelli, E. G.
- Malamou, B., Constantoulakis, M., Gyfiaki, E., Keme-Elias, M., and Augoustaki, O. 321
- Markkanen, T. Heidenheim, R., and Dahl, M., 148
- Marti, H. R., 128 (B) 254 (B) 362 (B)
- Martin, H., Khan, M. H.
- Mistral, K., Rahbar, J. R.
- Mayer G. Noël, Geneviève, et Walz, R., (et Wiesner Mariène), 27
- Mazza, U. Ricco, G.
- Moore, C. V. Brown, E. B.
- Moser K., Deutsch, E.
- Moser, K., Lechner K.
- Müller D., 208
- Nakatsui, T. 273
- Noel, Geneviève, Mayer G.
- Öworya, S. Yamak, B.
- Ogston, D. Dawson, A. A.
- Owen, Ch. A. Jr., Bown, E. W. Delfabehn, F. and Thomson, J. H., 363 (B)
- Pedersen, B., 362 (B)
- Petta, G. E., Zawadzki, Z. A.
- Perings, E., Hunstein, W.
- Pilla, G., Rondanelli, E. G.
- Pinckerton, P. H., Ray P. K.
- Pozo, E. del, del Pozo, E.
- Prato, V. Ricco, G.

- Rachmilewitz, E. A., v Zlotnick, A.
 Raccaglia, G., French, A., and Zarfonetis,
 C. J. D. 1
 Rahbar, S., Kinderlehrer Judith, L., and
 Lehmann, H., 169
 Rame, L., v Rohnd, J. R.
 Ray P. K., and Pinkerton, P. H., 18
 Ricco, G., Gallo, E., Marra, U. Bianco, G.,
 and Prato, V., 99
 Rigby P. G., and Johnson, D. M., 94
 Riggo, G., v Gelfinberti, A.
 Rondanelli, E. G., Magbalo E., Filla, G.,
 Falchi, F., and Benigazzi, G. M., 76
 Roscnow G., 128 (B) 191 (B), 363 (B)
 Rosenstajn, L. A., and Fischer, Dona, 138
 Rubini, J. R., Marini, K., and Rana, L.,
 129
 Schulte Wassermann, H., Hille, H., Jea-
 dinsky H. J. Göpfert, H., und Boro-
 vicinsky K. G. v 231
 Shahin, W. v Zlotnick, A.
 Shea, M. A., v Garfin, S. R.
 Sörner, C., Chini, V.
 Sonnenberg, O. W. v Hausmann, K.
 Stieglitz, R., v Stobbe, H.
 Stobbe, H., und Stieglitz, R., 361 (B)
 Stockinger L., v Lechner K.
 Studer E., 128 (B)
 Szeinberg, A., Kahana, D., Gavendo, Sava,
 Zalkman, J., and Ben-Ezer Judith, 111
 Thomson, J. H., v Owen, Ch. A. jr
 Tinson, J. 23
 Toro, G., v Bauer J. D.
 Uhl, N., v Humstein, W.
 Voss, M., 191 (B)
 Vlachar T. L., 361 (B)
 on Borovicksky K. G., v Borovicksky
 K. G. v
 Waite, R., v Mayer G.
 Wendel, E., v Lechner K.
 Wilmer Marlène, v Mayer G.
 Willenbockel, U. 191 (B)
 Wehrmann, F., 234 (B)
 Yonak, B., and Özyayin, S., 178
 Zalkman, J. v Szeinberg, A.
 Zarfonetis, C. J. D. (Editor), 191 (B)
 Zarfonetis, C. J. D. v Raccaglia, G.
 Zawadzki, Z. A., Peña, C. E., and Fisher
 E. R., 50
 Zlotnick, A., Shahin, W. and Rachmile-
 witz, E. A., 8
 Zöllinger H. U. 234 (B)

